<?xml version="1.0" standalone="yes"?>
<REMINDER_EXCHANGE_FILE_ENTRY>
<PACKAGE_VERSION>2.0P65</PACKAGE_VERSION>
<INDEX_AT>14494</INDEX_AT>
<SOURCE>
<NAME>UPDATE_2_0_570 VA-ONCOLOGY BLADDER CANCER PATHWAYS UPDATE</NAME>
<USER>PACKER,REMINDER</USER>
<SITE>FOIA</SITE>
<ENV>NATREM^NATREM^oitausdhctlexa.r02.domain.ext^NATREM:LEXR0TSVR</ENV>
<DATE_PACKED>04/27/2026@11:26:01</DATE_PACKED>
</SOURCE>
<DESCRIPTION><![CDATA[
The following Clinical Reminder items were selected for packing:
REMINDER DIALOG
  VA-ONCOLOGY BLADDER CANCER MUSCLE INVASIVE PATHWAYS
  VA-UPDATE 570 REVISED GROUPS

REMINDER TERM
  VA-REMINDER UPDATE_2_0_570
]]></DESCRIPTION>
<KEYWORDS>
</KEYWORDS>
<PACKING ATTRIBUTES><![CDATA[
<ATTRIBUTE>GROUPING DIALOG COMPONENTS</ATTRIBUTE>
]]></PACKING ATTRIBUTES>
<FILEMAN_FILE>
<FILE_NAME>REMINDER GENERAL FINDINGS</FILE_NAME>
<FILE_NUMBER>801.46</FILE_NUMBER>
<POINT_01>VIEW PROGRESS NOTE TEXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>454</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1980651110</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.46;+454,;.01~VIEW PROGRESS NOTE TEXT
801.46;+454,;2~CLINICAL REMINDERS^PXRM
801.46;+454,;3~801.41
801.46;+454,;10~GF_VIEW
801.46;+454,;11~VIEW PROGRESS NOTE TEXT
801.46;+454,;20~SINGLE VALUE
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC WP 2 LINES</POINT_01>
<INTERNAL_ENTRY_NUMBER>31008</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1208947677</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+31008,;.01~VA-ONC WP 2 LINES
8927.1;+31008,;.02~Word Processing
8927.1;+31008,;.03~NO
8927.1;+31008,;.04~60
8927.1;+31008,;.07~0
8927.1;+31008,;.08~NO
8927.1;+31008,;.09~NO
8927.1;+31008,;.1~2
8927.1;+31008,;.11~0
8927.1;+31008,;.12~0
8927.1;+31008,;.13~0
8927.1;+31008,;.14~0
8927.1;+31008,;.15~0
8927.1;+31008,;2~WP-start~1
VHA Oncology 7-21-22
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>TELEHEALTH EMERGENCIES VA LOCATIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>16568</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3467367255</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+16568,;.01~TELEHEALTH EMERGENCIES VA LOCATIONS
8927.1;+16568,;.02~Hyperlink
8927.1;+16568,;.03~NO
8927.1;+16568,;.04~0
8927.1;+16568,;.05~TELEHEALTH EMERGENCIES VA LOCATIONS
8927.1;+16568,;.07~0
8927.1;+16568,;.08~NO
8927.1;+16568,;.09~NO
8927.1;+16568,;.1~0
8927.1;+16568,;.11~0
8927.1;+16568,;.12~0
8927.1;+16568,;.13~0
8927.1;+16568,;.14~0
8927.1;+16568,;.15~0
8927.1;+16568,;3~http://vaots.blackboard.com/bbcswebdav/xid-1304763_1
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>TELEHEALTH EMERGENCIES NON-VA LOCATIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>16567</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1676708629</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+16567,;.01~TELEHEALTH EMERGENCIES NON-VA LOCATIONS
8927.1;+16567,;.02~Hyperlink
8927.1;+16567,;.03~NO
8927.1;+16567,;.04~0
8927.1;+16567,;.05~TELEHEALTH EMERGENCIES NON-VA LOCATIONS
8927.1;+16567,;.07~0
8927.1;+16567,;.08~NO
8927.1;+16567,;.09~NO
8927.1;+16567,;.1~0
8927.1;+16567,;.11~0
8927.1;+16567,;.12~0
8927.1;+16567,;.13~0
8927.1;+16567,;.14~0
8927.1;+16567,;.15~0
8927.1;+16567,;3~http://vaots.blackboard.com/bbcswebdav/xid-1765526_1
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>EDIT 55+</POINT_01>
<INTERNAL_ENTRY_NUMBER>939</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2533799999</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+939,;.01~EDIT 55+
8927.1;+939,;.02~Edit Box
8927.1;+939,;.03~NO
8927.1;+939,;.04~50
8927.1;+939,;.07~0
8927.1;+939,;.08~YES
8927.1;+939,;.09~NO
8927.1;+939,;.1~240
8927.1;+939,;.11~0
8927.1;+939,;.12~0
8927.1;+939,;.13~0
8927.1;+939,;.14~0
8927.1;+939,;.15~0
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>NTO PHONE FORMAT (RO)</POINT_01>
<INTERNAL_ENTRY_NUMBER>1395</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>99564854</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+1395,;.01~NTO PHONE FORMAT (RO)
8927.1;+1395,;.02~Text
8927.1;+1395,;.03~NO
8927.1;+1395,;.04~0
8927.1;+1395,;.07~0
8927.1;+1395,;.08~NO
8927.1;+1395,;.09~YES
8927.1;+1395,;.1~0
8927.1;+1395,;.11~0
8927.1;+1395,;.12~0
8927.1;+1395,;.13~0
8927.1;+1395,;.14~0
8927.1;+1395,;.15~0
8927.1;+1395,;10~WP-start~1
(xxx)xxx-xxxx
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC VAMC SITE NAME</POINT_01>
<INTERNAL_ENTRY_NUMBER>941</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3467747318</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+941,;.01~VA-ONC VAMC SITE NAME
8927.1;+941,;.02~Edit Box
8927.1;+941,;.03~NO
8927.1;+941,;.04~45
8927.1;+941,;.05~Enter site here
8927.1;+941,;.07~0
8927.1;+941,;.08~YES
8927.1;+941,;.09~NO
8927.1;+941,;.1~240
8927.1;+941,;.11~0
8927.1;+941,;.12~0
8927.1;+941,;.13~0
8927.1;+941,;.14~0
8927.1;+941,;.15~0
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>BLADDER CANCER CTDNA ATEZOLIZUMAB LINK</POINT_01>
<INTERNAL_ENTRY_NUMBER>26009</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3106163596</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+26009,;.01~BLADDER CANCER CTDNA ATEZOLIZUMAB LINK
8927.1;+26009,;.02~Hyperlink
8927.1;+26009,;.03~NO
8927.1;+26009,;.04~0
8927.1;+26009,;.05~ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
8927.1;+26009,;.07~0
8927.1;+26009,;.08~NO
8927.1;+26009,;.09~NO
8927.1;+26009,;.1~0
8927.1;+26009,;.11~0
8927.1;+26009,;.12~0
8927.1;+26009,;.13~0
8927.1;+26009,;.14~0
8927.1;+26009,;.15~0
8927.1;+26009,;3~https://www.nejm.org/doi/full/10.1056/NEJMoa2511885
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC OFF REASON TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>7551</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3060976492</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+7551,;.01~VA-ONC OFF REASON TXT
8927.1;+7551,;.02~Text
8927.1;+7551,;.03~NO
8927.1;+7551,;.04~0
8927.1;+7551,;.07~0
8927.1;+7551,;.08~NO
8927.1;+7551,;.09~NO
8927.1;+7551,;.1~0
8927.1;+7551,;.11~0
8927.1;+7551,;.12~0
8927.1;+7551,;.13~0
8927.1;+7551,;.14~0
8927.1;+7551,;.15~0
8927.1;+7551,;10~WP-start~1
REASON OFF PATHWAY:
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC TREATMENT REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>7550</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1969443347</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+7550,;.01~VA-ONC TREATMENT REASON
8927.1;+7550,;.02~Text
8927.1;+7550,;.03~NO
8927.1;+7550,;.04~0
8927.1;+7550,;.07~0
8927.1;+7550,;.08~NO
8927.1;+7550,;.09~YES
8927.1;+7550,;.1~0
8927.1;+7550,;.11~0
8927.1;+7550,;.12~0
8927.1;+7550,;.13~0
8927.1;+7550,;.14~0
8927.1;+7550,;.15~0
8927.1;+7550,;10~WP-start~1
(specify treatment Veteran will receive)
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>20438</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1857125923</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+20438,;.01~VA-ONC CLINICAL TRIAL
8927.1;+20438,;.02~Text
8927.1;+20438,;.03~NO
8927.1;+20438,;.04~0
8927.1;+20438,;.07~0
8927.1;+20438,;.08~NO
8927.1;+20438,;.09~YES
8927.1;+20438,;.1~0
8927.1;+20438,;.11~0
8927.1;+20438,;.12~0
8927.1;+20438,;.13~0
8927.1;+20438,;.14~0
8927.1;+20438,;.15~0
8927.1;+20438,;10~WP-start~1
Clinical trial (specify name of study and NCT number):
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC PRESUMPTIVE CONDITIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>11598</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2232043786</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+11598,;.01~VA-ONC PRESUMPTIVE CONDITIONS
8927.1;+11598,;.02~Hyperlink
8927.1;+11598,;.03~NO
8927.1;+11598,;.04~0
8927.1;+11598,;.05~Presumptive Disability Benefits
8927.1;+11598,;.07~0
8927.1;+11598,;.08~NO
8927.1;+11598,;.09~YES
8927.1;+11598,;.1~0
8927.1;+11598,;.11~2
8927.1;+11598,;.12~0
8927.1;+11598,;.13~0
8927.1;+11598,;.14~0
8927.1;+11598,;.15~0
8927.1;+11598,;3~https://www.benefits.domain.ext/BENEFITS/factsheets/serviceconnected/presumption.pdf
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC PATHWAYS SHAREPOINT</POINT_01>
<INTERNAL_ENTRY_NUMBER>18139</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1384808292</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+18139,;.01~VA-ONC PATHWAYS SHAREPOINT
8927.1;+18139,;.02~Hyperlink
8927.1;+18139,;.03~NO
8927.1;+18139,;.04~0
8927.1;+18139,;.05~Clinical Pathways SharePoint
8927.1;+18139,;.07~0
8927.1;+18139,;.08~NO
8927.1;+18139,;.09~YES
8927.1;+18139,;.1~0
8927.1;+18139,;.11~2
8927.1;+18139,;.12~0
8927.1;+18139,;.13~0
8927.1;+18139,;.14~0
8927.1;+18139,;.15~0
8927.1;+18139,;3~https://dvagov.sharepoint.com/sites/VHACP
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC CT RN NAV</POINT_01>
<INTERNAL_ENTRY_NUMBER>17561</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3884540967</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+17561,;.01~VA-ONC CT RN NAV
8927.1;+17561,;.02~Hyperlink
8927.1;+17561,;.03~NO
8927.1;+17561,;.04~0
8927.1;+17561,;.05~VA Cancer Clinical Trial Nurse Navigator
8927.1;+17561,;.07~0
8927.1;+17561,;.08~NO
8927.1;+17561,;.09~YES
8927.1;+17561,;.1~0
8927.1;+17561,;.11~0
8927.1;+17561,;.12~0
8927.1;+17561,;.13~0
8927.1;+17561,;.14~0
8927.1;+17561,;.15~0
8927.1;+17561,;3~mailto:CancerClinicalTrialsNavigation@domain.ext
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC NEITHER ON/OFF</POINT_01>
<INTERNAL_ENTRY_NUMBER>11983</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3160039956</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+11983,;.01~VA-ONC NEITHER ON/OFF
8927.1;+11983,;.02~Text
8927.1;+11983,;.03~NO
8927.1;+11983,;.04~0
8927.1;+11983,;.07~0
8927.1;+11983,;.08~NO
8927.1;+11983,;.09~YES
8927.1;+11983,;.1~0
8927.1;+11983,;.11~0
8927.1;+11983,;.12~0
8927.1;+11983,;.13~0
8927.1;+11983,;.14~0
8927.1;+11983,;.15~0
8927.1;+11983,;10~WP-start~1
(neither on or off pathway)
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-REMINDER UPDATES [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>8722</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>981639263</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+8722,;.01~VA-REMINDER UPDATES [C]
9999999.64;+8722,;.1~CATEGORY
9999999.64;+8722,;100~LOCAL
9999999.64;+8722,;200~Reminder Updates
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-UPDATE_2_0_570</POINT_01>
<INTERNAL_ENTRY_NUMBER>46034</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1588347827</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46034,;.01~VA-UPDATE_2_0_570
9999999.64;+46034,;.03~VA-REMINDER UPDATES [C]
9999999.64;+46034,;.08~YES
9999999.64;+46034,;.1~FACTOR
9999999.64;+46034,;100~NATIONAL
9999999.64;+46034,;200~Update_2_0_570
9999999.64;+46034,;201~WP-start~2
 
VA-UPDATE_2_0_567
9999999.65;+46035,+46034,;.01~MAR 24, 2026@12:07:09
9999999.65;+46035,+46034,;2~WP-start~1
Copied from VA-UPDATE_2_0_567
9999999.65;+46036,+46034,;.01~MAR 24, 2026@12:07:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46035^1
46036^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-NTO [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>27961</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>319548130</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+27961,;.01~VA-NTO [C]
9999999.64;+27961,;.08~YES
9999999.64;+27961,;.1~CATEGORY
9999999.64;+27961,;100~NATIONAL
9999999.64;+27961,;101~VHA ONCOLOGY
9999999.64;+27961,;200~National Teleoncology Hematology
9999999.64;+27961,;201~WP-start~1
Category for Teleoncology Hematology template
9999999.65;+27962,+27961,;.01~MAR 10, 2023@11:56:35
9999999.65;+27962,+27961,;2~WP-start~1
 Creation.
9999999.65;+27963,+27961,;.01~APR 05, 2023@09:06:19
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
27962^1
27963^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-NTO CN TOTAL TIME SPENT F2F/CVT/VVC/TELEPHONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>45981</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2864159607</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45981,;.01~VA-NTO CN TOTAL TIME SPENT F2F/CVT/VVC/TELEPHONE
9999999.64;+45981,;.03~VA-NTO [C]
9999999.64;+45981,;.08~YES
9999999.64;+45981,;.1~FACTOR
9999999.64;+45981,;100~NATIONAL
9999999.64;+45981,;101~VHA ONCOLOGY
9999999.64;+45981,;200~Total time spent:
9999999.64;+45981,;201~WP-start~2
National Teleoncology total time spent with Veteran (includes medical 
discussion, chart review, documentation, ordering, and care planning).
9999999.64;+45981,;220~1
9999999.64;+45981,;221~500
9999999.64;+45981,;222~0
9999999.64;+45981,;223~minute
9999999.64;+45981,;224~Minutes:
9999999.64;+45981,;225~NO DISPLAY
9999999.65;+45982,+45981,;.01~MAR 17, 2026@13:31:57
9999999.65;+45982,+45981,;2~WP-start~1
Copied from VA-NTO CN TIME SPENT CVT CHART REVIEW
9999999.65;+45983,+45981,;.01~MAR 17, 2026@13:34:23
9999999.65;+45984,+45981,;.01~MAR 17, 2026@13:35:42
9999999.65;+45985,+45981,;.01~MAR 17, 2026@13:36:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45982^1
45983^2
45984^3
45985^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT TELEPHONE TALK</POINT_01>
<INTERNAL_ENTRY_NUMBER>651187</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1503472943</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+651187,;.01~VA-NTO CN TIME SPENT TELEPHONE TALK
9999999.64;+651187,;.03~VA-NTO [C]
9999999.64;+651187,;.08~YES
9999999.64;+651187,;.1~FACTOR
9999999.64;+651187,;100~NATIONAL
9999999.64;+651187,;101~VHA ONCOLOGY
9999999.64;+651187,;200~Time Spent Talking on Telephone:
9999999.64;+651187,;201~WP-start~1
National Teleoncology Time spent telephone visit
9999999.64;+651187,;220~1
9999999.64;+651187,;221~500
9999999.64;+651187,;222~0
9999999.64;+651187,;223~minute
9999999.64;+651187,;224~Minutes:
9999999.64;+651187,;225~NO DISPLAY
9999999.65;+651188,+651187,;.01~APR 10, 2023@13:49:28
9999999.65;+651188,+651187,;2~WP-start~1
 Creation.
9999999.65;+651189,+651187,;.01~APR 10, 2023@13:52:03
9999999.65;+651190,+651187,;.01~APR 11, 2023@08:20:26
9999999.65;+651191,+651187,;.01~MAY 05, 2023@09:21:29
9999999.65;+651192,+651187,;.01~MAY 08, 2023@07:35
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
651188^1
651189^2
651190^3
651191^4
651192^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT VVC FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>28592</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3765431702</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+28592,;.01~VA-NTO CN TIME SPENT VVC FACE TO FACE
9999999.64;+28592,;.03~VA-NTO [C]
9999999.64;+28592,;.08~YES
9999999.64;+28592,;.1~FACTOR
9999999.64;+28592,;100~NATIONAL
9999999.64;+28592,;101~VHA ONCOLOGY
9999999.64;+28592,;200~Time Spent Face to Face via VVC:
9999999.64;+28592,;201~WP-start~1
National Teleoncology Time spent VVC face to face
9999999.64;+28592,;220~1
9999999.64;+28592,;221~500
9999999.64;+28592,;222~0
9999999.64;+28592,;223~minute
9999999.64;+28592,;224~Minutes:
9999999.64;+28592,;225~NO DISPLAY
9999999.65;+28593,+28592,;.01~MAY 05, 2023@09:30:46
9999999.65;+28593,+28592,;2~WP-start~1
 Creation.
9999999.65;+28594,+28592,;.01~MAY 08, 2023@07:31:41
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
28593^1
28594^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT CVT FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>28594</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>711800934</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+28594,;.01~VA-NTO CN TIME SPENT CVT FACE TO FACE
9999999.64;+28594,;.03~VA-NTO [C]
9999999.64;+28594,;.08~YES
9999999.64;+28594,;.1~FACTOR
9999999.64;+28594,;100~NATIONAL
9999999.64;+28594,;101~VHA ONCOLOGY
9999999.64;+28594,;200~Time Spent Face to Face via CVT:
9999999.64;+28594,;201~WP-start~1
National Teleoncology Time spent CVT face to face
9999999.64;+28594,;220~1
9999999.64;+28594,;221~500
9999999.64;+28594,;222~0
9999999.64;+28594,;223~minute
9999999.64;+28594,;224~Minutes:
9999999.64;+28594,;225~NO DISPLAY
9999999.65;+28595,+28594,;.01~MAY 05, 2023@09:33:27
9999999.65;+28595,+28594,;2~WP-start~1
 Creation.
9999999.65;+28596,+28594,;.01~MAY 08, 2023@07:17:46
9999999.65;+28597,+28594,;.01~MAY 08, 2023@07:24:04
9999999.65;+28598,+28594,;.01~JUN 13, 2023@12:47:30
9999999.65;+28599,+28594,;.01~JUL 11, 2023@13:23:06
9999999.65;+28600,+28594,;.01~JUL 11, 2023@13:26:19
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
28595^1
28596^2
28597^3
28598^4
28599^5
28600^6
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC CN [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>24920</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1877459699</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+24920,;.01~VA-ONC CN [C]
9999999.64;+24920,;.08~YES
9999999.64;+24920,;.1~CATEGORY
9999999.64;+24920,;100~NATIONAL
9999999.64;+24920,;101~VHA ONCOLOGY
9999999.64;+24920,;200~Oncology Clinic Note
9999999.64;+24920,;201~WP-start~1
Category for health factors used to branch the oncology clinic notes.
9999999.65;+24921,+24920,;.01~MAY 19, 2022@10:53:30
9999999.65;+24921,+24920,;2~WP-start~1
 Creation.
9999999.65;+24922,+24920,;.01~NOV 14, 2022@07:39:27
9999999.65;+24923,+24920,;.01~DEC 02, 2022@11:42:59
9999999.65;+24924,+24920,;.01~FEB 02, 2023@12:37:50
9999999.65;+24925,+24920,;.01~APR 12, 2023@13:18:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
24921^1
24922^2
24923^3
24924^4
24925^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>29448</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>82663493</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29448,;.01~VA-ONC CN TIME SPENT FACE TO FACE
9999999.64;+29448,;.03~VA-ONC CN [C]
9999999.64;+29448,;.08~YES
9999999.64;+29448,;.1~FACTOR
9999999.64;+29448,;100~NATIONAL
9999999.64;+29448,;101~VHA ONCOLOGY
9999999.64;+29448,;200~Time Spent Face to Face:
9999999.64;+29448,;201~WP-start~1
National Oncology time spent face to face.
9999999.64;+29448,;220~1
9999999.64;+29448,;221~500
9999999.64;+29448,;222~0
9999999.64;+29448,;223~minute
9999999.64;+29448,;224~Minutes:
9999999.64;+29448,;225~NO DISPLAY
9999999.65;+29449,+29448,;.01~JUL 12, 2023@14:06:29
9999999.65;+29449,+29448,;2~WP-start~1
Copied from VA-NTO CN TIME SPENT CVT FACE TO FACE
9999999.65;+29450,+29448,;.01~JUL 12, 2023@14:07:45
9999999.65;+29451,+29448,;.01~JUL 21, 2023@07:28:11
9999999.65;+29452,+29448,;.01~JUL 24, 2023@10:02:26
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29449^1
29450^2
29451^3
29452^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT VVC FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>29856</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>767036187</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29856,;.01~VA-ONC CN TIME SPENT VVC FACE TO FACE
9999999.64;+29856,;.03~VA-ONC CN [C]
9999999.64;+29856,;.08~YES
9999999.64;+29856,;.1~FACTOR
9999999.64;+29856,;100~NATIONAL
9999999.64;+29856,;101~VHA ONCOLOGY
9999999.64;+29856,;200~Time Spent Face to Face:
9999999.64;+29856,;201~WP-start~1
National Oncology time spent VVC face to face.
9999999.64;+29856,;220~1
9999999.64;+29856,;221~500
9999999.64;+29856,;222~0
9999999.64;+29856,;223~minute
9999999.64;+29856,;224~Minutes:
9999999.64;+29856,;225~NO DISPLAY
9999999.65;+29857,+29856,;.01~JUL 21, 2023@07:31:01
9999999.65;+29857,+29856,;2~WP-start~1
Copied from VA-ONC CN TIME SPENT FACE TO FACE
9999999.65;+29858,+29856,;.01~JUL 21, 2023@07:31:30
9999999.65;+29859,+29856,;.01~JUL 24, 2023@10:02:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29857^1
29858^2
29859^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT CVT FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>29858</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3176013702</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29858,;.01~VA-ONC CN TIME SPENT CVT FACE TO FACE
9999999.64;+29858,;.03~VA-ONC CN [C]
9999999.64;+29858,;.08~YES
9999999.64;+29858,;.1~FACTOR
9999999.64;+29858,;100~NATIONAL
9999999.64;+29858,;101~VHA ONCOLOGY
9999999.64;+29858,;200~Time Spent Face to Face:
9999999.64;+29858,;201~WP-start~1
National Oncology time spent CVT face to face.
9999999.64;+29858,;220~1
9999999.64;+29858,;221~500
9999999.64;+29858,;222~0
9999999.64;+29858,;223~minute
9999999.64;+29858,;224~Minutes:
9999999.64;+29858,;225~NO DISPLAY
9999999.65;+29859,+29858,;.01~JUL 21, 2023@07:36:09
9999999.65;+29859,+29858,;2~WP-start~1
Copied from VA-ONC CN TIME SPENT FACE TO FACE
9999999.65;+29860,+29858,;.01~JUL 21, 2023@07:36:44
9999999.65;+29861,+29858,;.01~JUL 24, 2023@10:04:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29859^1
29860^2
29861^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>38020</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2500080740</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38020,;.01~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38020,;.08~YES
9999999.64;+38020,;.1~CATEGORY
9999999.64;+38020,;100~NATIONAL
9999999.64;+38020,;101~VHA ONCOLOGY
9999999.64;+38020,;200~Bladder Muscle Invasive Stage II, III, IIIB Pathway
9999999.64;+38020,;201~WP-start~3
Muscle Invasive Stage II, IIIA, IIIB Bladder Cancer Pathway Category, All 
Health Factors for Stage II, IIIA, IIIB Muscle Invasive Bladder Cancer 
are Placed Under this Category.
9999999.65;+38021,+38020,;.01~OCT 08, 2024@11:29:43
9999999.65;+38021,+38020,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38021^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45976</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1913914318</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45976,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN
9999999.64;+45976,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45976,;.08~YES
9999999.64;+45976,;.1~FACTOR
9999999.64;+45976,;100~NATIONAL
9999999.64;+45976,;101~VHA ONCOLOGY
9999999.64;+45976,;200~MIBC Post Cystectomy ctDNA Negative Off Pathway Reason
9999999.64;+45976,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA negative. Off Pathway Reason.
9999999.65;+45977,+45976,;.01~MAR 12, 2026@09:58:06
9999999.65;+45977,+45976,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45977^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45975</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1930361921</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45975,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX
9999999.64;+45975,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45975,;.08~YES
9999999.64;+45975,;.1~FACTOR
9999999.64;+45975,;100~NATIONAL
9999999.64;+45975,;101~VHA ONCOLOGY
9999999.64;+45975,;200~MIBC Post Cystectomy ctDNA Negative Off Pathway Treatment
9999999.64;+45975,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA negative. Off Pathway Treatment.
9999999.65;+45976,+45975,;.01~MAR 12, 2026@09:57
9999999.65;+45976,+45975,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45976^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45974</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2573596366</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45974,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY
9999999.64;+45974,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45974,;.08~YES
9999999.64;+45974,;.1~FACTOR
9999999.64;+45974,;100~NATIONAL
9999999.64;+45974,;101~VHA ONCOLOGY
9999999.64;+45974,;200~MIBC Post Cystectomy ctDNA Negative Follow Pathway
9999999.64;+45974,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA negative. Follow Post Cystectomy Pathway.
9999999.65;+45975,+45974,;.01~MAR 12, 2026@09:55:57
9999999.65;+45975,+45974,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45975^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45973</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>60383223</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45973,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL
9999999.64;+45973,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45973,;.08~YES
9999999.64;+45973,;.1~FACTOR
9999999.64;+45973,;100~NATIONAL
9999999.64;+45973,;101~VHA ONCOLOGY
9999999.64;+45973,;200~MIBC Post Cystectomy ctDNA Negative Clinical Trial
9999999.64;+45973,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA negative. Clinical Trial.
9999999.65;+45974,+45973,;.01~MAR 12, 2026@09:54:24
9999999.65;+45974,+45973,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45974^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45972</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>263280008</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45972,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN
9999999.64;+45972,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45972,;.08~YES
9999999.64;+45972,;.1~FACTOR
9999999.64;+45972,;100~NATIONAL
9999999.64;+45972,;101~VHA ONCOLOGY
9999999.64;+45972,;200~MIBC Post Cystectomy ctDNA Positive Off Pathway Reason
9999999.64;+45972,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA positive. Off Pathway Reason.
9999999.65;+45973,+45972,;.01~MAR 12, 2026@09:53:07
9999999.65;+45973,+45972,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45973^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45971</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3251145245</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45971,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX
9999999.64;+45971,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45971,;.08~YES
9999999.64;+45971,;.1~FACTOR
9999999.64;+45971,;100~NATIONAL
9999999.64;+45971,;101~VHA ONCOLOGY
9999999.64;+45971,;200~MIBC Post Cystectomy ctDNA Positive Off Pathway Treatment
9999999.64;+45971,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA positive. Off Pathway Treatment.
9999999.65;+45972,+45971,;.01~MAR 12, 2026@09:52:07
9999999.65;+45972,+45971,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45972^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>45970</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3671339677</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45970,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB
9999999.64;+45970,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45970,;.08~YES
9999999.64;+45970,;.1~FACTOR
9999999.64;+45970,;100~NATIONAL
9999999.64;+45970,;101~VHA ONCOLOGY
9999999.64;+45970,;200~MIBC Post Cystectomy ctDNA Positive Atezolizumab
9999999.64;+45970,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA positive. Adjuvant atezolizumab.   ++ ctDNA-positive test result at 
any time during surveillance and remained disease-free as assessed 
radiographically. ++
9999999.65;+45971,+45970,;.01~MAR 12, 2026@09:50:51
9999999.65;+45971,+45970,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45971^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45969</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1071566773</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45969,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL
9999999.64;+45969,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45969,;.08~YES
9999999.64;+45969,;.1~FACTOR
9999999.64;+45969,;100~NATIONAL
9999999.64;+45969,;101~VHA ONCOLOGY
9999999.64;+45969,;200~MIBC Post Cystectomy ctDNA Positive Clinical Trial
9999999.64;+45969,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
ctDNA positive. Clinical Trial.
9999999.65;+45970,+45969,;.01~MAR 12, 2026@09:49:42
9999999.65;+45970,+45969,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45970^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45968</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3514466099</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45968,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN
9999999.64;+45968,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45968,;.08~YES
9999999.64;+45968,;.1~FACTOR
9999999.64;+45968,;100~NATIONAL
9999999.64;+45968,;101~VHA ONCOLOGY
9999999.64;+45968,;200~MIBC Post Cystectomy Not Stage Off Pathway Reason
9999999.64;+45968,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Not stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Off Pathway Reason.
9999999.65;+45969,+45968,;.01~MAR 12, 2026@09:48:29
9999999.65;+45969,+45968,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45969^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45967</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3886290557</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45967,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX
9999999.64;+45967,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45967,;.08~YES
9999999.64;+45967,;.1~FACTOR
9999999.64;+45967,;100~NATIONAL
9999999.64;+45967,;101~VHA ONCOLOGY
9999999.64;+45967,;200~MIBC Post Cystectomy Not Stage Off Pathway Treatment
9999999.64;+45967,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Not stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Off Pathway Treatment.
9999999.65;+45968,+45967,;.01~MAR 12, 2026@09:47:31
9999999.65;+45968,+45967,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45968^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45966</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1047691814</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45966,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY
9999999.64;+45966,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45966,;.08~YES
9999999.64;+45966,;.1~FACTOR
9999999.64;+45966,;100~NATIONAL
9999999.64;+45966,;101~VHA ONCOLOGY
9999999.64;+45966,;200~MIBC Post Cystectomy Not Stage Follow Pathway
9999999.64;+45966,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Not stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Follow Post Cystectomy Pathway.
9999999.65;+45967,+45966,;.01~MAR 12, 2026@09:46:27
9999999.65;+45967,+45966,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45967^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45965</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3103853488</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45965,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL
9999999.64;+45965,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45965,;.08~YES
9999999.64;+45965,;.1~FACTOR
9999999.64;+45965,;100~NATIONAL
9999999.64;+45965,;101~VHA ONCOLOGY
9999999.64;+45965,;200~MIBC Post Cystectomy Not Stage Clinical Trial
9999999.64;+45965,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Not stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Clinical Trial.
9999999.65;+45966,+45965,;.01~MAR 12, 2026@09:45:18
9999999.65;+45966,+45965,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45966^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45964</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>704624759</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45964,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN
9999999.64;+45964,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45964,;.08~YES
9999999.64;+45964,;.1~FACTOR
9999999.64;+45964,;100~NATIONAL
9999999.64;+45964,;101~VHA ONCOLOGY
9999999.64;+45964,;200~MIBC Post Cystectomy Stage Off Pathway Reason
9999999.64;+45964,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Off Pathway Reason.
9999999.65;+45965,+45964,;.01~MAR 12, 2026@09:44:14
9999999.65;+45965,+45964,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45965^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45963</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1973022922</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45963,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX
9999999.64;+45963,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45963,;.08~YES
9999999.64;+45963,;.1~FACTOR
9999999.64;+45963,;100~NATIONAL
9999999.64;+45963,;101~VHA ONCOLOGY
9999999.64;+45963,;200~MIBC Post Cystectomy Stage Off Pathway Treatment
9999999.64;+45963,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Off Pathway Treatment.
9999999.65;+45964,+45963,;.01~MAR 12, 2026@09:43:13
9999999.65;+45964,+45963,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45964^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING</POINT_01>
<INTERNAL_ENTRY_NUMBER>45962</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2545565717</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45962,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING
9999999.64;+45962,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45962,;.08~YES
9999999.64;+45962,;.1~FACTOR
9999999.64;+45962,;100~NATIONAL
9999999.64;+45962,;101~VHA ONCOLOGY
9999999.64;+45962,;200~MIBC Post Cystectomy Stage ctDNA Testing
9999999.64;+45962,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. ctDNA testing every 6 weeks for 9 
months, with a final test at 1 year after cystectomy.
9999999.65;+45963,+45962,;.01~MAR 12, 2026@09:42:10
9999999.65;+45963,+45962,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45963^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45961</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>834697218</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45961,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL
9999999.64;+45961,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45961,;.08~YES
9999999.64;+45961,;.1~FACTOR
9999999.64;+45961,;100~NATIONAL
9999999.64;+45961,;101~VHA ONCOLOGY
9999999.64;+45961,;200~MIBC Post Cystectomy Stage Clinical Trial
9999999.64;+45961,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Post cystectomy. 
Stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0. Clinical Trial.
9999999.65;+45962,+45961,;.01~MAR 12, 2026@09:40:28
9999999.65;+45962,+45961,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45962^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38058</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3753560059</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38058,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN
9999999.64;+38058,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38058,;.08~YES
9999999.64;+38058,;.1~FACTOR
9999999.64;+38058,;100~NATIONAL
9999999.64;+38058,;101~VHA ONCOLOGY
9999999.64;+38058,;200~MIBC No Cystectomy No Chemotherapy Off Pathway Rsn
9999999.64;+38058,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Not systemic chemotherapy 
candidate. Off Pathway Reason Text.
9999999.65;+38059,+38058,;.01~OCT 08, 2024@12:14:36
9999999.65;+38059,+38058,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38059^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38057</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1003931758</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38057,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX
9999999.64;+38057,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38057,;.08~YES
9999999.64;+38057,;.1~FACTOR
9999999.64;+38057,;100~NATIONAL
9999999.64;+38057,;101~VHA ONCOLOGY
9999999.64;+38057,;200~MIBC No Cystectomy No Chemotherapy Off Pathway Treatment
9999999.64;+38057,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Not systemic chemotherapy 
candidate. Off Pathway Treatment Reason.
9999999.65;+38058,+38057,;.01~OCT 08, 2024@12:13:40
9999999.65;+38058,+38057,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38058^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY</POINT_01>
<INTERNAL_ENTRY_NUMBER>38056</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1728512836</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38056,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY
9999999.64;+38056,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38056,;.08~YES
9999999.64;+38056,;.1~FACTOR
9999999.64;+38056,;100~NATIONAL
9999999.64;+38056,;101~VHA ONCOLOGY
9999999.64;+38056,;200~MIBC No Cystectomy No Chemotherapy Radiotherapy
9999999.64;+38056,;201~WP-start~5
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Not systemic chemotherapy 
candidate. Radiotherapy. ++Reassess tumor status at 3 month intervals and 
refer to Muscle Invasive Post Bladder Preservation Follow-Up chart++
9999999.65;+38057,+38056,;.01~OCT 08, 2024@12:12:43
9999999.65;+38057,+38056,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38057^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38055</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3355363186</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38055,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL
9999999.64;+38055,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38055,;.08~YES
9999999.64;+38055,;.1~FACTOR
9999999.64;+38055,;100~NATIONAL
9999999.64;+38055,;101~VHA ONCOLOGY
9999999.64;+38055,;200~MIBC No Cystectomy No Chemotherapy Clinical Trial
9999999.64;+38055,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Not systemic chemotherapy 
candidate. Clinical Trial.
9999999.65;+38056,+38055,;.01~OCT 08, 2024@12:11:30
9999999.65;+38056,+38055,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38056^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38053</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>500640739</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38053,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN
9999999.64;+38053,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38053,;.08~YES
9999999.64;+38053,;.1~FACTOR
9999999.64;+38053,;100~NATIONAL
9999999.64;+38053,;101~VHA ONCOLOGY
9999999.64;+38053,;200~MIBC No Cystectomy Chemo Candidate Off Pathway Reason
9999999.64;+38053,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Systemic chemotherapy 
candidate. Off Pathway Reason Text.
9999999.65;+38054,+38053,;.01~OCT 08, 2024@12:09:32
9999999.65;+38054,+38053,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38054^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38052</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2960772871</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38052,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX
9999999.64;+38052,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38052,;.08~YES
9999999.64;+38052,;.1~FACTOR
9999999.64;+38052,;100~NATIONAL
9999999.64;+38052,;101~VHA ONCOLOGY
9999999.64;+38052,;200~MIBC No Cystectomy Chemo Candidate Off Pathway Treatment
9999999.64;+38052,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Systemic chemotherapy 
candidate. Off Pathway Treatment Reason.
9999999.65;+38053,+38052,;.01~OCT 08, 2024@12:08:29
9999999.65;+38053,+38052,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38053^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU MITOMYCIN RAD</POINT_01>
<INTERNAL_ENTRY_NUMBER>38051</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1000347582</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38051,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU MITOMYCIN RAD
9999999.64;+38051,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38051,;.08~YES
9999999.64;+38051,;.1~FACTOR
9999999.64;+38051,;100~NATIONAL
9999999.64;+38051,;101~VHA ONCOLOGY
9999999.64;+38051,;200~MIBC No Cystectomy Chemo Candidate 5FU Mitomycin Radiation
9999999.64;+38051,;201~WP-start~5
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Systemic chemotherapy 
candidate. Bladder preservation with concurrent 5FU, mitomycin, and 
radiotherapy. ++Follow Post Bladder Preservation Pathway++
9999999.65;+38052,+38051,;.01~OCT 08, 2024@12:07:31
9999999.65;+38052,+38051,;2~WP-start~1
 Creation.
9999999.65;+38053,+38051,;.01~NOV 26, 2024@07:48:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38052^1
38053^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38050</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2594042055</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38050,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL
9999999.64;+38050,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38050,;.08~YES
9999999.64;+38050,;.1~FACTOR
9999999.64;+38050,;100~NATIONAL
9999999.64;+38050,;101~VHA ONCOLOGY
9999999.64;+38050,;200~MIBC No Cystectomy Chemo Candidate Clinical Trial
9999999.64;+38050,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a candidate for 
cystectomy. ++Avoid bladder preservation in patients with hydronephrosis 
and extensive or multifocal carcinoma in situ++ Systemic chemotherapy 
candidate. Clinical Trial.
9999999.65;+38051,+38050,;.01~OCT 08, 2024@12:06:12
9999999.65;+38051,+38050,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38051^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38027</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3126347946</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38027,;.01~VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH RSN
9999999.64;+38027,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38027,;.08~YES
9999999.64;+38027,;.1~FACTOR
9999999.64;+38027,;100~NATIONAL
9999999.64;+38027,;101~VHA ONCOLOGY
9999999.64;+38027,;200~MIBC Chemo Bladder Preserve Candidate Off Pathway Reason
9999999.64;+38027,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Systemic 
Chemotherapy Candidate. Off Pathway Reason Text.
9999999.65;+38028,+38027,;.01~OCT 08, 2024@11:37:32
9999999.65;+38028,+38027,;2~WP-start~1
 Creation.
9999999.65;+38029,+38027,;.01~NOV 22, 2024@12:00:25
9999999.65;+38030,+38027,;.01~NOV 22, 2024@13:02:14
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38028^1
38029^2
38030^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38026</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2585426714</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38026,;.01~VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH TX
9999999.64;+38026,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38026,;.08~YES
9999999.64;+38026,;.1~FACTOR
9999999.64;+38026,;100~NATIONAL
9999999.64;+38026,;101~VHA ONCOLOGY
9999999.64;+38026,;200~MIBC Chemo Bladder Preserve Candidate Off Pathway Treatment
9999999.64;+38026,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Systemic 
Chemotherapy Candidate. Off Pathway Treatment Reason.
9999999.65;+38027,+38026,;.01~OCT 08, 2024@11:36:45
9999999.65;+38027,+38026,;2~WP-start~1
 Creation.
9999999.65;+38028,+38026,;.01~NOV 22, 2024@11:58:24
9999999.65;+38029,+38026,;.01~NOV 22, 2024@13:03:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38027^1
38028^2
38029^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE 5FU MITOMYCIN RAD</POINT_01>
<INTERNAL_ENTRY_NUMBER>38025</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2535723655</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38025,;.01~VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE 5FU MITOMYCIN RAD
9999999.64;+38025,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38025,;.08~YES
9999999.64;+38025,;.1~FACTOR
9999999.64;+38025,;100~NATIONAL
9999999.64;+38025,;101~VHA ONCOLOGY
9999999.64;+38025,;200~MIBC Chemo Bladder Preserve Candidate 5FU Mitomycin Radiation
9999999.64;+38025,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. 
Systemic Chemotherapy Candidate. Bladder Preservation Candidate
5FU/Mitomycin/Radiation.
9999999.65;+38026,+38025,;.01~OCT 08, 2024@11:35:49
9999999.65;+38026,+38025,;2~WP-start~1
 Creation.
9999999.65;+38027,+38025,;.01~NOV 22, 2024@11:56:43
9999999.65;+38028,+38025,;.01~NOV 26, 2024@07:23:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38026^1
38027^2
38028^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38024</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1163084929</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38024,;.01~VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE CLINICAL TRIAL
9999999.64;+38024,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+38024,;.08~YES
9999999.64;+38024,;.1~FACTOR
9999999.64;+38024,;100~NATIONAL
9999999.64;+38024,;101~VHA ONCOLOGY
9999999.64;+38024,;200~MIBC Chemo Bladder Preserve Candidate Clinical Trial
9999999.64;+38024,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Systemic 
Chemotherapy Candidate. Clinical Trial.
9999999.65;+38025,+38024,;.01~OCT 08, 2024@11:34:42
9999999.65;+38025,+38024,;2~WP-start~1
 Creation.
9999999.65;+38026,+38024,;.01~NOV 22, 2024@11:59:26
9999999.65;+38027,+38024,;.01~NOV 26, 2024@07:25:32
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38025^1
38026^2
38027^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45960</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3090045666</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45960,;.01~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN
9999999.64;+45960,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45960,;.08~YES
9999999.64;+45960,;.1~FACTOR
9999999.64;+45960,;100~NATIONAL
9999999.64;+45960,;101~VHA ONCOLOGY
9999999.64;+45960,;200~MIBC No Bladder Preserve No Cis No Neoadjuvant Off Pathway Rsn
9999999.64;+45960,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB.Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Not a 
neoadjuvant therapy candidate. Off Pathway Reason.
9999999.65;+45961,+45960,;.01~MAR 12, 2026@09:38:53
9999999.65;+45961,+45960,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45961^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45959</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>7047165</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45959,;.01~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX
9999999.64;+45959,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45959,;.08~YES
9999999.64;+45959,;.1~FACTOR
9999999.64;+45959,;100~NATIONAL
9999999.64;+45959,;101~VHA ONCOLOGY
9999999.64;+45959,;200~MIBC No Bladder Preserve No Cis No Neoadjuvant Off Pathway Tx
9999999.64;+45959,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Not a 
neoadjuvant therapy candidate. Off Pathway Treatment.
9999999.65;+45960,+45959,;.01~MAR 12, 2026@09:37:15
9999999.65;+45960,+45959,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45960^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45958</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1133058942</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45958,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY
9999999.64;+45958,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45958,;.08~YES
9999999.64;+45958,;.1~FACTOR
9999999.64;+45958,;100~NATIONAL
9999999.64;+45958,;101~VHA ONCOLOGY
9999999.64;+45958,;200~MIBC No Bladder Preserve No Cis No Neoadjuvant Cystectomy
9999999.64;+45958,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Not a 
neoadjuvant therapy candidate. Cystectomy with pelvic lymph node 
dissection.
9999999.65;+45959,+45958,;.01~MAR 12, 2026@09:33:54
9999999.65;+45959,+45958,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45959^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45957</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2382947215</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45957,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL
9999999.64;+45957,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45957,;.08~YES
9999999.64;+45957,;.1~FACTOR
9999999.64;+45957,;100~NATIONAL
9999999.64;+45957,;101~VHA ONCOLOGY
9999999.64;+45957,;200~MIBC No Bladder Preserve No Cis No Neoadjuvant Clinical Trial
9999999.64;+45957,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Not a 
neoadjuvant therapy candidate. Clinical Trial.
9999999.65;+45958,+45957,;.01~MAR 12, 2026@09:32:28
9999999.65;+45958,+45957,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45958^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45956</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>257607386</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45956,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN
9999999.64;+45956,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45956,;.08~YES
9999999.64;+45956,;.1~FACTOR
9999999.64;+45956,;100~NATIONAL
9999999.64;+45956,;101~VHA ONCOLOGY
9999999.64;+45956,;200~MIBC No Bladder Preserve No Cis Neoadjuvant Off Pathway Reason
9999999.64;+45956,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB.Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Neoadjuvant 
therapy. Off Pathway Reason.
9999999.65;+45957,+45956,;.01~MAR 12, 2026@09:31:15
9999999.65;+45957,+45956,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45957^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45955</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1615010769</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45955,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX
9999999.64;+45955,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45955,;.08~YES
9999999.64;+45955,;.1~FACTOR
9999999.64;+45955,;100~NATIONAL
9999999.64;+45955,;101~VHA ONCOLOGY
9999999.64;+45955,;200~MIBC No Bladder Preserve No Cis Neoadjuvant Off Path Treatment
9999999.64;+45955,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Neoadjuvant 
therapy. Off Pathway Treatment.
9999999.65;+45956,+45955,;.01~MAR 12, 2026@09:30:08
9999999.65;+45956,+45955,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45956^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45954</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2957527078</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45954,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY
9999999.64;+45954,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45954,;.08~YES
9999999.64;+45954,;.1~FACTOR
9999999.64;+45954,;100~NATIONAL
9999999.64;+45954,;101~VHA ONCOLOGY
9999999.64;+45954,;200~MIBC No Bladder Preserve No Cis Neoadjuvant Cystectomy
9999999.64;+45954,;201~WP-start~5
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Neoadjuvant EV pembrolizumab (3 cycles) and 
radical cystectomy with pelvic lymph node dissection followed by adjuvant 
EV pembrolizumab (up to 6 cycles) followed by pembrolizumab (up to 8 
cycles). Follow Post Cystectomy Pathway.
9999999.65;+45955,+45954,;.01~MAR 12, 2026@09:28:06
9999999.65;+45955,+45954,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45955^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45953</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3959990408</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45953,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL
9999999.64;+45953,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45953,;.08~YES
9999999.64;+45953,;.1~FACTOR
9999999.64;+45953,;100~NATIONAL
9999999.64;+45953,;101~VHA ONCOLOGY
9999999.64;+45953,;200~MIBC No Bladder Preserve No Cis Neoadjuvant Clinical Trial
9999999.64;+45953,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Not a cisplatin therapy candidate. Neoadjuvant 
therapy. Clinical Trial.
9999999.65;+45954,+45953,;.01~MAR 12, 2026@09:26:43
9999999.65;+45954,+45953,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45954^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45952</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1063364525</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45952,;.01~VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH RSN
9999999.64;+45952,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45952,;.08~YES
9999999.64;+45952,;.1~FACTOR
9999999.64;+45952,;100~NATIONAL
9999999.64;+45952,;101~VHA ONCOLOGY
9999999.64;+45952,;200~MIBC No Bladder Preserve Cisplatin Off Pathway Reason
9999999.64;+45952,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB.Not a bladder 
preservation candidate. Cisplatin therapy candidate. Off Pathway Reason.
9999999.65;+45953,+45952,;.01~MAR 12, 2026@09:25:25
9999999.65;+45953,+45952,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45953^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45951</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4253398991</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45951,;.01~VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH TX
9999999.64;+45951,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45951,;.08~YES
9999999.64;+45951,;.1~FACTOR
9999999.64;+45951,;100~NATIONAL
9999999.64;+45951,;101~VHA ONCOLOGY
9999999.64;+45951,;200~MIBC No Bladder Preserve Cisplatin Off Pathway Treatment
9999999.64;+45951,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Cisplatin therapy candidate. Off Pathway 
Treatment.
9999999.65;+45952,+45951,;.01~MAR 12, 2026@09:24:09
9999999.65;+45952,+45951,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45952^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45950</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2667145456</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45950,;.01~VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY
9999999.64;+45950,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45950,;.08~YES
9999999.64;+45950,;.1~FACTOR
9999999.64;+45950,;100~NATIONAL
9999999.64;+45950,;101~VHA ONCOLOGY
9999999.64;+45950,;200~MIBC No Bladder Preserve Gem Cis Durvalumab Cystectomy
9999999.64;+45950,;201~WP-start~5
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Neoadjuvant (4 cycles) gemcitabine, cisplatin, 
durvalumab, and radical cystectomy with pelvic lymph node dissection 
followed by adjuvant durvalumab. Shared decision making. Follow Post 
Cystectomy Pathway.
9999999.65;+45951,+45950,;.01~MAR 12, 2026@09:22:45
9999999.65;+45951,+45950,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45949</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>563332529</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45949,;.01~VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN CLIN TRIAL
9999999.64;+45949,;.03~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
9999999.64;+45949,;.08~YES
9999999.64;+45949,;.1~FACTOR
9999999.64;+45949,;100~NATIONAL
9999999.64;+45949,;101~VHA ONCOLOGY
9999999.64;+45949,;200~MIBC No Bladder Preserve Cisplatin Clinical Trial
9999999.64;+45949,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage II, IIIA, IIIB. Not a bladder 
preservation candidate. Cisplatin therapy candidate. Clinical Trial.
9999999.65;+45950,+45949,;.01~MAR 12, 2026@09:19:42
9999999.65;+45950,+45949,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45950^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>23018</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1432377665</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23018,;.01~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+23018,;.08~YES
9999999.64;+23018,;.1~CATEGORY
9999999.64;+23018,;100~NATIONAL
9999999.64;+23018,;101~VHA ONCOLOGY
9999999.64;+23018,;200~Oncology Pathways
9999999.64;+23018,;201~WP-start~2
For all pathways; the health factor that designates that the template was 
opened.
9999999.65;+23019,+23018,;.01~AUG 24, 2021@09:05:11
9999999.65;+23019,+23018,;2~WP-start~1
 Creation.
9999999.65;+23020,+23018,;.01~SEP 03, 2024@07:46:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23019^1
23020^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB</POINT_01>
<INTERNAL_ENTRY_NUMBER>38017</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>331614654</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38017,;.01~VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB
9999999.64;+38017,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+38017,;.08~YES
9999999.64;+38017,;.1~FACTOR
9999999.64;+38017,;100~NATIONAL
9999999.64;+38017,;101~VHA ONCOLOGY
9999999.64;+38017,;200~Bladder Muscle Invasive Stage II, IIIA, IIIB Pathway
9999999.64;+38017,;201~WP-start~1
Muscle Invasive Stage II, IIIA, IIIB Bladder Cancer Pathway.
9999999.65;+38018,+38017,;.01~OCT 08, 2024@11:26:10
9999999.65;+38018,+38017,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38018^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>38299</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2584049907</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38299,;.01~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38299,;.08~YES
9999999.64;+38299,;.1~CATEGORY
9999999.64;+38299,;100~NATIONAL
9999999.64;+38299,;101~VHA ONCOLOGY
9999999.64;+38299,;200~MIBC Comprehensive Genetic Profiling (CGP) PD-L1 Pathway
9999999.64;+38299,;201~WP-start~4
Category for Muscle Invasive Bladder Cancer Comprehensive Genetic
Profiling Pathway with PD-L1 testing for Stages IVA and IVB. All Health 
Factors Related to Comprehensive Genetic Profiling with PD-L1 Testing for 
MIBC Stages IVA and IVB are Placed Under this Category.
9999999.65;+38300,+38299,;.01~OCT 16, 2024@10:31:14
9999999.65;+38300,+38299,;2~WP-start~1
 Creation.
9999999.65;+38301,+38299,;.01~OCT 16, 2024@12:26:51
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38300^1
38301^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING WITH PD-L1 TESTING</POINT_01>
<INTERNAL_ENTRY_NUMBER>38306</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2502097951</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38306,;.01~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING WITH PD-L1 TESTING
9999999.64;+38306,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38306,;.08~YES
9999999.64;+38306,;.1~FACTOR
9999999.64;+38306,;100~NATIONAL
9999999.64;+38306,;101~VHA ONCOLOGY
9999999.64;+38306,;200~MIBC Comprehensive Genetic Profiling (CGP) With PD-L1 Testing
9999999.64;+38306,;201~WP-start~2
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling Pathway 
with PD-L1 testing for Stages IVA and IVB.
9999999.65;+38307,+38306,;.01~OCT 16, 2024@12:21:50
9999999.65;+38307,+38306,;2~WP-start~1
 Creation.
9999999.65;+38308,+38306,;.01~NOV 27, 2024@08:41:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38307^1
38308^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38304</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1880340077</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38304,;.01~VA-ONC MIBC CGP PD-L1 OFF PATHWAY RSN
9999999.64;+38304,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38304,;.08~YES
9999999.64;+38304,;.1~FACTOR
9999999.64;+38304,;100~NATIONAL
9999999.64;+38304,;101~VHA ONCOLOGY
9999999.64;+38304,;200~MIBC CGP PD-L1 Off Pathway Reason
9999999.64;+38304,;201~WP-start~3
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling (CGP) 
Pathway with PD-L1 testing for Stages IVA and IVB. CGP and PD-L1 Not
Ordered. Off Pathway Reason.
9999999.65;+38305,+38304,;.01~OCT 16, 2024@10:38:03
9999999.65;+38305,+38304,;2~WP-start~1
 Creation.
9999999.65;+38306,+38304,;.01~OCT 16, 2024@12:30:48
9999999.65;+38307,+38304,;.01~OCT 17, 2024@09:19:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38305^1
38306^2
38307^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>ZZVA-ONC MIBC CGP PD-L1 PT DECLINED</POINT_01>
<INTERNAL_ENTRY_NUMBER>38303</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2429084068</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38303,;.01~ZZVA-ONC MIBC CGP PD-L1 PT DECLINED
9999999.64;+38303,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38303,;.08~YES
9999999.64;+38303,;.1~FACTOR
9999999.64;+38303,;100~LOCAL
9999999.64;+38303,;200~zzMIBC CGP PD-L1 Patient Declined
9999999.64;+38303,;201~WP-start~3
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling (CGP) 
Pathway with PD-L1 testing for Stages IVA and IVB. Veteran Declined. 
Neither On or Off Pathway.
9999999.65;+38304,+38303,;.01~OCT 16, 2024@10:36:57
9999999.65;+38304,+38303,;2~WP-start~1
 Creation.
9999999.65;+38305,+38303,;.01~OCT 16, 2024@12:16:39
9999999.65;+38306,+38303,;.01~OCT 16, 2024@12:31:15
9999999.65;+38307,+38303,;.01~OCT 17, 2024@09:21:55
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38304^1
38305^2
38306^3
38307^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 ORDER IN FUTURE</POINT_01>
<INTERNAL_ENTRY_NUMBER>38302</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4193599717</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38302,;.01~VA-ONC MIBC CGP PD-L1 ORDER IN FUTURE
9999999.64;+38302,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38302,;.08~YES
9999999.64;+38302,;.1~FACTOR
9999999.64;+38302,;100~NATIONAL
9999999.64;+38302,;101~VHA ONCOLOGY
9999999.64;+38302,;200~MIBC CGP PD-L1 Order In Future
9999999.64;+38302,;201~WP-start~3
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling (CGP) 
Pathway with PD-L1 testing for Stages IVA and IVB. CGP and PD-L1 to be
Ordered in the Future. Neither On or Off Pathway.
9999999.65;+38303,+38302,;.01~OCT 16, 2024@10:35:35
9999999.65;+38303,+38302,;2~WP-start~1
 Creation.
9999999.65;+38304,+38302,;.01~OCT 16, 2024@12:15:39
9999999.65;+38305,+38302,;.01~OCT 16, 2024@12:29:09
9999999.65;+38306,+38302,;.01~OCT 17, 2024@09:25:21
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38303^1
38304^2
38305^3
38306^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 PREVIOUSLY ORDERED</POINT_01>
<INTERNAL_ENTRY_NUMBER>38301</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>639504366</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38301,;.01~VA-ONC MIBC CGP PD-L1 PREVIOUSLY ORDERED
9999999.64;+38301,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38301,;.08~YES
9999999.64;+38301,;.1~FACTOR
9999999.64;+38301,;100~NATIONAL
9999999.64;+38301,;101~VHA ONCOLOGY
9999999.64;+38301,;200~MIBC CGP PD-L1 Previously Order
9999999.64;+38301,;201~WP-start~3
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling (CGP) 
Pathway with PD-L1 testing for Stages IVA and IVB. CGP and
PD-L1 Previously Ordered. On Pathway.
9999999.65;+38302,+38301,;.01~OCT 16, 2024@10:34:11
9999999.65;+38302,+38301,;2~WP-start~1
 Creation.
9999999.65;+38303,+38301,;.01~OCT 16, 2024@12:30:15
9999999.65;+38304,+38301,;.01~OCT 17, 2024@09:23:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38302^1
38303^2
38304^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 ORDER</POINT_01>
<INTERNAL_ENTRY_NUMBER>38300</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1514346571</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38300,;.01~VA-ONC MIBC CGP PD-L1 ORDER
9999999.64;+38300,;.03~VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
9999999.64;+38300,;.08~YES
9999999.64;+38300,;.1~FACTOR
9999999.64;+38300,;100~NATIONAL
9999999.64;+38300,;101~VHA ONCOLOGY
9999999.64;+38300,;200~MIBC CGP PD-L1 Order
9999999.64;+38300,;201~WP-start~3
Muscle Invasive Bladder Cancer Comprehensive Genetic Profiling (CGP) 
Pathway with PD-L1 testing for Stages IVA and IVB. CGP and PD-L1 Ordered.
On Pathway.
9999999.65;+38301,+38300,;.01~OCT 16, 2024@10:33:14
9999999.65;+38301,+38300,;2~WP-start~1
 Creation.
9999999.65;+38302,+38300,;.01~OCT 16, 2024@12:29:43
9999999.65;+38303,+38300,;.01~OCT 17, 2024@09:27:12
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38301^1
38302^2
38303^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>37051</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1679698212</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37051,;.01~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37051,;.08~YES
9999999.64;+37051,;.1~CATEGORY
9999999.64;+37051,;100~NATIONAL
9999999.64;+37051,;101~VHA ONCOLOGY
9999999.64;+37051,;200~Non-Muscle Invasive Bladder Cancer Low Risk Pathway
9999999.64;+37051,;201~WP-start~1
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway Category.
9999999.65;+37052,+37051,;.01~AUG 19, 2024@12:05:10
9999999.65;+37052,+37051,;2~WP-start~1
 Creation.
9999999.65;+37053,+37051,;.01~OCT 16, 2024@10:44:07
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37052^1
37053^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC LOW RISK OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37066</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2085024764</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37066,;.01~VA-ONC NMIBC LOW RISK OFF PATH RSN
9999999.64;+37066,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37066,;.08~YES
9999999.64;+37066,;.1~FACTOR
9999999.64;+37066,;100~NATIONAL
9999999.64;+37066,;101~VHA ONCOLOGY
9999999.64;+37066,;200~NMIBC Low Risk Off Path Reason
9999999.64;+37066,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Off Pathway 
Reason.
9999999.65;+37067,+37066,;.01~AUG 19, 2024@12:21:35
9999999.65;+37067,+37066,;2~WP-start~1
 Creation.
9999999.65;+37068,+37066,;.01~AUG 23, 2024@06:33:54
9999999.65;+37069,+37066,;.01~DEC 02, 2024@09:01:20
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37067^1
37068^2
37069^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC LOW RISK OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37063</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2511953673</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37063,;.01~VA-ONC NMIBC LOW RISK OFF PATH TX
9999999.64;+37063,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37063,;.08~YES
9999999.64;+37063,;.1~FACTOR
9999999.64;+37063,;100~NATIONAL
9999999.64;+37063,;101~VHA ONCOLOGY
9999999.64;+37063,;200~NMIBC Low Risk Off Path Treatment
9999999.64;+37063,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Off Pathway 
Treatment.
9999999.65;+37064,+37063,;.01~AUG 19, 2024@12:20:08
9999999.65;+37064,+37063,;2~WP-start~1
 Creation.
9999999.65;+37065,+37063,;.01~AUG 23, 2024@06:34:28
9999999.65;+37066,+37063,;.01~DEC 02, 2024@09:01:53
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37064^1
37065^2
37066^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>ZZVA-ONC BLADDER NMIBC LOW RISK OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>37061</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3834460505</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37061,;.01~ZZVA-ONC BLADDER NMIBC LOW RISK OFF PATH
9999999.64;+37061,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37061,;.08~YES
9999999.64;+37061,;.1~FACTOR
9999999.64;+37061,;100~LOCAL
9999999.64;+37061,;200~Oncology Bladder NMIBC Low Risk Off Path
9999999.64;+37061,;201~WP-start~1
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Off Pathway.
9999999.65;+37062,+37061,;.01~AUG 19, 2024@12:18:10
9999999.65;+37062,+37061,;2~WP-start~1
 Creation.
9999999.65;+37063,+37061,;.01~AUG 23, 2024@06:27:41
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37062^1
37063^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC LOW RISK ANNUAL CYSTO 5 YRS S/P TURBT</POINT_01>
<INTERNAL_ENTRY_NUMBER>37058</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3292077017</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37058,;.01~VA-ONC NMIBC LOW RISK ANNUAL CYSTO 5 YRS S/P TURBT
9999999.64;+37058,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37058,;.08~YES
9999999.64;+37058,;.1~FACTOR
9999999.64;+37058,;100~NATIONAL
9999999.64;+37058,;101~VHA ONCOLOGY
9999999.64;+37058,;200~NMIBC Low Risk Annual Cysto 5 Yrs s/p TURBT
9999999.64;+37058,;201~WP-start~3
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Annual 
Cystoscopy Until 5 Years Status Post Transurethral Resection of Bladder 
Tumor.
9999999.65;+37059,+37058,;.01~AUG 19, 2024@12:14:09
9999999.65;+37059,+37058,;2~WP-start~1
 Creation.
9999999.65;+37060,+37058,;.01~AUG 23, 2024@06:31:22
9999999.65;+37061,+37058,;.01~DEC 02, 2024@09:00:49
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37059^1
37060^2
37061^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC LOW RISK CYSTO 9-12M S/P TURBT</POINT_01>
<INTERNAL_ENTRY_NUMBER>37056</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2569227757</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37056,;.01~VA-ONC NMIBC LOW RISK CYSTO 9-12M S/P TURBT
9999999.64;+37056,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37056,;.08~YES
9999999.64;+37056,;.1~FACTOR
9999999.64;+37056,;100~NATIONAL
9999999.64;+37056,;101~VHA ONCOLOGY
9999999.64;+37056,;200~NMIBC Low Risk Cysto 9-12M s/p TURBT
9999999.64;+37056,;201~WP-start~3
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Annual 
Cystoscopy 9-12 Months Status Post Transurethral Resection of Bladder 
Tumor.
9999999.65;+37057,+37056,;.01~AUG 19, 2024@12:12:20
9999999.65;+37057,+37056,;2~WP-start~1
 Creation.
9999999.65;+37058,+37056,;.01~AUG 19, 2024@12:15:16
9999999.65;+37059,+37056,;.01~AUG 23, 2024@06:32:19
9999999.65;+37060,+37056,;.01~DEC 02, 2024@09:00:21
9999999.65;+37061,+37056,;.01~APR 02, 2025@12:25:11
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37057^1
37058^2
37059^3
37060^4
37061^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC LOW RISK CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37054</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1961859421</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37054,;.01~VA-ONC NMIBC LOW RISK CLINICAL TRIAL
9999999.64;+37054,;.03~VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
9999999.64;+37054,;.08~YES
9999999.64;+37054,;.1~FACTOR
9999999.64;+37054,;100~NATIONAL
9999999.64;+37054,;101~VHA ONCOLOGY
9999999.64;+37054,;200~NMIBC Low Risk Clinical Trial
9999999.64;+37054,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Low Risk Pathway, Clinical 
Trial.
9999999.65;+37055,+37054,;.01~AUG 19, 2024@12:08:54
9999999.65;+37055,+37054,;2~WP-start~1
 Creation.
9999999.65;+37056,+37054,;.01~AUG 23, 2024@06:30:48
9999999.65;+37057,+37054,;.01~DEC 02, 2024@08:59:39
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37055^1
37056^2
37057^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>37000</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>222634729</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37000,;.01~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37000,;.08~YES
9999999.64;+37000,;.1~CATEGORY
9999999.64;+37000,;100~NATIONAL
9999999.64;+37000,;101~VHA ONCOLOGY
9999999.64;+37000,;200~Non-Muscle Invasive Bladder Cancer Intermediate Risk Pathway
9999999.64;+37000,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk Pathway 
Category.
9999999.65;+37001,+37000,;.01~AUG 16, 2024@08:36:02
9999999.65;+37001,+37000,;2~WP-start~1
 Creation.
9999999.65;+37002,+37000,;.01~OCT 16, 2024@10:45:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37001^1
37002^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37336</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>405211191</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37336,;.01~VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE OFF PATH RSN
9999999.64;+37336,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37336,;.08~YES
9999999.64;+37336,;.1~FACTOR
9999999.64;+37336,;100~NATIONAL
9999999.64;+37336,;101~VHA ONCOLOGY
9999999.64;+37336,;200~NMIBC Intermediate Risk High Grade Off Path Reason
9999999.64;+37336,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, High Grade 
Pathway, Off Pathway Reason.
9999999.65;+37337,+37336,;.01~AUG 23, 2024@08:50:36
9999999.65;+37337,+37336,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37337^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37335</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1630137621</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37335,;.01~VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE OFF PATH TX
9999999.64;+37335,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37335,;.08~YES
9999999.64;+37335,;.1~FACTOR
9999999.64;+37335,;100~NATIONAL
9999999.64;+37335,;101~VHA ONCOLOGY
9999999.64;+37335,;200~NMIBC Intermediate Risk High Grade Off Path Treatment
9999999.64;+37335,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, High Grade 
Pathway, Off Pathway Treatment.
9999999.65;+37336,+37335,;.01~AUG 23, 2024@08:49:34
9999999.65;+37336,+37335,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37336^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE IVES BCG</POINT_01>
<INTERNAL_ENTRY_NUMBER>37329</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>66248693</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37329,;.01~VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE IVES BCG
9999999.64;+37329,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37329,;.08~YES
9999999.64;+37329,;.1~FACTOR
9999999.64;+37329,;100~NATIONAL
9999999.64;+37329,;101~VHA ONCOLOGY
9999999.64;+37329,;200~NMIBC Intermediate Risk Low Grade IVES BCG
9999999.64;+37329,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, Low Grade 
Pathway Intravesical BCG.
9999999.65;+37330,+37329,;.01~AUG 23, 2024@08:42:12
9999999.65;+37330,+37329,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37330^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37328</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3664397156</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37328,;.01~VA-ONC NMIBC INTERMEDIATE RISK HIGH GRADE CLINICAL TRIAL
9999999.64;+37328,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37328,;.08~YES
9999999.64;+37328,;.1~FACTOR
9999999.64;+37328,;100~NATIONAL
9999999.64;+37328,;101~VHA ONCOLOGY
9999999.64;+37328,;200~NMIBC Intermediate Risk High Grade Clinical Trial
9999999.64;+37328,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, High Grade 
Pathway Clinical Trial.
9999999.65;+37329,+37328,;.01~AUG 23, 2024@08:41:06
9999999.65;+37329,+37328,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37329^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37327</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3960636572</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37327,;.01~VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE OFF PATH RSN
9999999.64;+37327,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37327,;.08~YES
9999999.64;+37327,;.1~FACTOR
9999999.64;+37327,;100~NATIONAL
9999999.64;+37327,;101~VHA ONCOLOGY
9999999.64;+37327,;200~NMIBC Intermediate Risk Low Grade Off Path Reason
9999999.64;+37327,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, Low Grade 
Pathway, Off Pathway Reason.
9999999.65;+37328,+37327,;.01~AUG 23, 2024@08:39:40
9999999.65;+37328,+37327,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37328^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37326</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3405663001</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37326,;.01~VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE OFF PATH TX
9999999.64;+37326,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37326,;.08~YES
9999999.64;+37326,;.1~FACTOR
9999999.64;+37326,;100~NATIONAL
9999999.64;+37326,;101~VHA ONCOLOGY
9999999.64;+37326,;200~NMIBC Intermediate Risk Low Grade Off Path Treatment
9999999.64;+37326,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, Low Grade 
Pathway, Off Pathway Treatment.
9999999.65;+37327,+37326,;.01~AUG 23, 2024@08:38:18
9999999.65;+37327,+37326,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37327^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37322</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3368892149</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37322,;.01~VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE CLINICAL TRIAL
9999999.64;+37322,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37322,;.08~YES
9999999.64;+37322,;.1~FACTOR
9999999.64;+37322,;100~NATIONAL
9999999.64;+37322,;101~VHA ONCOLOGY
9999999.64;+37322,;200~NMIBC Intermediate Risk Low Grade Clinical Trial
9999999.64;+37322,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk, Pathway 
Category.
9999999.65;+37323,+37322,;.01~AUG 23, 2024@08:33:01
9999999.65;+37323,+37322,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37323^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE IVES GEMCITABINE</POINT_01>
<INTERNAL_ENTRY_NUMBER>37001</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>453176690</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37001,;.01~VA-ONC NMIBC INTERMEDIATE RISK LOW GRADE IVES GEMCITABINE
9999999.64;+37001,;.03~VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
9999999.64;+37001,;.08~YES
9999999.64;+37001,;.1~FACTOR
9999999.64;+37001,;100~NATIONAL
9999999.64;+37001,;101~VHA ONCOLOGY
9999999.64;+37001,;200~NMIBC Intermediate Risk Low Grade IVES Gemcitabine
9999999.64;+37001,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer Intermediate Risk Low Grade 
Pathway Intravesical Gemcitabine.
9999999.65;+37002,+37001,;.01~AUG 16, 2024@08:40:39
9999999.65;+37002,+37001,;2~WP-start~1
 Creation.
9999999.65;+37003,+37001,;.01~AUG 19, 2024@11:44:50
9999999.65;+37004,+37001,;.01~AUG 23, 2024@06:36:46
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37002^1
37003^2
37004^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>37413</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4253869903</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37413,;.01~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37413,;.08~YES
9999999.64;+37413,;.1~CATEGORY
9999999.64;+37413,;100~NATIONAL
9999999.64;+37413,;101~VHA ONCOLOGY
9999999.64;+37413,;200~Non-Muscle Invasive Bladder Cancer High Risk Pathway
9999999.64;+37413,;201~WP-start~1
Oncology Non-Muscle Invasive Bladder Cancer High Risk Pathway Category.
9999999.65;+37414,+37413,;.01~AUG 26, 2024@10:28:50
9999999.65;+37414,+37413,;2~WP-start~1
 Creation.
9999999.65;+37415,+37413,;.01~OCT 16, 2024@10:50:24
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37414^1
37415^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37445</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1353032669</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37445,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE OFF PATH RSN
9999999.64;+37445,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37445,;.08~YES
9999999.64;+37445,;.1~FACTOR
9999999.64;+37445,;100~NATIONAL
9999999.64;+37445,;101~VHA ONCOLOGY
9999999.64;+37445,;200~NMIBC No BCG Naive High Risk BCG Inadequate Off Path Reason
9999999.64;+37445,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Inadequate, 
Off Pathway Reason.
9999999.65;+37446,+37445,;.01~AUG 26, 2024@11:05:32
9999999.65;+37446,+37445,;2~WP-start~1
 Creation.
9999999.65;+37447,+37445,;.01~DEC 02, 2024@11:01:01
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37446^1
37447^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37444</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4084513807</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37444,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE OFF PATH TX
9999999.64;+37444,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37444,;.08~YES
9999999.64;+37444,;.1~FACTOR
9999999.64;+37444,;100~NATIONAL
9999999.64;+37444,;101~VHA ONCOLOGY
9999999.64;+37444,;200~NMIBC No BCG Naive High Risk BCG Inadequate Off Path Treatment
9999999.64;+37444,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Inadequate, 
Off Pathway Treatment.
9999999.65;+37445,+37444,;.01~AUG 26, 2024@11:04:43
9999999.65;+37445,+37444,;2~WP-start~1
 Creation.
9999999.65;+37446,+37444,;.01~DEC 02, 2024@11:02:27
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37445^1
37446^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE BCG 6WKS</POINT_01>
<INTERNAL_ENTRY_NUMBER>37443</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2003245303</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37443,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE BCG 6WKS
9999999.64;+37443,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37443,;.08~YES
9999999.64;+37443,;.1~FACTOR
9999999.64;+37443,;100~NATIONAL
9999999.64;+37443,;101~VHA ONCOLOGY
9999999.64;+37443,;200~NMIBC No BCG Naive High Risk BCG Inadequate BCG 6 Weeks
9999999.64;+37443,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Inadequate, 
BCG Induction for 6 Weeks.
9999999.65;+37444,+37443,;.01~AUG 26, 2024@11:03:40
9999999.65;+37444,+37443,;2~WP-start~1
 Creation.
9999999.65;+37445,+37443,;.01~DEC 02, 2024@10:59:54
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37444^1
37445^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37442</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2552076585</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37442,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG INADEQUATE CLIN TRIAL
9999999.64;+37442,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37442,;.08~YES
9999999.64;+37442,;.1~FACTOR
9999999.64;+37442,;100~NATIONAL
9999999.64;+37442,;101~VHA ONCOLOGY
9999999.64;+37442,;200~NMIBC No BCG Naive High Risk BCG Inadequate Clinical Trial
9999999.64;+37442,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Inadequate, 
Clinical Trial.
9999999.65;+37443,+37442,;.01~AUG 26, 2024@11:02:45
9999999.65;+37443,+37442,;2~WP-start~1
 Creation.
9999999.65;+37444,+37442,;.01~DEC 02, 2024@10:58:44
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37443^1
37444^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37440</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1324541449</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37440,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE OFF PATH RSN
9999999.64;+37440,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37440,;.08~YES
9999999.64;+37440,;.1~FACTOR
9999999.64;+37440,;100~NATIONAL
9999999.64;+37440,;101~VHA ONCOLOGY
9999999.64;+37440,;200~NMIBC No BCG Naive High Risk BCG Responsive Off Path Reason
9999999.64;+37440,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
No, Off Pathway Reason.
9999999.65;+37441,+37440,;.01~AUG 26, 2024@11:00:34
9999999.65;+37441,+37440,;2~WP-start~1
 Creation.
9999999.65;+37442,+37440,;.01~DEC 02, 2024@10:54:21
9999999.65;+37443,+37440,;.01~DEC 03, 2024@08:19:21
9999999.65;+37444,+37440,;.01~DEC 03, 2024@08:29:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37441^1
37442^2
37443^3
37444^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37439</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2115189454</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37439,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE OFF PATH TX
9999999.64;+37439,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37439,;.08~YES
9999999.64;+37439,;.1~FACTOR
9999999.64;+37439,;100~NATIONAL
9999999.64;+37439,;101~VHA ONCOLOGY
9999999.64;+37439,;200~NMIBC No BCG Naive High Risk BCG Responsive Off Path Treatment
9999999.64;+37439,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
No, Off Pathway Treatment.
9999999.65;+37440,+37439,;.01~AUG 26, 2024@10:59:18
9999999.65;+37440,+37439,;2~WP-start~1
 Creation.
9999999.65;+37441,+37439,;.01~DEC 02, 2024@10:51:32
9999999.65;+37442,+37439,;.01~DEC 03, 2024@08:21:05
9999999.65;+37443,+37439,;.01~DEC 03, 2024@08:30:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37440^1
37441^2
37442^3
37443^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE BCG 6WKS</POINT_01>
<INTERNAL_ENTRY_NUMBER>37438</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3665523852</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37438,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE BCG 6WKS
9999999.64;+37438,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37438,;.08~YES
9999999.64;+37438,;.1~FACTOR
9999999.64;+37438,;100~NATIONAL
9999999.64;+37438,;101~VHA ONCOLOGY
9999999.64;+37438,;200~NMIBC No BCG Naive High Risk BCG Responsive BCG 6 Weeks
9999999.64;+37438,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
No, BCG Induction for 6 Weeks.
9999999.65;+37439,+37438,;.01~AUG 26, 2024@10:58:23
9999999.65;+37439,+37438,;2~WP-start~1
 Creation.
9999999.65;+37440,+37438,;.01~DEC 02, 2024@10:46:07
9999999.65;+37441,+37438,;.01~DEC 03, 2024@08:23:56
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37439^1
37440^2
37441^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE CLINIC TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37437</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1282116836</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37437,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG RESPONSIVE CLINIC TRIAL
9999999.64;+37437,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37437,;.08~YES
9999999.64;+37437,;.1~FACTOR
9999999.64;+37437,;100~NATIONAL
9999999.64;+37437,;101~VHA ONCOLOGY
9999999.64;+37437,;200~NMIBC No BCG Naive High Risk BCG Responsive Clinical Trial
9999999.64;+37437,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
No, Clinical Trial.
9999999.65;+37438,+37437,;.01~AUG 26, 2024@10:57:34
9999999.65;+37438,+37437,;2~WP-start~1
 Creation.
9999999.65;+37439,+37437,;.01~DEC 02, 2024@10:44:58
9999999.65;+37440,+37437,;.01~DEC 03, 2024@08:28:47
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37438^1
37439^2
37440^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGHRISK BCG UNRESPONSIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37435</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>703557823</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37435,;.01~VA-ONC NMIBC NO BCG NAIVE HIGHRISK BCG UNRESPONSIVE OFF PATH RSN
9999999.64;+37435,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37435,;.08~YES
9999999.64;+37435,;.1~FACTOR
9999999.64;+37435,;100~NATIONAL
9999999.64;+37435,;101~VHA ONCOLOGY
9999999.64;+37435,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Off Path Reason
9999999.64;+37435,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Off Pathway Reason.
9999999.65;+37436,+37435,;.01~AUG 26, 2024@10:55:23
9999999.65;+37436,+37435,;2~WP-start~1
 Creation.
9999999.65;+37437,+37435,;.01~DEC 02, 2024@10:40:51
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37436^1
37437^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37434</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>238670503</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37434,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE OFF PATH TX
9999999.64;+37434,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37434,;.08~YES
9999999.64;+37434,;.1~FACTOR
9999999.64;+37434,;100~NATIONAL
9999999.64;+37434,;101~VHA ONCOLOGY
9999999.64;+37434,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Off Path Tx
9999999.64;+37434,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Off Pathway Treatment.
9999999.65;+37435,+37434,;.01~AUG 26, 2024@10:54:22
9999999.65;+37435,+37434,;2~WP-start~1
 Creation.
9999999.65;+37436,+37434,;.01~DEC 02, 2024@10:31:55
9999999.65;+37437,+37434,;.01~DEC 12, 2024@09:56:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37435^1
37436^2
37437^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE NADOFARAGEN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37433</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2483518952</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37433,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE NADOFARAGEN
9999999.64;+37433,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37433,;.08~YES
9999999.64;+37433,;.1~FACTOR
9999999.64;+37433,;100~NATIONAL
9999999.64;+37433,;101~VHA ONCOLOGY
9999999.64;+37433,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Nadofaragene
9999999.64;+37433,;201~WP-start~3
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Nadofaragene. Nadofaragene firadenvec: Carcinoma in situ (CIS) with 
or without papillarytumors (Ta or T1 high-grade tumors).
9999999.65;+37434,+37433,;.01~AUG 26, 2024@10:53:14
9999999.65;+37434,+37433,;2~WP-start~1
 Creation.
9999999.65;+37435,+37433,;.01~DEC 02, 2024@10:30:14
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37434^1
37435^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>37432</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1858685225</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37432,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE PEMBRO
9999999.64;+37432,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37432,;.08~YES
9999999.64;+37432,;.1~FACTOR
9999999.64;+37432,;100~NATIONAL
9999999.64;+37432,;101~VHA ONCOLOGY
9999999.64;+37432,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Pembrolizumab
9999999.64;+37432,;201~WP-start~4
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Pembrolizumab. Pembrolizumab: Carcinoma in situ (CIS) with or 
without papillary tumors(Ta or T1 high-grade tumors) who are ineligible 
for or have elected not toundergo cystectomy.
9999999.65;+37433,+37432,;.01~AUG 26, 2024@10:52:03
9999999.65;+37433,+37432,;2~WP-start~1
 Creation.
9999999.65;+37434,+37432,;.01~DEC 02, 2024@10:27:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37433^1
37434^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE GEM DOC</POINT_01>
<INTERNAL_ENTRY_NUMBER>37431</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1981813894</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37431,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE GEM DOC
9999999.64;+37431,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37431,;.08~YES
9999999.64;+37431,;.1~FACTOR
9999999.64;+37431,;100~NATIONAL
9999999.64;+37431,;101~VHA ONCOLOGY
9999999.64;+37431,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Gem Docetaxel
9999999.64;+37431,;201~WP-start~3
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Gemcitabine/Taxotere. Salvage Intravesical Therapy with Gemcitabine 
and Docetaxel/Taxotere.
9999999.65;+37432,+37431,;.01~AUG 26, 2024@10:50:43
9999999.65;+37432,+37431,;2~WP-start~1
 Creation.
9999999.65;+37433,+37431,;.01~DEC 02, 2024@10:25:36
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37432^1
37433^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE RAD CYSTECT</POINT_01>
<INTERNAL_ENTRY_NUMBER>37430</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3502957855</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37430,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE RAD CYSTECT
9999999.64;+37430,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37430,;.08~YES
9999999.64;+37430,;.1~FACTOR
9999999.64;+37430,;100~NATIONAL
9999999.64;+37430,;101~VHA ONCOLOGY
9999999.64;+37430,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Rad Cystectomy
9999999.64;+37430,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Radical Cystectomy.
9999999.65;+37431,+37430,;.01~AUG 26, 2024@10:49:02
9999999.65;+37431,+37430,;2~WP-start~1
 Creation.
9999999.65;+37432,+37430,;.01~DEC 02, 2024@10:19:45
9999999.65;+37433,+37430,;.01~DEC 12, 2024@09:57:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37431^1
37432^2
37433^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37429</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2011319096</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37429,;.01~VA-ONC NMIBC NO BCG NAIVE HIGH RISK BCG UNRESPONSIVE CLIN TRIAL
9999999.64;+37429,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37429,;.08~YES
9999999.64;+37429,;.1~FACTOR
9999999.64;+37429,;100~NATIONAL
9999999.64;+37429,;101~VHA ONCOLOGY
9999999.64;+37429,;200~NMIBC No BCG Naive High Risk BCG Unresponsive Clinical Trial
9999999.64;+37429,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, BCG Unresponsive 
Yes, Clinical Trial.
9999999.65;+37430,+37429,;.01~AUG 26, 2024@10:47:27
9999999.65;+37430,+37429,;2~WP-start~1
 Creation.
9999999.65;+37431,+37429,;.01~DEC 02, 2024@10:13:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37430^1
37431^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37425</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2232930177</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37425,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO OFF PATH RSN
9999999.64;+37425,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37425,;.08~YES
9999999.64;+37425,;.1~FACTOR
9999999.64;+37425,;100~NATIONAL
9999999.64;+37425,;101~VHA ONCOLOGY
9999999.64;+37425,;200~NMIBC BCG Naive High Risk Very High Risk No Off Path Reason
9999999.64;+37425,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk No, 
Off Pathway Reason.
9999999.65;+37426,+37425,;.01~AUG 26, 2024@10:43:20
9999999.65;+37426,+37425,;2~WP-start~1
 Creation.
9999999.65;+37427,+37425,;.01~DEC 02, 2024@10:02:39
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37426^1
37427^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37424</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2184509609</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37424,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO OFF PATH TX
9999999.64;+37424,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37424,;.08~YES
9999999.64;+37424,;.1~FACTOR
9999999.64;+37424,;100~NATIONAL
9999999.64;+37424,;101~VHA ONCOLOGY
9999999.64;+37424,;200~NMIBC BCG Naive High Risk Very High Risk No Off Path Treatment
9999999.64;+37424,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk No, 
Off Pathway Treatment.
9999999.65;+37425,+37424,;.01~AUG 26, 2024@10:42:23
9999999.65;+37425,+37424,;2~WP-start~1
 Creation.
9999999.65;+37426,+37424,;.01~DEC 02, 2024@10:01:32
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37425^1
37426^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO BCG 6WKS</POINT_01>
<INTERNAL_ENTRY_NUMBER>37423</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2714511693</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37423,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO BCG 6WKS
9999999.64;+37423,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37423,;.08~YES
9999999.64;+37423,;.1~FACTOR
9999999.64;+37423,;100~NATIONAL
9999999.64;+37423,;101~VHA ONCOLOGY
9999999.64;+37423,;200~NMIBC BCG Naive High Risk Very High Risk No BCG 6 Weeks
9999999.64;+37423,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk No, 
BCG Induction for 6 Weeks.
9999999.65;+37424,+37423,;.01~AUG 26, 2024@10:41:26
9999999.65;+37424,+37423,;2~WP-start~1
 Creation.
9999999.65;+37425,+37423,;.01~DEC 02, 2024@10:00:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37424^1
37425^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO CLINIC TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37422</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2510478291</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37422,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK NO CLINIC TRIAL
9999999.64;+37422,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37422,;.08~YES
9999999.64;+37422,;.1~FACTOR
9999999.64;+37422,;100~NATIONAL
9999999.64;+37422,;101~VHA ONCOLOGY
9999999.64;+37422,;200~NMIBC BCG Naive High Risk Very High Risk No Clinical Trial
9999999.64;+37422,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk No, 
Clinical Trial.
9999999.65;+37423,+37422,;.01~AUG 26, 2024@10:40:17
9999999.65;+37423,+37422,;2~WP-start~1
 Creation.
9999999.65;+37424,+37422,;.01~DEC 02, 2024@09:59:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37423^1
37424^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37420</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3157439989</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37420,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK OFF PATH RSN
9999999.64;+37420,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37420,;.08~YES
9999999.64;+37420,;.1~FACTOR
9999999.64;+37420,;100~NATIONAL
9999999.64;+37420,;101~VHA ONCOLOGY
9999999.64;+37420,;200~NMIBC BCG Naive High Risk Very High Risk Off Path Reason
9999999.64;+37420,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk 
Yes, Off Pathway Reason.
9999999.65;+37421,+37420,;.01~AUG 26, 2024@10:36:53
9999999.65;+37421,+37420,;2~WP-start~1
 Creation.
9999999.65;+37422,+37420,;.01~DEC 02, 2024@09:57:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37421^1
37422^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37419</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3583070144</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37419,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK OFF PATH TX
9999999.64;+37419,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37419,;.08~YES
9999999.64;+37419,;.1~FACTOR
9999999.64;+37419,;100~NATIONAL
9999999.64;+37419,;101~VHA ONCOLOGY
9999999.64;+37419,;200~NMIBC BCG Naive High Risk Very High Risk Off Path Treatment
9999999.64;+37419,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk 
Yes, Off Pathway Treatment.
9999999.65;+37420,+37419,;.01~AUG 26, 2024@10:35:54
9999999.65;+37420,+37419,;2~WP-start~1
 Creation.
9999999.65;+37421,+37419,;.01~DEC 02, 2024@09:54:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37420^1
37421^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK BCG 6WKS</POINT_01>
<INTERNAL_ENTRY_NUMBER>37418</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>847680312</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37418,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK BCG 6WKS
9999999.64;+37418,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37418,;.08~YES
9999999.64;+37418,;.1~FACTOR
9999999.64;+37418,;100~NATIONAL
9999999.64;+37418,;101~VHA ONCOLOGY
9999999.64;+37418,;200~NMIBC BCG Naive High Risk Very High Risk BCG 6 Weeks
9999999.64;+37418,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk 
Yes, BCG Induction for 6 Weeks.
9999999.65;+37419,+37418,;.01~AUG 26, 2024@10:34:55
9999999.65;+37419,+37418,;2~WP-start~1
 Creation.
9999999.65;+37420,+37418,;.01~DEC 02, 2024@09:52:53
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37419^1
37420^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK RAD CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>37417</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1983886274</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37417,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK RAD CYSTECTOMY
9999999.64;+37417,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37417,;.08~YES
9999999.64;+37417,;.1~FACTOR
9999999.64;+37417,;100~NATIONAL
9999999.64;+37417,;101~VHA ONCOLOGY
9999999.64;+37417,;200~NMIBC BCG Naive High Risk Very High Risk Radical Cystectomy
9999999.64;+37417,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk 
Yes, Radical Cystectomy.
9999999.65;+37418,+37417,;.01~AUG 26, 2024@10:33:45
9999999.65;+37418,+37417,;2~WP-start~1
 Creation.
9999999.65;+37419,+37417,;.01~DEC 02, 2024@09:50:41
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37418^1
37419^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37416</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2283438809</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37416,;.01~VA-ONC NMIBC BCG NAIVE HIGH RISK VERY HIGH RISK CLINICAL TRIAL
9999999.64;+37416,;.03~VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
9999999.64;+37416,;.08~YES
9999999.64;+37416,;.1~FACTOR
9999999.64;+37416,;100~NATIONAL
9999999.64;+37416,;101~VHA ONCOLOGY
9999999.64;+37416,;200~NMIBC BCG Naive High Risk Very High Risk Clinical Trial
9999999.64;+37416,;201~WP-start~2
Oncology Non-Muscle Invasive Bladder Cancer High Risk, Very High Risk 
Yes, Clinical Trial.
9999999.65;+37417,+37416,;.01~AUG 26, 2024@10:32:38
9999999.65;+37417,+37416,;2~WP-start~1
 Creation.
9999999.65;+37418,+37416,;.01~DEC 02, 2024@09:48:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37417^1
37418^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>37585</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2907387094</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37585,;.01~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37585,;.08~YES
9999999.64;+37585,;.1~CATEGORY
9999999.64;+37585,;100~NATIONAL
9999999.64;+37585,;101~VHA ONCOLOGY
9999999.64;+37585,;200~Upper Genitourinary (GU) Tract Carcinoma Pathway
9999999.64;+37585,;201~WP-start~2
Upper Genitourinary Tract Carcinoma Pathway Category. For all Upper GU 
Tract Carcinoma Health Factors.
9999999.65;+37586,+37585,;.01~SEP 03, 2024@09:10:26
9999999.65;+37586,+37585,;2~WP-start~1
 Creation.
9999999.65;+37587,+37585,;.01~NOV 29, 2024@06:56:55
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37586^1
37587^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE NEPHROURETERECTOMY DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>42574</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3574648168</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+42574,;.01~VA-ONC UPGU ANY VOL HIGH GRADE NEPHROURETERECTOMY DU
9999999.64;+42574,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+42574,;.08~YES
9999999.64;+42574,;.1~FACTOR
9999999.64;+42574,;100~NATIONAL
9999999.64;+42574,;101~VHA ONCOLOGY
9999999.64;+42574,;200~Upper GU Any Vol High Grade Nephroureterectomy Distal Ureter
9999999.64;+42574,;201~WP-start~4
Upper Genitourinary Tract Carcinoma Any Vol High Grade Distal Ureter 
Nephroureterectomy, Lymphadenectomy, and Single-Dose Intravesical 
Gemcitabine. ++ Consider neoadjuvant gemcitabine and cisplatin for select 
high grade patients; consider Tumor Board discussion. ++
9999999.65;+42575,+42574,;.01~JUL 09, 2025@10:06:51
9999999.65;+42575,+42574,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
42575^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU STAGE &gt;T2 OR NODE+ OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39591</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1329959898</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39591,;.01~VA-ONC UPGU STAGE >T2 OR NODE+ OFF PATH RSN
9999999.64;+39591,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39591,;.08~YES
9999999.64;+39591,;.1~FACTOR
9999999.64;+39591,;100~NATIONAL
9999999.64;+39591,;101~VHA ONCOLOGY
9999999.64;+39591,;200~Upper GU Stage >T2 or Node Positive Off Pathway Reason
9999999.64;+39591,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Stage Greater Than or Equal to T2 or 
Node Positive Off Pathway Reason.
9999999.65;+39592,+39591,;.01~FEB 19, 2025@13:15:36
9999999.65;+39592,+39591,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39592^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU STAGE &gt;T2 OR NODE+ OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39590</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2263282266</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39590,;.01~VA-ONC UPGU STAGE >T2 OR NODE+ OFF PATH TX
9999999.64;+39590,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39590,;.08~YES
9999999.64;+39590,;.1~FACTOR
9999999.64;+39590,;100~NATIONAL
9999999.64;+39590,;101~VHA ONCOLOGY
9999999.64;+39590,;200~Upper GU Stage >T2 or Node Positive Off Pathway Treatment
9999999.64;+39590,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Stage Greater Than or Equal to T2 or 
Node Positive Off Pathway Treatment.
9999999.65;+39591,+39590,;.01~FEB 19, 2025@13:14:18
9999999.65;+39591,+39590,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39591^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU STAGE &gt;T2 OR NODE+ CARBO &amp; GEMCITABINE</POINT_01>
<INTERNAL_ENTRY_NUMBER>39589</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>106350966</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39589,;.01~VA-ONC UPGU STAGE >T2 OR NODE+ CARBO & GEMCITABINE
9999999.64;+39589,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39589,;.08~YES
9999999.64;+39589,;.1~FACTOR
9999999.64;+39589,;100~NATIONAL
9999999.64;+39589,;101~VHA ONCOLOGY
9999999.64;+39589,;200~Upper GU Stage >T2 or Node Positive Carbo & Gemcitabine
9999999.64;+39589,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Stage Greater Than or Equal to T2 or 
Node Positive Carboplatin and Gemcitabine.
9999999.65;+39590,+39589,;.01~FEB 19, 2025@12:58:58
9999999.65;+39590,+39589,;2~WP-start~1
 Creation.
9999999.65;+39591,+39589,;.01~JUL 02, 2025@09:21:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39590^1
39591^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU STAGE &gt;T2 OR NODE+ CIS &amp; GEMCITABINE</POINT_01>
<INTERNAL_ENTRY_NUMBER>39588</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>417067152</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39588,;.01~VA-ONC UPGU STAGE >T2 OR NODE+ CIS & GEMCITABINE
9999999.64;+39588,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39588,;.08~YES
9999999.64;+39588,;.1~FACTOR
9999999.64;+39588,;100~NATIONAL
9999999.64;+39588,;101~VHA ONCOLOGY
9999999.64;+39588,;200~Upper GU Stage >T2 or Node Positive Cis & Gemcitabine
9999999.64;+39588,;201~WP-start~4
Upper Genitourinary Tract Carcinoma: Stage Greater Than or Equal to T2 or 
Node Positive Cisplatin and Gemcitabine. ++ Adjuvant 
therapy cisplatin if renal function allows; carboplatin if not a 
cisplatin candidate. ++
9999999.65;+39589,+39588,;.01~FEB 19, 2025@12:57:56
9999999.65;+39589,+39588,;2~WP-start~1
 Creation.
9999999.65;+39590,+39588,;.01~JUL 02, 2025@09:23:52
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39589^1
39590^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU STAGE &gt;T2 OR NODE+ CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39587</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>990099634</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39587,;.01~VA-ONC UPGU STAGE >T2 OR NODE+ CLINICAL TRIAL
9999999.64;+39587,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39587,;.08~YES
9999999.64;+39587,;.1~FACTOR
9999999.64;+39587,;100~NATIONAL
9999999.64;+39587,;101~VHA ONCOLOGY
9999999.64;+39587,;200~Upper GU Stage >T2 or Node Positive Clinical Trial
9999999.64;+39587,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Stage Greater Than or Equal to T2 or 
Node Positive Clinical Trial.
9999999.65;+39588,+39587,;.01~FEB 19, 2025@12:56:50
9999999.65;+39588,+39587,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39588^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFFPATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39586</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1653107150</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39586,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFFPATH RSN
9999999.64;+39586,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39586,;.08~YES
9999999.64;+39586,;.1~FACTOR
9999999.64;+39586,;100~NATIONAL
9999999.64;+39586,;101~VHA ONCOLOGY
9999999.64;+39586,;200~Upper GU Low Vol Low Grade Endo Resect No Resid Dx Off Path Rsn
9999999.64;+39586,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Off Pathway Reason Text.
9999999.65;+39587,+39586,;.01~FEB 19, 2025@08:41:28
9999999.65;+39587,+39586,;2~WP-start~1
 Creation.
9999999.65;+39588,+39586,;.01~FEB 19, 2025@08:47:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39587^1
39588^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFFPATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39584</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3985503194</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39584,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFFPATH TX
9999999.64;+39584,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39584,;.08~YES
9999999.64;+39584,;.1~FACTOR
9999999.64;+39584,;100~NATIONAL
9999999.64;+39584,;101~VHA ONCOLOGY
9999999.64;+39584,;200~Upper GU Low Vol Low Grade Endo Resect No Resid Dx Off Path Tx
9999999.64;+39584,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Off Pathway Treatment Reason.
9999999.65;+39585,+39584,;.01~FEB 19, 2025@08:38:46
9999999.65;+39585,+39584,;2~WP-start~1
 Creation.
9999999.65;+39586,+39584,;.01~FEB 19, 2025@08:48:55
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39585^1
39586^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39583</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3117939298</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39583,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFF PATH RSN
9999999.64;+39583,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39583,;.08~YES
9999999.64;+39583,;.1~FACTOR
9999999.64;+39583,;100~NATIONAL
9999999.64;+39583,;101~VHA ONCOLOGY
9999999.64;+39583,;200~Upper GU Low Vol Low Grade Endo Resect No Resid Dx Off Path Rsn
9999999.64;+39583,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Off Pathway Reason Text.
9999999.65;+39584,+39583,;.01~FEB 19, 2025@07:49:41
9999999.65;+39584,+39583,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39584^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39582</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2215520340</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39582,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX OFF PATH TX
9999999.64;+39582,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39582,;.08~YES
9999999.64;+39582,;.1~FACTOR
9999999.64;+39582,;100~NATIONAL
9999999.64;+39582,;101~VHA ONCOLOGY
9999999.64;+39582,;200~Upper GU Low Vol Low Grade Endo Resect No Resid Dx Off Path Tx
9999999.64;+39582,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Off Pathway Treatment Reason.
9999999.65;+39583,+39582,;.01~FEB 19, 2025@07:48:24
9999999.65;+39583,+39582,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39583^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX URETEROSCOPY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39581</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3873484695</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39581,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX URETEROSCOPY
9999999.64;+39581,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39581,;.08~YES
9999999.64;+39581,;.1~FACTOR
9999999.64;+39581,;100~NATIONAL
9999999.64;+39581,;101~VHA ONCOLOGY
9999999.64;+39581,;200~Upper GU Low Vol Low Grade Endo Resect No Resid Dx Ureteroscopy
9999999.64;+39581,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Surveillance Ureteroscopy.
9999999.65;+39582,+39581,;.01~FEB 19, 2025@07:29:21
9999999.65;+39582,+39581,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39582^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39580</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4288512083</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39580,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT NO RES DX CLIN TRIAL
9999999.64;+39580,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39580,;.08~YES
9999999.64;+39580,;.1~FACTOR
9999999.64;+39580,;100~NATIONAL
9999999.64;+39580,;101~VHA ONCOLOGY
9999999.64;+39580,;200~Upper GU Low Vol Low Grade Endo Resect No Residual Dx Clin Trial
9999999.64;+39580,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, No Residual Disease, Clinical Trial.
9999999.65;+39581,+39580,;.01~FEB 19, 2025@06:54:07
9999999.65;+39581,+39580,;2~WP-start~1
Copied from VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX CLIN TRIAL
9999999.65;+39582,+39580,;.01~FEB 19, 2025@07:19:27
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39581^1
39582^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE DISTAL URETERECTOMY DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>39579</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2540988942</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39579,;.01~VA-ONC UPGU ANY VOL HIGH GRADE DISTAL URETERECTOMY DU
9999999.64;+39579,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39579,;.08~YES
9999999.64;+39579,;.1~FACTOR
9999999.64;+39579,;100~NATIONAL
9999999.64;+39579,;101~VHA ONCOLOGY
9999999.64;+39579,;200~Upper GU Any Vol High Grade Distal Ureterectomy Distal Ureter
9999999.64;+39579,;201~WP-start~5
Upper Genitourinary Tract Carcinoma Any Vol High Grade Distal Ureter 
Distal Ureterectomy with Reimplantation, Lymphadenectomy, and Single-Dose 
Intravesical Gemcitabine. ++ Consider neoadjuvant gemcitabine and 
cisplatin for select high grade patients; consider Tumor Board 
discussion. ++
9999999.65;+39580,+39579,;.01~FEB 18, 2025@13:38:16
9999999.65;+39580,+39579,;2~WP-start~1
 Creation.
9999999.65;+39581,+39579,;.01~FEB 19, 2025@06:48:39
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39580^1
39581^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE DISTAL URETERECTOMY DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>39578</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3423307893</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39578,;.01~VA-ONC UPGU HIGH VOL LOW GRADE DISTAL URETERECTOMY DU
9999999.64;+39578,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39578,;.08~YES
9999999.64;+39578,;.1~FACTOR
9999999.64;+39578,;100~NATIONAL
9999999.64;+39578,;101~VHA ONCOLOGY
9999999.64;+39578,;200~Upper GU High Vol Low Grade Distal Ureterectomy Distal Ureter
9999999.64;+39578,;201~WP-start~3
Upper Genitourinary Tract Carcinoma: High Vol Low Grade Distal Ureter 
Distal Ureterectomy with Reimplantation and Single Dose Intravesical 
Gemcitabine.
9999999.65;+39579,+39578,;.01~FEB 18, 2025@13:13
9999999.65;+39579,+39578,;2~WP-start~1
 Creation.
9999999.65;+39580,+39578,;.01~FEB 19, 2025@06:44:47
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39579^1
39580^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE NEPHROURETERECTOMY DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>39577</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>580324873</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39577,;.01~VA-ONC UPGU HIGH VOL LOW GRADE NEPHROURETERECTOMY DU
9999999.64;+39577,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+39577,;.08~YES
9999999.64;+39577,;.1~FACTOR
9999999.64;+39577,;100~NATIONAL
9999999.64;+39577,;101~VHA ONCOLOGY
9999999.64;+39577,;200~Upper GU High Vol Low Grade Nephroureterectomy Distal Ureter
9999999.64;+39577,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Vol Low Grade Distal Ureter 
Nephroureterectomy with Single Dose Intravesical Gemcitabine.
9999999.65;+39578,+39577,;.01~FEB 18, 2025@12:56:43
9999999.65;+39578,+39577,;2~WP-start~1
 Creation.
9999999.65;+39579,+39577,;.01~FEB 18, 2025@13:01:31
9999999.65;+39580,+39577,;.01~FEB 19, 2025@06:43:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39578^1
39579^2
39580^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH RSN DU </POINT_01>
<INTERNAL_ENTRY_NUMBER>37763</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3973756973</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37763,;.01~VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH RSN DU 
9999999.64;+37763,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37763,;.08~YES
9999999.64;+37763,;.1~FACTOR
9999999.64;+37763,;100~NATIONAL
9999999.64;+37763,;101~VHA ONCOLOGY
9999999.64;+37763,;200~Upper GU Any Vol High Grade Off Pathway Reason Distal Ureter
9999999.64;+37763,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, Location 
Distal Ureter. Off Pathway Reason.
9999999.65;+37764,+37763,;.01~SEP 18, 2024@10:53:55
9999999.65;+37764,+37763,;2~WP-start~1
 Creation.
9999999.65;+37765,+37763,;.01~NOV 29, 2024@06:26:47
9999999.65;+37766,+37763,;.01~NOV 29, 2024@08:40:03
9999999.65;+37767,+37763,;.01~NOV 29, 2024@09:43:41
9999999.65;+37768,+37763,;.01~DEC 02, 2024@06:35:19
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37764^1
37765^2
37766^3
37767^4
37768^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH TX DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>37762</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2989406409</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37762,;.01~VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH TX DU
9999999.64;+37762,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37762,;.08~YES
9999999.64;+37762,;.1~FACTOR
9999999.64;+37762,;100~NATIONAL
9999999.64;+37762,;101~VHA ONCOLOGY
9999999.64;+37762,;200~Upper GU Any Vol High Grade Off Pathway Treatment Distal Ureter
9999999.64;+37762,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, Location 
Distal Ureter. Off Pathway Treatment.
9999999.65;+37763,+37762,;.01~SEP 18, 2024@10:51:32
9999999.65;+37763,+37762,;2~WP-start~1
 Creation.
9999999.65;+37764,+37762,;.01~NOV 29, 2024@08:51:43
9999999.65;+37765,+37762,;.01~NOV 29, 2024@09:44:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37763^1
37764^2
37765^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE NO SX DU </POINT_01>
<INTERNAL_ENTRY_NUMBER>37761</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>513030008</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37761,;.01~VA-ONC UPGU ANY VOL HIGH GRADE NO SX DU 
9999999.64;+37761,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37761,;.08~YES
9999999.64;+37761,;.1~FACTOR
9999999.64;+37761,;100~NATIONAL
9999999.64;+37761,;101~VHA ONCOLOGY
9999999.64;+37761,;200~Upper GU Any Vol High Grade No Surgery Distal Ureter
9999999.64;+37761,;201~WP-start~4
Upper Genitourinary Tract Carcinoma: Distal Ureter: Any Volume, High 
Grade (from biopsy): Surgery Not Completed. Recommend Nephroureterectomy 
or Distal Ureterectomy with Reimplantation and Single-Dose Intravesical 
Gemcitabine.
9999999.65;+37762,+37761,;.01~SEP 18, 2024@10:50:03
9999999.65;+37762,+37761,;2~WP-start~1
 Creation.
9999999.65;+37763,+37761,;.01~NOV 29, 2024@06:42:32
9999999.65;+37764,+37761,;.01~NOV 29, 2024@06:50:10
9999999.65;+37765,+37761,;.01~NOV 29, 2024@08:36:04
9999999.65;+37766,+37761,;.01~NOV 29, 2024@08:49:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37762^1
37763^2
37764^3
37765^4
37766^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE CLINICAL TRIAL DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>37754</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2960788611</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37754,;.01~VA-ONC UPGU ANY VOL HIGH GRADE CLINICAL TRIAL DU
9999999.64;+37754,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37754,;.08~YES
9999999.64;+37754,;.1~FACTOR
9999999.64;+37754,;100~NATIONAL
9999999.64;+37754,;101~VHA ONCOLOGY
9999999.64;+37754,;200~Upper GU Any Vol High Grade Clinical Trial Distal Ureter
9999999.64;+37754,;201~WP-start~2
Upper Genitourinary Tract Carcinoma Any Vol High Grade Distal Ureter 
Clinical Trial.
9999999.65;+37755,+37754,;.01~SEP 18, 2024@10:40:20
9999999.65;+37755,+37754,;2~WP-start~1
 Creation.
9999999.65;+37756,+37754,;.01~NOV 29, 2024@08:31:52
9999999.65;+37757,+37754,;.01~DEC 02, 2024@06:31:04
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37755^1
37756^2
37757^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH RSN DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>37752</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>69177702</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37752,;.01~VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH RSN DU
9999999.64;+37752,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37752,;.08~YES
9999999.64;+37752,;.1~FACTOR
9999999.64;+37752,;100~NATIONAL
9999999.64;+37752,;101~VHA ONCOLOGY
9999999.64;+37752,;200~Upper GU High Vol Any Grade Off Pathway Reason Distal Ureter
9999999.64;+37752,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Any Grade, Distal 
Ureter. Off Pathway Reason.
9999999.65;+37753,+37752,;.01~SEP 18, 2024@10:37:57
9999999.65;+37753,+37752,;2~WP-start~1
 Creation.
9999999.65;+37754,+37752,;.01~NOV 29, 2024@08:25:55
9999999.65;+37755,+37752,;.01~FEB 12, 2025@09:38:48
9999999.65;+37756,+37752,;.01~FEB 18, 2025@12:46:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37753^1
37754^2
37755^3
37756^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH TX DU </POINT_01>
<INTERNAL_ENTRY_NUMBER>37751</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3943513312</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37751,;.01~VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH TX DU 
9999999.64;+37751,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37751,;.08~YES
9999999.64;+37751,;.1~FACTOR
9999999.64;+37751,;100~NATIONAL
9999999.64;+37751,;101~VHA ONCOLOGY
9999999.64;+37751,;200~Upper GU High Vol Any Grade Off Pathway Treatment Distal Ureter 
9999999.64;+37751,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Any Grade, Distal 
Ureter. Off Pathway Treatment.
9999999.65;+37752,+37751,;.01~SEP 18, 2024@10:36:03
9999999.65;+37752,+37751,;2~WP-start~1
 Creation.
9999999.65;+37753,+37751,;.01~NOV 29, 2024@06:33:54
9999999.65;+37754,+37751,;.01~NOV 29, 2024@09:06:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37752^1
37753^2
37754^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE CLINICAL TRIAL DU</POINT_01>
<INTERNAL_ENTRY_NUMBER>37743</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1738139538</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37743,;.01~VA-ONC UPGU HIGH VOL LOW GRADE CLINICAL TRIAL DU
9999999.64;+37743,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37743,;.08~YES
9999999.64;+37743,;.1~FACTOR
9999999.64;+37743,;100~NATIONAL
9999999.64;+37743,;101~VHA ONCOLOGY
9999999.64;+37743,;200~Upper GU High Vol Low Grade Clinical Trial Distal Ureter
9999999.64;+37743,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Vol Low Grade Distal Ureter 
Clinical Trial.
9999999.65;+37744,+37743,;.01~SEP 18, 2024@10:28:13
9999999.65;+37744,+37743,;2~WP-start~1
 Creation.
9999999.65;+37745,+37743,;.01~NOV 29, 2024@09:02:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37744^1
37745^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH RSN UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37741</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>561955602</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37741,;.01~VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH RSN UP
9999999.64;+37741,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37741,;.08~YES
9999999.64;+37741,;.1~FACTOR
9999999.64;+37741,;100~NATIONAL
9999999.64;+37741,;101~VHA ONCOLOGY
9999999.64;+37741,;200~Upper GU Any Vol High Grade Off Pathway Reason Upper
9999999.64;+37741,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, Location 
(Renal Pelvis, Upper Ureter, Mid Ureter). Off Pathway Reason.
9999999.65;+37742,+37741,;.01~SEP 18, 2024@10:26:02
9999999.65;+37742,+37741,;2~WP-start~1
 Creation.
9999999.65;+37743,+37741,;.01~NOV 29, 2024@08:28:08
9999999.65;+37744,+37741,;.01~DEC 02, 2024@06:32:21
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37742^1
37743^2
37744^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH TX UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37740</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2712942507</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37740,;.01~VA-ONC UPGU ANY VOL HIGH GRADE OFF PATH TX UP
9999999.64;+37740,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37740,;.08~YES
9999999.64;+37740,;.1~FACTOR
9999999.64;+37740,;100~NATIONAL
9999999.64;+37740,;101~VHA ONCOLOGY
9999999.64;+37740,;200~Upper GU Any Vol High Grade Off Pathway Treatment Upper
9999999.64;+37740,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, Location 
(Renal Pelvis, Upper Ureter, Mid Ureter). Off Pathway Treatment.
9999999.65;+37741,+37740,;.01~SEP 18, 2024@10:24:23
9999999.65;+37741,+37740,;2~WP-start~1
 Creation.
9999999.65;+37742,+37740,;.01~NOV 29, 2024@08:29:28
9999999.65;+37743,+37740,;.01~DEC 02, 2024@06:32:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37741^1
37742^2
37743^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE NEPHROURETERECTOMY UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37735</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4276650364</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37735,;.01~VA-ONC UPGU ANY VOL HIGH GRADE NEPHROURETERECTOMY UP
9999999.64;+37735,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37735,;.08~YES
9999999.64;+37735,;.1~FACTOR
9999999.64;+37735,;100~NATIONAL
9999999.64;+37735,;101~VHA ONCOLOGY
9999999.64;+37735,;200~Upper GU Any Vol High Grade Nephroureterectomy Upper
9999999.64;+37735,;201~WP-start~3
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, 
Nephroureterectomy, Upper Tract (Renal Pelvis, Upper Ureter, Mid Ureter) 
and Single-Dose Intravesical Gemcitabine.
9999999.65;+37736,+37735,;.01~SEP 18, 2024@10:09:45
9999999.65;+37736,+37735,;2~WP-start~1
 Creation.
9999999.65;+37737,+37735,;.01~NOV 29, 2024@08:46:17
9999999.65;+37738,+37735,;.01~FEB 12, 2025@10:31:21
9999999.65;+37739,+37735,;.01~FEB 12, 2025@12:22:56
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37736^1
37737^2
37738^3
37739^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU ANY VOL HIGH GRADE CLINICAL TRIAL UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37734</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>226878254</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37734,;.01~VA-ONC UPGU ANY VOL HIGH GRADE CLINICAL TRIAL UP
9999999.64;+37734,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37734,;.08~YES
9999999.64;+37734,;.1~FACTOR
9999999.64;+37734,;100~NATIONAL
9999999.64;+37734,;101~VHA ONCOLOGY
9999999.64;+37734,;200~Upper GU Any Vol High Grade Clinical Trial Upper
9999999.64;+37734,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Any Volume, High Grade, Clinical 
Trial Upper Tract (Renal Pelvis, Upper Ureter, Mid Ureter).
9999999.65;+37735,+37734,;.01~SEP 18, 2024@10:08:43
9999999.65;+37735,+37734,;2~WP-start~1
 Creation.
9999999.65;+37736,+37734,;.01~NOV 29, 2024@07:56:46
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37735^1
37736^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH RSN UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37732</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2493412379</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37732,;.01~VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH RSN UP
9999999.64;+37732,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37732,;.08~YES
9999999.64;+37732,;.1~FACTOR
9999999.64;+37732,;100~NATIONAL
9999999.64;+37732,;101~VHA ONCOLOGY
9999999.64;+37732,;200~Upper GU High Vol Low Grade Off Pathway Reason Upper
9999999.64;+37732,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Low Grade, Location 
(Renal Pelvis, Upper Ureter, Mid Ureter). Off Pathway Reason.
9999999.65;+37733,+37732,;.01~SEP 18, 2024@10:06:11
9999999.65;+37733,+37732,;2~WP-start~1
 Creation.
9999999.65;+37734,+37732,;.01~NOV 29, 2024@07:05:16
9999999.65;+37735,+37732,;.01~NOV 29, 2024@09:15:29
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37733^1
37734^2
37735^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH TX UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37731</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1124133089</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37731,;.01~VA-ONC UPGU HIGH VOL LOW GRADE OFF PATH TX UP
9999999.64;+37731,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37731,;.08~YES
9999999.64;+37731,;.1~FACTOR
9999999.64;+37731,;100~NATIONAL
9999999.64;+37731,;101~VHA ONCOLOGY
9999999.64;+37731,;200~Upper GU High Vol Low Grade Off Pathway Treatment Upper
9999999.64;+37731,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Low Grade, Location 
(Renal Pelvis, Upper Ureter, Mid Ureter). Off Pathway Treatment.
9999999.65;+37732,+37731,;.01~SEP 18, 2024@10:03:29
9999999.65;+37732,+37731,;2~WP-start~1
 Creation.
9999999.65;+37733,+37731,;.01~NOV 29, 2024@07:06:42
9999999.65;+37734,+37731,;.01~NOV 29, 2024@09:16:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37732^1
37733^2
37734^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE NEPHROURETERECTOMY UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37726</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1686434075</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37726,;.01~VA-ONC UPGU HIGH VOL LOW GRADE NEPHROURETERECTOMY UP
9999999.64;+37726,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37726,;.08~YES
9999999.64;+37726,;.1~FACTOR
9999999.64;+37726,;100~NATIONAL
9999999.64;+37726,;101~VHA ONCOLOGY
9999999.64;+37726,;200~Upper GU High Vol Low Grade Nephroureterectomy Upper
9999999.64;+37726,;201~WP-start~3
Upper Genitourinary Tract Carcinoma: High Volume, Low Grade, 
Nephroureterectomy, Upper Tract (Renal Pelvis, Upper Ureter, Mid Ureter) 
and Single-Dose Intravesical Gemcitabine.
9999999.65;+37727,+37726,;.01~SEP 18, 2024@09:53:12
9999999.65;+37727,+37726,;2~WP-start~1
 Creation.
9999999.65;+37728,+37726,;.01~NOV 29, 2024@09:13:39
9999999.65;+37729,+37726,;.01~FEB 12, 2025@10:17:48
9999999.65;+37730,+37726,;.01~FEB 12, 2025@13:19:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37727^1
37728^2
37729^3
37730^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE CLINICAL TRIAL UP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37725</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3289356020</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37725,;.01~VA-ONC UPGU HIGH VOL LOW GRADE CLINICAL TRIAL UP
9999999.64;+37725,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37725,;.08~YES
9999999.64;+37725,;.1~FACTOR
9999999.64;+37725,;100~NATIONAL
9999999.64;+37725,;101~VHA ONCOLOGY
9999999.64;+37725,;200~Upper GU High Vol Low Grade Clinical Trial Upper
9999999.64;+37725,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Low Grade, Clinical 
Trial Upper Tract (Renal Pelvis, Upper Ureter, Mid Ureter).
9999999.65;+37726,+37725,;.01~SEP 18, 2024@09:51:20
9999999.65;+37726,+37725,;2~WP-start~1
 Creation.
9999999.65;+37727,+37725,;.01~NOV 29, 2024@07:08:01
9999999.65;+37728,+37725,;.01~NOV 29, 2024@09:00:13
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37726^1
37727^2
37728^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU HIGH VOL LOW GRADE LOCATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>37723</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4076051031</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37723,;.01~VA-ONC UPGU HIGH VOL LOW GRADE LOCATION
9999999.64;+37723,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37723,;.08~YES
9999999.64;+37723,;.1~FACTOR
9999999.64;+37723,;100~NATIONAL
9999999.64;+37723,;101~VHA ONCOLOGY
9999999.64;+37723,;200~Upper GU High Vol Low Grade Location
9999999.64;+37723,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: High Volume, Low Grade, Location 
(Renal Pelvis, Upper Ureter, Mid Ureter).
9999999.65;+37724,+37723,;.01~SEP 18, 2024@09:47:37
9999999.65;+37724,+37723,;2~WP-start~1
 Creation.
9999999.65;+37725,+37723,;.01~NOV 29, 2024@06:58:32
9999999.65;+37726,+37723,;.01~NOV 29, 2024@07:54:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37724^1
37725^2
37726^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37721</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>734460490</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37721,;.01~VA-ONC UPGU LOW VOL LOW GRADE OFF PATH RSN
9999999.64;+37721,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37721,;.08~YES
9999999.64;+37721,;.1~FACTOR
9999999.64;+37721,;100~NATIONAL
9999999.64;+37721,;101~VHA ONCOLOGY
9999999.64;+37721,;200~Upper GU Low Vol Low Grade Off Pathway Reason
9999999.64;+37721,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Off Pathway 
Reason.
9999999.65;+37722,+37721,;.01~SEP 18, 2024@09:45:04
9999999.65;+37722,+37721,;2~WP-start~1
 Creation.
9999999.65;+37723,+37721,;.01~NOV 29, 2024@07:19:01
9999999.65;+37724,+37721,;.01~NOV 29, 2024@09:23:18
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37722^1
37723^2
37724^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37720</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2632799597</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37720,;.01~VA-ONC UPGU LOW VOL LOW GRADE OFF PATH TX
9999999.64;+37720,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37720,;.08~YES
9999999.64;+37720,;.1~FACTOR
9999999.64;+37720,;100~NATIONAL
9999999.64;+37720,;101~VHA ONCOLOGY
9999999.64;+37720,;200~Upper GU Low Vol Low Grade Off Pathway Treatment
9999999.64;+37720,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Off Pathway 
Treatment.
9999999.65;+37721,+37720,;.01~SEP 18, 2024@09:43:39
9999999.65;+37721,+37720,;2~WP-start~1
 Creation.
9999999.65;+37722,+37720,;.01~NOV 29, 2024@07:20:40
9999999.65;+37723,+37720,;.01~NOV 29, 2024@09:23:44
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37721^1
37722^2
37723^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37717</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1778311409</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37717,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX OFF PATH RSN
9999999.64;+37717,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37717,;.08~YES
9999999.64;+37717,;.1~FACTOR
9999999.64;+37717,;100~NATIONAL
9999999.64;+37717,;101~VHA ONCOLOGY
9999999.64;+37717,;200~Upper GU Low Vol Low Grade Endo Resect Residual Dx Off Path Rsn
9999999.64;+37717,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, Residual Disease, Off Pathway Reason.
9999999.65;+37718,+37717,;.01~SEP 18, 2024@09:39:12
9999999.65;+37718,+37717,;2~WP-start~1
 Creation.
9999999.65;+37719,+37717,;.01~NOV 29, 2024@07:36:56
9999999.65;+37720,+37717,;.01~NOV 29, 2024@12:39:04
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37718^1
37719^2
37720^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37716</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2038482950</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37716,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX OFF PATH TX
9999999.64;+37716,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37716,;.08~YES
9999999.64;+37716,;.1~FACTOR
9999999.64;+37716,;100~NATIONAL
9999999.64;+37716,;101~VHA ONCOLOGY
9999999.64;+37716,;200~Upper GU Low Vol Low Grade Endo Resect Residual Dx Off Path Tx
9999999.64;+37716,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, Residual Disease, Off Pathway Treatment.
9999999.65;+37717,+37716,;.01~SEP 18, 2024@09:33:02
9999999.65;+37717,+37716,;2~WP-start~1
 Creation.
9999999.65;+37718,+37716,;.01~NOV 29, 2024@07:40:07
9999999.65;+37719,+37716,;.01~NOV 29, 2024@12:40:10
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37717^1
37718^2
37719^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT</POINT_01>
<INTERNAL_ENTRY_NUMBER>37714</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3906172655</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37714,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT
9999999.64;+37714,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37714,;.08~YES
9999999.64;+37714,;.1~FACTOR
9999999.64;+37714,;100~NATIONAL
9999999.64;+37714,;101~VHA ONCOLOGY
9999999.64;+37714,;200~Upper GU Low Vol Low Grade Endo Resect
9999999.64;+37714,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection.
9999999.65;+37715,+37714,;.01~SEP 18, 2024@09:28:06
9999999.65;+37715,+37714,;2~WP-start~1
 Creation.
9999999.65;+37716,+37714,;.01~NOV 29, 2024@07:16:33
9999999.65;+37717,+37714,;.01~NOV 29, 2024@09:21:43
9999999.65;+37718,+37714,;.01~NOV 29, 2024@09:32
9999999.65;+37719,+37714,;.01~NOV 29, 2024@12:37:52
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37715^1
37716^2
37717^3
37718^4
37719^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37713</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1437633592</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37713,;.01~VA-ONC UPGU LOW VOL LOW GRADE CLINICAL TRIAL
9999999.64;+37713,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37713,;.08~YES
9999999.64;+37713,;.1~FACTOR
9999999.64;+37713,;100~NATIONAL
9999999.64;+37713,;101~VHA ONCOLOGY
9999999.64;+37713,;200~Upper GU Low Vol Low Grade Clinical Trial
9999999.64;+37713,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Clinical 
Trial.
9999999.65;+37714,+37713,;.01~SEP 18, 2024@09:26:59
9999999.65;+37714,+37713,;2~WP-start~1
 Creation.
9999999.65;+37715,+37713,;.01~NOV 29, 2024@07:51:58
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37714^1
37715^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX MITOMYCIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37587</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2251600166</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37587,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX MITOMYCIN
9999999.64;+37587,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37587,;.08~YES
9999999.64;+37587,;.1~FACTOR
9999999.64;+37587,;100~NATIONAL
9999999.64;+37587,;101~VHA ONCOLOGY
9999999.64;+37587,;200~Upper GU Low Vol Low Grade Endo Resect Residual Dx Mitomycin
9999999.64;+37587,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, Residual Disease, Mitomycin.
9999999.65;+37588,+37587,;.01~SEP 03, 2024@09:22:49
9999999.65;+37588,+37587,;2~WP-start~1
 Creation.
9999999.65;+37589,+37587,;.01~NOV 29, 2024@07:46:59
9999999.65;+37590,+37587,;.01~NOV 29, 2024@12:44:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37588^1
37589^2
37590^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37586</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>908093770</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37586,;.01~VA-ONC UPGU LOW VOL LOW GRADE ENDO RESECT RES DX CLIN TRIAL
9999999.64;+37586,;.03~VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
9999999.64;+37586,;.08~YES
9999999.64;+37586,;.1~FACTOR
9999999.64;+37586,;100~NATIONAL
9999999.64;+37586,;101~VHA ONCOLOGY
9999999.64;+37586,;200~Upper GU Low Vol Low Grade Endo Resect Residual Dx Clin Trial
9999999.64;+37586,;201~WP-start~2
Upper Genitourinary Tract Carcinoma: Low Volume, Low Grade, Endoscopic 
Resection, Residual Disease, Clinical Trial.
9999999.65;+37587,+37586,;.01~SEP 03, 2024@09:18:36
9999999.65;+37587,+37586,;2~WP-start~1
 Creation.
9999999.65;+37588,+37586,;.01~NOV 29, 2024@07:44:09
9999999.65;+37589,+37586,;.01~NOV 29, 2024@09:27:48
9999999.65;+37590,+37586,;.01~NOV 29, 2024@12:47:44
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37587^1
37588^2
37589^3
37590^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>37764</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3960486808</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37764,;.01~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+37764,;.08~YES
9999999.64;+37764,;.1~CATEGORY
9999999.64;+37764,;100~NATIONAL
9999999.64;+37764,;101~VHA ONCOLOGY
9999999.64;+37764,;200~Urothelial Carcinoma of Prostatic Urethra Pathway
9999999.64;+37764,;201~WP-start~5
Urothelial Carcinoma of Prostatic Urethra Pathway Category. Urothelial 
carcinoma is cancer that develops in the urothelial cells. These cells 
are located in the urothelium, which lines the inside of the urinary 
tract. Urothelial carcinoma can develop in the upper urinary tract (renal 
pelvis, ureter) or the lower urinary tract (bladder, urethra).
9999999.65;+37765,+37764,;.01~SEP 18, 2024@11:37:23
9999999.65;+37765,+37764,;2~WP-start~1
 Creation.
9999999.65;+37766,+37764,;.01~FEB 28, 2025@06:48:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37765^1
37766^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS NO CHEMO OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39757</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2006015446</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39757,;.01~VA-ONC STROMAL NO METS NO CHEMO OFF PATHWAY RSN
9999999.64;+39757,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39757,;.08~YES
9999999.64;+39757,;.1~FACTOR
9999999.64;+39757,;100~NATIONAL
9999999.64;+39757,;101~VHA ONCOLOGY
9999999.64;+39757,;200~Stromal Invasion No Mets No Chemo Off Pathway Reason
9999999.64;+39757,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. Not 
a systemic chemotherapy candidate. Off Pathway Reason. 
9999999.65;+39758,+39757,;.01~FEB 28, 2025@13:39:44
9999999.65;+39758,+39757,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39758^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS NO CHEMO OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39756</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1477060432</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39756,;.01~VA-ONC STROMAL NO METS NO CHEMO OFF PATHWAY TX
9999999.64;+39756,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39756,;.08~YES
9999999.64;+39756,;.1~FACTOR
9999999.64;+39756,;100~NATIONAL
9999999.64;+39756,;101~VHA ONCOLOGY
9999999.64;+39756,;200~Stromal Inv No Mets No Chemo Off Pathway Treatment
9999999.64;+39756,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. Not 
a systemic chemotherapy candidate. Off Pathway Treatment.
9999999.65;+39757,+39756,;.01~FEB 28, 2025@13:38:58
9999999.65;+39757,+39756,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39757^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS NO CHEMO CYSTOPROSTATECTOMY URETHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39755</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>28431722</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39755,;.01~VA-ONC STROMAL NO METS NO CHEMO CYSTOPROSTATECTOMY URETHRECTOMY
9999999.64;+39755,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39755,;.08~YES
9999999.64;+39755,;.1~FACTOR
9999999.64;+39755,;100~NATIONAL
9999999.64;+39755,;101~VHA ONCOLOGY
9999999.64;+39755,;200~Stromal Inv No Mets No Chemo Cystoprostatectomy Urethrectomy
9999999.64;+39755,;201~WP-start~6
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. Not 
a systemic chemotherapy candidate. Veteran has elected to pursue 
Cystoprostatectomy with Urethrectomy. ++ Only if prior metastatic 
disease, reimage with a PET scan to ensure no metastatic disease prior to 
proceding with surgery. ++ 
9999999.65;+39756,+39755,;.01~FEB 28, 2025@13:37:09
9999999.65;+39756,+39755,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39756^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS NO CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39754</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2678233923</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39754,;.01~VA-ONC STROMAL NO METS NO CHEMO CLINICAL TRIAL
9999999.64;+39754,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39754,;.08~YES
9999999.64;+39754,;.1~FACTOR
9999999.64;+39754,;100~NATIONAL
9999999.64;+39754,;101~VHA ONCOLOGY
9999999.64;+39754,;200~Stromal Invasion No Mets No Chemo Clinical Trial
9999999.64;+39754,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. Not 
a systemic chemotherapy candidate. Clinical Trial.
9999999.65;+39755,+39754,;.01~FEB 28, 2025@13:35:29
9999999.65;+39755,+39754,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39755^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS CHEMO OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39753</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>341806370</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39753,;.01~VA-ONC STROMAL NO METS CHEMO OFF PATHWAY RSN
9999999.64;+39753,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39753,;.08~YES
9999999.64;+39753,;.1~FACTOR
9999999.64;+39753,;100~NATIONAL
9999999.64;+39753,;101~VHA ONCOLOGY
9999999.64;+39753,;200~Stromal Invasion No Mets Chemo Off Pathway Reason
9999999.64;+39753,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. 
Systemic chemotherapy candidate. Off Pathway Reason.
9999999.65;+39754,+39753,;.01~FEB 28, 2025@13:34:44
9999999.65;+39754,+39753,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39754^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS CHEMO OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39752</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2501157090</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39752,;.01~VA-ONC STROMAL NO METS CHEMO OFF PATHWAY TX
9999999.64;+39752,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39752,;.08~YES
9999999.64;+39752,;.1~FACTOR
9999999.64;+39752,;100~NATIONAL
9999999.64;+39752,;101~VHA ONCOLOGY
9999999.64;+39752,;200~Stromal Invasion No Mets Chemo Off Pathway Treatment
9999999.64;+39752,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. 
Systemic chemotherapy candidate. Off Pathway Treatment.
9999999.65;+39753,+39752,;.01~FEB 28, 2025@13:34
9999999.65;+39753,+39752,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39753^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS CHEMO CYSTOPROSTATECTOMY URETHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39751</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1721715196</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39751,;.01~VA-ONC STROMAL NO METS CHEMO CYSTOPROSTATECTOMY URETHRECTOMY
9999999.64;+39751,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39751,;.08~YES
9999999.64;+39751,;.1~FACTOR
9999999.64;+39751,;100~NATIONAL
9999999.64;+39751,;101~VHA ONCOLOGY
9999999.64;+39751,;200~Stromal Invasion No Mets Chemo Cystoprostatectomy Urethrectomy
9999999.64;+39751,;201~WP-start~7
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. 
Systemic chemotherapy candidate. Veteran has elected to pursue 
neoadjuvant gemcitabine and cisplatin  (4 cycles) and Cystoprostatectomy 
with Urethrectomy. ++ Only if prior metastatic disease, reimage with a 
PET scan to ensure no metastatic disease prior to proceding with surgery.
++ 
9999999.65;+39752,+39751,;.01~FEB 28, 2025@13:33:02
9999999.65;+39752,+39751,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39752^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS CHEMO CYSTOPROSTATECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39750</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2158330063</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39750,;.01~VA-ONC STROMAL NO METS CHEMO CYSTOPROSTATECTOMY
9999999.64;+39750,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39750,;.08~YES
9999999.64;+39750,;.1~FACTOR
9999999.64;+39750,;100~NATIONAL
9999999.64;+39750,;101~VHA ONCOLOGY
9999999.64;+39750,;200~Stromal Invasion No Mets Chemo Cystoprostatectomy
9999999.64;+39750,;201~WP-start~6
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. 
Systemic chemotherapy candidate. Veteran has elected to pursue 
neoadjuvant gemcitabine and cisplatin  (4 cycles) and Cystoprostatectomy. 
++ Only if prior metastatic disease, reimage with a PET scan to ensure no 
metastatic disease prior to proceding with surgery. ++ 
9999999.65;+39751,+39750,;.01~FEB 28, 2025@13:31:51
9999999.65;+39751,+39750,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39751^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL NO METS CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39749</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>483079787</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39749,;.01~VA-ONC STROMAL NO METS CHEMO CLINICAL TRIAL
9999999.64;+39749,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39749,;.08~YES
9999999.64;+39749,;.1~FACTOR
9999999.64;+39749,;100~NATIONAL
9999999.64;+39749,;101~VHA ONCOLOGY
9999999.64;+39749,;200~Stromal Invasion No Mets Chemo Clinical Trial
9999999.64;+39749,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis shows no metastatic disease. 
Systemic chemotherapy candidate. Clinical Trial.
9999999.65;+39750,+39749,;.01~FEB 28, 2025@13:30:52
9999999.65;+39750,+39749,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39750^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI NO METS POST DEC OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39748</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2168295583</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39748,;.01~VA-ONC DUCTAL & ACINI NO METS POST DEC OFF PATHWAY RSN
9999999.64;+39748,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39748,;.08~YES
9999999.64;+39748,;.1~FACTOR
9999999.64;+39748,;100~NATIONAL
9999999.64;+39748,;101~VHA ONCOLOGY
9999999.64;+39748,;200~Ductal & Acini No Mets Post Decision Off Pathway Reason
9999999.64;+39748,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: Off Pathway Reason.
9999999.65;+39749,+39748,;.01~FEB 28, 2025@13:30:03
9999999.65;+39749,+39748,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39749^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI NO METS POST DEC OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39747</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1521434131</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39747,;.01~VA-ONC DUCTAL & ACINI NO METS POST DEC OFF PATHWAY TX
9999999.64;+39747,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39747,;.08~YES
9999999.64;+39747,;.1~FACTOR
9999999.64;+39747,;100~NATIONAL
9999999.64;+39747,;101~VHA ONCOLOGY
9999999.64;+39747,;200~Ductal & Acini No Mets Post Decision Off Pathway Treatment
9999999.64;+39747,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: Off Pathway Treatment.
9999999.65;+39748,+39747,;.01~FEB 28, 2025@13:29:11
9999999.65;+39748,+39747,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39748^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC D&amp;A NO METS POST DEC CYSTOPROSTATECTOMY URETHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39746</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3263699457</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39746,;.01~VA-ONC D&A NO METS POST DEC CYSTOPROSTATECTOMY URETHRECTOMY
9999999.64;+39746,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39746,;.08~YES
9999999.64;+39746,;.1~FACTOR
9999999.64;+39746,;100~NATIONAL
9999999.64;+39746,;101~VHA ONCOLOGY
9999999.64;+39746,;200~Ductal & Acini No Mets Post Dec Cystoprostatectomy Urethrectomy
9999999.64;+39746,;201~WP-start~7
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: Cystoprostatectomy with Urethrectomy. Follow 
Post Cystectomy Follow Up Pathway. ++ Only if prior metastatic disease, 
reimage with a PET scan to ensure no metastatic disease prior to 
proceeding with surgery. ++
9999999.65;+39747,+39746,;.01~FEB 28, 2025@13:28:17
9999999.65;+39747,+39746,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39747^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI NO METS POST DEC CYSTOPROSTATECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39745</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2434867576</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39745,;.01~VA-ONC DUCTAL & ACINI NO METS POST DEC CYSTOPROSTATECTOMY
9999999.64;+39745,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39745,;.08~YES
9999999.64;+39745,;.1~FACTOR
9999999.64;+39745,;100~NATIONAL
9999999.64;+39745,;101~VHA ONCOLOGY
9999999.64;+39745,;200~Ductal & Acini No Mets Post Decision Cystoprostatectomy
9999999.64;+39745,;201~WP-start~7
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, 
T1) based on Transurethral Resection: Confirm subepithelial involvement. 
CT chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: Cystoprostatectomy. Follow Post Cystectomy 
Follow Up Pathway. ++ Only if prior metastatic disease, reimage with a 
PET scan to ensure no metastatic disease prior to proceeding with 
surgery. ++
9999999.65;+39746,+39745,;.01~FEB 28, 2025@13:26:32
9999999.65;+39746,+39745,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39746^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI NO METS POST DEC TURP BCG</POINT_01>
<INTERNAL_ENTRY_NUMBER>39744</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3155090439</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39744,;.01~VA-ONC DUCTAL & ACINI NO METS POST DEC TURP BCG
9999999.64;+39744,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39744,;.08~YES
9999999.64;+39744,;.1~FACTOR
9999999.64;+39744,;100~NATIONAL
9999999.64;+39744,;101~VHA ONCOLOGY
9999999.64;+39744,;200~Ductal & Acini No Mets Post Decision TURP BCG
9999999.64;+39744,;201~WP-start~5
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: TURP followed by BCG. Then follow NMIBC High 
Risk Pathway.
9999999.65;+39745,+39744,;.01~FEB 28, 2025@13:25:27
9999999.65;+39745,+39744,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39745^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI NO METS POST DEC CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39743</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2638581949</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39743,;.01~VA-ONC DUCTAL & ACINI NO METS POST DEC CLINICAL TRIAL
9999999.64;+39743,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39743,;.08~YES
9999999.64;+39743,;.1~FACTOR
9999999.64;+39743,;100~NATIONAL
9999999.64;+39743,;101~VHA ONCOLOGY
9999999.64;+39743,;200~Ductal & Acini No Mets Post Decision Clinical Trial
9999999.64;+39743,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis shows no metastatic disease. Patient preference 
post shared decision making: Clinical Trial.
9999999.65;+39744,+39743,;.01~FEB 28, 2025@13:24:27
9999999.65;+39744,+39743,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39744^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL INVASION OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39742</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2333992158</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39742,;.01~VA-ONC STROMAL INVASION OFF PATHWAY RSN
9999999.64;+39742,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39742,;.08~YES
9999999.64;+39742,;.1~FACTOR
9999999.64;+39742,;100~NATIONAL
9999999.64;+39742,;101~VHA ONCOLOGY
9999999.64;+39742,;200~Stromal Invasion Off Pathway Reason
9999999.64;+39742,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis not completed. Recommend CT 
chest, abdoment, pelvis for staging. Off Pathway Reason.
9999999.65;+39743,+39742,;.01~FEB 28, 2025@13:23:35
9999999.65;+39743,+39742,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39743^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL INVASION OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39741</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1285248988</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39741,;.01~VA-ONC STROMAL INVASION OFF PATHWAY TX
9999999.64;+39741,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39741,;.08~YES
9999999.64;+39741,;.1~FACTOR
9999999.64;+39741,;100~NATIONAL
9999999.64;+39741,;101~VHA ONCOLOGY
9999999.64;+39741,;200~Stromal Invasion Off Pathway Treatment
9999999.64;+39741,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis not completed. Recommend CT 
chest, abdoment, pelvis for staging. Off Pathway Treatment.
9999999.65;+39742,+39741,;.01~FEB 28, 2025@13:22:42
9999999.65;+39742,+39741,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39742^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL INVASION CT SCAN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39740</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>831290839</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39740,;.01~VA-ONC STROMAL INVASION CT SCAN
9999999.64;+39740,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39740,;.08~YES
9999999.64;+39740,;.1~FACTOR
9999999.64;+39740,;100~NATIONAL
9999999.64;+39740,;101~VHA ONCOLOGY
9999999.64;+39740,;200~Stromal Invasion CT Scan
9999999.64;+39740,;201~WP-start~2
Urothelial Carcinoma of Prostatic Urethra: Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis completed.
9999999.65;+39741,+39740,;.01~FEB 28, 2025@13:21:52
9999999.65;+39741,+39740,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39741^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC STROMAL INVASION CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39739</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1075106340</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39739,;.01~VA-ONC STROMAL INVASION CLINICAL TRIAL
9999999.64;+39739,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39739,;.08~YES
9999999.64;+39739,;.1~FACTOR
9999999.64;+39739,;100~NATIONAL
9999999.64;+39739,;101~VHA ONCOLOGY
9999999.64;+39739,;200~Stromal Invasion Clinical Trial
9999999.64;+39739,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra:  Stromal Invasion Prostatic 
Urethra (T2). CT chest, abdomen, pelvis not completed. Recommend CT chest,
abdoment, pelvis for staging. Clinical Trial.
9999999.65;+39740,+39739,;.01~FEB 28, 2025@13:20:16
9999999.65;+39740,+39739,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39740^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39738</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1467511888</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39738,;.01~VA-ONC DUCTAL & ACINI OFF PATHWAY RSN
9999999.64;+39738,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39738,;.08~YES
9999999.64;+39738,;.1~FACTOR
9999999.64;+39738,;100~NATIONAL
9999999.64;+39738,;101~VHA ONCOLOGY
9999999.64;+39738,;200~Ductal & Acini Off Pathway Reason
9999999.64;+39738,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis not completed. Recommend CT chest, abdomen, pelvis 
for staging. Off Pathway Reason.
9999999.65;+39739,+39738,;.01~FEB 28, 2025@13:18:01
9999999.65;+39739,+39738,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39739^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39737</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3048570046</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39737,;.01~VA-ONC DUCTAL & ACINI OFF PATHWAY TX
9999999.64;+39737,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39737,;.08~YES
9999999.64;+39737,;.1~FACTOR
9999999.64;+39737,;100~NATIONAL
9999999.64;+39737,;101~VHA ONCOLOGY
9999999.64;+39737,;200~Ductal & Acini Off Pathway Treatment
9999999.64;+39737,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis not completed. Recommend CT chest, abdomen, pelvis 
for staging. Off Pathway Treatment.
9999999.65;+39738,+39737,;.01~FEB 28, 2025@13:16:58
9999999.65;+39738,+39737,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39738^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI CT SCAN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39736</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>276693557</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39736,;.01~VA-ONC DUCTAL & ACINI CT SCAN
9999999.64;+39736,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39736,;.08~YES
9999999.64;+39736,;.1~FACTOR
9999999.64;+39736,;100~NATIONAL
9999999.64;+39736,;101~VHA ONCOLOGY
9999999.64;+39736,;200~Ductal & Acini CT Scan
9999999.64;+39736,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis completed.
9999999.65;+39737,+39736,;.01~FEB 28, 2025@13:15:54
9999999.65;+39737,+39736,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39737^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC DUCTAL &amp; ACINI CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39735</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1340380332</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39735,;.01~VA-ONC DUCTAL & ACINI CLINICAL TRIAL
9999999.64;+39735,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+39735,;.08~YES
9999999.64;+39735,;.1~FACTOR
9999999.64;+39735,;100~NATIONAL
9999999.64;+39735,;101~VHA ONCOLOGY
9999999.64;+39735,;200~Ductal & Acini Clinical Trial
9999999.64;+39735,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Ductal and Acini (Ta, Tis, T1) 
based on Transurethral Resection: Confirm subepithelial involvement. CT 
chest, abdomen, pelvis not completed. Recommend CT chest, abdomen, pelvis 
for staging. Clinical Trial.
9999999.65;+39736,+39735,;.01~FEB 28, 2025@13:14:26
9999999.65;+39736,+39735,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39736^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MUCOSAL PROSTATIC URETHRA OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>37769</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3849670393</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37769,;.01~VA-ONC MUCOSAL PROSTATIC URETHRA OFF PATHWAY RSN
9999999.64;+37769,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+37769,;.08~YES
9999999.64;+37769,;.1~FACTOR
9999999.64;+37769,;100~NATIONAL
9999999.64;+37769,;101~VHA ONCOLOGY
9999999.64;+37769,;200~Mucosal Prostatic Urethra Off Pathway Reason
9999999.64;+37769,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra: Mucosal Prostatic Urethra (Ta, 
Tis, T1) based on Transurethral Resection: Confirm subepithelial 
involvement. Off Pathway Reason.
9999999.65;+37770,+37769,;.01~SEP 18, 2024@11:45:15
9999999.65;+37770,+37769,;2~WP-start~1
 Creation.
9999999.65;+37771,+37769,;.01~NOV 29, 2024@10:10:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37770^1
37771^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MUCOSAL PROSTATIC URETHRA OFF PATHWAY TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>37768</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>505392633</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37768,;.01~VA-ONC MUCOSAL PROSTATIC URETHRA OFF PATHWAY TX
9999999.64;+37768,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+37768,;.08~YES
9999999.64;+37768,;.1~FACTOR
9999999.64;+37768,;100~NATIONAL
9999999.64;+37768,;101~VHA ONCOLOGY
9999999.64;+37768,;200~Mucosal Prostatic Urethra Off Pathway Treatment
9999999.64;+37768,;201~WP-start~3
Urothelial Carcinoma of Prostatic Urethra: Mucosal Prostatic Urethra (Ta, 
Tis, T1) based on Transurethral Resection: Confirm subepithelial 
involvement. Off Pathway Treatment.
9999999.65;+37769,+37768,;.01~SEP 18, 2024@11:44:33
9999999.65;+37769,+37768,;2~WP-start~1
 Creation.
9999999.65;+37770,+37768,;.01~NOV 29, 2024@10:10:36
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37769^1
37770^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MUCOSAL PROSTATIC URETHRA TURP</POINT_01>
<INTERNAL_ENTRY_NUMBER>37767</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1210611208</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37767,;.01~VA-ONC MUCOSAL PROSTATIC URETHRA TURP
9999999.64;+37767,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+37767,;.08~YES
9999999.64;+37767,;.1~FACTOR
9999999.64;+37767,;100~NATIONAL
9999999.64;+37767,;101~VHA ONCOLOGY
9999999.64;+37767,;200~Mucosal Prostatic Urethra TURP
9999999.64;+37767,;201~WP-start~4
Urothelial Carcinoma of Prostatic Urethra: Mucosal Prostatic Urethra (Ta, 
Tis, T1) based on Transurethral Resection: Confirm subepithelial 
involvement. TURP, followed by BCG, and then follow NMIBC High Risk 
pathway.
9999999.65;+37768,+37767,;.01~SEP 18, 2024@11:43:44
9999999.65;+37768,+37767,;2~WP-start~1
 Creation.
9999999.65;+37769,+37767,;.01~NOV 29, 2024@10:09:23
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37768^1
37769^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MUCOSAL PROSTATIC URETHRA CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>37766</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2965774524</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+37766,;.01~VA-ONC MUCOSAL PROSTATIC URETHRA CLINICAL TRIAL
9999999.64;+37766,;.03~VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
9999999.64;+37766,;.08~YES
9999999.64;+37766,;.1~FACTOR
9999999.64;+37766,;100~NATIONAL
9999999.64;+37766,;101~VHA ONCOLOGY
9999999.64;+37766,;200~Mucosal Prostatic Urethra Clinical Trial
9999999.64;+37766,;201~WP-start~2
Urothelial Carcinoma of Prostatic Urethra: Mucosal Prostatic Urethra (Ta, 
Tis, T1) based on Transurethral Resection: Clinical Trial.
9999999.65;+37767,+37766,;.01~SEP 18, 2024@11:39:38
9999999.65;+37767,+37766,;2~WP-start~1
 Creation.
9999999.65;+37768,+37766,;.01~NOV 29, 2024@10:08:59
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
37767^1
37768^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE IVB [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>38073</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>426104357</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38073,;.01~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38073,;.08~YES
9999999.64;+38073,;.1~CATEGORY
9999999.64;+38073,;100~NATIONAL
9999999.64;+38073,;101~VHA ONCOLOGY
9999999.64;+38073,;200~Bladder Muscle Invasive Stage IVB Pathway
9999999.64;+38073,;201~WP-start~3
Muscle Invasive Stage IVB Bladder Cancer Pathway Category, All Health 
Factors for Stage IVB Muscle Invasive Bladder Cancer are Placed Under 
this Category.
9999999.65;+38074,+38073,;.01~OCT 08, 2024@13:25:28
9999999.65;+38074,+38073,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38074^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38101</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3056813259</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38101,;.01~VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN
9999999.64;+38101,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38101,;.08~YES
9999999.64;+38101,;.1~FACTOR
9999999.64;+38101,;100~NATIONAL
9999999.64;+38101,;101~VHA ONCOLOGY
9999999.64;+38101,;200~MIBC IVB 2L No FGFR3 Alt HER2 Exp Off Pathway Reason
9999999.64;+38101,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. No FGFR3 
alteration and HER2 over-expression. Off Pathway Reason Text.
9999999.65;+38102,+38101,;.01~OCT 08, 2024@14:05:12
9999999.65;+38102,+38101,;2~WP-start~1
 Creation.
9999999.65;+38103,+38101,;.01~NOV 26, 2024@10:37:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38102^1
38103^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38100</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3979752332</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38100,;.01~VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX
9999999.64;+38100,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38100,;.08~YES
9999999.64;+38100,;.1~FACTOR
9999999.64;+38100,;100~NATIONAL
9999999.64;+38100,;101~VHA ONCOLOGY
9999999.64;+38100,;200~MIBC IVB 2L No FGFR3 Alt HER2 Exp Off Pathway Treatment
9999999.64;+38100,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. No FGFR3 
alteration and HER2 over-expression. Off Pathway Treatment Reason.
9999999.65;+38101,+38100,;.01~OCT 08, 2024@14:04:21
9999999.65;+38101,+38100,;2~WP-start~1
 Creation.
9999999.65;+38102,+38100,;.01~NOV 26, 2024@10:38:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38101^1
38102^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38099</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2892067119</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38099,;.01~VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX
9999999.64;+38099,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38099,;.08~YES
9999999.64;+38099,;.1~FACTOR
9999999.64;+38099,;100~NATIONAL
9999999.64;+38099,;101~VHA ONCOLOGY
9999999.64;+38099,;200~MIBC IVB 2L No FGFR3 Alt HER2 Exp Famtrastruzumab Treatment
9999999.64;+38099,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. No FGFR3 
alteration and HER2 over-expression. Fam-trastuzumab deruxtecan 
Treatment. ++If not a candidate for fam-trastuzumab deruxtecan, consider 
hospice and/or palliative radiation++.
9999999.65;+38100,+38099,;.01~OCT 08, 2024@14:03:15
9999999.65;+38100,+38099,;2~WP-start~1
 Creation.
9999999.65;+38101,+38099,;.01~NOV 26, 2024@10:37:18
9999999.65;+38102,+38099,;.01~NOV 26, 2024@10:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38100^1
38101^2
38102^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38098</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>22360816</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38098,;.01~VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL
9999999.64;+38098,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38098,;.08~YES
9999999.64;+38098,;.1~FACTOR
9999999.64;+38098,;100~NATIONAL
9999999.64;+38098,;101~VHA ONCOLOGY
9999999.64;+38098,;200~MIBC IVB 2L No FGFR3 Alt HER2 Exp Clinical Trial
9999999.64;+38098,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. No FGFR3 
alteration and HER2 over-expression. Clinical Trial.
9999999.65;+38099,+38098,;.01~OCT 08, 2024@14:01:19
9999999.65;+38099,+38098,;2~WP-start~1
 Creation.
9999999.65;+38100,+38098,;.01~NOV 26, 2024@10:36:24
9999999.65;+38101,+38098,;.01~NOV 26, 2024@11:07:07
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38099^1
38100^2
38101^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38096</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>692772917</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38096,;.01~VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH RSN
9999999.64;+38096,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38096,;.08~YES
9999999.64;+38096,;.1~FACTOR
9999999.64;+38096,;100~NATIONAL
9999999.64;+38096,;101~VHA ONCOLOGY
9999999.64;+38096,;200~MIBC IVB 2L FGFR3 Alteration Off Pathway Reason
9999999.64;+38096,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. Fibroblast 
Growth Factor Receptor 3 (FGFR3) alteration. Off Pathway Reason Text.
9999999.65;+38097,+38096,;.01~OCT 08, 2024@13:57:49
9999999.65;+38097,+38096,;2~WP-start~1
 Creation.
9999999.65;+38098,+38096,;.01~NOV 26, 2024@10:35:16
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38097^1
38098^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38095</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1573133701</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38095,;.01~VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH TX
9999999.64;+38095,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38095,;.08~YES
9999999.64;+38095,;.1~FACTOR
9999999.64;+38095,;100~NATIONAL
9999999.64;+38095,;101~VHA ONCOLOGY
9999999.64;+38095,;200~MIBC IVB 2L FGFR3 Alteration Off Pathway Treatment
9999999.64;+38095,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. Fibroblast 
Growth Factor Receptor 3 (FGFR3) alteration. Off Pathway Treatment Reason.
9999999.65;+38096,+38095,;.01~OCT 08, 2024@13:56:55
9999999.65;+38096,+38095,;2~WP-start~1
 Creation.
9999999.65;+38097,+38095,;.01~NOV 26, 2024@10:34:47
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38096^1
38097^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L FGFR3 ALTERATION ERDAFITINIB TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38094</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2279159737</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38094,;.01~VA-ONC MIBC IVB 2L FGFR3 ALTERATION ERDAFITINIB TX
9999999.64;+38094,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38094,;.08~YES
9999999.64;+38094,;.1~FACTOR
9999999.64;+38094,;100~NATIONAL
9999999.64;+38094,;101~VHA ONCOLOGY
9999999.64;+38094,;200~MIBC IVB 2L FGFR3 Alteration Erdafitinib Treatment
9999999.64;+38094,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. Fibroblast 
Growth Factor Receptor 3 (FGFR3) alteration. Erdafitinib Treatment. ++If 
not a candidate for erdafitinib, consider hospice and/or palliative 
radiation++.
9999999.65;+38095,+38094,;.01~OCT 08, 2024@13:55:47
9999999.65;+38095,+38094,;2~WP-start~1
 Creation.
9999999.65;+38096,+38094,;.01~NOV 26, 2024@10:33:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38095^1
38096^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 2L FGFR3 ALTERATION CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38093</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3073039738</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38093,;.01~VA-ONC MIBC IVB 2L FGFR3 ALTERATION CLINICAL TRIAL
9999999.64;+38093,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38093,;.08~YES
9999999.64;+38093,;.1~FACTOR
9999999.64;+38093,;100~NATIONAL
9999999.64;+38093,;101~VHA ONCOLOGY
9999999.64;+38093,;200~MIBC IVB 2L FGFR3 Alteration Clinical Trial
9999999.64;+38093,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 2nd Line Therapy. Fibroblast 
Growth Factor Receptor 3 (FGFR3) alteration. Clinical Trial.
9999999.65;+38094,+38093,;.01~OCT 08, 2024@13:54:53
9999999.65;+38094,+38093,;2~WP-start~1
 Creation.
9999999.65;+38095,+38093,;.01~NOV 26, 2024@10:33:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38094^1
38095^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38090</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3228036831</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38090,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH RSN
9999999.64;+38090,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38090,;.08~YES
9999999.64;+38090,;.1~FACTOR
9999999.64;+38090,;100~NATIONAL
9999999.64;+38090,;101~VHA ONCOLOGY
9999999.64;+38090,;200~MIBC IVB 1L No EV Pembro No Chemo Off Path Reason
9999999.64;+38090,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Not chemotherapy eligible. 
Off Pathway Reason Text.
9999999.65;+38091,+38090,;.01~OCT 08, 2024@13:52:12
9999999.65;+38091,+38090,;2~WP-start~1
 Creation.
9999999.65;+38092,+38090,;.01~NOV 26, 2024@10:31:46
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38091^1
38092^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38089</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2509761133</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38089,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH TX
9999999.64;+38089,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38089,;.08~YES
9999999.64;+38089,;.1~FACTOR
9999999.64;+38089,;100~NATIONAL
9999999.64;+38089,;101~VHA ONCOLOGY
9999999.64;+38089,;200~MIBC IVB 1L No EV Pembro No Chemo Off Path Treatment
9999999.64;+38089,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Not chemotherapy eligible. 
Off Pathway Treatment Reason.
9999999.65;+38090,+38089,;.01~OCT 08, 2024@13:51:15
9999999.65;+38090,+38089,;2~WP-start~1
 Creation.
9999999.65;+38091,+38089,;.01~NOV 26, 2024@10:26:49
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38090^1
38091^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38088</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>250114047</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38088,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX
9999999.64;+38088,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38088,;.08~YES
9999999.64;+38088,;.1~FACTOR
9999999.64;+38088,;100~NATIONAL
9999999.64;+38088,;101~VHA ONCOLOGY
9999999.64;+38088,;200~MIBC IVB 1L No EV Pembro No Chemo Pembro Treatment
9999999.64;+38088,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Not chemotherapy eligible. 
Pembrolizumab treatment. 
9999999.65;+38089,+38088,;.01~OCT 08, 2024@13:50:10
9999999.65;+38089,+38088,;2~WP-start~1
 Creation.
9999999.65;+38090,+38088,;.01~NOV 26, 2024@10:29:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38089^1
38090^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38087</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>406219586</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38087,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL
9999999.64;+38087,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38087,;.08~YES
9999999.64;+38087,;.1~FACTOR
9999999.64;+38087,;100~NATIONAL
9999999.64;+38087,;101~VHA ONCOLOGY
9999999.64;+38087,;200~MIBC IVB 1L No EV Pembro No Chemo Clinical Trial
9999999.64;+38087,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Not chemotherapy eligible. 
Clinical Trial.
9999999.65;+38088,+38087,;.01~OCT 08, 2024@13:48:26
9999999.65;+38088,+38087,;2~WP-start~1
 Creation.
9999999.65;+38089,+38087,;.01~NOV 26, 2024@10:27:54
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38088^1
38089^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38085</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1783745001</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38085,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN
9999999.64;+38085,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38085,;.08~YES
9999999.64;+38085,;.1~FACTOR
9999999.64;+38085,;100~NATIONAL
9999999.64;+38085,;101~VHA ONCOLOGY
9999999.64;+38085,;200~MIBC IVB 1L No EV Pembro, Chemo Eligible Off Path Reason
9999999.64;+38085,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Chemotherapy eligible. Off 
Pathway Reason Text.
9999999.65;+38086,+38085,;.01~OCT 08, 2024@13:45:21
9999999.65;+38086,+38085,;2~WP-start~1
 Creation.
9999999.65;+38087,+38085,;.01~NOV 26, 2024@10:25:46
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38086^1
38087^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38084</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>762069798</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38084,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX
9999999.64;+38084,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38084,;.08~YES
9999999.64;+38084,;.1~FACTOR
9999999.64;+38084,;100~NATIONAL
9999999.64;+38084,;101~VHA ONCOLOGY
9999999.64;+38084,;200~MIBC IVB 1L No EV Pembro Chemo Eligible Off Path Treatment
9999999.64;+38084,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Chemotherapy eligible. Off 
Pathway Treatment Reason.
9999999.65;+38085,+38084,;.01~OCT 08, 2024@13:44:28
9999999.65;+38085,+38084,;2~WP-start~1
 Creation.
9999999.65;+38086,+38084,;.01~NOV 26, 2024@10:30:58
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38085^1
38086^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO GEM</POINT_01>
<INTERNAL_ENTRY_NUMBER>38083</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1375675342</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38083,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO GEM
9999999.64;+38083,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38083,;.08~YES
9999999.64;+38083,;.1~FACTOR
9999999.64;+38083,;100~NATIONAL
9999999.64;+38083,;101~VHA ONCOLOGY
9999999.64;+38083,;200~MIBC IVB 1L No EV Pembro Chemo Eligible Carbo Gem
9999999.64;+38083,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Chemotherapy eligible. 
Carboplatin and gemcitabine followed by avelumab maintenance.
9999999.65;+38084,+38083,;.01~OCT 08, 2024@13:43:35
9999999.65;+38084,+38083,;2~WP-start~1
 Creation.
9999999.65;+38085,+38083,;.01~OCT 08, 2024@14:07:40
9999999.65;+38086,+38083,;.01~NOV 26, 2024@10:22:51
9999999.65;+38087,+38083,;.01~NOV 27, 2024@08:48:12
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38084^1
38085^2
38086^3
38087^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38082</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2602322880</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38082,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLINICAL TRIAL
9999999.64;+38082,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38082,;.08~YES
9999999.64;+38082,;.1~FACTOR
9999999.64;+38082,;100~NATIONAL
9999999.64;+38082,;101~VHA ONCOLOGY
9999999.64;+38082,;200~MIBC IVB 1L No EV Pembro Chemo Eligible Clinical Trial
9999999.64;+38082,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Not 
enfortumab vedotin and pembrolizumab eligible. Chemotherapy eligible. 
Clinical Trial.
9999999.65;+38083,+38082,;.01~OCT 08, 2024@13:42:12
9999999.65;+38083,+38082,;2~WP-start~1
 Creation.
9999999.65;+38084,+38082,;.01~OCT 08, 2024@14:08:06
9999999.65;+38085,+38082,;.01~NOV 26, 2024@10:24:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38083^1
38084^2
38085^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38079</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3724358787</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38079,;.01~VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN
9999999.64;+38079,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38079,;.08~YES
9999999.64;+38079,;.1~FACTOR
9999999.64;+38079,;100~NATIONAL
9999999.64;+38079,;101~VHA ONCOLOGY
9999999.64;+38079,;200~MIBC IVB 1L EV Pembro Eligible Off Pathway Reason
9999999.64;+38079,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Enfortumab 
vedotin and pembrolizumab eligible. Off Pathway Reason Text.
9999999.65;+38080,+38079,;.01~OCT 08, 2024@13:34:11
9999999.65;+38080,+38079,;2~WP-start~1
 Creation.
9999999.65;+38081,+38079,;.01~NOV 26, 2024@08:58:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38080^1
38081^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38078</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3893435324</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38078,;.01~VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX
9999999.64;+38078,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38078,;.08~YES
9999999.64;+38078,;.1~FACTOR
9999999.64;+38078,;100~NATIONAL
9999999.64;+38078,;101~VHA ONCOLOGY
9999999.64;+38078,;200~MIBC IVB 1L EV Pembro Eligible Off Pathway Treatment
9999999.64;+38078,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Enfortumab 
vedotin and pembrolizumab eligible. Off Pathway Treatment Reason.
9999999.65;+38079,+38078,;.01~OCT 08, 2024@13:33:04
9999999.65;+38079,+38078,;2~WP-start~1
 Creation.
9999999.65;+38080,+38078,;.01~NOV 26, 2024@08:58:36
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38079^1
38080^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L EV PEMBRO TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38077</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2151347707</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38077,;.01~VA-ONC MIBC IVB 1L EV PEMBRO TX
9999999.64;+38077,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38077,;.08~YES
9999999.64;+38077,;.1~FACTOR
9999999.64;+38077,;100~NATIONAL
9999999.64;+38077,;101~VHA ONCOLOGY
9999999.64;+38077,;200~MIBC IVB 1L EV Pembro Eligible Pembro Treatment
9999999.64;+38077,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Enfortumab 
vedotin and pembrolizumab eligible. Enfortumab vedotin and pembrolizumab 
treatment.
9999999.65;+38078,+38077,;.01~OCT 08, 2024@13:32:16
9999999.65;+38078,+38077,;2~WP-start~1
 Creation.
9999999.65;+38079,+38077,;.01~NOV 26, 2024@09:00:10
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38078^1
38079^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38076</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2168532359</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38076,;.01~VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL
9999999.64;+38076,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
9999999.64;+38076,;.08~YES
9999999.64;+38076,;.1~FACTOR
9999999.64;+38076,;100~NATIONAL
9999999.64;+38076,;101~VHA ONCOLOGY
9999999.64;+38076,;200~MIBC IVB 1L EV Pembro Eligible Clinical Trial
9999999.64;+38076,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVB. 1st Line Therapy. Enfortumab 
vedotin and pembrolizumab eligible. Clinical Trial.
9999999.65;+38077,+38076,;.01~OCT 08, 2024@13:30:28
9999999.65;+38077,+38076,;2~WP-start~1
 Creation.
9999999.65;+38078,+38076,;.01~NOV 26, 2024@08:56:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38077^1
38078^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE IVA [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>38059</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3918175809</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38059,;.01~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38059,;.08~YES
9999999.64;+38059,;.1~CATEGORY
9999999.64;+38059,;100~NATIONAL
9999999.64;+38059,;101~VHA ONCOLOGY
9999999.64;+38059,;200~Bladder Muscle Invasive Stage IVA Pathway
9999999.64;+38059,;201~WP-start~3
Muscle Invasive Stage IVA Bladder Cancer Pathway Category, All Health 
Factors for Stage IVA Muscle Invasive Bladder Cancer are Placed Under 
this Category.
9999999.65;+38060,+38059,;.01~OCT 08, 2024@12:15:33
9999999.65;+38060,+38059,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38060^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39079</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1730303576</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39079,;.01~VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH RSN
9999999.64;+39079,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39079,;.08~YES
9999999.64;+39079,;.1~FACTOR
9999999.64;+39079,;100~NATIONAL
9999999.64;+39079,;101~VHA ONCOLOGY
9999999.64;+39079,;200~MIBC IVA 5FU Mitomycin Radiation Off Pathway Reason
9999999.64;+39079,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (2-3 months 
post chemo/radiation) for concurrent 5FU, mitomycin, and radiation. Off 
Pathway Reason Text.
9999999.65;+39080,+39079,;.01~NOV 25, 2024@11:34:27
9999999.65;+39080,+39079,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39080^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39078</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>188603299</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39078,;.01~VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH TX
9999999.64;+39078,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39078,;.08~YES
9999999.64;+39078,;.1~FACTOR
9999999.64;+39078,;100~NATIONAL
9999999.64;+39078,;101~VHA ONCOLOGY
9999999.64;+39078,;200~MIBC IVA 5FU Mitomycin Radiation Off Pathway Treatment
9999999.64;+39078,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (2-3 months 
post chemo/radiation) for concurrent 5FU, mitomycin, and radiation. Off 
Pathway Treatment Reason.
9999999.65;+39079,+39078,;.01~NOV 25, 2024@11:33:24
9999999.65;+39079,+39078,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39079^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39077</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4131918602</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39077,;.01~VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CYSTECTOMY
9999999.64;+39077,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39077,;.08~YES
9999999.64;+39077,;.1~FACTOR
9999999.64;+39077,;100~NATIONAL
9999999.64;+39077,;101~VHA ONCOLOGY
9999999.64;+39077,;200~MIBC IVA 5FU Mitomycin Radiation Cystectomy
9999999.64;+39077,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (2-3 months 
post chemo/radiation) for concurrent 5FU, mitomycin, and radiation. 
Cystectomy.
9999999.65;+39078,+39077,;.01~NOV 25, 2024@11:31:15
9999999.65;+39078,+39077,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39078^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39076</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2738549784</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39076,;.01~VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CLINICAL TRIAL
9999999.64;+39076,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39076,;.08~YES
9999999.64;+39076,;.1~FACTOR
9999999.64;+39076,;100~NATIONAL
9999999.64;+39076,;101~VHA ONCOLOGY
9999999.64;+39076,;200~MIBC IVA 5FU Mitomycin Radiation Clinical Trial
9999999.64;+39076,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (2-3 months 
post chemo/radiation) for concurrent 5FU, mitomycin, and radiation. 
Clinical Trial.
9999999.65;+39077,+39076,;.01~NOV 25, 2024@11:30:05
9999999.65;+39077,+39076,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39077^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39075</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1378331297</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39075,;.01~VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH RSN
9999999.64;+39075,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39075,;.08~YES
9999999.64;+39075,;.1~FACTOR
9999999.64;+39075,;100~NATIONAL
9999999.64;+39075,;101~VHA ONCOLOGY
9999999.64;+39075,;200~MIBC IVA Reassess EV Pembro Gem Cis Off Pathway Reason
9999999.64;+39075,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (every 2-3 
cycles) for enfortumab vedotin and  pembrolizumab -OR- gemcitabine and 
cisplatin. Off Pathway Reason Text.
9999999.65;+39076,+39075,;.01~NOV 25, 2024@11:29:03
9999999.65;+39076,+39075,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39076^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39074</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2870685472</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39074,;.01~VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH TX
9999999.64;+39074,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39074,;.08~YES
9999999.64;+39074,;.1~FACTOR
9999999.64;+39074,;100~NATIONAL
9999999.64;+39074,;101~VHA ONCOLOGY
9999999.64;+39074,;200~MIBC IVA Reassess EV Pembro Gem Cis Off Pathway Treatment
9999999.64;+39074,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (every 2-3 
cycles) for enfortumab vedotin and  pembrolizumab -OR- gemcitabine and 
cisplatin. Off Pathway Treatment Reason.
9999999.65;+39075,+39074,;.01~NOV 25, 2024@11:28:07
9999999.65;+39075,+39074,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39075^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>39073</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>891684236</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39073,;.01~VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS RADIATION
9999999.64;+39073,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39073,;.08~YES
9999999.64;+39073,;.1~FACTOR
9999999.64;+39073,;100~NATIONAL
9999999.64;+39073,;101~VHA ONCOLOGY
9999999.64;+39073,;200~MIBC IVA Reassess EV Pembro Gem Cis Radiation
9999999.64;+39073,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (every 2-3 
cycles) for enfortumab vedotin and  pembrolizumab -OR- gemcitabine and 
cisplatin. Radiation.
9999999.65;+39074,+39073,;.01~NOV 25, 2024@11:27:09
9999999.65;+39074,+39073,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39074^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39072</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3597052081</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39072,;.01~VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CYSTECTOMY
9999999.64;+39072,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39072,;.08~YES
9999999.64;+39072,;.1~FACTOR
9999999.64;+39072,;100~NATIONAL
9999999.64;+39072,;101~VHA ONCOLOGY
9999999.64;+39072,;200~MIBC IVA Reassess EV Pembro Gem Cis Cystectomy
9999999.64;+39072,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (every 2-3 
cycles) for enfortumab vedotin and  pembrolizumab -OR- gemcitabine and 
cisplatin. Cystectomy.
9999999.65;+39073,+39072,;.01~NOV 25, 2024@11:26:16
9999999.65;+39073,+39072,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39073^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39071</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1262677800</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39071,;.01~VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CLINICAL TRIAL
9999999.64;+39071,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+39071,;.08~YES
9999999.64;+39071,;.1~FACTOR
9999999.64;+39071,;100~NATIONAL
9999999.64;+39071,;101~VHA ONCOLOGY
9999999.64;+39071,;200~MIBC IVA Reassess EV Pembro Gem Cis Clinical Trial
9999999.64;+39071,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA. Interim assessment (every 2-3 
cycles) for enfortumab vedotin and  pembrolizumab -OR- gemcitabine and 
cisplatin. Clinical Trial.
9999999.65;+39072,+39071,;.01~NOV 25, 2024@11:25:04
9999999.65;+39072,+39071,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39072^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38066</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4188145370</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38066,;.01~VA-ONC MIBC IVA OFF PATH RSN
9999999.64;+38066,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38066,;.08~YES
9999999.64;+38066,;.1~FACTOR
9999999.64;+38066,;100~NATIONAL
9999999.64;+38066,;101~VHA ONCOLOGY
9999999.64;+38066,;200~MIBC IVA Off Pathway Reason
9999999.64;+38066,;201~WP-start~1
Muscle Invasive Bladder Cancer: Stage IVA. Off Pathway Reason Text.
9999999.65;+38067,+38066,;.01~OCT 08, 2024@12:24:09
9999999.65;+38067,+38066,;2~WP-start~1
 Creation.
9999999.65;+38068,+38066,;.01~NOV 26, 2024@08:54:19
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38067^1
38068^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>38065</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>686267260</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38065,;.01~VA-ONC MIBC IVA OFF PATH TX
9999999.64;+38065,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38065,;.08~YES
9999999.64;+38065,;.1~FACTOR
9999999.64;+38065,;100~NATIONAL
9999999.64;+38065,;101~VHA ONCOLOGY
9999999.64;+38065,;200~MIBC IVA Off Pathway Treatment
9999999.64;+38065,;201~WP-start~1
Muscle Invasive Bladder Cancer: Stage IVA. Off Pathway Treatment Reason.
9999999.65;+38066,+38065,;.01~OCT 08, 2024@12:23:10
9999999.65;+38066,+38065,;2~WP-start~1
 Creation.
9999999.65;+38067,+38065,;.01~NOV 26, 2024@08:54:59
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38066^1
38067^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA PALLIATIVE OR HOSPICE</POINT_01>
<INTERNAL_ENTRY_NUMBER>38064</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1025055441</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38064,;.01~VA-ONC MIBC IVA PALLIATIVE OR HOSPICE
9999999.64;+38064,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38064,;.08~YES
9999999.64;+38064,;.1~FACTOR
9999999.64;+38064,;100~NATIONAL
9999999.64;+38064,;101~VHA ONCOLOGY
9999999.64;+38064,;200~MIBC IVA Palliative or Hospice
9999999.64;+38064,;201~WP-start~2
Muscle Invasive Bladder Cancer: Stage IVA.  Palliative radiation, 
palliative care, or hospice. ++Follow up as clinically indicated++
9999999.65;+38065,+38064,;.01~OCT 08, 2024@12:22:12
9999999.65;+38065,+38064,;2~WP-start~1
 Creation.
9999999.65;+38066,+38064,;.01~NOV 26, 2024@12:02:14
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38065^1
38066^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>38063</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3680705461</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38063,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RADIATION
9999999.64;+38063,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38063,;.08~YES
9999999.64;+38063,;.1~FACTOR
9999999.64;+38063,;100~NATIONAL
9999999.64;+38063,;101~VHA ONCOLOGY
9999999.64;+38063,;200~MIBC IVA 5FU Mitomycin Radiation
9999999.64;+38063,;201~WP-start~3
Muscle Invasive Bladder Cancer: Stage IVA.  Concurrent 5FU, mitomycin, 
and radiation only for no distant metastasis (M0). ++Reassess tumor 2-3 
months post Treatment Reason++
9999999.65;+38064,+38063,;.01~OCT 08, 2024@12:21:15
9999999.65;+38064,+38063,;2~WP-start~1
 Creation.
9999999.65;+38065,+38063,;.01~NOV 26, 2024@07:54:03
9999999.65;+38066,+38063,;.01~NOV 27, 2024@08:25:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38064^1
38065^2
38066^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA GEMCITABINE CISPLATIN NIVOLUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>38062</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1800841897</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38062,;.01~VA-ONC MIBC IVA GEMCITABINE CISPLATIN NIVOLUMAB
9999999.64;+38062,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38062,;.08~YES
9999999.64;+38062,;.1~FACTOR
9999999.64;+38062,;100~NATIONAL
9999999.64;+38062,;101~VHA ONCOLOGY
9999999.64;+38062,;200~MIBC Stage IVA Gemcitabine Cisplatin Nivolumab
9999999.64;+38062,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage IVA.  Gemcitabine, Cisplatin, and 
Nivolumab.
++Interim Assessment includes EUA, cystoscopy, and CT 
chest/abdomen/pelvis++
9999999.65;+38063,+38062,;.01~OCT 08, 2024@12:19:17
9999999.65;+38063,+38062,;2~WP-start~1
 Creation.
9999999.65;+38064,+38062,;.01~MAR 13, 2025@06:12:03
9999999.65;+38065,+38062,;.01~MAR 13, 2025@06:15:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38063^1
38064^2
38065^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV AND PEMBROLIZUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>38061</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1104766969</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38061,;.01~VA-ONC MIBC IVA EV AND PEMBROLIZUMAB
9999999.64;+38061,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38061,;.08~YES
9999999.64;+38061,;.1~FACTOR
9999999.64;+38061,;100~NATIONAL
9999999.64;+38061,;101~VHA ONCOLOGY
9999999.64;+38061,;200~MIBC Stage IVA EV & Pembrolizumab
9999999.64;+38061,;201~WP-start~4
Muscle Invasive Bladder Cancer: Stage IVA. Enfortumab Vedotin and 
Pembrolizumab. ++Exclude patients with preexisting peripheral neuropathy 
Grade 2, baseline ocular disorders, uncontrolled diabetes at baseline, 
Interim Assessment includes EUA, cystoscopy, and CT chest/abdomen/pelvis++
9999999.65;+38062,+38061,;.01~OCT 08, 2024@12:18:04
9999999.65;+38062,+38061,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38062^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>38060</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3859904873</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38060,;.01~VA-ONC MIBC IVA CLINICAL TRIAL
9999999.64;+38060,;.03~VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
9999999.64;+38060,;.08~YES
9999999.64;+38060,;.1~FACTOR
9999999.64;+38060,;100~NATIONAL
9999999.64;+38060,;101~VHA ONCOLOGY
9999999.64;+38060,;200~MIBC IVA Clinical Trial
9999999.64;+38060,;201~WP-start~1
Muscle Invasive Bladder Cancer: Stage IVA. Clinical Trial.
9999999.65;+38061,+38060,;.01~OCT 08, 2024@12:17:08
9999999.65;+38061,+38060,;2~WP-start~1
 Creation.
9999999.65;+38062,+38060,;.01~NOV 26, 2024@08:53:26
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38061^1
38062^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE IVB</POINT_01>
<INTERNAL_ENTRY_NUMBER>38019</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4036266197</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38019,;.01~VA-ONC BLADDER MUSCLE INVASIVE IVB
9999999.64;+38019,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+38019,;.08~YES
9999999.64;+38019,;.1~FACTOR
9999999.64;+38019,;100~NATIONAL
9999999.64;+38019,;101~VHA ONCOLOGY
9999999.64;+38019,;200~Bladder Muscle Invasive Stage IVB Pathway
9999999.64;+38019,;201~WP-start~1
Muscle Invasive Stage IVB Bladder Cancer Pathway.
9999999.65;+38020,+38019,;.01~OCT 08, 2024@11:28:24
9999999.65;+38020,+38019,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38020^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE IVA</POINT_01>
<INTERNAL_ENTRY_NUMBER>38018</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1835438912</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+38018,;.01~VA-ONC BLADDER MUSCLE INVASIVE IVA
9999999.64;+38018,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+38018,;.08~YES
9999999.64;+38018,;.1~FACTOR
9999999.64;+38018,;100~NATIONAL
9999999.64;+38018,;101~VHA ONCOLOGY
9999999.64;+38018,;200~Bladder Muscle Invasive Stage IVA Pathway
9999999.64;+38018,;201~WP-start~1
Muscle Invasive Stage IVA Bladder Cancer Pathway.
9999999.65;+38019,+38018,;.01~OCT 08, 2024@11:27:19
9999999.65;+38019,+38018,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38019^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER SPONSOR</FILE_NAME>
<FILE_NUMBER>811.6</FILE_NUMBER>
<POINT_01>VHA ONCOLOGY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2932841009</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
811.6;+39,;.01~VHA ONCOLOGY
811.6;+39,;100~NATIONAL
811.63;+40,+39,;.01~04/27/2026@11:26:12
811.63;+40,+39,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
40^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER TERM</FILE_NAME>
<FILE_NUMBER>811.5</FILE_NUMBER>
<POINT_01>VA-REMINDER UPDATE_2_0_570</POINT_01>
<INTERNAL_ENTRY_NUMBER>3490</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>878420099</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
811.5;+3490,;.01~VA-REMINDER UPDATE_2_0_570
811.5;+3490,;100~NATIONAL
811.52;+3491,+3490,;.01~HF.VA-UPDATE_2_0_570
811.52;+3491,+3490,;11~0
811.52;+3491,+3490,;15~NO
811.53;+3492,+3490,;.01~04/27/2026@11:26:12
811.53;+3492,+3490,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
3491^1
3492^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY COMPONENT</FILE_NAME>
<FILE_NUMBER>142.1</FILE_NUMBER>
<POINT_01>PCE HEALTH FACTORS SELECTED</POINT_01>
<INTERNAL_ENTRY_NUMBER>203</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1531877056</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142.1;+203,;.01~PCE HEALTH FACTORS SELECTED
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY TYPE</FILE_NAME>
<FILE_NUMBER>142</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS BLADDER</POINT_01>
<INTERNAL_ENTRY_NUMBER>2757</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2588687710</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142;+2757,;.01~VA-ONCOLOGY PATHWAYS BLADDER
142;+2757,;.08~yes
142;+2757,;99~67269,22563
142.01;+2758,+2757,;.01~5
142.01;+2758,+2757,;1~PCE HEALTH FACTORS SELECTED
142.01;+2758,+2757,;5~Health Factor Select
142.14;+2759,+2758,+2757,;.01~F.VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB [C]
142.14;+2760,+2758,+2757,;.01~F.VA-ONC BLADDER MUSCLE INVASIVE IVA [C]
142.14;+2761,+2758,+2757,;.01~F.VA-ONC BLADDER MUSCLE INVASIVE IVB [C]
142.14;+2762,+2758,+2757,;.01~F.VA-ONC UROTHELIAL CARCINOMA OF PROSTATIC URETHRA PATHWAY [C]
142.14;+2763,+2758,+2757,;.01~F.VA-ONC BLADDER UPGU TRACT CARCINOMA PATHWAY [C]
142.14;+2764,+2758,+2757,;.01~F.VA-ONC BLADDER NMIBC HIGH RISK PATHWAY [C]
142.14;+2765,+2758,+2757,;.01~F.VA-ONC BLADDER NMIBC INTERMEDIATE RISK PATHWAY [C]
142.14;+2766,+2758,+2757,;.01~F.VA-ONC BLADDER NMIBC LOW RISK PATHWAY [C]
142.14;+2767,+2758,+2757,;.01~F.VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING PD-L1 PATHWAY [C]
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
2758^5
2759^1
2760^2
2761^3
2762^4
2763^5
2764^6
2765^7
2766^8
2767^9
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY OBJECTS</FILE_NAME>
<FILE_NUMBER>142.5</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS BLADDER (TIU)</POINT_01>
<INTERNAL_ENTRY_NUMBER>6600786</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1510813564</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142.5;+6600786,;.01~VA-ONCOLOGY PATHWAYS BLADDER (TIU)
142.5;+6600786,;.03~VA-ONCOLOGY PATHWAYS BLADDER
142.5;+6600786,;.05~YES
142.5;+6600786,;.06~YES
142.5;+6600786,;.07~NO
142.5;+6600786,;.08~NO
142.5;+6600786,;.09~NO
142.5;+6600786,;.1~NO
142.5;+6600786,;.11~NO
142.5;+6600786,;.12~NO
142.5;+6600786,;.13~NO
142.5;+6600786,;.14~NO
142.5;+6600786,;.15~NO
142.5;+6600786,;.16~NO
142.5;+6600786,;.18~MAR 12, 2024@07:02:57
142.5;+6600786,;.19~OCT 10, 2024@09:45:02
142.5;+6600786,;.2~NO
142.5;+6600786,;2~No pathways data found
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU DOCUMENT DEFINITION</FILE_NAME>
<FILE_NUMBER>8925.1</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS BLADDER</POINT_01>
<INTERNAL_ENTRY_NUMBER>2009</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1532065020</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8925.1;+2009,;.01~VA-ONCOLOGY PATHWAYS BLADDER
8925.1;+2009,;.03~VA-ONCOLOGY PATHWAYS BLADDER
8925.1;+2009,;.04~OBJECT
8925.1;+2009,;.07~ACTIVE
8925.1;+2009,;9~S X=$$TIU^GMTSOBJ(DFN,VA-ONCOLOGY PATHWAYS BLADDER (TIU))
8925.1;+2009,;99~
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN TOTAL TIME SPENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>108583</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3708613222</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108583,;.01~VA-NTO CN TOTAL TIME SPENT
801.41;+108583,;4~dialog element
801.41;+108583,;15~HF.VA-NTO CN TOTAL TIME SPENT F2F/CVT/VVC/TELEPHONE
801.41;+108583,;25~WP-start~1
Total time spent:
801.41;+108583,;51~SUPPRESS
801.41;+108583,;100~NATIONAL
801.41;+108583,;101~VHA ONCOLOGY
801.44;+108584,+108583,;.01~04/27/2026@11:26:12
801.44;+108584,+108583,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108584^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT TELEPHONE TALK</POINT_01>
<INTERNAL_ENTRY_NUMBER>67738</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>721634745</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67738,;.01~VA-NTO CN TIME SPENT TELEPHONE TALK
801.41;+67738,;4~dialog element
801.41;+67738,;15~HF.VA-NTO CN TIME SPENT TELEPHONE TALK
801.41;+67738,;25~WP-start~1
Time spent in medical discussion with Veteran via telephone:
801.41;+67738,;51~SUPPRESS
801.41;+67738,;100~NATIONAL
801.44;+67739,+67738,;.01~04/27/2026@11:26:12
801.44;+67739,+67738,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67739^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN TIME SPENT TELEPHONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>67737</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>269453175</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67737,;.01~VA-GP NTO CN TIME SPENT TELEPHONE
801.41;+67737,;4~dialog group
801.41;+67737,;6~YES
801.41;+67737,;7~2
801.41;+67737,;25~WP-start~1
Time Spent:
801.41;+67737,;51~SUPPRESS
801.41;+67737,;52~INDENT
801.41;+67737,;100~NATIONAL
801.412;+67738,+67737,;.01~20
801.412;+67738,+67737,;2~VA-NTO CN TIME SPENT TELEPHONE TALK
801.412;+67739,+67737,;.01~30
801.412;+67739,+67737,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+67740,+67737,;.01~04/27/2026@11:26:12
801.44;+67740,+67737,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67738^1
67739^2
67740^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT TELEPHONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>67736</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>127116351</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67736,;.01~VA-GP NTO CN VISIT TELEPHONE
801.41;+67736,;4~dialog group
801.41;+67736,;6~YES
801.41;+67736,;7~2
801.41;+67736,;25~WP-start~1
Telephone:
801.41;+67736,;52~INDENT
801.41;+67736,;100~NATIONAL
801.412;+67737,+67736,;.01~20
801.412;+67737,+67736,;2~VA-GP NTO CN TIME SPENT TELEPHONE
801.44;+67738,+67736,;.01~04/27/2026@11:26:12
801.44;+67738,+67736,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67737^1
67738^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC VISIT LATERALITY CONFIRMATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>100924</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1828894756</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+100924,;.01~VA-ONC VISIT LATERALITY CONFIRMATION
801.41;+100924,;4~dialog element
801.41;+100924,;25~WP-start~2
Verbal and visual validation of laterality confirmed prior to beginning
the telehealth visit/exam.
801.41;+100924,;35~WP-start~2
\\Verbal and visual validation of laterality confirmed prior to beginning 
the telehealth visit/exam.
801.41;+100924,;100~NATIONAL
801.44;+100925,+100924,;.01~04/27/2026@11:26:12
801.44;+100925,+100924,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
100925^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN VISIT VVC TELEHEALTH DISCLOSURE</POINT_01>
<INTERNAL_ENTRY_NUMBER>69225</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2312551590</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+69225,;.01~VA-NTO CN VISIT VVC TELEHEALTH DISCLOSURE
801.41;+69225,;4~dialog element
801.41;+69225,;25~WP-start~6
Telehealth Disclosure: 
  Visit conducted by synchronous telehealth. 
  Patient's verbal consent obtained. 
  Location/emergency number confirmed.
  Environment surveyed and all participants identified.
  Virtual conference room locked.
801.41;+69225,;35~WP-start~6
\\Telehealth Disclosure: 
  Visit conducted by synchronous telehealth. 
  Patient's verbal consent obtained. 
  Location/emergency number confirmed.
  Environment surveyed and all participants identified.
  Virtual conference room locked.
801.41;+69225,;51~SUPPRESS
801.41;+69225,;100~NATIONAL
801.44;+69226,+69225,;.01~04/27/2026@11:26:12
801.44;+69226,+69225,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
69226^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN WP BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57253</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4016076497</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57253,;.01~VA-ONC CN WP BOX
801.41;+57253,;4~dialog element
801.41;+57253,;25~WP-start~1
{FLD:VA-ONC WP 2 LINES}
801.41;+57253,;51~SUPPRESS
801.41;+57253,;100~NATIONAL
801.44;+57254,+57253,;.01~04/27/2026@11:26:12
801.44;+57254,+57253,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57254^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT VVC OTHERS PRESENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>69226</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3520472183</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+69226,;.01~VA-GP NTO CN VISIT VVC OTHERS PRESENT
801.41;+69226,;4~dialog group
801.41;+69226,;6~YES
801.41;+69226,;7~2
801.41;+69226,;25~WP-start~1
Others present for this visit with the Veteran's consent:
801.41;+69226,;52~INDENT
801.41;+69226,;100~NATIONAL
801.412;+69227,+69226,;.01~40
801.412;+69227,+69226,;2~VA-ONC CN WP BOX
801.44;+69228,+69226,;.01~04/27/2026@11:26:12
801.44;+69228,+69226,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
69227^2
69228^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN VISIT VVC EMERGENCY CONTACT</POINT_01>
<INTERNAL_ENTRY_NUMBER>67872</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1426346434</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67872,;.01~VA-NTO CN VISIT VVC EMERGENCY CONTACT
801.41;+67872,;4~dialog element
801.41;+67872,;23~YES
801.41;+67872,;25~WP-start~12
In Case of EMERGENCY:\\
====================
  Veteran Crisis Line:
   Dial 988 then Press 1
 
  e911:
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO THE HOME, 
   ACCESSING TELEHEALTH THROUGH LOCAL AREA STATIONS, OR NON-VA LOCATIONS: 
   {FLD:TELEHEALTH EMERGENCIES NON-VA LOCATIONS}
 
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO A VA 
   CLINIC:{FLD:TELEHEALTH EMERGENCIES VA LOCATIONS}
801.41;+67872,;35~WP-start~12
\\In Case of EMERGENCY:\\
====================
  Veteran Crisis Line:
   Dial 988 then Press 1
 
  e911:
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO THE HOME, 
   ACCESSING TELEHEALTH THROUGH LOCAL AREA STATIONS, OR NON-VA LOCATIONS: 
   {FLD:TELEHEALTH EMERGENCIES NON-VA LOCATIONS}
 
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO A VA 
   CLINIC:{FLD:TELEHEALTH EMERGENCIES VA LOCATIONS}
801.41;+67872,;51~SUPPRESS
801.41;+67872,;100~NATIONAL
801.44;+67873,+67872,;.01~04/27/2026@11:26:12
801.44;+67873,+67872,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67873^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT VVC F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67865</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3511975177</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67865,;.01~VA-NTO CN TIME SPENT VVC F2F
801.41;+67865,;4~dialog element
801.41;+67865,;15~HF.VA-NTO CN TIME SPENT VVC FACE TO FACE
801.41;+67865,;25~WP-start~1
VVC face-to-face time for assessment, counseling, & medical discussion:
801.41;+67865,;51~SUPPRESS
801.41;+67865,;100~NATIONAL
801.44;+67866,+67865,;.01~04/27/2026@11:26:12
801.44;+67866,+67865,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67866^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN TIME SPENT VVC F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67864</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3325236192</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67864,;.01~VA-GP NTO CN TIME SPENT VVC F2F
801.41;+67864,;4~dialog group
801.41;+67864,;6~YES
801.41;+67864,;7~2
801.41;+67864,;25~WP-start~1
Time spent:
801.41;+67864,;35~WP-start~1
\\Time Spent:
801.41;+67864,;51~SUPPRESS
801.41;+67864,;52~INDENT
801.41;+67864,;100~NATIONAL
801.412;+67865,+67864,;.01~20
801.412;+67865,+67864,;2~VA-NTO CN TIME SPENT VVC F2F
801.412;+67866,+67864,;.01~30
801.412;+67866,+67864,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+67867,+67864,;.01~04/27/2026@11:26:12
801.44;+67867,+67864,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67865^1
67866^2
67867^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER WORK</POINT_01>
<INTERNAL_ENTRY_NUMBER>67875</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3436625698</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67875,;.01~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER WORK
801.41;+67875,;4~dialog element
801.41;+67875,;25~WP-start~1
Work phone: (ADD patient work phone object here)\\
801.41;+67875,;100~LOCAL
801.44;+67876,+67875,;.01~04/27/2026@11:26:12
801.44;+67876,+67875,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67876^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER HOME</POINT_01>
<INTERNAL_ENTRY_NUMBER>67874</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2838867269</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67874,;.01~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER HOME
801.41;+67874,;4~dialog element
801.41;+67874,;25~WP-start~1
Home phone: (ADD patient home phone object here)\\
801.41;+67874,;100~LOCAL
801.44;+67875,+67874,;.01~04/27/2026@11:26:12
801.44;+67875,+67874,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67875^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN VISIT VVC CONTACT PHONE NUMBER OTHER</POINT_01>
<INTERNAL_ENTRY_NUMBER>67871</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>822916629</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67871,;.01~VA-NTO CN VISIT VVC CONTACT PHONE NUMBER OTHER
801.41;+67871,;4~dialog element
801.41;+67871,;25~WP-start~1
Other phone number:{FLD:NTO PHONE FORMAT (RO)}{FLD:EDIT 55+}
801.41;+67871,;100~NATIONAL
801.44;+67872,+67871,;.01~04/27/2026@11:26:12
801.44;+67872,+67871,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67872^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER CELL</POINT_01>
<INTERNAL_ENTRY_NUMBER>67873</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3017457802</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67873,;.01~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER CELL
801.41;+67873,;4~dialog element
801.41;+67873,;25~WP-start~1
Cell phone: (ADD patient cell phone object here)\\
801.41;+67873,;100~LOCAL
801.44;+67874,+67873,;.01~04/27/2026@11:26:12
801.44;+67874,+67873,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67874^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT VVC CONTACT PHONE NUMBER</POINT_01>
<INTERNAL_ENTRY_NUMBER>67870</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3964153746</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67870,;.01~VA-GP NTO CN VISIT VVC CONTACT PHONE NUMBER
801.41;+67870,;4~dialog group
801.41;+67870,;6~YES
801.41;+67870,;7~2
801.41;+67870,;9~ONE OR MORE SELECTIONS
801.41;+67870,;25~WP-start~1
Telephone number:
801.41;+67870,;51~SUPPRESS
801.41;+67870,;52~INDENT
801.41;+67870,;100~NATIONAL
801.412;+67871,+67870,;.01~20
801.412;+67871,+67870,;2~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER CELL
801.412;+67872,+67870,;.01~40
801.412;+67872,+67870,;2~VA-NTO CN VISIT VVC CONTACT PHONE NUMBER OTHER
801.412;+67873,+67870,;.01~10
801.412;+67873,+67870,;2~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER HOME
801.412;+67874,+67870,;.01~30
801.412;+67874,+67870,;2~VAL-NTO CN VISIT VVC CONTACT PHONE NUMBER WORK
801.44;+67875,+67870,;.01~04/27/2026@11:26:12
801.44;+67875,+67870,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67871^1
67872^2
67873^3
67874^4
67875^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN VISIT VVC OTHER ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>67869</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2447535502</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67869,;.01~VA-NTO CN VISIT VVC OTHER ADDRESS
801.41;+67869,;4~dialog element
801.41;+67869,;25~WP-start~1
Non-VA location: {FLD:EDIT 55+}
801.41;+67869,;100~NATIONAL
801.44;+67870,+67869,;.01~04/27/2026@11:26:12
801.44;+67870,+67869,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67870^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-NTO CN VISIT VVC CONTACT HOME ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>67868</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>230217125</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67868,;.01~VAL-NTO CN VISIT VVC CONTACT HOME ADDRESS
801.41;+67868,;4~dialog element
801.41;+67868,;25~WP-start~1
Home address: (ADD local patient address object here)
801.41;+67868,;100~LOCAL
801.44;+67869,+67868,;.01~04/27/2026@11:26:12
801.44;+67869,+67868,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67869^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT VVC CONTACT ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>67867</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3943265277</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67867,;.01~VA-GP NTO CN VISIT VVC CONTACT ADDRESS
801.41;+67867,;4~dialog group
801.41;+67867,;6~YES
801.41;+67867,;7~2
801.41;+67867,;9~ONE SELECTION ONLY
801.41;+67867,;25~WP-start~1
Patient's location during this session:
801.41;+67867,;51~SUPPRESS
801.41;+67867,;52~INDENT
801.41;+67867,;100~NATIONAL
801.412;+67868,+67867,;.01~20
801.412;+67868,+67867,;2~VAL-NTO CN VISIT VVC CONTACT HOME ADDRESS
801.412;+67869,+67867,;.01~40
801.412;+67869,+67867,;2~VA-NTO CN VISIT VVC OTHER ADDRESS
801.44;+67870,+67867,;.01~04/27/2026@11:26:12
801.44;+67870,+67867,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67868^1
67869^2
67870^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT VVC</POINT_01>
<INTERNAL_ENTRY_NUMBER>67862</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1996760200</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67862,;.01~VA-GP NTO CN VISIT VVC
801.41;+67862,;4~dialog group
801.41;+67862,;6~YES
801.41;+67862,;7~2
801.41;+67862,;25~WP-start~1
VA Video Connect (VVC):
801.41;+67862,;52~INDENT
801.41;+67862,;100~NATIONAL
801.412;+67863,+67862,;.01~20
801.412;+67863,+67862,;2~VA-GP NTO CN VISIT VVC CONTACT ADDRESS
801.412;+67864,+67862,;.01~60
801.412;+67864,+67862,;2~VA-GP NTO CN VISIT VVC OTHERS PRESENT
801.412;+67865,+67862,;.01~90
801.412;+67865,+67862,;2~VA-NTO CN VISIT VVC TELEHEALTH DISCLOSURE
801.412;+67866,+67862,;.01~100
801.412;+67866,+67862,;2~VA-ONC VISIT LATERALITY CONFIRMATION
801.412;+67867,+67862,;.01~40
801.412;+67867,+67862,;2~VA-GP NTO CN VISIT VVC CONTACT PHONE NUMBER
801.412;+67868,+67862,;.01~120
801.412;+67868,+67862,;2~VA-GP NTO CN TIME SPENT VVC F2F
801.412;+67869,+67862,;.01~80
801.412;+67869,+67862,;2~VA-NTO CN VISIT VVC EMERGENCY CONTACT
801.44;+67870,+67862,;.01~04/27/2026@11:26:12
801.44;+67870,+67862,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67863^1
67864^10
67865^11
67866^12
67867^2
67868^7
67869^9
67870^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN TIME SPENT CVT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67740</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3688106724</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67740,;.01~VA-NTO CN TIME SPENT CVT F2F
801.41;+67740,;4~dialog element
801.41;+67740,;15~HF.VA-NTO CN TIME SPENT CVT FACE TO FACE
801.41;+67740,;25~WP-start~1
CVT face-to-face time for assessment, counseling, & medical discussion:
801.41;+67740,;51~SUPPRESS
801.41;+67740,;100~NATIONAL
801.41;+67740,;101~VHA ONCOLOGY
801.44;+67741,+67740,;.01~04/27/2026@11:26:12
801.44;+67741,+67740,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67741^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN TIME SPENT CVT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67739</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>881258673</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67739,;.01~VA-GP NTO CN TIME SPENT CVT F2F
801.41;+67739,;4~dialog group
801.41;+67739,;6~YES
801.41;+67739,;7~2
801.41;+67739,;25~WP-start~1
Time spent:
801.41;+67739,;35~WP-start~1
\\Time spent:
801.41;+67739,;51~SUPPRESS
801.41;+67739,;52~INDENT
801.41;+67739,;100~NATIONAL
801.412;+67740,+67739,;.01~20
801.412;+67740,+67739,;2~VA-NTO CN TIME SPENT CVT F2F
801.412;+67741,+67739,;.01~40
801.412;+67741,+67739,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+67742,+67739,;.01~04/27/2026@11:26:12
801.44;+67742,+67739,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67740^4
67741^5
67742^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-NTO CN VISIT CVT TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>67859</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3509108696</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67859,;.01~VA-NTO CN VISIT CVT TXT
801.41;+67859,;4~dialog element
801.41;+67859,;25~WP-start~4
Visit conducted by clinical video telehealth. Veteran is suitable for
Telehealth interaction, the Telehealth program was explained, and verbal
consent was obtained. Location/emergency number confirmed. Patient is
located at the {FLD:VA-ONC VAMC SITE NAME}.
801.41;+67859,;51~SUPPRESS
801.41;+67859,;100~NATIONAL
801.44;+67860,+67859,;.01~04/27/2026@11:26:12
801.44;+67860,+67859,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67860^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT CVT</POINT_01>
<INTERNAL_ENTRY_NUMBER>67858</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1507736923</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67858,;.01~VA-GP NTO CN VISIT CVT
801.41;+67858,;4~dialog group
801.41;+67858,;6~YES
801.41;+67858,;7~2
801.41;+67858,;25~WP-start~1
Clinical Video Telehealth (CVT):
801.41;+67858,;52~INDENT
801.41;+67858,;100~NATIONAL
801.412;+67859,+67858,;.01~20
801.412;+67859,+67858,;2~VA-NTO CN VISIT CVT TXT
801.412;+67860,+67858,;.01~60
801.412;+67860,+67858,;2~VA-GP NTO CN TIME SPENT CVT F2F
801.412;+67861,+67858,;.01~40
801.412;+67861,+67858,;2~VA-ONC VISIT LATERALITY CONFIRMATION
801.44;+67862,+67858,;.01~04/27/2026@11:26:12
801.44;+67862,+67858,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67859^1
67860^3
67861^4
67862^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP NTO CN VISIT TYPE</POINT_01>
<INTERNAL_ENTRY_NUMBER>67735</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3466671632</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67735,;.01~VA-GP NTO CN VISIT TYPE
801.41;+67735,;4~dialog group
801.41;+67735,;6~YES
801.41;+67735,;7~2
801.41;+67735,;9~ONE SELECTION ONLY
801.41;+67735,;25~WP-start~1
*VISIT CONDUCTED VIA:
801.41;+67735,;35~WP-start~1
\\VISIT CONDUCTED VIA:
801.41;+67735,;51~SUPPRESS
801.41;+67735,;52~INDENT
801.41;+67735,;100~NATIONAL
801.412;+67736,+67735,;.01~20
801.412;+67736,+67735,;2~VA-GP NTO CN VISIT CVT
801.412;+67737,+67735,;.01~80
801.412;+67737,+67735,;2~VA-GP NTO CN VISIT VVC
801.412;+67738,+67735,;.01~100
801.412;+67738,+67735,;2~VA-GP NTO CN VISIT TELEPHONE
801.44;+67739,+67735,;.01~04/27/2026@11:26:12
801.44;+67739,+67735,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67736^1
67737^4
67738^5
67739^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>58487</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>552278608</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+58487,;.01~VA-ONC CN TIME SPENT F2F
801.41;+58487,;4~dialog element
801.41;+58487,;15~HF.VA-ONC CN TIME SPENT FACE TO FACE
801.41;+58487,;25~WP-start~1
Time spent face-to-face for assessment, counseling, & medical discussion:
801.41;+58487,;51~SUPPRESS
801.41;+58487,;100~NATIONAL
801.41;+58487,;101~VHA ONCOLOGY
801.44;+58488,+58487,;.01~04/27/2026@11:26:12
801.44;+58488,+58487,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
58488^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN TIME SPENT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>58486</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3200874366</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+58486,;.01~VA-GP ONC CN TIME SPENT F2F
801.41;+58486,;4~dialog group
801.41;+58486,;6~YES
801.41;+58486,;7~2
801.41;+58486,;25~WP-start~1
Time Spent:
801.41;+58486,;35~WP-start~1
\\Time spent:
801.41;+58486,;51~SUPPRESS
801.41;+58486,;52~INDENT
801.41;+58486,;100~NATIONAL
801.41;+58486,;101~VHA ONCOLOGY
801.412;+58487,+58486,;.01~20
801.412;+58487,+58486,;2~VA-ONC CN TIME SPENT F2F
801.412;+58488,+58486,;.01~30
801.412;+58488,+58486,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+58489,+58486,;.01~04/27/2026@11:26:12
801.44;+58489,+58486,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
58487^1
58488^2
58489^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT FACE TO FACE</POINT_01>
<INTERNAL_ENTRY_NUMBER>57216</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1338600504</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57216,;.01~VA-GP ONC CN VISIT FACE TO FACE
801.41;+57216,;4~dialog group
801.41;+57216,;6~YES
801.41;+57216,;7~2
801.41;+57216,;25~WP-start~1
Face-to-Face
801.41;+57216,;52~INDENT
801.41;+57216,;100~NATIONAL
801.41;+57216,;101~VHA ONCOLOGY
801.412;+57217,+57216,;.01~20
801.412;+57217,+57216,;2~VA-GP ONC CN TIME SPENT F2F
801.44;+57218,+57216,;.01~04/27/2026@11:26:12
801.44;+57218,+57216,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57217^1
57218^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN VISIT VVC EMERGENCY CONTACT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57214</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3991941184</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57214,;.01~VA-ONC CN VISIT VVC EMERGENCY CONTACT
801.41;+57214,;4~dialog element
801.41;+57214,;23~YES
801.41;+57214,;25~WP-start~12
In Case of EMERGENCY:\\
====================
  Veteran Crisis Line:
   Dial 988 then Press 1
 
  e911:
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO THE HOME, 
   ACCESSING TELEHEALTH THROUGH LOCAL AREA STATIONS, OR NON-VA LOCATIONS: 
   {FLD:TELEHEALTH EMERGENCIES NON-VA LOCATIONS}
 
   EMERGENCIES DURING SYNCHRONOUS VIDEO TELEHEALTH VISITS INTO A VA 
   CLINIC:\\   {FLD:TELEHEALTH EMERGENCIES VA LOCATIONS}
801.41;+57214,;51~SUPPRESS
801.41;+57214,;100~NATIONAL
801.41;+57214,;101~VHA ONCOLOGY
801.44;+57215,+57214,;.01~04/27/2026@11:26:12
801.44;+57215,+57214,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57215^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT VVC F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67744</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>496179056</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67744,;.01~VA-ONC CN TIME SPENT VVC F2F
801.41;+67744,;4~dialog element
801.41;+67744,;15~HF.VA-ONC CN TIME SPENT VVC FACE TO FACE
801.41;+67744,;25~WP-start~1
VVC face-to-face time for assessment, counseling, & medical discussion:
801.41;+67744,;51~SUPPRESS
801.41;+67744,;100~NATIONAL
801.41;+67744,;101~VHA ONCOLOGY
801.44;+67745,+67744,;.01~04/27/2026@11:26:12
801.44;+67745,+67744,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67745^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN TIME SPENT VVC F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67743</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>352744239</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67743,;.01~VA-GP ONC CN TIME SPENT VVC F2F
801.41;+67743,;4~dialog group
801.41;+67743,;6~YES
801.41;+67743,;7~2
801.41;+67743,;25~WP-start~1
Time spent:
801.41;+67743,;35~WP-start~1
\\Time spent:
801.41;+67743,;51~SUPPRESS
801.41;+67743,;52~INDENT
801.41;+67743,;100~NATIONAL
801.41;+67743,;101~VHA ONCOLOGY
801.412;+67744,+67743,;.01~20
801.412;+67744,+67743,;2~VA-ONC CN TIME SPENT VVC F2F
801.412;+67745,+67743,;.01~30
801.412;+67745,+67743,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+67746,+67743,;.01~04/27/2026@11:26:12
801.44;+67746,+67743,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67744^1
67745^2
67746^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN VISIT VVC TELEHEALTH DISCLOSURE</POINT_01>
<INTERNAL_ENTRY_NUMBER>71420</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2996878380</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+71420,;.01~VA-ONC CN VISIT VVC TELEHEALTH DISCLOSURE
801.41;+71420,;4~dialog element
801.41;+71420,;25~WP-start~6
Telehealth Disclosure: 
  Visit conducted by synchronous telehealth. 
  Patient's verbal consent obtained. 
  Location/emergency number confirmed.
  Environment surveyed and all participants identified.
  Virtual conference room locked.
801.41;+71420,;35~WP-start~6
\\Telehealth Disclosure: 
  Visit conducted by synchronous telehealth. 
  Patient's verbal consent obtained. 
  Location/emergency number confirmed.
  Environment surveyed and all participants identified.
  Virtual conference room locked.
801.41;+71420,;51~SUPPRESS
801.41;+71420,;100~NATIONAL
801.41;+71420,;101~VHA ONCOLOGY
801.44;+71421,+71420,;.01~04/27/2026@11:26:12
801.44;+71421,+71420,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
71421^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>BLANK LINE &lt;BR&gt; DIA EXCLUDE FROM PN</POINT_01>
<INTERNAL_ENTRY_NUMBER>59706</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3675275985</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+59706,;.01~BLANK LINE <BR> DIA EXCLUDE FROM PN
801.41;+59706,;4~dialog element
801.41;+59706,;23~YES
801.41;+59706,;25~WP-start~1
<br>
801.41;+59706,;51~SUPPRESS
801.41;+59706,;100~LOCAL
801.44;+59707,+59706,;.01~04/27/2026@11:26:12
801.44;+59707,+59706,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
59707^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT VVC OTHERS PRESENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>71421</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>723620241</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+71421,;.01~VA-GP ONC CN VISIT VVC OTHERS PRESENT
801.41;+71421,;4~dialog group
801.41;+71421,;6~YES
801.41;+71421,;7~2
801.41;+71421,;25~WP-start~1
Others present for this visit with the Veteran's consent:
801.41;+71421,;52~INDENT
801.41;+71421,;100~NATIONAL
801.41;+71421,;101~VHA ONCOLOGY
801.412;+71422,+71421,;.01~40
801.412;+71422,+71421,;2~VA-ONC CN WP BOX
801.44;+71423,+71421,;.01~04/27/2026@11:26:12
801.44;+71423,+71421,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
71422^2
71423^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN VISIT VVC CONTACT PHONE NUMBER OTHER</POINT_01>
<INTERNAL_ENTRY_NUMBER>57213</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>115107792</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57213,;.01~VA-ONC CN VISIT VVC CONTACT PHONE NUMBER OTHER
801.41;+57213,;4~dialog element
801.41;+57213,;25~WP-start~1
Other phone number: {FLD:EDIT 55+}
801.41;+57213,;100~NATIONAL
801.41;+57213,;101~VHA ONCOLOGY
801.44;+57214,+57213,;.01~04/27/2026@11:26:12
801.44;+57214,+57213,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57214^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-ONC CN VISIT VVC CONTACT PHONE NUMBER HOME/CELL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57212</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>325326616</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57212,;.01~VAL-ONC CN VISIT VVC CONTACT PHONE NUMBER HOME/CELL
801.41;+57212,;4~dialog element
801.41;+57212,;25~WP-start~3
Cell phone: (ADD patient cell phone object here)\\
Home phone: (ADD patient home phone object here)\\
Work phone: (ADD patient work phone object here)\\
801.41;+57212,;100~LOCAL
801.44;+57213,+57212,;.01~04/27/2026@11:26:12
801.44;+57213,+57212,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57213^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT VVC CONTACT PHONE NUMBER</POINT_01>
<INTERNAL_ENTRY_NUMBER>57211</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1071092723</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57211,;.01~VA-GP ONC CN VISIT VVC CONTACT PHONE NUMBER
801.41;+57211,;4~dialog group
801.41;+57211,;6~YES
801.41;+57211,;7~2
801.41;+57211,;9~ONE OR MORE SELECTIONS
801.41;+57211,;25~WP-start~1
Telephone number:
801.41;+57211,;51~SUPPRESS
801.41;+57211,;52~INDENT
801.41;+57211,;100~NATIONAL
801.41;+57211,;101~VHA ONCOLOGY
801.412;+57212,+57211,;.01~20
801.412;+57212,+57211,;2~VAL-ONC CN VISIT VVC CONTACT PHONE NUMBER HOME/CELL
801.412;+57213,+57211,;.01~40
801.412;+57213,+57211,;2~VA-ONC CN VISIT VVC CONTACT PHONE NUMBER OTHER
801.44;+57214,+57211,;.01~04/27/2026@11:26:12
801.44;+57214,+57211,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57212^1
57213^2
57214^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN VISIT VVC OTHER ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57210</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2958627113</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57210,;.01~VA-ONC CN VISIT VVC OTHER ADDRESS
801.41;+57210,;4~dialog element
801.41;+57210,;25~WP-start~1
Non-VA location: {FLD:EDIT 55+}
801.41;+57210,;100~NATIONAL
801.41;+57210,;101~VHA ONCOLOGY
801.44;+57211,+57210,;.01~04/27/2026@11:26:12
801.44;+57211,+57210,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57211^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VAL-ONC CN VISIT VVC CONTACT HOME ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57209</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3861813151</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57209,;.01~VAL-ONC CN VISIT VVC CONTACT HOME ADDRESS
801.41;+57209,;4~dialog element
801.41;+57209,;25~WP-start~1
Home address: ADD local patient address object here
801.41;+57209,;100~LOCAL
801.44;+57210,+57209,;.01~04/27/2026@11:26:12
801.44;+57210,+57209,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57210^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT VVC CONTACT ADDRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57208</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4281108557</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57208,;.01~VA-GP ONC CN VISIT VVC CONTACT ADDRESS
801.41;+57208,;4~dialog group
801.41;+57208,;6~YES
801.41;+57208,;7~2
801.41;+57208,;9~ONE SELECTION ONLY
801.41;+57208,;25~WP-start~1
Patient's location during this session:
801.41;+57208,;51~SUPPRESS
801.41;+57208,;52~INDENT
801.41;+57208,;100~NATIONAL
801.41;+57208,;101~VHA ONCOLOGY
801.412;+57209,+57208,;.01~20
801.412;+57209,+57208,;2~VAL-ONC CN VISIT VVC CONTACT HOME ADDRESS
801.412;+57210,+57208,;.01~40
801.412;+57210,+57208,;2~VA-ONC CN VISIT VVC OTHER ADDRESS
801.44;+57211,+57208,;.01~04/27/2026@11:26:12
801.44;+57211,+57208,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57209^1
57210^2
57211^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT VVC</POINT_01>
<INTERNAL_ENTRY_NUMBER>57207</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>60860608</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57207,;.01~VA-GP ONC CN VISIT VVC
801.41;+57207,;4~dialog group
801.41;+57207,;6~YES
801.41;+57207,;7~2
801.41;+57207,;25~WP-start~1
VA Video Connect (VVC):
801.41;+57207,;52~INDENT
801.41;+57207,;100~NATIONAL
801.41;+57207,;101~VHA ONCOLOGY
801.412;+57208,+57207,;.01~20
801.412;+57208,+57207,;2~VA-GP ONC CN VISIT VVC CONTACT ADDRESS
801.412;+57209,+57207,;.01~43
801.412;+57209,+57207,;2~VA-GP ONC CN VISIT VVC OTHERS PRESENT
801.412;+57210,+57207,;.01~45
801.412;+57210,+57207,;2~BLANK LINE <BR> DIA EXCLUDE FROM PN
801.412;+57211,+57207,;.01~60
801.412;+57211,+57207,;2~VA-ONC CN VISIT VVC TELEHEALTH DISCLOSURE
801.412;+57212,+57207,;.01~80
801.412;+57212,+57207,;2~VA-GP ONC CN TIME SPENT VVC F2F
801.412;+57213,+57207,;.01~50
801.412;+57213,+57207,;2~VA-ONC CN VISIT VVC EMERGENCY CONTACT
801.412;+57214,+57207,;.01~70
801.412;+57214,+57207,;2~VA-ONC VISIT LATERALITY CONFIRMATION
801.412;+57215,+57207,;.01~40
801.412;+57215,+57207,;2~VA-GP ONC CN VISIT VVC CONTACT PHONE NUMBER
801.44;+57216,+57207,;.01~04/27/2026@11:26:12
801.44;+57216,+57207,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57208^1
57209^12
57210^14
57211^15
57212^16
57213^17
57214^18
57215^2
57216^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN TIME SPENT CVT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>61495</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3913136349</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+61495,;.01~VA-ONC CN TIME SPENT CVT F2F
801.41;+61495,;4~dialog element
801.41;+61495,;15~HF.VA-ONC CN TIME SPENT CVT FACE TO FACE
801.41;+61495,;25~WP-start~1
CVT face-to-face time for assessment, counseling, & medical discussion:
801.41;+61495,;51~SUPPRESS
801.41;+61495,;100~NATIONAL
801.41;+61495,;101~VHA ONCOLOGY
801.44;+61496,+61495,;.01~04/27/2026@11:26:12
801.44;+61496,+61495,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
61496^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN TIME SPENT CVT F2F</POINT_01>
<INTERNAL_ENTRY_NUMBER>67812</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1340602559</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+67812,;.01~VA-GP ONC CN TIME SPENT CVT F2F
801.41;+67812,;4~dialog group
801.41;+67812,;6~YES
801.41;+67812,;7~2
801.41;+67812,;25~WP-start~1
Time spent:
801.41;+67812,;35~WP-start~1
\\Time spent:
801.41;+67812,;51~SUPPRESS
801.41;+67812,;52~INDENT
801.41;+67812,;100~NATIONAL
801.41;+67812,;101~VHA ONCOLOGY
801.412;+67813,+67812,;.01~20
801.412;+67813,+67812,;2~VA-ONC CN TIME SPENT CVT F2F
801.412;+67814,+67812,;.01~40
801.412;+67814,+67812,;2~VA-NTO CN TOTAL TIME SPENT
801.44;+67815,+67812,;.01~04/27/2026@11:26:12
801.44;+67815,+67812,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
67813^7
67814^8
67815^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CN VISIT CVT TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57204</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1349105402</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57204,;.01~VA-ONC CN VISIT CVT TXT
801.41;+57204,;4~dialog element
801.41;+57204,;25~WP-start~4
Visit conducted by clinical video telehealth. Veteran is suitable for
Telehealth interaction, the Telehealth program was explained, and verbal
consent was obtained. Location/emergency number confirmed. Patient is
located at the {FLD:VA-ONC VAMC SITE NAME}.
801.41;+57204,;51~SUPPRESS
801.41;+57204,;100~NATIONAL
801.41;+57204,;101~VHA ONCOLOGY
801.44;+57205,+57204,;.01~04/27/2026@11:26:12
801.44;+57205,+57204,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57205^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT CLINICAL VIDEO TELEHEALTH</POINT_01>
<INTERNAL_ENTRY_NUMBER>57203</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3793942301</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57203,;.01~VA-GP ONC CN VISIT CLINICAL VIDEO TELEHEALTH
801.41;+57203,;4~dialog group
801.41;+57203,;6~YES
801.41;+57203,;7~2
801.41;+57203,;25~WP-start~1
Clinical Video Telehealth (CVT):
801.41;+57203,;52~INDENT
801.41;+57203,;100~NATIONAL
801.41;+57203,;101~VHA ONCOLOGY
801.412;+57204,+57203,;.01~20
801.412;+57204,+57203,;2~VA-ONC CN VISIT CVT TXT
801.412;+57205,+57203,;.01~40
801.412;+57205,+57203,;2~VA-GP ONC CN TIME SPENT CVT F2F
801.412;+57206,+57203,;.01~30
801.412;+57206,+57203,;2~VA-ONC VISIT LATERALITY CONFIRMATION
801.44;+57207,+57203,;.01~04/27/2026@11:26:12
801.44;+57207,+57203,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57204^1
57205^2
57206^3
57207^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC CN VISIT TYPE</POINT_01>
<INTERNAL_ENTRY_NUMBER>57202</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2596291052</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57202,;.01~VA-GP ONC CN VISIT TYPE
801.41;+57202,;4~dialog group
801.41;+57202,;6~YES
801.41;+57202,;7~2
801.41;+57202,;9~ONE SELECTION ONLY
801.41;+57202,;25~WP-start~1
*VISIT CONDUCTED VIA:
801.41;+57202,;35~WP-start~1
\\VISIT CONDUCTED VIA:
801.41;+57202,;51~SUPPRESS
801.41;+57202,;52~INDENT
801.41;+57202,;100~NATIONAL
801.41;+57202,;101~VHA ONCOLOGY
801.412;+57203,+57202,;.01~20
801.412;+57203,+57202,;2~VA-GP ONC CN VISIT CLINICAL VIDEO TELEHEALTH
801.412;+57204,+57202,;.01~80
801.412;+57204,+57202,;2~VA-GP ONC CN VISIT VVC
801.412;+57205,+57202,;.01~10
801.412;+57205,+57202,;2~VA-GP ONC CN VISIT FACE TO FACE
801.44;+57206,+57202,;.01~04/27/2026@11:26:12
801.44;+57206,+57202,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57203^1
57204^4
57205^5
57206^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>PXRM GF VIEW BUTTON</POINT_01>
<INTERNAL_ENTRY_NUMBER>38861</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1501895938</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+38861,;.01~PXRM GF VIEW BUTTON
801.41;+38861,;4~prompt
801.41;+38861,;23~YES
801.41;+38861,;24~View Data
801.41;+38861,;46~GF_VIEW
801.41;+38861,;100~NATIONAL
801.44;+38862,+38861,;.01~04/27/2026@11:26:12
801.44;+38862,+38861,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38862^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC BLADDER CANCER STAGING 8TH EDITION</POINT_01>
<INTERNAL_ENTRY_NUMBER>108574</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>83845416</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108574,;.01~VA-ONC MIBC BLADDER CANCER STAGING 8TH EDITION
801.41;+108574,;4~dialog element
801.41;+108574,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+108574,;23~YES
801.41;+108574,;25~WP-start~1
{FLD:BLADDER CANCER CTDNA ATEZOLIZUMAB LINK}
801.41;+108574,;35~WP-start~49
American Joint Committee on Cancer TNM Staging System for Bladder 
Cancer 8th Edition, 2017:\\
\\
  T     Primary Tumor\\
  TX    Primary tumor cannot be assessed\\
  T0    No evidence of primary tumor\\
  Ta    Noninvasive papillary carcinoma\\
  Tis   Urothelial carcinoma in situ: "flat tumor"\\
  T1    Tumor invades lamina propria (subepithelial connective tissue)\\
  T2    Tumor invades muscularis propria\\
  pT2a  Tumor invades superficial muscularis propria (inner half)\\
  pT2b  Tumor invades deep muscularis propria (outer half)\\
  T3    Tumor invades perivesical tissue\\
  pT3a  Microscopically\\
  pT3b  Macroscopically (extravesical mass)\\
  T4    Extravesical tumor directly invades any of the following:\\ 
       prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall,\\
        abdominal wall\\
  T4a   Extravesical tumor invades prostatic stoma, seminal vesicles,\\ 
       uterus, vagina\\
  T4b   Extravesical tumor invades pelvic wall, abdominal wall\\
\\
========================================================================\\
  N     Regional Lymph Nodes\\
  NX    Lymph nodes cannot be assessed\\
  N0    No lymph node metastasis\\
  N1    Single regional lymph node metastasis in the true pelvis:\\
        perivesical, obturator, internal and external iliac, or sacral\\ 
       lymph node\\
  N2    Multiple regional lymph node metastasis in the true pelvis:\\
        perivesical, obturator, internal and external iliac, or sacral\\ 
       lymph node\\
  N3    Lymph node metastasis to the common iliac lymph nodes\\
\\
========================================================================\\
  M     Distant Metastasis\\
  M0    No distant metastasis\\
  M1    Distant metastasis\\
  M1a   Distant metastasis limited to lymph nodes beyond common iliacs\\
  M1b   Non-lymph-node distant metastasis\\
\\
========================================================================\\
  G     Histologic Grade\\
  LG    Low-grade\\
  HG    High-grade\\
  GX    Grade cannot be assessed\\
  G1    Well differentiated\\
  G2    Moderately differentiated\\
  G3    Poorly differentiated\\
801.41;+108574,;51~SUPPRESS
801.41;+108574,;100~NATIONAL
801.41;+108574,;101~VHA ONCOLOGY
801.412;+108575,+108574,;.01~5
801.412;+108575,+108574,;2~PXRM GF VIEW BUTTON
801.412;+108575,+108574,;6~Bladder Cancer Staging
801.44;+108576,+108574,;.01~04/27/2026@11:26:12
801.44;+108576,+108574,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108575^1
108576^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45345</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1161991404</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+45345,;.01~VA-ONC OFF PATHWAY
801.41;+45345,;4~prompt
801.41;+45345,;24~   
801.41;+45345,;46~COM
801.41;+45345,;100~NATIONAL
801.4145;+45346,+45345,;.01~1
801.4145;+45346,+45345,;2~Patient preference/declined
801.4145;+45347,+45345,;.01~2
801.4145;+45347,+45345,;2~Toxicity and/or comorbidity
801.4145;+45348,+45345,;.01~3
801.4145;+45348,+45345,;2~Prior treatment continued
801.4145;+45349,+45345,;.01~4
801.4145;+45349,+45345,;2~Prior treatment precludes
801.4145;+45350,+45345,;.01~5
801.4145;+45350,+45345,;2~Pathway guidance needs update
801.4145;+45351,+45345,;.01~6
801.4145;+45351,+45345,;2~Patient barriers
801.4145;+45352,+45345,;.01~8
801.4145;+45352,+45345,;2~Other:
801.4145;+45353,+45345,;.01~7
801.4145;+45353,+45345,;2~Treatment unavailable
801.44;+45354,+45345,;.01~04/27/2026@11:26:13
801.44;+45354,+45345,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45346^1
45347^2
45348^3
45349^4
45350^5
45351^6
45352^8
45353^9
45354^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107907</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3050753944</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107907,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN
801.41;+107907,;4~dialog element
801.41;+107907,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN
801.41;+107907,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107907,;51~SUPPRESS
801.41;+107907,;100~NATIONAL
801.41;+107907,;101~VHA ONCOLOGY
801.412;+107908,+107907,;.01~5
801.412;+107908,+107907,;2~VA-ONC OFF PATHWAY
801.412;+107908,+107907,;7~YES
801.412;+107908,+107907,;9~YES
801.44;+107909,+107907,;.01~04/27/2026@11:26:13
801.44;+107909,+107907,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107908^1
107909^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLANK</POINT_01>
<INTERNAL_ENTRY_NUMBER>46240</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>274383172</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+46240,;.01~VA-ONC BLANK
801.41;+46240,;4~prompt
801.41;+46240,;24~   
801.41;+46240,;46~COM
801.41;+46240,;100~NATIONAL
801.44;+46241,+46240,;.01~04/27/2026@11:26:13
801.44;+46241,+46240,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46241^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107906</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1069041275</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107906,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX
801.41;+107906,;4~dialog element
801.41;+107906,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX
801.41;+107906,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107906,;51~SUPPRESS
801.41;+107906,;100~NATIONAL
801.41;+107906,;101~VHA ONCOLOGY
801.412;+107907,+107906,;.01~5
801.412;+107907,+107906,;2~VA-ONC BLANK
801.412;+107907,+107906,;7~YES
801.412;+107907,+107906,;9~YES
801.44;+107908,+107906,;.01~04/27/2026@11:26:13
801.44;+107908,+107906,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107907^1
107908^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107905</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2745436705</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107905,;.01~VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH
801.41;+107905,;4~dialog group
801.41;+107905,;7~2
801.41;+107905,;9~ONE OR MORE SELECTIONS
801.41;+107905,;23~YES
801.41;+107905,;25~WP-start~1
Off pathway:
801.41;+107905,;100~NATIONAL
801.41;+107905,;101~VHA ONCOLOGY
801.412;+107906,+107905,;.01~10
801.412;+107906,+107905,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH TX
801.412;+107907,+107905,;.01~20
801.412;+107907,+107905,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH RSN
801.44;+107908,+107905,;.01~04/27/2026@11:26:13
801.44;+107908,+107905,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107906^1
107907^2
107908^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>107904</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4036483446</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107904,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY
801.41;+107904,;4~dialog element
801.41;+107904,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY
801.41;+107904,;25~WP-start~1
Follow Post Cystectomy Pathway.
801.41;+107904,;100~NATIONAL
801.41;+107904,;101~VHA ONCOLOGY
801.44;+107905,+107904,;.01~04/27/2026@11:26:13
801.44;+107905,+107904,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107905^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45369</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>475371082</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+45369,;.01~VA-ONC CLINICAL TRIAL
801.41;+45369,;4~prompt
801.41;+45369,;24~Clinical Trial:
801.41;+45369,;46~COM
801.41;+45369,;100~NATIONAL
801.44;+45370,+45369,;.01~04/27/2026@11:26:13
801.44;+45370,+45369,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45370^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107903</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3862084048</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107903,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL
801.41;+107903,;4~dialog element
801.41;+107903,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL
801.41;+107903,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107903,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107903,;100~NATIONAL
801.41;+107903,;101~VHA ONCOLOGY
801.412;+107904,+107903,;.01~5
801.412;+107904,+107903,;2~VA-ONC CLINICAL TRIAL
801.412;+107904,+107903,;9~YES
801.44;+107905,+107903,;.01~04/27/2026@11:26:13
801.44;+107905,+107903,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107904^1
107905^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE</POINT_01>
<INTERNAL_ENTRY_NUMBER>107897</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>286560171</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107897,;.01~VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE
801.41;+107897,;4~dialog group
801.41;+107897,;6~YES
801.41;+107897,;7~2
801.41;+107897,;9~ONE SELECTION ONLY
801.41;+107897,;25~WP-start~1
ctDNA negative.
801.41;+107897,;52~INDENT
801.41;+107897,;100~NATIONAL
801.41;+107897,;101~VHA ONCOLOGY
801.412;+107898,+107897,;.01~5
801.412;+107898,+107897,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE CLIN TRIAL
801.412;+107899,+107897,;.01~10
801.412;+107899,+107897,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE FOLLOW PATHWAY
801.412;+107900,+107897,;.01~15
801.412;+107900,+107897,;2~VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE OFF PATH
801.44;+107901,+107897,;.01~04/27/2026@11:26:13
801.44;+107901,+107897,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107898^1
107899^2
107900^3
107901^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107902</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2076499705</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107902,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN
801.41;+107902,;4~dialog element
801.41;+107902,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN
801.41;+107902,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107902,;51~SUPPRESS
801.41;+107902,;100~NATIONAL
801.41;+107902,;101~VHA ONCOLOGY
801.412;+107903,+107902,;.01~5
801.412;+107903,+107902,;2~VA-ONC OFF PATHWAY
801.412;+107903,+107902,;7~YES
801.412;+107903,+107902,;9~YES
801.44;+107904,+107902,;.01~04/27/2026@11:26:13
801.44;+107904,+107902,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107903^1
107904^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107901</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1732763571</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107901,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX
801.41;+107901,;4~dialog element
801.41;+107901,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX
801.41;+107901,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107901,;51~SUPPRESS
801.41;+107901,;100~NATIONAL
801.41;+107901,;101~VHA ONCOLOGY
801.412;+107902,+107901,;.01~5
801.412;+107902,+107901,;2~VA-ONC BLANK
801.412;+107902,+107901,;7~YES
801.412;+107902,+107901,;9~YES
801.44;+107903,+107901,;.01~04/27/2026@11:26:13
801.44;+107903,+107901,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107902^1
107903^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107900</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2506253121</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107900,;.01~VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH
801.41;+107900,;4~dialog group
801.41;+107900,;7~2
801.41;+107900,;9~ONE OR MORE SELECTIONS
801.41;+107900,;23~YES
801.41;+107900,;25~WP-start~1
Off pathway:
801.41;+107900,;100~NATIONAL
801.41;+107900,;101~VHA ONCOLOGY
801.412;+107901,+107900,;.01~10
801.412;+107901,+107900,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH TX
801.412;+107902,+107900,;.01~20
801.412;+107902,+107900,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH RSN
801.44;+107903,+107900,;.01~04/27/2026@11:26:13
801.44;+107903,+107900,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107901^1
107902^2
107903^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>107899</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>6363963</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107899,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB
801.41;+107899,;4~dialog element
801.41;+107899,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB
801.41;+107899,;25~WP-start~3
Adjuvant atezolizumab.
  ++ ctDNA-positive test result at any time during surveillance and
     remained disease-free as assessed radiographically. ++
801.41;+107899,;100~NATIONAL
801.41;+107899,;101~VHA ONCOLOGY
801.44;+107900,+107899,;.01~04/27/2026@11:26:13
801.44;+107900,+107899,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107900^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107898</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1720620935</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107898,;.01~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL
801.41;+107898,;4~dialog element
801.41;+107898,;15~HF.VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL
801.41;+107898,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107898,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107898,;100~NATIONAL
801.41;+107898,;101~VHA ONCOLOGY
801.412;+107899,+107898,;.01~5
801.412;+107899,+107898,;2~VA-ONC CLINICAL TRIAL
801.412;+107899,+107898,;9~YES
801.44;+107900,+107898,;.01~04/27/2026@11:26:13
801.44;+107900,+107898,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107899^1
107900^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE</POINT_01>
<INTERNAL_ENTRY_NUMBER>107896</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3742480620</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107896,;.01~VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE
801.41;+107896,;4~dialog group
801.41;+107896,;6~YES
801.41;+107896,;7~2
801.41;+107896,;9~ONE SELECTION ONLY
801.41;+107896,;25~WP-start~1
ctDNA positive.
801.41;+107896,;52~INDENT
801.41;+107896,;100~NATIONAL
801.41;+107896,;101~VHA ONCOLOGY
801.412;+107897,+107896,;.01~5
801.412;+107897,+107896,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE CLIN TRIAL
801.412;+107898,+107896,;.01~10
801.412;+107898,+107896,;2~VA-ONC MIBC POST CYSTECTOMY CTDNA POSITIVE ATEZOLIZUMAB
801.412;+107899,+107896,;.01~15
801.412;+107899,+107896,;2~VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE OFF PATH
801.44;+107900,+107896,;.01~04/27/2026@11:26:13
801.44;+107900,+107896,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107897^1
107898^2
107899^3
107900^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107885</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>335262242</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107885,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN
801.41;+107885,;4~dialog element
801.41;+107885,;15~HF.VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN
801.41;+107885,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107885,;51~SUPPRESS
801.41;+107885,;100~NATIONAL
801.41;+107885,;101~VHA ONCOLOGY
801.412;+107886,+107885,;.01~5
801.412;+107886,+107885,;2~VA-ONC OFF PATHWAY
801.412;+107886,+107885,;7~YES
801.412;+107886,+107885,;9~YES
801.44;+107887,+107885,;.01~04/27/2026@11:26:13
801.44;+107887,+107885,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107886^1
107887^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107884</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3963124826</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107884,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX
801.41;+107884,;4~dialog element
801.41;+107884,;15~HF.VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX
801.41;+107884,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107884,;51~SUPPRESS
801.41;+107884,;100~NATIONAL
801.41;+107884,;101~VHA ONCOLOGY
801.412;+107885,+107884,;.01~5
801.412;+107885,+107884,;2~VA-ONC BLANK
801.412;+107885,+107884,;7~YES
801.412;+107885,+107884,;9~YES
801.44;+107886,+107884,;.01~04/27/2026@11:26:13
801.44;+107886,+107884,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107885^1
107886^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107883</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2577497860</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107883,;.01~VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH
801.41;+107883,;4~dialog group
801.41;+107883,;7~2
801.41;+107883,;9~ONE OR MORE SELECTIONS
801.41;+107883,;23~YES
801.41;+107883,;25~WP-start~1
Off pathway:
801.41;+107883,;100~NATIONAL
801.41;+107883,;101~VHA ONCOLOGY
801.412;+107884,+107883,;.01~10
801.412;+107884,+107883,;2~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH TX
801.412;+107885,+107883,;.01~20
801.412;+107885,+107883,;2~VA-ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH RSN
801.44;+107886,+107883,;.01~04/27/2026@11:26:13
801.44;+107886,+107883,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107884^1
107885^2
107886^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>107882</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3767038279</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107882,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY
801.41;+107882,;4~dialog element
801.41;+107882,;15~HF.VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY
801.41;+107882,;25~WP-start~1
Follow Post Cystectomy Pathway.
801.41;+107882,;100~NATIONAL
801.41;+107882,;101~VHA ONCOLOGY
801.44;+107883,+107882,;.01~04/27/2026@11:26:13
801.44;+107883,+107882,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107883^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107881</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>795287340</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107881,;.01~VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL
801.41;+107881,;4~dialog element
801.41;+107881,;15~HF.VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL
801.41;+107881,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107881,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107881,;100~NATIONAL
801.41;+107881,;101~VHA ONCOLOGY
801.412;+107882,+107881,;.01~5
801.412;+107882,+107881,;2~VA-ONC CLINICAL TRIAL
801.412;+107882,+107881,;9~YES
801.44;+107883,+107881,;.01~04/27/2026@11:26:13
801.44;+107883,+107881,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107882^1
107883^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE</POINT_01>
<INTERNAL_ENTRY_NUMBER>107846</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3745894412</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107846,;.01~VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE
801.41;+107846,;4~dialog group
801.41;+107846,;6~YES
801.41;+107846,;7~2
801.41;+107846,;9~ONE SELECTION ONLY
801.41;+107846,;25~WP-start~1
Not stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0.
801.41;+107846,;52~INDENT
801.41;+107846,;100~NATIONAL
801.41;+107846,;101~VHA ONCOLOGY
801.412;+107847,+107846,;.01~5
801.412;+107847,+107846,;2~VA-ONC MIBC POST CYSTECTOMY NOT STAGE CLIN TRIAL
801.412;+107848,+107846,;.01~10
801.412;+107848,+107846,;2~VA-ONC MIBC POST CYSTECTOMY NOT STAGE FOLLOW PATHWAY
801.412;+107849,+107846,;.01~15
801.412;+107849,+107846,;2~VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE OFF PATH
801.44;+107850,+107846,;.01~04/27/2026@11:26:13
801.44;+107850,+107846,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107847^1
107848^2
107849^3
107850^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107878</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2580252268</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107878,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN
801.41;+107878,;4~dialog element
801.41;+107878,;15~HF.VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN
801.41;+107878,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107878,;51~SUPPRESS
801.41;+107878,;100~NATIONAL
801.41;+107878,;101~VHA ONCOLOGY
801.412;+107879,+107878,;.01~5
801.412;+107879,+107878,;2~VA-ONC OFF PATHWAY
801.412;+107879,+107878,;7~YES
801.412;+107879,+107878,;9~YES
801.44;+107880,+107878,;.01~04/27/2026@11:26:13
801.44;+107880,+107878,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107879^1
107880^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107877</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1237931323</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107877,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX
801.41;+107877,;4~dialog element
801.41;+107877,;15~HF.VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX
801.41;+107877,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107877,;51~SUPPRESS
801.41;+107877,;100~NATIONAL
801.41;+107877,;101~VHA ONCOLOGY
801.412;+107878,+107877,;.01~5
801.412;+107878,+107877,;2~VA-ONC BLANK
801.412;+107878,+107877,;7~YES
801.412;+107878,+107877,;9~YES
801.44;+107879,+107877,;.01~04/27/2026@11:26:13
801.44;+107879,+107877,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107878^1
107879^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY STAGE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107876</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2953503342</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107876,;.01~VA-GP ONC MIBC POST CYSTECTOMY STAGE OFF PATH
801.41;+107876,;4~dialog group
801.41;+107876,;7~2
801.41;+107876,;9~ONE OR MORE SELECTIONS
801.41;+107876,;23~YES
801.41;+107876,;25~WP-start~1
Off pathway:
801.41;+107876,;100~NATIONAL
801.41;+107876,;101~VHA ONCOLOGY
801.412;+107877,+107876,;.01~10
801.412;+107877,+107876,;2~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH TX
801.412;+107878,+107876,;.01~20
801.412;+107878,+107876,;2~VA-ONC MIBC POST CYSTECTOMY STAGE OFF PATH RSN
801.44;+107879,+107876,;.01~04/27/2026@11:26:13
801.44;+107879,+107876,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107877^1
107878^2
107879^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING</POINT_01>
<INTERNAL_ENTRY_NUMBER>107870</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>232769902</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107870,;.01~VA-GP ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING
801.41;+107870,;4~dialog group
801.41;+107870,;6~YES
801.41;+107870,;7~2
801.41;+107870,;9~ONE SELECTION ONLY
801.41;+107870,;15~HF.VA-ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING
801.41;+107870,;25~WP-start~2
ctDNA testing every 6 weeks for 9 months, with a final test at 1 year 
after cystectomy.
801.41;+107870,;52~INDENT
801.41;+107870,;100~NATIONAL
801.41;+107870,;101~VHA ONCOLOGY
801.44;+107871,+107870,;.01~04/27/2026@11:26:13
801.44;+107871,+107870,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107871^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107868</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3568324702</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107868,;.01~VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL
801.41;+107868,;4~dialog element
801.41;+107868,;15~HF.VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL
801.41;+107868,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107868,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107868,;100~NATIONAL
801.41;+107868,;101~VHA ONCOLOGY
801.412;+107869,+107868,;.01~5
801.412;+107869,+107868,;2~VA-ONC CLINICAL TRIAL
801.412;+107869,+107868,;9~YES
801.44;+107870,+107868,;.01~04/27/2026@11:26:13
801.44;+107870,+107868,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107869^1
107870^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY STAGE</POINT_01>
<INTERNAL_ENTRY_NUMBER>107845</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2559901860</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107845,;.01~VA-GP ONC MIBC POST CYSTECTOMY STAGE
801.41;+107845,;4~dialog group
801.41;+107845,;6~YES
801.41;+107845,;7~2
801.41;+107845,;9~ONE SELECTION ONLY
801.41;+107845,;25~WP-start~1
Stage (y)pT2-4aN0M0 or (y)pT0-4aN+M0.
801.41;+107845,;52~INDENT
801.41;+107845,;100~NATIONAL
801.41;+107845,;101~VHA ONCOLOGY
801.412;+107846,+107845,;.01~5
801.412;+107846,+107845,;2~VA-ONC MIBC POST CYSTECTOMY STAGE CLIN TRIAL
801.412;+107847,+107845,;.01~10
801.412;+107847,+107845,;2~VA-GP ONC MIBC POST CYSTECTOMY STAGE CTDNA TESTING
801.412;+107848,+107845,;.01~15
801.412;+107848,+107845,;2~VA-GP ONC MIBC POST CYSTECTOMY STAGE OFF PATH
801.44;+107849,+107845,;.01~04/27/2026@11:26:13
801.44;+107849,+107845,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107846^1
107847^2
107848^3
107849^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC POST CYSTECTOMY OPTIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>92773</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3339863407</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+92773,;.01~VA-GP ONC MIBC POST CYSTECTOMY OPTIONS
801.41;+92773,;4~dialog group
801.41;+92773,;6~YES
801.41;+92773,;7~2
801.41;+92773,;9~ONE SELECTION ONLY
801.41;+92773,;23~NO
801.41;+92773,;25~WP-start~1
POST CYSTECTOMY OPTIONS:
801.41;+92773,;35~WP-start~1
\\POST CYSTECTOMY WITH PELVIC LYMPH NODE DISSECTION OPTIONS:
801.41;+92773,;52~INDENT
801.41;+92773,;100~NATIONAL
801.41;+92773,;101~VHA ONCOLOGY
801.412;+92774,+92773,;.01~5
801.412;+92774,+92773,;2~VA-GP ONC MIBC POST CYSTECTOMY STAGE
801.412;+92775,+92773,;.01~10
801.412;+92775,+92773,;2~VA-GP ONC MIBC POST CYSTECTOMY NOT STAGE
801.412;+92776,+92773,;.01~15
801.412;+92776,+92773,;2~VA-GP ONC MIBC POST CYSTECTOMY CTDNA POSITIVE
801.412;+92777,+92773,;.01~20
801.412;+92777,+92773,;2~VA-GP ONC MIBC POST CYSTECTOMY CTDNA NEGATIVE
801.412;+92778,+92773,;.01~3
801.412;+92778,+92773,;2~VA-ONC MIBC BLADDER CANCER STAGING 8TH EDITION
801.44;+92779,+92773,;.01~04/27/2026@11:26:13
801.44;+92779,+92773,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
92774^1
92775^2
92776^3
92777^4
92778^5
92779^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>85995</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2975700548</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85995,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN
801.41;+85995,;4~dialog element
801.41;+85995,;15~HF.VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN
801.41;+85995,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+85995,;51~SUPPRESS
801.41;+85995,;100~NATIONAL
801.41;+85995,;101~VHA ONCOLOGY
801.412;+85996,+85995,;.01~5
801.412;+85996,+85995,;2~VA-ONC OFF PATHWAY
801.412;+85996,+85995,;7~YES
801.412;+85996,+85995,;9~YES
801.44;+85997,+85995,;.01~04/27/2026@11:26:13
801.44;+85997,+85995,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85996^1
85997^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>85993</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3660068430</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85993,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX
801.41;+85993,;4~dialog element
801.41;+85993,;15~HF.VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX
801.41;+85993,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+85993,;51~SUPPRESS
801.41;+85993,;100~NATIONAL
801.41;+85993,;101~VHA ONCOLOGY
801.412;+85994,+85993,;.01~5
801.412;+85994,+85993,;2~VA-ONC BLANK
801.412;+85994,+85993,;7~YES
801.412;+85994,+85993,;9~YES
801.44;+85995,+85993,;.01~04/27/2026@11:26:13
801.44;+85995,+85993,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85994^1
85995^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>85992</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2240737534</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85992,;.01~VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH
801.41;+85992,;4~dialog group
801.41;+85992,;7~2
801.41;+85992,;9~ONE OR MORE SELECTIONS
801.41;+85992,;23~YES
801.41;+85992,;25~WP-start~1
Off pathway:
801.41;+85992,;100~NATIONAL
801.41;+85992,;101~VHA ONCOLOGY
801.412;+85993,+85992,;.01~10
801.412;+85993,+85992,;2~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH TX
801.412;+85994,+85992,;.01~20
801.412;+85994,+85992,;2~VA-ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH RSN
801.44;+85995,+85992,;.01~04/27/2026@11:26:13
801.44;+85995,+85992,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85993^1
85994^2
85995^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY</POINT_01>
<INTERNAL_ENTRY_NUMBER>85991</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2581753306</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85991,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY
801.41;+85991,;4~dialog element
801.41;+85991,;15~HF.VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY
801.41;+85991,;25~WP-start~3
Radiotherapy
 ++ Reassess tumor status at 3 month intervals and follow appropriately
    staged pathway. ++
801.41;+85991,;35~WP-start~3
Veteran has elected to pursue RADIOTHERAPY.
 ++ Reassess tumor status at 3 month intervals and follow appropriately
    staged pathway. ++
801.41;+85991,;100~NATIONAL
801.41;+85991,;101~VHA ONCOLOGY
801.44;+85992,+85991,;.01~04/27/2026@11:26:13
801.44;+85992,+85991,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85992^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>85989</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4156218289</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85989,;.01~VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL
801.41;+85989,;4~dialog element
801.41;+85989,;15~HF.VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL
801.41;+85989,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+85989,;35~WP-start~1
Veteran has elected to pursue:
801.41;+85989,;100~NATIONAL
801.41;+85989,;101~VHA ONCOLOGY
801.412;+85990,+85989,;.01~5
801.412;+85990,+85989,;2~VA-ONC CLINICAL TRIAL
801.412;+85990,+85989,;9~YES
801.44;+85991,+85989,;.01~04/27/2026@11:26:13
801.44;+85991,+85989,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85990^1
85991^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO</POINT_01>
<INTERNAL_ENTRY_NUMBER>85974</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2083127177</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85974,;.01~VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO
801.41;+85974,;4~dialog group
801.41;+85974,;6~YES
801.41;+85974,;7~2
801.41;+85974,;9~ONE SELECTION ONLY
801.41;+85974,;25~WP-start~1
Not systemic chemotherapy candidate:
801.41;+85974,;52~INDENT
801.41;+85974,;100~NATIONAL
801.41;+85974,;101~VHA ONCOLOGY
801.412;+85975,+85974,;.01~20
801.412;+85975,+85974,;2~VA-ONC MIBC NO CYSTECTOMY NO CHEMO CLINICAL TRIAL
801.412;+85976,+85974,;.01~40
801.412;+85976,+85974,;2~VA-ONC MIBC NO CYSTECTOMY NO CHEMO RADIOTHERAPY
801.412;+85977,+85974,;.01~60
801.412;+85977,+85974,;2~VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO OFF PATH
801.44;+85978,+85974,;.01~04/27/2026@11:26:13
801.44;+85978,+85974,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85975^1
85976^2
85977^3
85978^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>85986</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3829666951</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85986,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN
801.41;+85986,;4~dialog element
801.41;+85986,;15~HF.VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN
801.41;+85986,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+85986,;51~SUPPRESS
801.41;+85986,;100~NATIONAL
801.41;+85986,;101~VHA ONCOLOGY
801.412;+85987,+85986,;.01~5
801.412;+85987,+85986,;2~VA-ONC OFF PATHWAY
801.412;+85987,+85986,;7~YES
801.412;+85987,+85986,;9~YES
801.44;+85988,+85986,;.01~04/27/2026@11:26:13
801.44;+85988,+85986,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85987^1
85988^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>85985</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1971569855</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85985,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX
801.41;+85985,;4~dialog element
801.41;+85985,;15~HF.VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX
801.41;+85985,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+85985,;51~SUPPRESS
801.41;+85985,;100~NATIONAL
801.41;+85985,;101~VHA ONCOLOGY
801.412;+85986,+85985,;.01~5
801.412;+85986,+85985,;2~VA-ONC BLANK
801.412;+85986,+85985,;7~YES
801.412;+85986,+85985,;9~YES
801.44;+85987,+85985,;.01~04/27/2026@11:26:13
801.44;+85987,+85985,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85986^1
85987^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO CYSTECTOMY CHEMO OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>85983</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>382268869</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85983,;.01~VA-GP ONC MIBC NO CYSTECTOMY CHEMO OFF PATH
801.41;+85983,;4~dialog group
801.41;+85983,;7~2
801.41;+85983,;23~YES
801.41;+85983,;25~WP-start~1
Off pathway:
801.41;+85983,;100~NATIONAL
801.41;+85983,;101~VHA ONCOLOGY
801.412;+85984,+85983,;.01~10
801.412;+85984,+85983,;2~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH TX
801.412;+85985,+85983,;.01~20
801.412;+85985,+85983,;2~VA-ONC MIBC NO CYSTECTOMY CHEMO OFF PATH RSN
801.44;+85986,+85983,;.01~04/27/2026@11:26:13
801.44;+85986,+85983,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85984^1
85985^2
85986^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU/MITOMYCIN/RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>85981</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2591090600</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85981,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU/MITOMYCIN/RADIATION
801.41;+85981,;4~dialog element
801.41;+85981,;15~HF.VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU MITOMYCIN RAD
801.41;+85981,;25~WP-start~3
Bladder preservation with concurrent 5FU, mitomycin, and radiotherapy.
 ++ Reassess tumor status at 3 month intervals and follow appropriately
    staged pathway. ++
801.41;+85981,;35~WP-start~4
Veteran has elected to pursue BLADDER PRESERVATION with CONCURRENT 5FU,
MITOMYCIN, and RADIOTHERAPY.
 ++ Reassess tumor status at 3 month intervals and follow appropriately
    staged pathway. ++
801.41;+85981,;100~NATIONAL
801.41;+85981,;101~VHA ONCOLOGY
801.44;+85982,+85981,;.01~04/27/2026@11:26:13
801.44;+85982,+85981,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85982^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>85979</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2840020251</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85979,;.01~VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL
801.41;+85979,;4~dialog element
801.41;+85979,;15~HF.VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL
801.41;+85979,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+85979,;35~WP-start~1
Veteran has elected to pursue:
801.41;+85979,;100~NATIONAL
801.41;+85979,;101~VHA ONCOLOGY
801.412;+85980,+85979,;.01~5
801.412;+85980,+85979,;2~VA-ONC CLINICAL TRIAL
801.412;+85980,+85979,;9~YES
801.44;+85981,+85979,;.01~04/27/2026@11:26:13
801.44;+85981,+85979,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85980^1
85981^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO CYSTECTOMY CHEMO</POINT_01>
<INTERNAL_ENTRY_NUMBER>85972</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>599302789</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+85972,;.01~VA-GP ONC MIBC NO CYSTECTOMY CHEMO
801.41;+85972,;4~dialog group
801.41;+85972,;6~YES
801.41;+85972,;7~2
801.41;+85972,;9~ONE SELECTION ONLY
801.41;+85972,;25~WP-start~1
Systemic chemotherapy candidate:
801.41;+85972,;52~INDENT
801.41;+85972,;100~NATIONAL
801.41;+85972,;101~VHA ONCOLOGY
801.412;+85973,+85972,;.01~20
801.412;+85973,+85972,;2~VA-ONC MIBC NO CYSTECTOMY CHEMO CLINICAL TRIAL
801.412;+85974,+85972,;.01~40
801.412;+85974,+85972,;2~VA-ONC MIBC NO CYSTECTOMY CHEMO 5FU/MITOMYCIN/RADIATION
801.412;+85975,+85972,;.01~60
801.412;+85975,+85972,;2~VA-GP ONC MIBC NO CYSTECTOMY CHEMO OFF PATH
801.44;+85976,+85972,;.01~04/27/2026@11:26:13
801.44;+85976,+85972,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
85973^1
85974^2
85975^3
85976^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>84565</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3616046693</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84565,;.01~VA-GP ONC MIBC NO CYSTECTOMY
801.41;+84565,;4~dialog group
801.41;+84565,;6~YES
801.41;+84565,;7~2
801.41;+84565,;9~ONE SELECTION ONLY
801.41;+84565,;25~WP-start~3
Not a candidate for cystectomy:
 ++ Avoid bladder preservation in patients with hydronephrosis and 
    extensive or multifocal carcinoma in situ. ++
801.41;+84565,;52~INDENT
801.41;+84565,;100~NATIONAL
801.41;+84565,;101~VHA ONCOLOGY
801.412;+84566,+84565,;.01~20
801.412;+84566,+84565,;2~VA-GP ONC MIBC NO CYSTECTOMY CHEMO
801.412;+84567,+84565,;.01~40
801.412;+84567,+84565,;2~VA-GP ONC MIBC NO CYSTECTOMY NO CHEMO
801.44;+84568,+84565,;.01~04/27/2026@11:26:13
801.44;+84568,+84565,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84566^1
84567^2
84568^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>84649</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1365689483</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84649,;.01~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH RSN
801.41;+84649,;4~dialog element
801.41;+84649,;15~HF.VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH RSN
801.41;+84649,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+84649,;51~SUPPRESS
801.41;+84649,;100~NATIONAL
801.41;+84649,;101~VHA ONCOLOGY
801.412;+84650,+84649,;.01~5
801.412;+84650,+84649,;2~VA-ONC OFF PATHWAY
801.412;+84650,+84649,;7~YES
801.412;+84650,+84649,;9~YES
801.44;+84651,+84649,;.01~04/27/2026@11:26:13
801.44;+84651,+84649,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84650^1
84651^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>84648</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3327329833</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84648,;.01~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH TX
801.41;+84648,;4~dialog element
801.41;+84648,;15~HF.VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE OFF PATH TX
801.41;+84648,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+84648,;51~SUPPRESS
801.41;+84648,;100~NATIONAL
801.41;+84648,;101~VHA ONCOLOGY
801.412;+84649,+84648,;.01~5
801.412;+84649,+84648,;2~VA-ONC BLANK
801.412;+84649,+84648,;7~YES
801.412;+84649,+84648,;9~YES
801.44;+84650,+84648,;.01~04/27/2026@11:26:13
801.44;+84650,+84648,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84649^1
84650^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>84647</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3235827469</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84647,;.01~VA-GP ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH
801.41;+84647,;4~dialog group
801.41;+84647,;7~2
801.41;+84647,;9~ONE OR MORE SELECTIONS
801.41;+84647,;23~YES
801.41;+84647,;25~WP-start~1
Off pathway:
801.41;+84647,;100~NATIONAL
801.41;+84647,;101~VHA ONCOLOGY
801.412;+84648,+84647,;.01~10
801.412;+84648,+84647,;2~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH TX
801.412;+84649,+84647,;.01~20
801.412;+84649,+84647,;2~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH RSN
801.44;+84650,+84647,;.01~04/27/2026@11:26:13
801.44;+84650,+84647,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84648^1
84649^2
84650^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC BLADDER PRESERVE CANDIDATE 5FU/MITOMYCIN/RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>84646</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2699285651</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84646,;.01~VA-ONC MIBC BLADDER PRESERVE CANDIDATE 5FU/MITOMYCIN/RADIATION
801.41;+84646,;4~dialog element
801.41;+84646,;15~HF.VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE 5FU MITOMYCIN RAD
801.41;+84646,;25~WP-start~2
Bladder preservation with concurrent 5FU, mitomycin, and radiotherapy.
 ++ Follow Post Bladder Preservation Pathway. ++
801.41;+84646,;35~WP-start~3
Veteran has elected to pursue BLADDER PRESERVATION with CONCURRENT 5FU, 
MITOMYCIN, and RADIOTHERAPY.
 ++ Follow Post Bladder Preservation Pathway. ++
801.41;+84646,;100~NATIONAL
801.41;+84646,;101~VHA ONCOLOGY
801.44;+84647,+84646,;.01~04/27/2026@11:26:13
801.44;+84647,+84646,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84647^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC BLADDER PRESERVATION CANDIDATE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>84645</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>649787597</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84645,;.01~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE CLINICAL TRIAL
801.41;+84645,;4~dialog element
801.41;+84645,;15~HF.VA-ONC MIBC CHEMO BLADDER PRESERVE CANDIDATE CLINICAL TRIAL
801.41;+84645,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+84645,;35~WP-start~1
Veteran has elected to pursue:
801.41;+84645,;100~NATIONAL
801.41;+84645,;101~VHA ONCOLOGY
801.412;+84646,+84645,;.01~5
801.412;+84646,+84645,;2~VA-ONC CLINICAL TRIAL
801.412;+84646,+84645,;9~YES
801.44;+84647,+84645,;.01~04/27/2026@11:26:13
801.44;+84647,+84645,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84646^1
84647^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CYSTECTOMY BLADDER PRESERVATION CANDIDATE</POINT_01>
<INTERNAL_ENTRY_NUMBER>84640</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>586972724</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84640,;.01~VA-GP ONC MIBC CYSTECTOMY BLADDER PRESERVATION CANDIDATE
801.41;+84640,;4~dialog group
801.41;+84640,;6~YES
801.41;+84640,;7~2
801.41;+84640,;9~ONE SELECTION ONLY
801.41;+84640,;25~WP-start~3
Bladder preservation candidate:
 ++ Avoid bladder preservation in patients with hydronephrosis and 
    extensive or multifocal carcinoma in situ. ++
801.41;+84640,;52~INDENT
801.41;+84640,;100~NATIONAL
801.41;+84640,;101~VHA ONCOLOGY
801.412;+84641,+84640,;.01~20
801.412;+84641,+84640,;2~VA-ONC MIBC BLADDER PRESERVATION CANDIDATE CLINICAL TRIAL
801.412;+84642,+84640,;.01~40
801.412;+84642,+84640,;2~VA-ONC MIBC BLADDER PRESERVE CANDIDATE 5FU/MITOMYCIN/RADIATION
801.412;+84643,+84640,;.01~60
801.412;+84643,+84640,;2~VA-GP ONC MIBC BLADDER PRESERVATION CANDIDATE OFF PATH
801.44;+84644,+84640,;.01~04/27/2026@11:26:13
801.44;+84644,+84640,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84641^1
84642^2
84643^3
84644^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107842</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1063898112</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107842,;.01~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN
801.41;+107842,;4~dialog element
801.41;+107842,;15~HF.VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN
801.41;+107842,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107842,;51~SUPPRESS
801.41;+107842,;100~NATIONAL
801.41;+107842,;101~VHA ONCOLOGY
801.412;+107843,+107842,;.01~5
801.412;+107843,+107842,;2~VA-ONC OFF PATHWAY
801.412;+107843,+107842,;7~YES
801.412;+107843,+107842,;9~YES
801.44;+107844,+107842,;.01~04/27/2026@11:26:13
801.44;+107844,+107842,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107843^1
107844^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107841</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3535101792</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107841,;.01~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX
801.41;+107841,;4~dialog element
801.41;+107841,;15~HF.VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX
801.41;+107841,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107841,;51~SUPPRESS
801.41;+107841,;100~NATIONAL
801.41;+107841,;101~VHA ONCOLOGY
801.412;+107842,+107841,;.01~5
801.412;+107842,+107841,;2~VA-ONC BLANK
801.412;+107842,+107841,;7~YES
801.412;+107842,+107841,;9~YES
801.44;+107843,+107841,;.01~04/27/2026@11:26:13
801.44;+107843,+107841,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107842^1
107843^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107840</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>962679542</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107840,;.01~VA-GP ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH
801.41;+107840,;4~dialog group
801.41;+107840,;7~2
801.41;+107840,;9~ONE OR MORE SELECTIONS
801.41;+107840,;23~YES
801.41;+107840,;25~WP-start~1
Off pathway:
801.41;+107840,;100~NATIONAL
801.41;+107840,;101~VHA ONCOLOGY
801.412;+107841,+107840,;.01~10
801.412;+107841,+107840,;2~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH TX
801.412;+107842,+107840,;.01~20
801.412;+107842,+107840,;2~VA-ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH RSN
801.44;+107843,+107840,;.01~04/27/2026@11:26:13
801.44;+107843,+107840,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107841^1
107842^2
107843^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>107839</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2043323832</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107839,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY
801.41;+107839,;4~dialog element
801.41;+107839,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY
801.41;+107839,;25~WP-start~1
Cystectomy with pelvic lymph node dissection.
801.41;+107839,;35~WP-start~2
Veteran has elected to pursue CYSTECTOMY with PELVIC LYMPH NODE 
DISSECTION.
801.41;+107839,;100~NATIONAL
801.41;+107839,;101~VHA ONCOLOGY
801.44;+107840,+107839,;.01~04/27/2026@11:26:13
801.44;+107840,+107839,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107840^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107838</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1150484572</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107838,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL
801.41;+107838,;4~dialog element
801.41;+107838,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL
801.41;+107838,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107838,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107838,;100~NATIONAL
801.41;+107838,;101~VHA ONCOLOGY
801.412;+107839,+107838,;.01~5
801.412;+107839,+107838,;2~VA-ONC CLINICAL TRIAL
801.412;+107839,+107838,;9~YES
801.44;+107840,+107838,;.01~04/27/2026@11:26:13
801.44;+107840,+107838,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107839^1
107840^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT</POINT_01>
<INTERNAL_ENTRY_NUMBER>107828</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4252551439</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107828,;.01~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT
801.41;+107828,;4~dialog group
801.41;+107828,;6~YES
801.41;+107828,;7~2
801.41;+107828,;9~ONE SELECTION ONLY
801.41;+107828,;25~WP-start~4
Not a neoadjuvant candidate:
  ++ Enfortumab Vedotin - Exclude patients with preexisting peripheral
  neuropathy greater than or equal to Grade 2, baseline ocular disorders,
  uncontrolled diabetes at baseline. ++
801.41;+107828,;52~INDENT
801.41;+107828,;100~NATIONAL
801.41;+107828,;101~VHA ONCOLOGY
801.412;+107829,+107828,;.01~5
801.412;+107829,+107828,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CLIN TRIAL
801.412;+107830,+107828,;.01~10
801.412;+107830,+107828,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT CYSTECTOMY
801.412;+107831,+107828,;.01~15
801.412;+107831,+107828,;2~VA-GP ONC MIBC NO BLAD PRESERVE NO CIS NO NEOADJUVANT OFF PATH
801.44;+107832,+107828,;.01~04/27/2026@11:26:13
801.44;+107832,+107828,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107829^1
107830^2
107831^3
107832^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107837</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1280266681</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107837,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN
801.41;+107837,;4~dialog element
801.41;+107837,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN
801.41;+107837,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107837,;51~SUPPRESS
801.41;+107837,;100~NATIONAL
801.41;+107837,;101~VHA ONCOLOGY
801.412;+107838,+107837,;.01~5
801.412;+107838,+107837,;2~VA-ONC OFF PATHWAY
801.412;+107838,+107837,;7~YES
801.412;+107838,+107837,;9~YES
801.44;+107839,+107837,;.01~04/27/2026@11:26:13
801.44;+107839,+107837,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107838^1
107839^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107836</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3717055993</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107836,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX
801.41;+107836,;4~dialog element
801.41;+107836,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX
801.41;+107836,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107836,;51~SUPPRESS
801.41;+107836,;100~NATIONAL
801.41;+107836,;101~VHA ONCOLOGY
801.412;+107837,+107836,;.01~5
801.412;+107837,+107836,;2~VA-ONC BLANK
801.412;+107837,+107836,;7~YES
801.412;+107837,+107836,;9~YES
801.44;+107838,+107836,;.01~04/27/2026@11:26:13
801.44;+107838,+107836,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107837^1
107838^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107835</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1186853519</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107835,;.01~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH
801.41;+107835,;4~dialog group
801.41;+107835,;7~2
801.41;+107835,;9~ONE OR MORE SELECTIONS
801.41;+107835,;23~YES
801.41;+107835,;25~WP-start~1
Off pathway:
801.41;+107835,;100~NATIONAL
801.41;+107835,;101~VHA ONCOLOGY
801.412;+107836,+107835,;.01~10
801.412;+107836,+107835,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH TX
801.412;+107837,+107835,;.01~20
801.412;+107837,+107835,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH RSN
801.44;+107838,+107835,;.01~04/27/2026@11:26:13
801.44;+107838,+107835,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107836^1
107837^2
107838^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>107834</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2178464858</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107834,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY
801.41;+107834,;4~dialog element
801.41;+107834,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY
801.41;+107834,;25~WP-start~4
Neoadjuvant EV pembrolizumab (3 cycles) and radical cystectomy with 
pelvic lymph node dissection followed by adjuvant EV pembrolizumab (up to
6 cycles) followed by pembrolizumab (up to 8 cycles).
  ++ Follow Post Cystectomy Pathway. ++
801.41;+107834,;35~WP-start~5
Veteran has elected to pursue NEOADJUVANT EV PEMBROLIZUMAB (3 cycles) and 
RADICAL CYSTECTOMY with PELVIC LYMPH NODE DISSECTION followed by ADJUVANT 
EV PEMBROLIZUMAB (up to 6 cycles) followed by PEMBROLIZUMAB (up to 8 
cycles).
  ++ Follow Post Cystectomy Pathway. ++
801.41;+107834,;100~NATIONAL
801.41;+107834,;101~VHA ONCOLOGY
801.44;+107835,+107834,;.01~04/27/2026@11:26:13
801.44;+107835,+107834,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107835^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107833</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2964389415</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107833,;.01~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL
801.41;+107833,;4~dialog element
801.41;+107833,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL
801.41;+107833,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107833,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107833,;100~NATIONAL
801.41;+107833,;101~VHA ONCOLOGY
801.412;+107834,+107833,;.01~5
801.412;+107834,+107833,;2~VA-ONC CLINICAL TRIAL
801.412;+107834,+107833,;9~YES
801.44;+107835,+107833,;.01~04/27/2026@11:26:13
801.44;+107835,+107833,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107834^1
107835^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT</POINT_01>
<INTERNAL_ENTRY_NUMBER>107827</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>345446382</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107827,;.01~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT
801.41;+107827,;4~dialog group
801.41;+107827,;6~YES
801.41;+107827,;7~2
801.41;+107827,;9~ONE SELECTION ONLY
801.41;+107827,;25~WP-start~4
Neoadjuvant candidate:
  ++ Enfortumab Vedotin - Exclude patients with preexisting peripheral
  neuropathy greater than or equal to Grade 2, baseline ocular disorders,
  uncontrolled diabetes at baseline. ++
801.41;+107827,;52~INDENT
801.41;+107827,;100~NATIONAL
801.41;+107827,;101~VHA ONCOLOGY
801.412;+107828,+107827,;.01~5
801.412;+107828,+107827,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CLIN TRIAL
801.412;+107829,+107827,;.01~10
801.412;+107829,+107827,;2~VA-ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT CYSTECTOMY
801.412;+107830,+107827,;.01~15
801.412;+107830,+107827,;2~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT OFF PATH
801.44;+107831,+107827,;.01~04/27/2026@11:26:13
801.44;+107831,+107827,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107828^1
107829^2
107830^3
107831^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVATION NO CISPLATIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107759</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2997607432</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107759,;.01~VA-GP ONC MIBC NO BLADDER PRESERVATION NO CISPLATIN
801.41;+107759,;4~dialog group
801.41;+107759,;6~YES
801.41;+107759,;7~2
801.41;+107759,;9~ONE SELECTION ONLY
801.41;+107759,;25~WP-start~4
Not a candidate for cisplatin:
  ++ Cisplatin Ineligible if more than one of the following: impaired
  renal function, ECOG PS 2, greater than 2 audiometric hearing loss, or
  New York Heart Association (NYHA) class III heart failure. ++
801.41;+107759,;52~INDENT
801.41;+107759,;100~NATIONAL
801.41;+107759,;101~VHA ONCOLOGY
801.412;+107760,+107759,;.01~5
801.412;+107760,+107759,;2~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NEOADJUVANT
801.412;+107761,+107759,;.01~10
801.412;+107761,+107759,;2~VA-GP ONC MIBC NO BLADDER PRESERVE NO CIS NO NEOADJUVANT
801.44;+107762,+107759,;.01~04/27/2026@11:26:13
801.44;+107762,+107759,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107760^1
107761^2
107762^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107765</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3205033735</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107765,;.01~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH RSN
801.41;+107765,;4~dialog element
801.41;+107765,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH RSN
801.41;+107765,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+107765,;51~SUPPRESS
801.41;+107765,;100~NATIONAL
801.41;+107765,;101~VHA ONCOLOGY
801.412;+107766,+107765,;.01~5
801.412;+107766,+107765,;2~VA-ONC OFF PATHWAY
801.412;+107766,+107765,;7~YES
801.412;+107766,+107765,;9~YES
801.44;+107767,+107765,;.01~04/27/2026@11:26:13
801.44;+107767,+107765,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107766^1
107767^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>107764</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2252958931</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107764,;.01~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH TX
801.41;+107764,;4~dialog element
801.41;+107764,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN OFF PATH TX
801.41;+107764,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+107764,;51~SUPPRESS
801.41;+107764,;100~NATIONAL
801.41;+107764,;101~VHA ONCOLOGY
801.412;+107765,+107764,;.01~5
801.412;+107765,+107764,;2~VA-ONC BLANK
801.412;+107765,+107764,;7~YES
801.412;+107765,+107764,;9~YES
801.44;+107766,+107764,;.01~04/27/2026@11:26:14
801.44;+107766,+107764,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107765^1
107766^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>107763</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1805466084</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107763,;.01~VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH
801.41;+107763,;4~dialog group
801.41;+107763,;7~2
801.41;+107763,;9~ONE OR MORE SELECTIONS
801.41;+107763,;23~YES
801.41;+107763,;25~WP-start~1
Off pathway:
801.41;+107763,;100~NATIONAL
801.41;+107763,;101~VHA ONCOLOGY
801.412;+107764,+107763,;.01~10
801.412;+107764,+107763,;2~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH TX
801.412;+107765,+107763,;.01~20
801.412;+107765,+107763,;2~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH RSN
801.44;+107766,+107763,;.01~04/27/2026@11:26:14
801.44;+107766,+107763,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107764^1
107765^2
107766^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>107761</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>321351522</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107761,;.01~VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY
801.41;+107761,;4~dialog element
801.41;+107761,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY
801.41;+107761,;25~WP-start~10
Neoadjuvant (4 cycles) gemcitabine, cisplatin, durvalumab, and radical 
cystectomy with pelvic lymph node dissection followed by adjuvant
durvalumb.
  ++ Shared decision making is critical at the time of consideration of
     durvalumab; in clinical trials, the control arm was chemotherapy
     alone and contained no information regarding any subsequent therapies
     in the control arm; thus, it is unclear if survival benefit is from
     neoadjuvant therapy alone, adjuvant therapy, or both components;
     physician should discuss these uncertainties with patients. ++
  ++ Follow Post Cystectomy Pathway. ++
801.41;+107761,;35~WP-start~10
Veteran has elected to pursue NEOADJUVANT GEMCITABINE (4 cycles), 
CISPLATIN, DURVALUMAB, and RADICAL CYSTECTOMY with PELVIC LYMPH NODE 
DISSECTION followed by ADJUVANT DURVALUMAB.
  ++ Shared decision making is critical at the time of consideration of
     durvalumab; in clinical trials, the control arm was chemotherapy
     alone and contained no information regarding any subsequent therapies
     in the control arm; thus, it is unclear if survival benefit is from
     neoadjuvant therapy alone, adjuvant therapy, or both components;
     physician should discuss these uncertainties with patients. ++
  ++ Follow Post Cystectomy Pathway. ++
801.41;+107761,;100~NATIONAL
801.41;+107761,;101~VHA ONCOLOGY
801.44;+107762,+107761,;.01~04/27/2026@11:26:14
801.44;+107762,+107761,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107762^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>107760</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>571246728</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107760,;.01~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN CLINICAL TRIAL
801.41;+107760,;4~dialog element
801.41;+107760,;15~HF.VA-ONC MIBC NO BLADDER PRESERVE CISPLATIN CLIN TRIAL
801.41;+107760,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+107760,;35~WP-start~1
Veteran has elected to pursue:
801.41;+107760,;100~NATIONAL
801.41;+107760,;101~VHA ONCOLOGY
801.412;+107761,+107760,;.01~5
801.412;+107761,+107760,;2~VA-ONC CLINICAL TRIAL
801.412;+107761,+107760,;9~YES
801.44;+107762,+107760,;.01~04/27/2026@11:26:14
801.44;+107762,+107760,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107761^1
107762^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>107758</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>114902913</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107758,;.01~VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN
801.41;+107758,;4~dialog group
801.41;+107758,;6~YES
801.41;+107758,;7~2
801.41;+107758,;9~ONE SELECTION ONLY
801.41;+107758,;25~WP-start~4
Candidate for cisplatin:
  ++ Cisplatin Ineligible if more than one of the following: impaired
  renal function, ECOG PS 2, greater than 2 audiometric hearing loss, or
  New York Heart Association (NYHA) class III heart failure. ++
801.41;+107758,;52~INDENT
801.41;+107758,;100~NATIONAL
801.41;+107758,;101~VHA ONCOLOGY
801.412;+107759,+107758,;.01~5
801.412;+107759,+107758,;2~VA-ONC MIBC NO BLADDER PRESERVATION CISPLATIN CLINICAL TRIAL
801.412;+107760,+107758,;.01~10
801.412;+107760,+107758,;2~VA-ONC MIBC NO BLADDER PRESERVE GEM CIS DURVALUMAB CYSTECTOMY
801.412;+107761,+107758,;.01~15
801.412;+107761,+107758,;2~VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN OFF PATH
801.44;+107762,+107758,;.01~04/27/2026@11:26:14
801.44;+107762,+107758,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107759^1
107760^2
107761^3
107762^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CYSTECTOMY NO BLADDER PRESERVATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>107757</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2077474810</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+107757,;.01~VA-GP ONC MIBC CYSTECTOMY NO BLADDER PRESERVATION
801.41;+107757,;4~dialog group
801.41;+107757,;6~YES
801.41;+107757,;7~2
801.41;+107757,;9~ONE SELECTION ONLY
801.41;+107757,;25~WP-start~3
Not a bladder preservation candidate:
  ++ Avoid bladder preservation in patients with hydronephrosis and 
    extensive or multifocal carcinoma in situ. ++
801.41;+107757,;52~INDENT
801.41;+107757,;100~NATIONAL
801.41;+107757,;101~VHA ONCOLOGY
801.412;+107758,+107757,;.01~5
801.412;+107758,+107757,;2~VA-GP ONC MIBC NO BLADDER PRESERVATION CISPLATIN
801.412;+107759,+107757,;.01~10
801.412;+107759,+107757,;2~VA-GP ONC MIBC NO BLADDER PRESERVATION NO CISPLATIN
801.44;+107760,+107757,;.01~04/27/2026@11:26:14
801.44;+107760,+107757,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
107758^1
107759^2
107760^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CANDIDATE CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>84564</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1143317405</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84564,;.01~VA-GP ONC MIBC CANDIDATE CYSTECTOMY
801.41;+84564,;4~dialog group
801.41;+84564,;6~YES
801.41;+84564,;7~2
801.41;+84564,;9~ONE SELECTION ONLY
801.41;+84564,;25~WP-start~3
Candidate for cystectomy:
 ++ Patients with clinical node positive disease should have resolution 
    of adenopathy post chemotherapy to become eligible for cystectomy. ++
801.41;+84564,;52~INDENT
801.41;+84564,;100~NATIONAL
801.41;+84564,;101~VHA ONCOLOGY
801.412;+84565,+84564,;.01~10
801.412;+84565,+84564,;2~VA-GP ONC MIBC CYSTECTOMY NO BLADDER PRESERVATION
801.412;+84566,+84564,;.01~5
801.412;+84566,+84564,;2~VA-GP ONC MIBC CYSTECTOMY BLADDER PRESERVATION CANDIDATE
801.44;+84567,+84564,;.01~04/27/2026@11:26:14
801.44;+84567,+84564,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84565^2
84566^3
84567^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CANDIDATE CYSTECTOMY MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>92732</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3598094353</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+92732,;.01~VA-GP ONC MIBC CANDIDATE CYSTECTOMY MAIN
801.41;+92732,;4~dialog group
801.41;+92732,;6~YES
801.41;+92732,;9~NONE OR ONE SELECTION
801.41;+92732,;51~SUPPRESS
801.41;+92732,;100~NATIONAL
801.41;+92732,;101~VHA ONCOLOGY
801.412;+92733,+92732,;.01~10
801.412;+92733,+92732,;2~VA-GP ONC MIBC CANDIDATE CYSTECTOMY
801.412;+92734,+92732,;.01~20
801.412;+92734,+92732,;2~VA-GP ONC MIBC NO CYSTECTOMY
801.44;+92735,+92732,;.01~04/27/2026@11:26:14
801.44;+92735,+92732,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
92733^1
92734^2
92735^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE II, IIIA, IIIB PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>84575</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3890797827</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84575,;.01~VA-GP ONC MIBC STAGE II, IIIA, IIIB PATHWAY
801.41;+84575,;4~dialog group
801.41;+84575,;6~YES
801.41;+84575,;15~HF.VA-ONC BLADDER MUSCLE INVASIVE II, IIIA, IIIB
801.41;+84575,;25~WP-start~1
Muscle Invasive Stage II, IIIA, IIIB Pathway:
801.41;+84575,;35~WP-start~2
Muscle Invasive Stage II, IIIA, IIIB Pathway\\
============================================
801.41;+84575,;100~NATIONAL
801.41;+84575,;101~VHA ONCOLOGY
801.412;+84576,+84575,;.01~15
801.412;+84576,+84575,;2~VA-GP ONC MIBC CANDIDATE CYSTECTOMY MAIN
801.412;+84577,+84575,;.01~40
801.412;+84577,+84575,;2~VA-GP ONC MIBC POST CYSTECTOMY OPTIONS
801.44;+84578,+84575,;.01~04/27/2026@11:26:14
801.44;+84578,+84575,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84576^4
84577^5
84578^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-UPDATE 570 REVISED GROUPS</POINT_01>
<INTERNAL_ENTRY_NUMBER>109276</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>531400602</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109276,;.01~VA-UPDATE 570 REVISED GROUPS
801.41;+109276,;4~reminder dialog
801.41;+109276,;100~NATIONAL
801.412;+109277,+109276,;.01~5
801.412;+109277,+109276,;2~VA-GP ONC MIBC STAGE II, IIIA, IIIB PATHWAY
801.412;+109278,+109276,;.01~10
801.412;+109278,+109276,;2~VA-GP ONC CN VISIT TYPE
801.412;+109279,+109276,;.01~15
801.412;+109279,+109276,;2~VA-GP NTO CN VISIT TYPE
801.44;+109280,+109276,;.01~04/27/2026@11:26:14
801.44;+109280,+109276,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109277^1
109278^2
109279^3
109280^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER PATHWAYS PREVIOUS DATA CLICK TO INCLUDE</POINT_01>
<INTERNAL_ENTRY_NUMBER>96720</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2989624700</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+96720,;.01~VA-ONC BLADDER PATHWAYS PREVIOUS DATA CLICK TO INCLUDE
801.41;+96720,;4~dialog element
801.41;+96720,;25~WP-start~1
Include previous Oncology documentation in progress note\\
801.41;+96720,;35~WP-start~3
\\Previous Oncology Pathways documented:
  |VA-ONCOLOGY PATHWAYS BLADDER|\\
=========================================================
801.41;+96720,;100~NATIONAL
801.41;+96720,;101~VHA ONCOLOGY
801.44;+96721,+96720,;.01~04/27/2026@11:26:14
801.44;+96721,+96720,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
96721^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER CLINICAL &amp; SURGICAL EVAL VIEW</POINT_01>
<INTERNAL_ENTRY_NUMBER>78055</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1372724003</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+78055,;.01~VA-ONC BLADDER CLINICAL & SURGICAL EVAL VIEW
801.41;+78055,;4~dialog element
801.41;+78055,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+78055,;23~YES
801.41;+78055,;25~WP-start~1
========================================================
801.41;+78055,;35~WP-start~25
Clinical Presentation and Evaluation for Bladder Cancer:\\
========================================================\\
\\
Assessments:\\
------------\\-Tobacco Use\\-Exposure History\\-Family History\\
\\ 
\\Recommended Diagnostics:\\
------------------------\\
-CT Urogram (if Veteran unable to receive IV contrast, order alternative\\
 upper tract imaging).\\
-Cystoscopy\\
-Cytology (only order if results would change clinical management).\\
-TURBT with EUA (include blue-light cystoscopy if clinically appropriate\\
 with single dose intravesical Gemcitabine for known or presumed low\\
 grade bladder cancer).\\
 
Surgical Presentation and Evaluation for Bladder Cancer:\\
========================================================\\
\\
Recommended Diagnostics:\\
------------------------\\
-Surgical Variant Histology includes micropapillary, nested,
plasmacytoid,\\
 neuroendocrine, sarcomatoid, squamous, or glandular predominant.\\
-Repeat TURBT if prostate tissue still visibly present or if T1 disease.\\
801.41;+78055,;51~SUPPRESS
801.41;+78055,;100~NATIONAL
801.41;+78055,;101~VHA ONCOLOGY
801.412;+78056,+78055,;.01~5
801.412;+78056,+78055,;2~PXRM GF VIEW BUTTON
801.412;+78056,+78055,;6~VIEW Clinical and Surgical Eval
801.412;+78056,+78055,;8~YES
801.44;+78057,+78055,;.01~04/27/2026@11:26:14
801.44;+78057,+78055,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
78056^1
78057^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER PATHWAYS PRIOR DATA OBJECT</POINT_01>
<INTERNAL_ENTRY_NUMBER>86041</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1609478952</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86041,;.01~VA-ONC BLADDER PATHWAYS PRIOR DATA OBJECT
801.41;+86041,;4~dialog element
801.41;+86041,;23~YES
801.41;+86041,;25~WP-start~2
=======================================================\\
Oncology Pathways Documented:\\|VA-ONCOLOGY PATHWAYS BLADDER|\\
801.41;+86041,;51~SUPPRESS
801.41;+86041,;100~NATIONAL
801.41;+86041,;101~VHA ONCOLOGY
801.44;+86042,+86041,;.01~04/27/2026@11:26:14
801.44;+86042,+86041,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86042^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER VIEW PRESUMPTIVE CONDITIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>78054</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1982555814</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+78054,;.01~VA-ONC BLADDER VIEW PRESUMPTIVE CONDITIONS
801.41;+78054,;4~dialog element
801.41;+78054,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+78054,;23~YES
801.41;+78054,;25~WP-start~1
{FLD:VA-ONC PRESUMPTIVE CONDITIONS}
801.41;+78054,;35~WP-start~20
Bladder Cancer-Presumptive Conditions:\\
======================================\\
 
VA automatically presumes that certain disabilities were caused by 
military service. This is because of the unique circumstances of a 
specific Veteran's military service. If a presumed condition is diagnosed 
in a Veteran within a certain group, they can be awarded disability 
compensation.\\
 
Vietnam-era Veterans:\\
-------------------------------\\
Veterans that were exposed to Agent Orange or served in an approved
service location, are approved for the following presumptive condition:\\
 -Bladder cancer\\
 
Atomic Veterans:\\
-------------------------------\\
Veterans that were exposed to Ionizing Radiation from various sources,
are approved for the following presumptive condition:\\ 
 - Cancer of the urinary tract
801.41;+78054,;51~SUPPRESS
801.41;+78054,;100~NATIONAL
801.41;+78054,;101~VHA ONCOLOGY
801.412;+78055,+78054,;.01~5
801.412;+78055,+78054,;2~PXRM GF VIEW BUTTON
801.412;+78055,+78054,;6~VIEW Bladder Presumptive Conditions
801.44;+78056,+78054,;.01~04/27/2026@11:26:14
801.44;+78056,+78054,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
78055^1
78056^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER SHAREPOINT VIEW ABBREVIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>78052</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3531192551</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+78052,;.01~VA-ONC BLADDER SHAREPOINT VIEW ABBREVIATION
801.41;+78052,;4~dialog element
801.41;+78052,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+78052,;23~YES
801.41;+78052,;25~WP-start~1
{FLD:VA-ONC PATHWAYS SHAREPOINT}
801.41;+78052,;35~WP-start~24
Bladder Cancer Abbreviations:\\
  BCG = Bacillus Calmette-Guerin\\
  CGP = Comprehensive Genomic Profiling\\
  CT = Computerized Tomography\\
  DRE = Digital Rectal Exam\\
  EUA = Exam Under Anesthesia\\
  EV = Enfortumab Vedotin\\
  FGFR3 = Fibroblast Growth Factor Receptor 3\\
  GU = Genitourinary\\
  HER2 = Human Epidermal Growth Factor Receptor 2\\
  MIBC = Muscle Invasive Bladder Cancer\\
  MVAC = A chemotherapy combination of drugs used to treat advanced\\
         bladder cancer and urethral cancer. It's an acronym for the\\ 
        drugs used in the treatment:\\
                Methotrexate\\
                Vinblastine\\
                Adriamycin (Doxorubicin)\\
                Cisplatin\\
  NMIBC = Non-Muscle Invasive Bladder Cancer\\
  PD-L1 = Programmed Cell Death Ligand 1\\
  PET = Positron Emission Tomography\\
  PSA = Prostate-Specific Antigen\\
  TUR = Transurethral Resection\\
  TURP = Transurethral Resection of the Prostate\\
801.41;+78052,;51~SUPPRESS
801.41;+78052,;100~NATIONAL
801.41;+78052,;101~VHA ONCOLOGY
801.412;+78053,+78052,;.01~5
801.412;+78053,+78052,;2~PXRM GF VIEW BUTTON
801.412;+78053,+78052,;6~VIEW Abbreviations
801.44;+78054,+78052,;.01~04/27/2026@11:26:14
801.44;+78054,+78052,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
78053^1
78054^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER</POINT_01>
<INTERNAL_ENTRY_NUMBER>49891</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1563233907</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+49891,;.01~VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER
801.41;+49891,;4~dialog element
801.41;+49891,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+49891,;23~YES
801.41;+49891,;25~WP-start~6
Intended User: Oncology Practitioners: Physician (Attending, Resident,
Fellow), Nurse Practitioner,\\               Physician Assistant, 
Clinical Pharmacist Practitioner, Pathologist, Clinical Nurse
               Specialist, Surgical Oncologist, and Radiation Oncologist
 
++ For help finding a Clinical Trial, email: {FLD:VA-ONC CT RN NAV} ++
801.41;+49891,;35~WP-start~61
Oncology Clinical Pathways are a decision support tool designed by 
interdisciplinary subject matter experts for all members of a Veteran's
care team to use for the treatment of specific cancers.
 
Clinical Pathways templates facilitate the documentation of medical 
decision-making. 
 
Document using the pathway templates when a treatment decision is made. 
Documentation of historical treatments is not necessary (except for 
molecular testing).
 
Pathway recommended care is stated for each pathway. Indicate use 
of the pathway by checking the check box. Recommended treatment listed 
is considered 'On Pathway', unless otherwise stated.
 
Clinical trial and shared decision making always considered on pathway.
Document the name and number of the clinical trial.\\
    Please contact CancerClinicalTrialsNavigation@domain.ext for\\
     assistance with cancer trial navigation.
 
If off pathway, document the treatment that is being pursued and a reason
why treating off pathway.\\
    Off Pathway Options:\\
      Patient preference/declined: Patient prefers not to receive the 
treatment\\        specified on pathway or declines that treatment after
the provider has\\        discussed the evidence and best clinical
practice.\\
      Toxicity and/or comorbidity: Provider does not recommend on 
pathway\\        treatment due to concerns about anticipated toxicities or
due to medical\\        problems the patient has that impact their
eligibility for the on\\        pathway treatment.\\
      Prior treatment continued: Patient was started on another treatment 
prior\\        to pathways and a change in therapy is not indicated.\\
      Prior treatment precludes: Patient's prior cancer history or 
treatment\\        precludes abiding by the pathway.\\
      Pathway guidance needs update: Pathway or CPRS template has not 
been\\        updated to reflect most recent data.\\
      Patient barriers: Patient related factors other than medical issues 
that\\        potentially make them not eligible for on pathway choice,
such as\\        transportation issues, support barriers, etc.\\
      Treatment unavailable: Specified on pathway treatments are not 
available\\        at specific center due to national shortages, or other
factors.
 
Some templates have detailed instructions that provide specific data 
definitions of each selection.
 
Document that molecular testing has been ordered for complete data 
capture (i.e., molecular testing completed 3 years ago, choose 
'Previously ordered'). 
 
When a choice is followed by a colon (:), there will be more selections 
revealed when clicked.
 
Uncheck a checkbox if you change your mind and do not wish to indicate 
use for a section of the pathway.
 
If you click Finish on the template, any selections you made will
add health factors to the encounter. If you make an incorrect selection
and click Finish, you should remove the incorrect health factor from the 
encounter.
801.41;+49891,;51~SUPPRESS
801.41;+49891,;100~NATIONAL
801.412;+49892,+49891,;.01~5
801.412;+49892,+49891,;2~PXRM GF VIEW BUTTON
801.412;+49892,+49891,;6~VIEW General Instructions
801.412;+49892,+49891,;8~YES
801.44;+49893,+49891,;.01~04/27/2026@11:26:14
801.44;+49893,+49891,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
49892^1
49893^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLADDER MUSCLE INVASIVE PATHWAYS VERSION</POINT_01>
<INTERNAL_ENTRY_NUMBER>39099</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>390059825</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+39099,;.01~VA-ONC BLADDER MUSCLE INVASIVE PATHWAYS VERSION
801.41;+39099,;4~dialog element
801.41;+39099,;23~YES
801.41;+39099,;25~WP-start~1
Bladder Cancer Muscle Invasive Pathways  v1.3
801.41;+39099,;51~SUPPRESS
801.41;+39099,;100~NATIONAL
801.41;+39099,;101~VHA ONCOLOGY
801.44;+39100,+39099,;.01~04/27/2026@11:26:14
801.44;+39100,+39099,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39100^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS INFO</POINT_01>
<INTERNAL_ENTRY_NUMBER>93846</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2896645059</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93846,;.01~VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS INFO
801.41;+93846,;4~dialog group
801.41;+93846,;6~YES
801.41;+93846,;9~NO SELECTION REQUIRED
801.41;+93846,;51~SUPPRESS
801.41;+93846,;100~NATIONAL
801.41;+93846,;101~VHA ONCOLOGY
801.412;+93847,+93846,;.01~10
801.412;+93847,+93846,;2~VA-ONC BLADDER MUSCLE INVASIVE PATHWAYS VERSION
801.412;+93848,+93846,;.01~20
801.412;+93848,+93846,;2~VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER
801.412;+93849,+93846,;.01~30
801.412;+93849,+93846,;2~VA-ONC BLADDER SHAREPOINT VIEW ABBREVIATION
801.412;+93850,+93846,;.01~40
801.412;+93850,+93846,;2~VA-ONC BLADDER VIEW PRESUMPTIVE CONDITIONS
801.412;+93851,+93846,;.01~50
801.412;+93851,+93846,;2~VA-ONC BLADDER PATHWAYS PRIOR DATA OBJECT
801.412;+93852,+93846,;.01~70
801.412;+93852,+93846,;2~VA-ONC BLADDER CLINICAL & SURGICAL EVAL VIEW
801.412;+93853,+93846,;.01~60
801.412;+93853,+93846,;2~VA-ONC BLADDER PATHWAYS PREVIOUS DATA CLICK TO INCLUDE
801.44;+93854,+93846,;.01~04/27/2026@11:26:14
801.44;+93854,+93846,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93847^1
93848^2
93849^3
93850^4
93851^5
93852^7
93853^9
93854^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>87021</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>318685388</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87021,;.01~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL
801.41;+87021,;4~dialog element
801.41;+87021,;15~HF.VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL
801.41;+87021,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+87021,;35~WP-start~1
Veteran has elected to pursue:
801.41;+87021,;100~NATIONAL
801.41;+87021,;101~VHA ONCOLOGY
801.412;+87022,+87021,;.01~5
801.412;+87022,+87021,;2~VA-ONC CLINICAL TRIAL
801.412;+87022,+87021,;9~YES
801.44;+87023,+87021,;.01~04/27/2026@11:26:14
801.44;+87023,+87021,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87022^1
87023^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>87025</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2603304807</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87025,;.01~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN
801.41;+87025,;4~dialog element
801.41;+87025,;15~HF.VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN
801.41;+87025,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+87025,;51~SUPPRESS
801.41;+87025,;100~NATIONAL
801.41;+87025,;101~VHA ONCOLOGY
801.412;+87026,+87025,;.01~5
801.412;+87026,+87025,;2~VA-ONC OFF PATHWAY
801.412;+87026,+87025,;7~YES
801.412;+87026,+87025,;9~YES
801.44;+87027,+87025,;.01~04/27/2026@11:26:14
801.44;+87027,+87025,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87026^1
87027^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>87024</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1421145415</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87024,;.01~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX
801.41;+87024,;4~dialog element
801.41;+87024,;15~HF.VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX
801.41;+87024,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+87024,;51~SUPPRESS
801.41;+87024,;100~NATIONAL
801.41;+87024,;101~VHA ONCOLOGY
801.412;+87025,+87024,;.01~5
801.412;+87025,+87024,;2~VA-ONC BLANK
801.412;+87025,+87024,;7~YES
801.412;+87025,+87024,;9~YES
801.44;+87026,+87024,;.01~04/27/2026@11:26:14
801.44;+87026,+87024,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87025^1
87026^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>87023</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2171058772</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87023,;.01~VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH
801.41;+87023,;4~dialog group
801.41;+87023,;7~2
801.41;+87023,;9~ONE OR MORE SELECTIONS
801.41;+87023,;23~YES
801.41;+87023,;25~WP-start~1
Off pathway:
801.41;+87023,;100~NATIONAL
801.41;+87023,;101~VHA ONCOLOGY
801.412;+87024,+87023,;.01~10
801.412;+87024,+87023,;2~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH TX
801.412;+87025,+87023,;.01~20
801.412;+87025,+87023,;2~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH RSN
801.44;+87026,+87023,;.01~04/27/2026@11:26:14
801.44;+87026,+87023,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87024^1
87025^2
87026^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>87022</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3084109432</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87022,;.01~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX
801.41;+87022,;4~dialog element
801.41;+87022,;15~HF.VA-ONC MIBC IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX
801.41;+87022,;25~WP-start~1
Fam-trastuzumab deruxtecan
801.41;+87022,;35~WP-start~1
Veteran has elected to pursue FAM-TRASTUZUMAB DERUXTECAN.
801.41;+87022,;100~NATIONAL
801.41;+87022,;101~VHA ONCOLOGY
801.44;+87023,+87022,;.01~04/27/2026@11:26:14
801.44;+87023,+87022,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87023^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALTERATION HER2 EXPRESSION</POINT_01>
<INTERNAL_ENTRY_NUMBER>87014</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>719235556</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87014,;.01~VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALTERATION HER2 EXPRESSION
801.41;+87014,;4~dialog group
801.41;+87014,;6~YES
801.41;+87014,;7~2
801.41;+87014,;9~ONE SELECTION ONLY
801.41;+87014,;25~WP-start~2
No Fibroblast Growth Factor Receptor 3 (FGFR3) alteration and Human 
Epidermal Growth Factor Receptor 2 (HER2) over-expression:
801.41;+87014,;35~WP-start~1
No FGFR3 alteration and HER2 over-expression:
801.41;+87014,;52~INDENT
801.41;+87014,;100~NATIONAL
801.41;+87014,;101~VHA ONCOLOGY
801.412;+87015,+87014,;.01~40
801.412;+87015,+87014,;2~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP FAMTRASTUZUMAB TX
801.412;+87016,+87014,;.01~60
801.412;+87016,+87014,;2~VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP OFF PATH
801.412;+87017,+87014,;.01~20
801.412;+87017,+87014,;2~VA-ONC MIBC STAGE IVB 2L NO FGFR3 ALT HER2 EXP CLINICAL TRIAL
801.44;+87018,+87014,;.01~04/27/2026@11:26:14
801.44;+87018,+87014,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87015^2
87016^3
87017^4
87018^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>87016</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3207137752</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87016,;.01~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION CLINICAL TRIAL
801.41;+87016,;4~dialog element
801.41;+87016,;15~HF.VA-ONC MIBC IVB 2L FGFR3 ALTERATION CLINICAL TRIAL
801.41;+87016,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+87016,;35~WP-start~1
Veteran has elected to pursue:
801.41;+87016,;100~NATIONAL
801.41;+87016,;101~VHA ONCOLOGY
801.412;+87017,+87016,;.01~5
801.412;+87017,+87016,;2~VA-ONC CLINICAL TRIAL
801.412;+87017,+87016,;9~YES
801.44;+87018,+87016,;.01~04/27/2026@11:26:14
801.44;+87018,+87016,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87017^1
87018^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>87020</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>903256562</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87020,;.01~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH RSN
801.41;+87020,;4~dialog element
801.41;+87020,;15~HF.VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH RSN
801.41;+87020,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+87020,;51~SUPPRESS
801.41;+87020,;100~NATIONAL
801.41;+87020,;101~VHA ONCOLOGY
801.412;+87021,+87020,;.01~5
801.412;+87021,+87020,;2~VA-ONC OFF PATHWAY
801.412;+87021,+87020,;7~YES
801.412;+87021,+87020,;9~YES
801.44;+87022,+87020,;.01~04/27/2026@11:26:14
801.44;+87022,+87020,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87021^1
87022^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>87019</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2183483805</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87019,;.01~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH TX
801.41;+87019,;4~dialog element
801.41;+87019,;15~HF.VA-ONC MIBC IVB 2L FGFR3 ALTERATION OFF PATH TX
801.41;+87019,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+87019,;51~SUPPRESS
801.41;+87019,;100~NATIONAL
801.41;+87019,;101~VHA ONCOLOGY
801.412;+87020,+87019,;.01~5
801.412;+87020,+87019,;2~VA-ONC BLANK
801.412;+87020,+87019,;7~YES
801.412;+87020,+87019,;9~YES
801.44;+87021,+87019,;.01~04/27/2026@11:26:14
801.44;+87021,+87019,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87020^1
87021^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>87018</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3304312644</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87018,;.01~VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH
801.41;+87018,;4~dialog group
801.41;+87018,;7~2
801.41;+87018,;9~ONE OR MORE SELECTIONS
801.41;+87018,;23~YES
801.41;+87018,;25~WP-start~1
Off pathway:
801.41;+87018,;100~NATIONAL
801.41;+87018,;101~VHA ONCOLOGY
801.412;+87019,+87018,;.01~10
801.412;+87019,+87018,;2~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH TX
801.412;+87020,+87018,;.01~20
801.412;+87020,+87018,;2~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH RSN
801.44;+87021,+87018,;.01~04/27/2026@11:26:14
801.44;+87021,+87018,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87019^1
87020^2
87021^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION ERDAFITINIB TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>87017</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3095211982</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87017,;.01~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION ERDAFITINIB TX
801.41;+87017,;4~dialog element
801.41;+87017,;15~HF.VA-ONC MIBC IVB 2L FGFR3 ALTERATION ERDAFITINIB TX
801.41;+87017,;25~WP-start~1
Erdafitinib
801.41;+87017,;35~WP-start~1
Veteran has elected to pursue ERDAFITINIB.
801.41;+87017,;100~NATIONAL
801.41;+87017,;101~VHA ONCOLOGY
801.44;+87018,+87017,;.01~04/27/2026@11:26:14
801.44;+87018,+87017,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87018^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>87013</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2502592669</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+87013,;.01~VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION
801.41;+87013,;4~dialog group
801.41;+87013,;6~YES
801.41;+87013,;7~2
801.41;+87013,;9~ONE SELECTION ONLY
801.41;+87013,;25~WP-start~1
Fibroblast Growth Factor Receptor 3 (FGFR3) alteration:
801.41;+87013,;52~INDENT
801.41;+87013,;100~NATIONAL
801.41;+87013,;101~VHA ONCOLOGY
801.412;+87014,+87013,;.01~40
801.412;+87014,+87013,;2~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION ERDAFITINIB TX
801.412;+87015,+87013,;.01~60
801.412;+87015,+87013,;2~VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION OFF PATH
801.412;+87016,+87013,;.01~20
801.412;+87016,+87013,;2~VA-ONC MIBC STAGE IVB 2L FGFR3 ALTERATION CLINICAL TRIAL
801.44;+87017,+87013,;.01~04/27/2026@11:26:14
801.44;+87017,+87013,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
87014^2
87015^3
87016^4
87017^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 2ND LINE (2L)</POINT_01>
<INTERNAL_ENTRY_NUMBER>86937</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1970291833</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86937,;.01~VA-GP ONC MIBC STAGE IVB 2ND LINE (2L)
801.41;+86937,;4~dialog group
801.41;+86937,;6~YES
801.41;+86937,;7~2
801.41;+86937,;9~ONE SELECTION ONLY
801.41;+86937,;25~WP-start~3
2nd Line Therapy:
 ++ If not a candidate for these therapies, consider 
    hospice and/or palliative radiation. ++
801.41;+86937,;52~INDENT
801.41;+86937,;100~NATIONAL
801.41;+86937,;101~VHA ONCOLOGY
801.412;+86938,+86937,;.01~20
801.412;+86938,+86937,;2~VA-GP ONC MIBC STAGE IVB 2L FGFR3 ALTERATION
801.412;+86939,+86937,;.01~40
801.412;+86939,+86937,;2~VA-GP ONC MIBC STAGE IVB 2L NO FGFR3 ALTERATION HER2 EXPRESSION
801.44;+86940,+86937,;.01~04/27/2026@11:26:14
801.44;+86940,+86937,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86938^1
86939^2
86940^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86970</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3029542118</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86970,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH RSN
801.41;+86970,;4~dialog element
801.41;+86970,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH RSN
801.41;+86970,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86970,;51~SUPPRESS
801.41;+86970,;100~NATIONAL
801.41;+86970,;101~VHA ONCOLOGY
801.412;+86971,+86970,;.01~5
801.412;+86971,+86970,;2~VA-ONC OFF PATHWAY
801.412;+86971,+86970,;7~YES
801.412;+86971,+86970,;9~YES
801.44;+86972,+86970,;.01~04/27/2026@11:26:14
801.44;+86972,+86970,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86971^1
86972^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86969</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1034298506</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86969,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH TX
801.41;+86969,;4~dialog element
801.41;+86969,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE OFF PATH TX
801.41;+86969,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86969,;51~SUPPRESS
801.41;+86969,;100~NATIONAL
801.41;+86969,;101~VHA ONCOLOGY
801.412;+86970,+86969,;.01~5
801.412;+86970,+86969,;2~VA-ONC BLANK
801.412;+86970,+86969,;7~YES
801.412;+86970,+86969,;9~YES
801.44;+86971,+86969,;.01~04/27/2026@11:26:14
801.44;+86971,+86969,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86970^1
86971^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>86968</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1543056790</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86968,;.01~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH
801.41;+86968,;4~dialog group
801.41;+86968,;7~2
801.41;+86968,;9~ONE OR MORE SELECTIONS
801.41;+86968,;23~YES
801.41;+86968,;25~WP-start~1
Off pathway:
801.41;+86968,;100~NATIONAL
801.41;+86968,;101~VHA ONCOLOGY
801.412;+86969,+86968,;.01~10
801.412;+86969,+86968,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH TX
801.412;+86970,+86968,;.01~20
801.412;+86970,+86968,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH RSN
801.44;+86971,+86968,;.01~04/27/2026@11:26:14
801.44;+86971,+86968,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86969^1
86970^2
86971^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86966</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4125071171</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86966,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX
801.41;+86966,;4~dialog element
801.41;+86966,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX
801.41;+86966,;25~WP-start~1
Pembrolizumab
801.41;+86966,;35~WP-start~1
Veteran has elected to pursue PEMBROLIZUMAB.
801.41;+86966,;100~NATIONAL
801.41;+86966,;101~VHA ONCOLOGY
801.44;+86967,+86966,;.01~04/27/2026@11:26:14
801.44;+86967,+86966,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86967^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86965</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3661185383</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86965,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL
801.41;+86965,;4~dialog element
801.41;+86965,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL
801.41;+86965,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86965,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86965,;100~NATIONAL
801.41;+86965,;101~VHA ONCOLOGY
801.412;+86966,+86965,;.01~5
801.412;+86966,+86965,;2~VA-ONC CLINICAL TRIAL
801.412;+86966,+86965,;9~YES
801.44;+86967,+86965,;.01~04/27/2026@11:26:14
801.44;+86967,+86965,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86966^1
86967^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NOT CHEMO ELIGIBLE</POINT_01>
<INTERNAL_ENTRY_NUMBER>86955</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3000536022</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86955,;.01~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NOT CHEMO ELIGIBLE
801.41;+86955,;4~dialog group
801.41;+86955,;6~YES
801.41;+86955,;7~2
801.41;+86955,;9~ONE SELECTION ONLY
801.41;+86955,;25~WP-start~1
Not chemotherapy eligible:
801.41;+86955,;52~INDENT
801.41;+86955,;100~NATIONAL
801.41;+86955,;101~VHA ONCOLOGY
801.412;+86956,+86955,;.01~20
801.412;+86956,+86955,;2~VA-ONC MIBC IVB 1L NO EV PEMBRO NO CHEMO ELIGIBLE CLINICAL TRIAL
801.412;+86957,+86955,;.01~40
801.412;+86957,+86955,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO PEMBRO TX
801.412;+86958,+86955,;.01~60
801.412;+86958,+86955,;2~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NO CHEMO OFF PATH
801.44;+86959,+86955,;.01~04/27/2026@11:26:14
801.44;+86959,+86955,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86956^1
86957^2
86958^3
86959^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86963</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>268582689</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86963,;.01~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN
801.41;+86963,;4~dialog element
801.41;+86963,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN
801.41;+86963,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86963,;51~SUPPRESS
801.41;+86963,;100~NATIONAL
801.41;+86963,;101~VHA ONCOLOGY
801.412;+86964,+86963,;.01~5
801.412;+86964,+86963,;2~VA-ONC OFF PATHWAY
801.412;+86964,+86963,;7~YES
801.412;+86964,+86963,;9~YES
801.44;+86965,+86963,;.01~04/27/2026@11:26:14
801.44;+86965,+86963,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86964^1
86965^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86961</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2870683201</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86961,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX
801.41;+86961,;4~dialog element
801.41;+86961,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX
801.41;+86961,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86961,;51~SUPPRESS
801.41;+86961,;100~NATIONAL
801.41;+86961,;101~VHA ONCOLOGY
801.412;+86962,+86961,;.01~5
801.412;+86962,+86961,;2~VA-ONC BLANK
801.412;+86962,+86961,;7~YES
801.412;+86962,+86961,;9~YES
801.44;+86963,+86961,;.01~04/27/2026@11:26:14
801.44;+86963,+86961,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86962^1
86963^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>86960</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1463454047</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86960,;.01~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH
801.41;+86960,;4~dialog group
801.41;+86960,;7~2
801.41;+86960,;9~ONE OR MORE SELECTIONS
801.41;+86960,;23~YES
801.41;+86960,;25~WP-start~1
Off pathway:
801.41;+86960,;100~NATIONAL
801.41;+86960,;101~VHA ONCOLOGY
801.412;+86961,+86960,;.01~10
801.412;+86961,+86960,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH TX
801.412;+86962,+86960,;.01~20
801.412;+86962,+86960,;2~VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH RSN
801.44;+86963,+86960,;.01~04/27/2026@11:26:14
801.44;+86963,+86960,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86961^1
86962^2
86963^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>86958</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2418510159</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86958,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO
801.41;+86958,;4~dialog element
801.41;+86958,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO GEM
801.41;+86958,;25~WP-start~1
Carboplatin and gemcitabine followed by avelumab maintenance.
801.41;+86958,;35~WP-start~2
Veteran has elected to pursue CARBOPLATIN and GEMCITABINE followed by 
AVELUMAB maintenance.
801.41;+86958,;100~NATIONAL
801.41;+86958,;101~VHA ONCOLOGY
801.44;+86959,+86958,;.01~04/27/2026@11:26:14
801.44;+86959,+86958,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86959^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86957</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3041971792</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86957,;.01~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLIN TRIAL
801.41;+86957,;4~dialog element
801.41;+86957,;15~HF.VA-ONC MIBC IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLINICAL TRIAL
801.41;+86957,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86957,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86957,;100~NATIONAL
801.41;+86957,;101~VHA ONCOLOGY
801.412;+86958,+86957,;.01~5
801.412;+86958,+86957,;2~VA-ONC CLINICAL TRIAL
801.412;+86958,+86957,;9~YES
801.44;+86959,+86957,;.01~04/27/2026@11:26:14
801.44;+86959,+86957,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86958^1
86959^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE</POINT_01>
<INTERNAL_ENTRY_NUMBER>86954</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1943603532</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86954,;.01~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE
801.41;+86954,;4~dialog group
801.41;+86954,;6~YES
801.41;+86954,;7~2
801.41;+86954,;9~ONE SELECTION ONLY
801.41;+86954,;25~WP-start~1
Chemotherapy eligible:
801.41;+86954,;52~INDENT
801.41;+86954,;100~NATIONAL
801.41;+86954,;101~VHA ONCOLOGY
801.412;+86955,+86954,;.01~20
801.412;+86955,+86954,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CLIN TRIAL
801.412;+86956,+86954,;.01~40
801.412;+86956,+86954,;2~VA-ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE CARBRO
801.412;+86957,+86954,;.01~60
801.412;+86957,+86954,;2~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE OFF PATH
801.44;+86958,+86954,;.01~04/27/2026@11:26:14
801.44;+86958,+86954,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86955^1
86956^2
86957^3
86958^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L NOT EV PEMBRO ELIGIBLE</POINT_01>
<INTERNAL_ENTRY_NUMBER>86948</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>147837151</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86948,;.01~VA-GP ONC MIBC STAGE IVB 1L NOT EV PEMBRO ELIGIBLE
801.41;+86948,;4~dialog group
801.41;+86948,;6~YES
801.41;+86948,;7~2
801.41;+86948,;9~ONE SELECTION ONLY
801.41;+86948,;25~WP-start~1
Not enfortumab vedotin and pembrolizumab eligible:
801.41;+86948,;52~INDENT
801.41;+86948,;100~NATIONAL
801.41;+86948,;101~VHA ONCOLOGY
801.412;+86949,+86948,;.01~20
801.412;+86949,+86948,;2~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO CHEMO ELIGIBLE
801.412;+86950,+86948,;.01~40
801.412;+86950,+86948,;2~VA-GP ONC MIBC STAGE IVB 1L NO EV PEMBRO NOT CHEMO ELIGIBLE
801.44;+86951,+86948,;.01~04/27/2026@11:26:14
801.44;+86951,+86948,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86949^1
86950^2
86951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86953</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2858464138</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86953,;.01~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN
801.41;+86953,;4~dialog element
801.41;+86953,;15~HF.VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN
801.41;+86953,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86953,;51~SUPPRESS
801.41;+86953,;100~NATIONAL
801.41;+86953,;101~VHA ONCOLOGY
801.412;+86954,+86953,;.01~5
801.412;+86954,+86953,;2~VA-ONC OFF PATHWAY
801.412;+86954,+86953,;7~YES
801.412;+86954,+86953,;9~YES
801.44;+86955,+86953,;.01~04/27/2026@11:26:14
801.44;+86955,+86953,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86954^1
86955^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86952</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3744751769</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86952,;.01~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX
801.41;+86952,;4~dialog element
801.41;+86952,;15~HF.VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX
801.41;+86952,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86952,;51~SUPPRESS
801.41;+86952,;100~NATIONAL
801.41;+86952,;101~VHA ONCOLOGY
801.412;+86953,+86952,;.01~5
801.412;+86953,+86952,;2~VA-ONC BLANK
801.412;+86953,+86952,;7~YES
801.412;+86953,+86952,;9~YES
801.44;+86954,+86952,;.01~04/27/2026@11:26:14
801.44;+86954,+86952,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86953^1
86954^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>86951</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2192703580</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86951,;.01~VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH
801.41;+86951,;4~dialog group
801.41;+86951,;7~2
801.41;+86951,;9~ONE OR MORE SELECTIONS
801.41;+86951,;23~YES
801.41;+86951,;25~WP-start~1
Off pathway:
801.41;+86951,;100~NATIONAL
801.41;+86951,;101~VHA ONCOLOGY
801.412;+86952,+86951,;.01~10
801.412;+86952,+86951,;2~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH TX
801.412;+86953,+86951,;.01~20
801.412;+86953,+86951,;2~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH RSN
801.44;+86954,+86951,;.01~04/27/2026@11:26:14
801.44;+86954,+86951,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86952^1
86953^2
86954^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L EV PEMBRO TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86950</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1636473503</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86950,;.01~VA-ONC MIBC STAGE IVB 1L EV PEMBRO TX
801.41;+86950,;4~dialog element
801.41;+86950,;15~HF.VA-ONC MIBC IVB 1L EV PEMBRO TX
801.41;+86950,;25~WP-start~1
Enfortumab vedotin and pembrolizumab.
801.41;+86950,;35~WP-start~1
Veteran has elected to pursue ENFORTUMAB VEDOTIN and PEMBROLIZUMAB.
801.41;+86950,;100~NATIONAL
801.41;+86950,;101~VHA ONCOLOGY
801.44;+86951,+86950,;.01~04/27/2026@11:26:14
801.44;+86951,+86950,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86949</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1116667481</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86949,;.01~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL
801.41;+86949,;4~dialog element
801.41;+86949,;15~HF.VA-ONC MIBC IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL
801.41;+86949,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86949,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86949,;100~NATIONAL
801.41;+86949,;101~VHA ONCOLOGY
801.412;+86950,+86949,;.01~5
801.412;+86950,+86949,;2~VA-ONC CLINICAL TRIAL
801.412;+86950,+86949,;9~YES
801.44;+86951,+86949,;.01~04/27/2026@11:26:14
801.44;+86951,+86949,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86950^1
86951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE</POINT_01>
<INTERNAL_ENTRY_NUMBER>86947</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1843257263</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86947,;.01~VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE
801.41;+86947,;4~dialog group
801.41;+86947,;6~YES
801.41;+86947,;7~2
801.41;+86947,;9~ONE SELECTION ONLY
801.41;+86947,;25~WP-start~1
Enfortumab vedotin and pembrolizumab eligible:
801.41;+86947,;52~INDENT
801.41;+86947,;100~NATIONAL
801.41;+86947,;101~VHA ONCOLOGY
801.412;+86948,+86947,;.01~20
801.412;+86948,+86947,;2~VA-ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE CLINICAL TRIAL
801.412;+86949,+86947,;.01~40
801.412;+86949,+86947,;2~VA-ONC MIBC STAGE IVB 1L EV PEMBRO TX
801.412;+86950,+86947,;.01~60
801.412;+86950,+86947,;2~VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE OFF PATH
801.44;+86951,+86947,;.01~04/27/2026@11:26:14
801.44;+86951,+86947,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86948^1
86949^2
86950^3
86951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB 1ST LINE (1L)</POINT_01>
<INTERNAL_ENTRY_NUMBER>86936</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2502599294</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86936,;.01~VA-GP ONC MIBC STAGE IVB 1ST LINE (1L)
801.41;+86936,;4~dialog group
801.41;+86936,;6~YES
801.41;+86936,;7~2
801.41;+86936,;9~ONE SELECTION ONLY
801.41;+86936,;25~WP-start~1
1st Line Therapy:
801.41;+86936,;52~INDENT
801.41;+86936,;100~NATIONAL
801.41;+86936,;101~VHA ONCOLOGY
801.412;+86937,+86936,;.01~20
801.412;+86937,+86936,;2~VA-GP ONC MIBC STAGE IVB 1L EV PEMBRO ELIGIBLE
801.412;+86938,+86936,;.01~40
801.412;+86938,+86936,;2~VA-GP ONC MIBC STAGE IVB 1L NOT EV PEMBRO ELIGIBLE
801.44;+86939,+86936,;.01~04/27/2026@11:26:14
801.44;+86939,+86936,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86937^1
86938^2
86939^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVB PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>84582</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3236302008</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84582,;.01~VA-GP ONC MIBC STAGE IVB PATHWAY
801.41;+84582,;4~dialog group
801.41;+84582,;6~YES
801.41;+84582,;15~HF.VA-ONC BLADDER MUSCLE INVASIVE IVB
801.41;+84582,;25~WP-start~1
Muscle Invasive Stage IVB Pathway:
801.41;+84582,;35~WP-start~2
Muscle Invasive Stage IVB Pathway\\
=================================
801.41;+84582,;100~NATIONAL
801.41;+84582,;101~VHA ONCOLOGY
801.412;+84583,+84582,;.01~20
801.412;+84583,+84582,;2~VA-GP ONC MIBC STAGE IVB 1ST LINE (1L)
801.412;+84584,+84582,;.01~40
801.412;+84584,+84582,;2~VA-GP ONC MIBC STAGE IVB 2ND LINE (2L)
801.44;+84585,+84582,;.01~04/27/2026@11:26:14
801.44;+84585,+84582,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84583^1
84584^2
84585^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>93070</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>381936523</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93070,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH RSN
801.41;+93070,;4~dialog element
801.41;+93070,;15~HF.VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH RSN
801.41;+93070,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+93070,;51~SUPPRESS
801.41;+93070,;100~NATIONAL
801.41;+93070,;101~VHA ONCOLOGY
801.412;+93071,+93070,;.01~5
801.412;+93071,+93070,;2~VA-ONC OFF PATHWAY
801.412;+93071,+93070,;7~YES
801.412;+93071,+93070,;9~YES
801.44;+93072,+93070,;.01~04/27/2026@11:26:14
801.44;+93072,+93070,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93071^1
93072^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>93069</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4095097789</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93069,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH TX
801.41;+93069,;4~dialog element
801.41;+93069,;15~HF.VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD OFF PATH TX
801.41;+93069,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+93069,;51~SUPPRESS
801.41;+93069,;100~NATIONAL
801.41;+93069,;101~VHA ONCOLOGY
801.412;+93070,+93069,;.01~5
801.412;+93070,+93069,;2~VA-ONC BLANK
801.412;+93070,+93069,;7~YES
801.412;+93070,+93069,;9~YES
801.44;+93071,+93069,;.01~04/27/2026@11:26:14
801.44;+93071,+93069,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93070^1
93071^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>93068</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1279804688</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93068,;.01~VA-GP ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH
801.41;+93068,;4~dialog group
801.41;+93068,;7~2
801.41;+93068,;9~ONE OR MORE SELECTIONS
801.41;+93068,;23~YES
801.41;+93068,;25~WP-start~1
Off pathway:
801.41;+93068,;100~NATIONAL
801.41;+93068,;101~VHA ONCOLOGY
801.412;+93069,+93068,;.01~10
801.412;+93069,+93068,;2~VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH TX
801.412;+93070,+93068,;.01~20
801.412;+93070,+93068,;2~VA-ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH RSN
801.44;+93071,+93068,;.01~04/27/2026@11:26:14
801.44;+93071,+93068,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93069^1
93070^2
93071^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RAD CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>93066</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2406747168</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93066,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RAD CYSTECTOMY
801.41;+93066,;4~dialog element
801.41;+93066,;15~HF.VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CYSTECTOMY
801.41;+93066,;25~WP-start~1
Cystectomy
801.41;+93066,;35~WP-start~1
Veteran has elected to pursue CYSTECTOMY.
801.41;+93066,;100~NATIONAL
801.41;+93066,;101~VHA ONCOLOGY
801.44;+93067,+93066,;.01~04/27/2026@11:26:14
801.44;+93067,+93066,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93067^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RAD CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>93065</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2127353868</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93065,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RAD CLINICAL TRIAL
801.41;+93065,;4~dialog element
801.41;+93065,;15~HF.VA-ONC MIBC IVA REASSESS 5FU MITOMYCIN RAD CLINICAL TRIAL
801.41;+93065,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+93065,;35~WP-start~1
Veteran has elected to pursue:
801.41;+93065,;100~NATIONAL
801.41;+93065,;101~VHA ONCOLOGY
801.412;+93066,+93065,;.01~5
801.412;+93066,+93065,;2~VA-ONC CLINICAL TRIAL
801.412;+93066,+93065,;9~YES
801.44;+93067,+93065,;.01~04/27/2026@11:26:14
801.44;+93067,+93065,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93066^1
93067^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA 5FU MITOMYCIN RAD LOCAL THERAPY</POINT_01>
<INTERNAL_ENTRY_NUMBER>86246</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>350254096</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86246,;.01~VA-ONC MIBC IVA 5FU MITOMYCIN RAD LOCAL THERAPY
801.41;+86246,;4~dialog group
801.41;+86246,;6~YES
801.41;+86246,;7~2
801.41;+86246,;9~ONE SELECTION ONLY
801.41;+86246,;25~WP-start~1
Candidate for LOCAL THERAPY (cystectomy):
801.41;+86246,;51~SUPPRESS
801.41;+86246,;52~INDENT
801.41;+86246,;100~NATIONAL
801.41;+86246,;101~VHA ONCOLOGY
801.412;+86247,+86246,;.01~20
801.412;+86247,+86246,;2~VA-ONC MIBC IVA 5FU MITOMYCIN RAD CLINICAL TRIAL
801.412;+86248,+86246,;.01~40
801.412;+86248,+86246,;2~VA-ONC MIBC IVA 5FU MITOMYCIN RAD CYSTECTOMY
801.412;+86249,+86246,;.01~80
801.412;+86249,+86246,;2~VA-GP ONC MIBC IVA 5FU MITOMYCIN RAD OFF PATH
801.44;+86250,+86246,;.01~04/27/2026@11:26:14
801.44;+86250,+86246,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86247^1
86248^2
86249^4
86250^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION REASSESSMENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>86427</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3703856015</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86427,;.01~VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION REASSESSMENT
801.41;+86427,;4~dialog group
801.41;+86427,;6~YES
801.41;+86427,;7~2
801.41;+86427,;9~ONE SELECTION ONLY
801.41;+86427,;25~WP-start~4
Interim assessment (2-3 months post chemo/radiation) for concurrent 5FU,
mitomycin, and radiation.
 ++ If not a candidate for radiation or cystectomy, follow stage 
    IVB metastatic pathway. ++
801.41;+86427,;52~INDENT
801.41;+86427,;100~NATIONAL
801.41;+86427,;101~VHA ONCOLOGY
801.412;+86428,+86427,;.01~20
801.412;+86428,+86427,;2~VA-ONC MIBC IVA 5FU MITOMYCIN RAD LOCAL THERAPY
801.44;+86429,+86427,;.01~04/27/2026@11:26:14
801.44;+86429,+86427,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86428^1
86429^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>93064</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2731444136</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93064,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH RSN
801.41;+93064,;4~dialog element
801.41;+93064,;15~HF.VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH RSN
801.41;+93064,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+93064,;51~SUPPRESS
801.41;+93064,;100~NATIONAL
801.41;+93064,;101~VHA ONCOLOGY
801.412;+93065,+93064,;.01~5
801.412;+93065,+93064,;2~VA-ONC OFF PATHWAY
801.412;+93065,+93064,;7~YES
801.412;+93065,+93064,;9~YES
801.44;+93066,+93064,;.01~04/27/2026@11:26:14
801.44;+93066,+93064,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93065^1
93066^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>93063</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>186190091</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93063,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH TX
801.41;+93063,;4~dialog element
801.41;+93063,;15~HF.VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS OFF PATH TX
801.41;+93063,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+93063,;51~SUPPRESS
801.41;+93063,;100~NATIONAL
801.41;+93063,;101~VHA ONCOLOGY
801.412;+93064,+93063,;.01~5
801.412;+93064,+93063,;2~VA-ONC BLANK
801.412;+93064,+93063,;7~YES
801.412;+93064,+93063,;9~YES
801.44;+93065,+93063,;.01~04/27/2026@11:26:14
801.44;+93065,+93063,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93064^1
93065^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>93062</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1649699636</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93062,;.01~VA-GP ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH
801.41;+93062,;4~dialog group
801.41;+93062,;7~2
801.41;+93062,;9~ONE OR MORE SELECTIONS
801.41;+93062,;23~YES
801.41;+93062,;25~WP-start~1
Off pathway:
801.41;+93062,;100~NATIONAL
801.41;+93062,;101~VHA ONCOLOGY
801.412;+93063,+93062,;.01~10
801.412;+93063,+93062,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH TX
801.412;+93064,+93062,;.01~20
801.412;+93064,+93062,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH RSN
801.44;+93065,+93062,;.01~04/27/2026@11:26:14
801.44;+93065,+93062,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93063^1
93064^2
93065^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>93061</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3855239482</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93061,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS RADIATION
801.41;+93061,;4~dialog element
801.41;+93061,;15~HF.VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS RADIATION
801.41;+93061,;25~WP-start~1
Radiation
801.41;+93061,;35~WP-start~1
Veteran has elected to pursue RADIATION.
801.41;+93061,;100~NATIONAL
801.41;+93061,;101~VHA ONCOLOGY
801.44;+93062,+93061,;.01~04/27/2026@11:26:14
801.44;+93062,+93061,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93062^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS CYSTECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>93060</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2023118529</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93060,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS CYSTECTOMY
801.41;+93060,;4~dialog element
801.41;+93060,;15~HF.VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CYSTECTOMY
801.41;+93060,;25~WP-start~1
Cystectomy
801.41;+93060,;35~WP-start~1
Veteran has elected to pursue CYSTECTOMY.
801.41;+93060,;100~NATIONAL
801.41;+93060,;101~VHA ONCOLOGY
801.44;+93061,+93060,;.01~04/27/2026@11:26:14
801.44;+93061,+93060,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93061^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>93058</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>953620065</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+93058,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS CLINICAL TRIAL
801.41;+93058,;4~dialog element
801.41;+93058,;15~HF.VA-ONC MIBC IVA REASSESS EV PEMBRO GEM CIS CLINICAL TRIAL
801.41;+93058,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+93058,;35~WP-start~1
Veteran has elected to pursue:
801.41;+93058,;100~NATIONAL
801.41;+93058,;101~VHA ONCOLOGY
801.412;+93059,+93058,;.01~5
801.412;+93059,+93058,;2~VA-ONC CLINICAL TRIAL
801.412;+93059,+93058,;9~YES
801.44;+93060,+93058,;.01~04/27/2026@11:26:14
801.44;+93060,+93058,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
93059^1
93060^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA EV PEMBRO GEM CIS LOCAL THERAPY</POINT_01>
<INTERNAL_ENTRY_NUMBER>86241</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3169762540</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86241,;.01~VA-ONC MIBC IVA EV PEMBRO GEM CIS LOCAL THERAPY
801.41;+86241,;4~dialog group
801.41;+86241,;6~YES
801.41;+86241,;7~2
801.41;+86241,;9~ONE SELECTION ONLY
801.41;+86241,;25~WP-start~1
Candidate for LOCAL THERAPY (radiation or cystectomy):
801.41;+86241,;51~SUPPRESS
801.41;+86241,;52~INDENT
801.41;+86241,;100~NATIONAL
801.41;+86241,;101~VHA ONCOLOGY
801.412;+86242,+86241,;.01~20
801.412;+86242,+86241,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS CLINICAL TRIAL
801.412;+86243,+86241,;.01~40
801.412;+86243,+86241,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS CYSTECTOMY
801.412;+86244,+86241,;.01~60
801.412;+86244,+86241,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS RADIATION
801.412;+86245,+86241,;.01~80
801.412;+86245,+86241,;2~VA-GP ONC MIBC IVA EV PEMBRO GEM CIS OFF PATH
801.44;+86246,+86241,;.01~04/27/2026@11:26:14
801.44;+86246,+86241,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86242^1
86243^2
86244^3
86245^4
86246^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA EV PEMBRO GEM CIS REASSESSMENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>86426</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>457119757</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86426,;.01~VA-GP ONC MIBC IVA EV PEMBRO GEM CIS REASSESSMENT
801.41;+86426,;4~dialog group
801.41;+86426,;7~2
801.41;+86426,;9~ONE SELECTION ONLY
801.41;+86426,;25~WP-start~4
Interim assessment (every 2-3 cycles) for enfortumab vedotin and
pembrolizumab -OR- gemcitabine and cisplatin.
 ++ If not a candidate for radiation or cystectomy, follow stage 
    IVB metastatic pathway. ++
801.41;+86426,;52~INDENT
801.41;+86426,;100~NATIONAL
801.41;+86426,;101~VHA ONCOLOGY
801.412;+86427,+86426,;.01~20
801.412;+86427,+86426,;2~VA-ONC MIBC IVA EV PEMBRO GEM CIS LOCAL THERAPY
801.44;+86428,+86426,;.01~04/27/2026@11:26:14
801.44;+86428,+86426,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86427^1
86428^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA REASSESSMENT</POINT_01>
<INTERNAL_ENTRY_NUMBER>86424</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3678943628</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86424,;.01~VA-GP ONC MIBC IVA REASSESSMENT
801.41;+86424,;4~dialog group
801.41;+86424,;5~REASSESSMENT
801.41;+86424,;6~YES
801.41;+86424,;7~2
801.41;+86424,;9~NONE OR ONE SELECTION
801.41;+86424,;51~SUPPRESS
801.41;+86424,;52~INDENT
801.41;+86424,;100~NATIONAL
801.41;+86424,;101~VHA ONCOLOGY
801.412;+86425,+86424,;.01~20
801.412;+86425,+86424,;2~VA-GP ONC MIBC IVA EV PEMBRO GEM CIS REASSESSMENT
801.412;+86426,+86424,;.01~40
801.412;+86426,+86424,;2~VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION REASSESSMENT
801.44;+86427,+86424,;.01~04/27/2026@11:26:14
801.44;+86427,+86424,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86425^1
86426^2
86427^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVA OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86112</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>119073732</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86112,;.01~VA-ONC MIBC STAGE IVA OFF PATH RSN
801.41;+86112,;4~dialog element
801.41;+86112,;15~HF.VA-ONC MIBC IVA OFF PATH RSN
801.41;+86112,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86112,;51~SUPPRESS
801.41;+86112,;100~NATIONAL
801.41;+86112,;101~VHA ONCOLOGY
801.412;+86113,+86112,;.01~5
801.412;+86113,+86112,;2~VA-ONC OFF PATHWAY
801.412;+86113,+86112,;7~YES
801.412;+86113,+86112,;9~YES
801.44;+86114,+86112,;.01~04/27/2026@11:26:14
801.44;+86114,+86112,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86113^1
86114^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVA OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86111</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1663711247</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86111,;.01~VA-ONC MIBC STAGE IVA OFF PATH TX
801.41;+86111,;4~dialog element
801.41;+86111,;15~HF.VA-ONC MIBC IVA OFF PATH TX
801.41;+86111,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86111,;51~SUPPRESS
801.41;+86111,;100~NATIONAL
801.41;+86111,;101~VHA ONCOLOGY
801.412;+86112,+86111,;.01~5
801.412;+86112,+86111,;2~VA-ONC BLANK
801.412;+86112,+86111,;7~YES
801.412;+86112,+86111,;9~YES
801.44;+86113,+86111,;.01~04/27/2026@11:26:14
801.44;+86113,+86111,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86112^1
86113^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVA OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>86110</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1257030370</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86110,;.01~VA-GP ONC MIBC STAGE IVA OFF PATH
801.41;+86110,;4~dialog group
801.41;+86110,;7~2
801.41;+86110,;9~ONE OR MORE SELECTIONS
801.41;+86110,;23~YES
801.41;+86110,;25~WP-start~1
Off pathway:
801.41;+86110,;100~NATIONAL
801.41;+86110,;101~VHA ONCOLOGY
801.412;+86111,+86110,;.01~10
801.412;+86111,+86110,;2~VA-ONC MIBC STAGE IVA OFF PATH TX
801.412;+86112,+86110,;.01~20
801.412;+86112,+86110,;2~VA-ONC MIBC STAGE IVA OFF PATH RSN
801.44;+86113,+86110,;.01~04/27/2026@11:26:14
801.44;+86113,+86110,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86111^1
86112^2
86113^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA PALLIATIVE OR HOSPICE</POINT_01>
<INTERNAL_ENTRY_NUMBER>86109</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2734884960</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86109,;.01~VA-ONC MIBC IVA PALLIATIVE OR HOSPICE
801.41;+86109,;4~dialog element
801.41;+86109,;15~HF.VA-ONC MIBC IVA PALLIATIVE OR HOSPICE
801.41;+86109,;25~WP-start~2
Palliative radiation, palliative care, or hospice.
 ++ Follow up as clinically indicated. ++
801.41;+86109,;35~WP-start~3
Veteran has elected to pursue PALLIATIVE RADIATION, PALLIATIVE CARE, or 
HOSPICE.
 ++ Follow up as clinically indicated. ++
801.41;+86109,;100~NATIONAL
801.41;+86109,;101~VHA ONCOLOGY
801.44;+86110,+86109,;.01~04/27/2026@11:26:14
801.44;+86110,+86109,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86110^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>86108</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2455462793</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86108,;.01~VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION
801.41;+86108,;4~dialog group
801.41;+86108,;7~2
801.41;+86108,;9~NO SELECTION REQUIRED
801.41;+86108,;15~HF.VA-ONC MIBC IVA 5FU MITOMYCIN RADIATION
801.41;+86108,;25~WP-start~3
Concurrent 5FU, mitomycin, and radiation only for no distant metastasis
(M0).
 ++ Reassess tumor 2-3 months post treatment. ++
801.41;+86108,;35~WP-start~3
Veteran has elected to pursue CONCURRENT 5FU, MITOMYCIN, and RADIATION
only for no distant metastasis.
 ++ Reassess tumor 2-3 months post treatment. ++
801.41;+86108,;52~INDENT
801.41;+86108,;100~NATIONAL
801.41;+86108,;101~VHA ONCOLOGY
801.44;+86109,+86108,;.01~04/27/2026@11:26:15
801.44;+86109,+86108,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86109^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC IVA GEM, CIS, NIVOLUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>86107</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3767478691</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86107,;.01~VA-ONC MIBC IVA GEM, CIS, NIVOLUMAB
801.41;+86107,;4~dialog group
801.41;+86107,;7~2
801.41;+86107,;9~NO SELECTION REQUIRED
801.41;+86107,;15~HF.VA-ONC MIBC IVA GEMCITABINE CISPLATIN NIVOLUMAB
801.41;+86107,;25~WP-start~3
Gemcitabine, cisplatin, and nivolumab
 ++ Interim Assessment includes EUA, cystoscopy, and CT chest, abdomen, 
    and pelvis. ++
801.41;+86107,;35~WP-start~3
Veteran has elected to pursue GEMCITABINE, CISPLATIN, and NIVOLUMAB.
 ++ Interim Assessment includes EUA, cystoscopy, and CT chest, abdomen, 
    and pevis. ++
801.41;+86107,;52~INDENT
801.41;+86107,;100~NATIONAL
801.41;+86107,;101~VHA ONCOLOGY
801.44;+86108,+86107,;.01~04/27/2026@11:26:15
801.44;+86108,+86107,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86108^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC IVA EV AND PEMBROLIZUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>86106</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1254595724</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86106,;.01~VA-GP ONC MIBC IVA EV AND PEMBROLIZUMAB
801.41;+86106,;4~dialog group
801.41;+86106,;7~2
801.41;+86106,;9~NO SELECTION REQUIRED
801.41;+86106,;15~HF.VA-ONC MIBC IVA EV AND PEMBROLIZUMAB
801.41;+86106,;25~WP-start~5
Enfortumab vedotin and pembrolizumab
 ++ Exclude patients with preexisting peripheral neuropathy Grade 2, 
    baseline ocular disorders, uncontrolled diabetes at baseline. ++ 
 ++ Interim Assessment includes EUA, cystoscopy, and CT chest, abdomen, 
    and pelvis. ++
801.41;+86106,;35~WP-start~5
Veteran has elected to pursue ENFORTUMAB VEDOTIN and PEMBROLIZUMAB.
 ++ Exclude patients with preexisting peripheral neuropathy Grade 2, 
    baseline ocular disorders, uncontrolled diabetes at baseline. ++
 ++ Interim Assessment includes EUA, cystoscopy, and CT chest, abdomen, 
    and pelvis. ++
801.41;+86106,;52~INDENT
801.41;+86106,;100~NATIONAL
801.41;+86106,;101~VHA ONCOLOGY
801.44;+86107,+86106,;.01~04/27/2026@11:26:15
801.44;+86107,+86106,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86107^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC STAGE IVA CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86105</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>169513163</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86105,;.01~VA-ONC MIBC STAGE IVA CLINICAL TRIAL
801.41;+86105,;4~dialog element
801.41;+86105,;15~HF.VA-ONC MIBC IVA CLINICAL TRIAL
801.41;+86105,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86105,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86105,;100~NATIONAL
801.41;+86105,;101~VHA ONCOLOGY
801.412;+86106,+86105,;.01~5
801.412;+86106,+86105,;2~VA-ONC CLINICAL TRIAL
801.412;+86106,+86105,;9~YES
801.44;+86107,+86105,;.01~04/27/2026@11:26:15
801.44;+86107,+86105,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86106^1
86107^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVA SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86101</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4290441584</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86101,;.01~VA-GP ONC MIBC STAGE IVA SUBMAIN
801.41;+86101,;4~dialog group
801.41;+86101,;5~INITIAL TREATMENT
801.41;+86101,;6~YES
801.41;+86101,;7~2
801.41;+86101,;9~NONE OR ONE SELECTION
801.41;+86101,;25~WP-start~1
\\
801.41;+86101,;35~WP-start~1
After multidisciplinary discussion and shared decision making:
801.41;+86101,;51~SUPPRESS
801.41;+86101,;52~INDENT
801.41;+86101,;100~NATIONAL
801.41;+86101,;101~VHA ONCOLOGY
801.412;+86102,+86101,;.01~20
801.412;+86102,+86101,;2~VA-ONC MIBC STAGE IVA CLINICAL TRIAL
801.412;+86103,+86101,;.01~40
801.412;+86103,+86101,;2~VA-GP ONC MIBC IVA EV AND PEMBROLIZUMAB
801.412;+86104,+86101,;.01~60
801.412;+86104,+86101,;2~VA-ONC MIBC IVA GEM, CIS, NIVOLUMAB
801.412;+86105,+86101,;.01~80
801.412;+86105,+86101,;2~VA-GP ONC MIBC IVA 5FU MITOMYCIN RADIATION
801.412;+86106,+86101,;.01~100
801.412;+86106,+86101,;2~VA-ONC MIBC IVA PALLIATIVE OR HOSPICE
801.412;+86107,+86101,;.01~120
801.412;+86107,+86101,;2~VA-GP ONC MIBC STAGE IVA OFF PATH
801.44;+86108,+86101,;.01~04/27/2026@11:26:15
801.44;+86108,+86101,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86102^1
86103^2
86104^3
86105^4
86106^5
86107^6
86108^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC STAGE IVA PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>84578</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>183122850</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+84578,;.01~VA-GP ONC MIBC STAGE IVA PATHWAY
801.41;+84578,;4~dialog group
801.41;+84578,;6~YES
801.41;+84578,;9~NO SELECTION REQUIRED
801.41;+84578,;15~HF.VA-ONC BLADDER MUSCLE INVASIVE IVA
801.41;+84578,;25~WP-start~1
Muscle Invasive Stage IVA Pathway:
801.41;+84578,;35~WP-start~2
Muscle Invasive Stage IVA Pathway\\
=================================
801.41;+84578,;100~NATIONAL
801.41;+84578,;101~VHA ONCOLOGY
801.412;+84579,+84578,;.01~20
801.412;+84579,+84578,;2~VA-GP ONC MIBC STAGE IVA SUBMAIN
801.412;+84580,+84578,;.01~40
801.412;+84580,+84578,;2~VA-GP ONC MIBC IVA REASSESSMENT
801.44;+84581,+84578,;.01~04/27/2026@11:26:15
801.44;+84581,+84578,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
84579^1
84580^2
84581^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC GHOST</POINT_01>
<INTERNAL_ENTRY_NUMBER>90555</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2701710077</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90555,;.01~VA-GP ONC MIBC GHOST
801.41;+90555,;4~dialog group
801.41;+90555,;6~YES
801.41;+90555,;9~NONE OR ONE SELECTION
801.41;+90555,;23~YES
801.41;+90555,;25~WP-start~2
Muscle Invasive Bladder Cancer\\
==============================\\
801.41;+90555,;51~SUPPRESS
801.41;+90555,;100~NATIONAL
801.41;+90555,;101~VHA ONCOLOGY
801.412;+90556,+90555,;.01~10
801.412;+90556,+90555,;2~VA-GP ONC MIBC STAGE II, IIIA, IIIB PATHWAY
801.412;+90557,+90555,;.01~20
801.412;+90557,+90555,;2~VA-GP ONC MIBC STAGE IVA PATHWAY
801.412;+90558,+90555,;.01~30
801.412;+90558,+90555,;2~VA-GP ONC MIBC STAGE IVB PATHWAY
801.44;+90559,+90555,;.01~04/27/2026@11:26:15
801.44;+90559,+90555,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90556^1
90557^2
90558^3
90559^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>BLANK LINE IN NOTE, NOT TEMPLATE</POINT_01>
<INTERNAL_ENTRY_NUMBER>58817</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>919076761</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+58817,;.01~BLANK LINE IN NOTE, NOT TEMPLATE
801.41;+58817,;4~dialog element
801.41;+58817,;35~WP-start~1
                     \\
801.41;+58817,;51~SUPPRESS
801.41;+58817,;100~LOCAL
801.44;+58818,+58817,;.01~04/27/2026@11:26:15
801.44;+58818,+58817,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
58818^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 INSTRUCTIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>90921</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3317763667</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90921,;.01~VA-ONC MIBC CGP PD-L1 INSTRUCTIONS
801.41;+90921,;4~dialog element
801.41;+90921,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+90921,;23~YES
801.41;+90921,;25~WP-start~6
++ Comprehensive genomic profiling by solid biopsy (through NPOP
preferred) or by\\   liquid biopsy if there is insufficient tissue. ++
 
++ PD-L1 expression by IHC using 22C3 antibody (pembrolizumab), SP142 
antibody (atezolizumab),\\   28-8 pharmDx antibody (nivolumab), SP263
antibody (durvalumab). ++
801.41;+90921,;35~WP-start~27
Only select the option that applies to your patient currently.
 
Off Pathway is expected at some time for some patients and should not be 
viewed a failure. Not all patients will be appropriate for testing.
 
Tumor Genomic Testing:\\
=====================\\
*ORDER - choose this option if you will be placing an order to have
testing done. The order may be linked to this selection depending on 
your facility's process for ordering. This is an ON PATHWAY OPTION.
 
*PREVIOUSLY ORDERED - choose this option if this test has been ordered in
the past. This ordering may have occurred at an outside facility, during 
a clinical trial, or any other scenario where testing could be done. This 
is an ON PATHWAY OPTION.
 
*ORDER IN FUTURE - choose this option to document that you will not be 
ordering the test today, but in the future, it may be appropriate for this
Veteran. If you choose this option, you should return to the template 
when the decision to order the test is made, or if you decide that the 
test is not appropriate for this Veteran. This is NEITHER an ON PATHWAY 
or OFF PATHWAY OPTION. It is a placeholder until a decision can be made 
on whether to test or not to test.
 
*I DO NOT INTEND to order the testing - choose this option if testing 
will not be ordered for this Veteran. Please indicate the reason that 
you will not be ordering the test. This is an OFF PATHWAY OPTION.
801.41;+90921,;51~SUPPRESS
801.41;+90921,;100~NATIONAL
801.41;+90921,;101~VHA ONCOLOGY
801.412;+90922,+90921,;.01~5
801.412;+90922,+90921,;2~PXRM GF VIEW BUTTON
801.412;+90922,+90921,;6~VIEW Genomic Instructions
801.412;+90922,+90921,;8~YES
801.44;+90923,+90921,;.01~04/27/2026@11:26:15
801.44;+90923,+90921,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90922^1
90923^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 PATHWAY ORDER</POINT_01>
<INTERNAL_ENTRY_NUMBER>90682</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>620127709</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90682,;.01~VA-ONC MIBC CGP PD-L1 PATHWAY ORDER
801.41;+90682,;4~dialog element
801.41;+90682,;15~HF.VA-ONC MIBC CGP PD-L1 ORDER
801.41;+90682,;25~WP-start~1
Order Comprehensive Genomic Profiling with PD-L1.
801.41;+90682,;35~WP-start~1
Comprehensive genomic profile (CGP) with PD-L1 ORDERED. 
801.41;+90682,;100~NATIONAL
801.41;+90682,;101~VHA ONCOLOGY
801.44;+90683,+90682,;.01~04/27/2026@11:26:15
801.44;+90683,+90682,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90683^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>90672</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>981040598</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90672,;.01~VA-ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY RSN
801.41;+90672,;4~dialog element
801.41;+90672,;15~HF.VA-ONC MIBC CGP PD-L1 OFF PATHWAY RSN
801.41;+90672,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+90672,;51~SUPPRESS
801.41;+90672,;100~NATIONAL
801.41;+90672,;101~VHA ONCOLOGY
801.412;+90673,+90672,;.01~5
801.412;+90673,+90672,;2~VA-ONC OFF PATHWAY
801.412;+90673,+90672,;7~YES
801.412;+90673,+90672,;9~YES
801.44;+90674,+90672,;.01~04/27/2026@11:26:15
801.44;+90674,+90672,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90673^1
90674^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>90671</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>591421666</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90671,;.01~VA-GP ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY
801.41;+90671,;4~dialog group
801.41;+90671,;6~YES
801.41;+90671,;7~2
801.41;+90671,;25~WP-start~2
I do not intend to order Comprehensive Genetic Profiling with PD-L1 for
this Veteran (off pathway):
801.41;+90671,;35~WP-start~2
Comprehensive genomic profile (CGP) with PD-L1 will NOT be ORDERED for 
this Veteran.
801.41;+90671,;52~INDENT
801.41;+90671,;100~NATIONAL
801.41;+90671,;101~VHA ONCOLOGY
801.412;+90672,+90671,;.01~10
801.412;+90672,+90671,;2~VA-ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY RSN
801.44;+90673,+90671,;.01~04/27/2026@11:26:15
801.44;+90673,+90671,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90672^1
90673^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 PATHWAY ORDER FUTURE</POINT_01>
<INTERNAL_ENTRY_NUMBER>90669</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1246584662</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90669,;.01~VA-ONC MIBC CGP PD-L1 PATHWAY ORDER FUTURE
801.41;+90669,;4~dialog element
801.41;+90669,;15~HF.VA-ONC MIBC CGP PD-L1 ORDER IN FUTURE
801.41;+90669,;25~WP-start~1
Order in future {FLD:VA-ONC NEITHER ON/OFF}.
801.41;+90669,;35~WP-start~2
Comprehensive genomic profile (CGP) with PD-L1 will be ordered in the 
FUTURE.
801.41;+90669,;100~NATIONAL
801.41;+90669,;101~VHA ONCOLOGY
801.44;+90670,+90669,;.01~04/27/2026@11:26:15
801.44;+90670,+90669,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90670^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC MIBC CGP PD-L1 PATHWAY PREVIOUSLY ORDERED</POINT_01>
<INTERNAL_ENTRY_NUMBER>90668</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2262178696</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90668,;.01~VA-ONC MIBC CGP PD-L1 PATHWAY PREVIOUSLY ORDERED
801.41;+90668,;4~dialog element
801.41;+90668,;15~HF.VA-ONC MIBC CGP PD-L1 PREVIOUSLY ORDERED
801.41;+90668,;25~WP-start~1
Previously ordered.
801.41;+90668,;35~WP-start~1
Comprehensive genomic profile (CGP) with PD-L1 PREVIOUSLY ORDERED.
801.41;+90668,;100~NATIONAL
801.41;+90668,;101~VHA ONCOLOGY
801.44;+90669,+90668,;.01~04/27/2026@11:26:15
801.44;+90669,+90668,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90669^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CGP PD-L1 PATHWAY GHOST</POINT_01>
<INTERNAL_ENTRY_NUMBER>90663</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1760518418</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90663,;.01~VA-GP ONC MIBC CGP PD-L1 PATHWAY GHOST
801.41;+90663,;4~dialog group
801.41;+90663,;6~YES
801.41;+90663,;7~2
801.41;+90663,;9~NONE OR ONE SELECTION
801.41;+90663,;51~SUPPRESS
801.41;+90663,;52~INDENT
801.41;+90663,;100~NATIONAL
801.41;+90663,;101~VHA ONCOLOGY
801.412;+90664,+90663,;.01~40
801.412;+90664,+90663,;2~VA-ONC MIBC CGP PD-L1 PATHWAY PREVIOUSLY ORDERED
801.412;+90665,+90663,;.01~60
801.412;+90665,+90663,;2~VA-ONC MIBC CGP PD-L1 PATHWAY ORDER FUTURE
801.412;+90666,+90663,;.01~100
801.412;+90666,+90663,;2~VA-GP ONC MIBC CGP PD-L1 PATHWAY OFF PATHWAY
801.412;+90667,+90663,;.01~20
801.412;+90667,+90663,;2~VA-ONC MIBC CGP PD-L1 PATHWAY ORDER
801.44;+90668,+90663,;.01~04/27/2026@11:26:15
801.44;+90668,+90663,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90664^2
90665^3
90666^5
90667^6
90668^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CGP PD-L1 PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>90645</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3635860447</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+90645,;.01~VA-GP ONC MIBC CGP PD-L1 PATHWAY
801.41;+90645,;4~dialog group
801.41;+90645,;6~YES
801.41;+90645,;7~2
801.41;+90645,;15~HF.VA-ONC MIBC COMPREHENSIVE GENETIC PROFILING WITH PD-L1 TESTING
801.41;+90645,;25~WP-start~2
Comprehensive Genomic Profiling on tissue with PD-L1 for stages IVA and 
IVB:
801.41;+90645,;35~WP-start~2
Comprehensive Genomic Profiling on tissue with PD-L1 for stages IVA and 
IVB:
801.41;+90645,;52~INDENT
801.41;+90645,;100~NATIONAL
801.41;+90645,;101~VHA ONCOLOGY
801.412;+90646,+90645,;.01~30
801.412;+90646,+90645,;2~VA-GP ONC MIBC CGP PD-L1 PATHWAY GHOST
801.412;+90647,+90645,;.01~20
801.412;+90647,+90645,;2~VA-ONC MIBC CGP PD-L1 INSTRUCTIONS
801.412;+90648,+90645,;.01~40
801.412;+90648,+90645,;2~BLANK LINE IN NOTE, NOT TEMPLATE
801.44;+90649,+90645,;.01~04/27/2026@11:26:15
801.44;+90649,+90645,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
90646^17
90647^18
90648^19
90649^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC CGP INFORMATIONAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57104</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1886413814</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57104,;.01~VA-GP ONC MIBC CGP INFORMATIONAL
801.41;+57104,;4~dialog group
801.41;+57104,;6~YES
801.41;+57104,;9~NO SELECTION REQUIRED
801.41;+57104,;23~YES
801.41;+57104,;25~WP-start~2
Comprehensive Genomic Profiling\\
===============================
801.41;+57104,;51~SUPPRESS
801.41;+57104,;100~NATIONAL
801.41;+57104,;101~VHA ONCOLOGY
801.412;+57105,+57104,;.01~10
801.412;+57105,+57104,;2~VA-GP ONC MIBC CGP PD-L1 PATHWAY
801.44;+57106,+57104,;.01~04/27/2026@11:26:15
801.44;+57106,+57104,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57105^1
57106^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC MIBC PATHWAY SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>49849</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3951785160</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+49849,;.01~VA-GP ONC MIBC PATHWAY SUBMAIN
801.41;+49849,;4~dialog group
801.41;+49849,;6~YES
801.41;+49849,;9~NO SELECTION REQUIRED
801.41;+49849,;51~SUPPRESS
801.41;+49849,;100~NATIONAL
801.41;+49849,;101~VHA ONCOLOGY
801.412;+49850,+49849,;.01~80
801.412;+49850,+49849,;2~VA-GP ONC MIBC CGP INFORMATIONAL
801.412;+49851,+49849,;.01~100
801.412;+49851,+49849,;2~VA-GP ONC MIBC GHOST
801.44;+49852,+49849,;.01~04/27/2026@11:26:15
801.44;+49852,+49849,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
49850^5
49851^6
49852^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>38452</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1104210037</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+38452,;.01~VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS MAIN
801.41;+38452,;4~dialog group
801.41;+38452,;51~SUPPRESS
801.41;+38452,;100~NATIONAL
801.41;+38452,;101~VHA ONCOLOGY
801.412;+38453,+38452,;.01~40
801.412;+38453,+38452,;2~VA-GP ONC MIBC PATHWAY SUBMAIN
801.412;+38454,+38452,;.01~20
801.412;+38454,+38452,;2~VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS INFO
801.44;+38455,+38452,;.01~04/27/2026@11:26:15
801.44;+38455,+38452,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38453^29
38454^30
38455^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY BLADDER CANCER MUSCLE INVASIVE PATHWAYS</POINT_01>
<INTERNAL_ENTRY_NUMBER>80399</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3313993523</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+80399,;.01~VA-ONCOLOGY BLADDER CANCER MUSCLE INVASIVE PATHWAYS
801.41;+80399,;4~reminder dialog
801.41;+80399,;100~NATIONAL
801.41;+80399,;101~VHA ONCOLOGY
801.41;+80399,;112~TRUE
801.412;+80400,+80399,;.01~10
801.412;+80400,+80399,;2~VA-GP ONC BLADDER CANCER MUSCLE INVASIVE PATHWAYS MAIN
801.44;+80401,+80399,;.01~04/27/2026@11:26:15
801.44;+80401,+80399,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
80400^2
80401^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<INDEX>
<NUMBER_OF_COMPONENTS>432</NUMBER_OF_COMPONENTS>
<COMPONENT>
<FDA_END>40</FDA_END>
<FDA_START>35</FDA_START>
<FILE_START>26</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>67</FDA_END>
<FDA_START>53</FDA_START>
<FILE_START>44</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>94</FDA_END>
<FDA_START>80</FDA_START>
<FILE_START>71</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>121</FDA_END>
<FDA_START>107</FDA_START>
<FILE_START>98</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>146</FDA_END>
<FDA_START>134</FDA_START>
<FILE_START>125</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>173</FDA_END>
<FDA_START>159</FDA_START>
<FILE_START>150</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>199</FDA_END>
<FDA_START>186</FDA_START>
<FILE_START>177</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>226</FDA_END>
<FDA_START>212</FDA_START>
<FILE_START>203</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>253</FDA_END>
<FDA_START>239</FDA_START>
<FILE_START>230</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>280</FDA_END>
<FDA_START>266</FDA_START>
<FILE_START>257</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>307</FDA_END>
<FDA_START>293</FDA_START>
<FILE_START>284</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>334</FDA_END>
<FDA_START>320</FDA_START>
<FILE_START>311</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>361</FDA_END>
<FDA_START>347</FDA_START>
<FILE_START>338</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>388</FDA_END>
<FDA_START>374</FDA_START>
<FILE_START>365</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>415</FDA_END>
<FDA_START>401</FDA_START>
<FILE_START>392</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>431</FDA_END>
<FDA_START>428</FDA_START>
<FILE_START>419</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>456</FDA_END>
<FDA_START>444</FDA_START>
<FILE_START>435</FILE_START>
<IEN_ROOT_END>462</IEN_ROOT_END>
<IEN_ROOT_START>461</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>486</FDA_END>
<FDA_START>475</FDA_START>
<FILE_START>466</FILE_START>
<IEN_ROOT_END>492</IEN_ROOT_END>
<IEN_ROOT_START>491</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>526</FDA_END>
<FDA_START>505</FDA_START>
<FILE_START>496</FILE_START>
<IEN_ROOT_END>534</IEN_ROOT_END>
<IEN_ROOT_START>531</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>568</FDA_END>
<FDA_START>547</FDA_START>
<FILE_START>538</FILE_START>
<IEN_ROOT_END>577</IEN_ROOT_END>
<IEN_ROOT_START>573</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>608</FDA_END>
<FDA_START>590</FDA_START>
<FILE_START>581</FILE_START>
<IEN_ROOT_END>614</IEN_ROOT_END>
<IEN_ROOT_START>613</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>649</FDA_END>
<FDA_START>627</FDA_START>
<FILE_START>618</FILE_START>
<IEN_ROOT_END>659</IEN_ROOT_END>
<IEN_ROOT_START>654</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>686</FDA_END>
<FDA_START>672</FDA_START>
<FILE_START>663</FILE_START>
<IEN_ROOT_END>695</IEN_ROOT_END>
<IEN_ROOT_START>691</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>728</FDA_END>
<FDA_START>708</FDA_START>
<FILE_START>699</FILE_START>
<IEN_ROOT_END>736</IEN_ROOT_END>
<IEN_ROOT_START>733</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>768</FDA_END>
<FDA_START>749</FDA_START>
<FILE_START>740</FILE_START>
<IEN_ROOT_END>775</IEN_ROOT_END>
<IEN_ROOT_START>773</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>807</FDA_END>
<FDA_START>788</FDA_START>
<FILE_START>779</FILE_START>
<IEN_ROOT_END>814</IEN_ROOT_END>
<IEN_ROOT_START>812</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>839</FDA_END>
<FDA_START>827</FDA_START>
<FILE_START>818</FILE_START>
<IEN_ROOT_END>844</IEN_ROOT_END>
<IEN_ROOT_START>844</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>869</FDA_END>
<FDA_START>857</FDA_START>
<FILE_START>848</FILE_START>
<IEN_ROOT_END>874</IEN_ROOT_END>
<IEN_ROOT_START>874</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>899</FDA_END>
<FDA_START>887</FDA_START>
<FILE_START>878</FILE_START>
<IEN_ROOT_END>904</IEN_ROOT_END>
<IEN_ROOT_START>904</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>929</FDA_END>
<FDA_START>917</FDA_START>
<FILE_START>908</FILE_START>
<IEN_ROOT_END>934</IEN_ROOT_END>
<IEN_ROOT_START>934</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>959</FDA_END>
<FDA_START>947</FDA_START>
<FILE_START>938</FILE_START>
<IEN_ROOT_END>964</IEN_ROOT_END>
<IEN_ROOT_START>964</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>989</FDA_END>
<FDA_START>977</FDA_START>
<FILE_START>968</FILE_START>
<IEN_ROOT_END>994</IEN_ROOT_END>
<IEN_ROOT_START>994</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1019</FDA_END>
<FDA_START>1007</FDA_START>
<FILE_START>998</FILE_START>
<IEN_ROOT_END>1024</IEN_ROOT_END>
<IEN_ROOT_START>1024</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1051</FDA_END>
<FDA_START>1037</FDA_START>
<FILE_START>1028</FILE_START>
<IEN_ROOT_END>1056</IEN_ROOT_END>
<IEN_ROOT_START>1056</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1081</FDA_END>
<FDA_START>1069</FDA_START>
<FILE_START>1060</FILE_START>
<IEN_ROOT_END>1086</IEN_ROOT_END>
<IEN_ROOT_START>1086</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1111</FDA_END>
<FDA_START>1099</FDA_START>
<FILE_START>1090</FILE_START>
<IEN_ROOT_END>1116</IEN_ROOT_END>
<IEN_ROOT_START>1116</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1141</FDA_END>
<FDA_START>1129</FDA_START>
<FILE_START>1120</FILE_START>
<IEN_ROOT_END>1146</IEN_ROOT_END>
<IEN_ROOT_START>1146</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1171</FDA_END>
<FDA_START>1159</FDA_START>
<FILE_START>1150</FILE_START>
<IEN_ROOT_END>1176</IEN_ROOT_END>
<IEN_ROOT_START>1176</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1201</FDA_END>
<FDA_START>1189</FDA_START>
<FILE_START>1180</FILE_START>
<IEN_ROOT_END>1206</IEN_ROOT_END>
<IEN_ROOT_START>1206</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1231</FDA_END>
<FDA_START>1219</FDA_START>
<FILE_START>1210</FILE_START>
<IEN_ROOT_END>1236</IEN_ROOT_END>
<IEN_ROOT_START>1236</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1261</FDA_END>
<FDA_START>1249</FDA_START>
<FILE_START>1240</FILE_START>
<IEN_ROOT_END>1266</IEN_ROOT_END>
<IEN_ROOT_START>1266</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1292</FDA_END>
<FDA_START>1279</FDA_START>
<FILE_START>1270</FILE_START>
<IEN_ROOT_END>1297</IEN_ROOT_END>
<IEN_ROOT_START>1297</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1322</FDA_END>
<FDA_START>1310</FDA_START>
<FILE_START>1301</FILE_START>
<IEN_ROOT_END>1327</IEN_ROOT_END>
<IEN_ROOT_START>1327</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1354</FDA_END>
<FDA_START>1340</FDA_START>
<FILE_START>1331</FILE_START>
<IEN_ROOT_END>1359</IEN_ROOT_END>
<IEN_ROOT_START>1359</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1386</FDA_END>
<FDA_START>1372</FDA_START>
<FILE_START>1363</FILE_START>
<IEN_ROOT_END>1391</IEN_ROOT_END>
<IEN_ROOT_START>1391</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1419</FDA_END>
<FDA_START>1404</FDA_START>
<FILE_START>1395</FILE_START>
<IEN_ROOT_END>1424</IEN_ROOT_END>
<IEN_ROOT_START>1424</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1451</FDA_END>
<FDA_START>1437</FDA_START>
<FILE_START>1428</FILE_START>
<IEN_ROOT_END>1456</IEN_ROOT_END>
<IEN_ROOT_START>1456</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1483</FDA_END>
<FDA_START>1469</FDA_START>
<FILE_START>1460</FILE_START>
<IEN_ROOT_END>1488</IEN_ROOT_END>
<IEN_ROOT_START>1488</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1515</FDA_END>
<FDA_START>1501</FDA_START>
<FILE_START>1492</FILE_START>
<IEN_ROOT_END>1520</IEN_ROOT_END>
<IEN_ROOT_START>1520</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1549</FDA_END>
<FDA_START>1533</FDA_START>
<FILE_START>1524</FILE_START>
<IEN_ROOT_END>1555</IEN_ROOT_END>
<IEN_ROOT_START>1554</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1582</FDA_END>
<FDA_START>1568</FDA_START>
<FILE_START>1559</FILE_START>
<IEN_ROOT_END>1587</IEN_ROOT_END>
<IEN_ROOT_START>1587</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1614</FDA_END>
<FDA_START>1600</FDA_START>
<FILE_START>1591</FILE_START>
<IEN_ROOT_END>1621</IEN_ROOT_END>
<IEN_ROOT_START>1619</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1648</FDA_END>
<FDA_START>1634</FDA_START>
<FILE_START>1625</FILE_START>
<IEN_ROOT_END>1655</IEN_ROOT_END>
<IEN_ROOT_START>1653</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1683</FDA_END>
<FDA_START>1668</FDA_START>
<FILE_START>1659</FILE_START>
<IEN_ROOT_END>1690</IEN_ROOT_END>
<IEN_ROOT_START>1688</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1717</FDA_END>
<FDA_START>1703</FDA_START>
<FILE_START>1694</FILE_START>
<IEN_ROOT_END>1724</IEN_ROOT_END>
<IEN_ROOT_START>1722</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1750</FDA_END>
<FDA_START>1737</FDA_START>
<FILE_START>1728</FILE_START>
<IEN_ROOT_END>1755</IEN_ROOT_END>
<IEN_ROOT_START>1755</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1781</FDA_END>
<FDA_START>1768</FDA_START>
<FILE_START>1759</FILE_START>
<IEN_ROOT_END>1786</IEN_ROOT_END>
<IEN_ROOT_START>1786</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1813</FDA_END>
<FDA_START>1799</FDA_START>
<FILE_START>1790</FILE_START>
<IEN_ROOT_END>1818</IEN_ROOT_END>
<IEN_ROOT_START>1818</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1844</FDA_END>
<FDA_START>1831</FDA_START>
<FILE_START>1822</FILE_START>
<IEN_ROOT_END>1849</IEN_ROOT_END>
<IEN_ROOT_START>1849</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1875</FDA_END>
<FDA_START>1862</FDA_START>
<FILE_START>1853</FILE_START>
<IEN_ROOT_END>1880</IEN_ROOT_END>
<IEN_ROOT_START>1880</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1906</FDA_END>
<FDA_START>1893</FDA_START>
<FILE_START>1884</FILE_START>
<IEN_ROOT_END>1911</IEN_ROOT_END>
<IEN_ROOT_START>1911</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1939</FDA_END>
<FDA_START>1924</FDA_START>
<FILE_START>1915</FILE_START>
<IEN_ROOT_END>1944</IEN_ROOT_END>
<IEN_ROOT_START>1944</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1970</FDA_END>
<FDA_START>1957</FDA_START>
<FILE_START>1948</FILE_START>
<IEN_ROOT_END>1975</IEN_ROOT_END>
<IEN_ROOT_START>1975</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2000</FDA_END>
<FDA_START>1988</FDA_START>
<FILE_START>1979</FILE_START>
<IEN_ROOT_END>2005</IEN_ROOT_END>
<IEN_ROOT_START>2005</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2031</FDA_END>
<FDA_START>2018</FDA_START>
<FILE_START>2009</FILE_START>
<IEN_ROOT_END>2036</IEN_ROOT_END>
<IEN_ROOT_START>2036</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2064</FDA_END>
<FDA_START>2049</FDA_START>
<FILE_START>2040</FILE_START>
<IEN_ROOT_END>2069</IEN_ROOT_END>
<IEN_ROOT_START>2069</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2094</FDA_END>
<FDA_START>2082</FDA_START>
<FILE_START>2073</FILE_START>
<IEN_ROOT_END>2099</IEN_ROOT_END>
<IEN_ROOT_START>2099</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2124</FDA_END>
<FDA_START>2112</FDA_START>
<FILE_START>2103</FILE_START>
<IEN_ROOT_END>2130</IEN_ROOT_END>
<IEN_ROOT_START>2129</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2154</FDA_END>
<FDA_START>2143</FDA_START>
<FILE_START>2134</FILE_START>
<IEN_ROOT_END>2159</IEN_ROOT_END>
<IEN_ROOT_START>2159</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2186</FDA_END>
<FDA_START>2172</FDA_START>
<FILE_START>2163</FILE_START>
<IEN_ROOT_END>2192</IEN_ROOT_END>
<IEN_ROOT_START>2191</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2218</FDA_END>
<FDA_START>2205</FDA_START>
<FILE_START>2196</FILE_START>
<IEN_ROOT_END>2224</IEN_ROOT_END>
<IEN_ROOT_START>2223</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2252</FDA_END>
<FDA_START>2237</FDA_START>
<FILE_START>2228</FILE_START>
<IEN_ROOT_END>2259</IEN_ROOT_END>
<IEN_ROOT_START>2257</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2287</FDA_END>
<FDA_START>2272</FDA_START>
<FILE_START>2263</FILE_START>
<IEN_ROOT_END>2295</IEN_ROOT_END>
<IEN_ROOT_START>2292</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2324</FDA_END>
<FDA_START>2308</FDA_START>
<FILE_START>2299</FILE_START>
<IEN_ROOT_END>2332</IEN_ROOT_END>
<IEN_ROOT_START>2329</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2360</FDA_END>
<FDA_START>2345</FDA_START>
<FILE_START>2336</FILE_START>
<IEN_ROOT_END>2367</IEN_ROOT_END>
<IEN_ROOT_START>2365</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2395</FDA_END>
<FDA_START>2380</FDA_START>
<FILE_START>2371</FILE_START>
<IEN_ROOT_END>2402</IEN_ROOT_END>
<IEN_ROOT_START>2400</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2426</FDA_END>
<FDA_START>2415</FDA_START>
<FILE_START>2406</FILE_START>
<IEN_ROOT_END>2432</IEN_ROOT_END>
<IEN_ROOT_START>2431</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2459</FDA_END>
<FDA_START>2445</FDA_START>
<FILE_START>2436</FILE_START>
<IEN_ROOT_END>2466</IEN_ROOT_END>
<IEN_ROOT_START>2464</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2493</FDA_END>
<FDA_START>2479</FDA_START>
<FILE_START>2470</FILE_START>
<IEN_ROOT_END>2500</IEN_ROOT_END>
<IEN_ROOT_START>2498</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2524</FDA_END>
<FDA_START>2513</FDA_START>
<FILE_START>2504</FILE_START>
<IEN_ROOT_END>2530</IEN_ROOT_END>
<IEN_ROOT_START>2529</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2558</FDA_END>
<FDA_START>2543</FDA_START>
<FILE_START>2534</FILE_START>
<IEN_ROOT_END>2565</IEN_ROOT_END>
<IEN_ROOT_START>2563</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2595</FDA_END>
<FDA_START>2578</FDA_START>
<FILE_START>2569</FILE_START>
<IEN_ROOT_END>2604</IEN_ROOT_END>
<IEN_ROOT_START>2600</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2631</FDA_END>
<FDA_START>2617</FDA_START>
<FILE_START>2608</FILE_START>
<IEN_ROOT_END>2638</IEN_ROOT_END>
<IEN_ROOT_START>2636</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2663</FDA_END>
<FDA_START>2651</FDA_START>
<FILE_START>2642</FILE_START>
<IEN_ROOT_END>2669</IEN_ROOT_END>
<IEN_ROOT_START>2668</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2694</FDA_END>
<FDA_START>2682</FDA_START>
<FILE_START>2673</FILE_START>
<IEN_ROOT_END>2699</IEN_ROOT_END>
<IEN_ROOT_START>2699</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2724</FDA_END>
<FDA_START>2712</FDA_START>
<FILE_START>2703</FILE_START>
<IEN_ROOT_END>2729</IEN_ROOT_END>
<IEN_ROOT_START>2729</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2754</FDA_END>
<FDA_START>2742</FDA_START>
<FILE_START>2733</FILE_START>
<IEN_ROOT_END>2759</IEN_ROOT_END>
<IEN_ROOT_START>2759</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2784</FDA_END>
<FDA_START>2772</FDA_START>
<FILE_START>2763</FILE_START>
<IEN_ROOT_END>2789</IEN_ROOT_END>
<IEN_ROOT_START>2789</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2814</FDA_END>
<FDA_START>2802</FDA_START>
<FILE_START>2793</FILE_START>
<IEN_ROOT_END>2819</IEN_ROOT_END>
<IEN_ROOT_START>2819</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2844</FDA_END>
<FDA_START>2832</FDA_START>
<FILE_START>2823</FILE_START>
<IEN_ROOT_END>2849</IEN_ROOT_END>
<IEN_ROOT_START>2849</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2874</FDA_END>
<FDA_START>2862</FDA_START>
<FILE_START>2853</FILE_START>
<IEN_ROOT_END>2879</IEN_ROOT_END>
<IEN_ROOT_START>2879</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2906</FDA_END>
<FDA_START>2892</FDA_START>
<FILE_START>2883</FILE_START>
<IEN_ROOT_END>2913</IEN_ROOT_END>
<IEN_ROOT_START>2911</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2937</FDA_END>
<FDA_START>2926</FDA_START>
<FILE_START>2917</FILE_START>
<IEN_ROOT_END>2943</IEN_ROOT_END>
<IEN_ROOT_START>2942</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2969</FDA_END>
<FDA_START>2956</FDA_START>
<FILE_START>2947</FILE_START>
<IEN_ROOT_END>2975</IEN_ROOT_END>
<IEN_ROOT_START>2974</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3001</FDA_END>
<FDA_START>2988</FDA_START>
<FILE_START>2979</FILE_START>
<IEN_ROOT_END>3007</IEN_ROOT_END>
<IEN_ROOT_START>3006</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3033</FDA_END>
<FDA_START>3020</FDA_START>
<FILE_START>3011</FILE_START>
<IEN_ROOT_END>3039</IEN_ROOT_END>
<IEN_ROOT_START>3038</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3065</FDA_END>
<FDA_START>3052</FDA_START>
<FILE_START>3043</FILE_START>
<IEN_ROOT_END>3071</IEN_ROOT_END>
<IEN_ROOT_START>3070</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3099</FDA_END>
<FDA_START>3084</FDA_START>
<FILE_START>3075</FILE_START>
<IEN_ROOT_END>3107</IEN_ROOT_END>
<IEN_ROOT_START>3104</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3135</FDA_END>
<FDA_START>3120</FDA_START>
<FILE_START>3111</FILE_START>
<IEN_ROOT_END>3143</IEN_ROOT_END>
<IEN_ROOT_START>3140</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3170</FDA_END>
<FDA_START>3156</FDA_START>
<FILE_START>3147</FILE_START>
<IEN_ROOT_END>3177</IEN_ROOT_END>
<IEN_ROOT_START>3175</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3204</FDA_END>
<FDA_START>3190</FDA_START>
<FILE_START>3181</FILE_START>
<IEN_ROOT_END>3211</IEN_ROOT_END>
<IEN_ROOT_START>3209</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3237</FDA_END>
<FDA_START>3224</FDA_START>
<FILE_START>3215</FILE_START>
<IEN_ROOT_END>3243</IEN_ROOT_END>
<IEN_ROOT_START>3242</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3270</FDA_END>
<FDA_START>3256</FDA_START>
<FILE_START>3247</FILE_START>
<IEN_ROOT_END>3277</IEN_ROOT_END>
<IEN_ROOT_START>3275</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3304</FDA_END>
<FDA_START>3290</FDA_START>
<FILE_START>3281</FILE_START>
<IEN_ROOT_END>3310</IEN_ROOT_END>
<IEN_ROOT_START>3309</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3338</FDA_END>
<FDA_START>3323</FDA_START>
<FILE_START>3314</FILE_START>
<IEN_ROOT_END>3344</IEN_ROOT_END>
<IEN_ROOT_START>3343</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3371</FDA_END>
<FDA_START>3357</FDA_START>
<FILE_START>3348</FILE_START>
<IEN_ROOT_END>3377</IEN_ROOT_END>
<IEN_ROOT_START>3376</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3404</FDA_END>
<FDA_START>3390</FDA_START>
<FILE_START>3381</FILE_START>
<IEN_ROOT_END>3411</IEN_ROOT_END>
<IEN_ROOT_START>3409</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3437</FDA_END>
<FDA_START>3424</FDA_START>
<FILE_START>3415</FILE_START>
<IEN_ROOT_END>3443</IEN_ROOT_END>
<IEN_ROOT_START>3442</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3469</FDA_END>
<FDA_START>3456</FDA_START>
<FILE_START>3447</FILE_START>
<IEN_ROOT_END>3475</IEN_ROOT_END>
<IEN_ROOT_START>3474</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3501</FDA_END>
<FDA_START>3488</FDA_START>
<FILE_START>3479</FILE_START>
<IEN_ROOT_END>3507</IEN_ROOT_END>
<IEN_ROOT_START>3506</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3533</FDA_END>
<FDA_START>3520</FDA_START>
<FILE_START>3511</FILE_START>
<IEN_ROOT_END>3539</IEN_ROOT_END>
<IEN_ROOT_START>3538</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3565</FDA_END>
<FDA_START>3552</FDA_START>
<FILE_START>3543</FILE_START>
<IEN_ROOT_END>3571</IEN_ROOT_END>
<IEN_ROOT_START>3570</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3597</FDA_END>
<FDA_START>3584</FDA_START>
<FILE_START>3575</FILE_START>
<IEN_ROOT_END>3603</IEN_ROOT_END>
<IEN_ROOT_START>3602</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3629</FDA_END>
<FDA_START>3616</FDA_START>
<FILE_START>3607</FILE_START>
<IEN_ROOT_END>3635</IEN_ROOT_END>
<IEN_ROOT_START>3634</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3661</FDA_END>
<FDA_START>3648</FDA_START>
<FILE_START>3639</FILE_START>
<IEN_ROOT_END>3667</IEN_ROOT_END>
<IEN_ROOT_START>3666</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3693</FDA_END>
<FDA_START>3680</FDA_START>
<FILE_START>3671</FILE_START>
<IEN_ROOT_END>3699</IEN_ROOT_END>
<IEN_ROOT_START>3698</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3725</FDA_END>
<FDA_START>3712</FDA_START>
<FILE_START>3703</FILE_START>
<IEN_ROOT_END>3731</IEN_ROOT_END>
<IEN_ROOT_START>3730</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3756</FDA_END>
<FDA_START>3744</FDA_START>
<FILE_START>3735</FILE_START>
<IEN_ROOT_END>3762</IEN_ROOT_END>
<IEN_ROOT_START>3761</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3789</FDA_END>
<FDA_START>3775</FDA_START>
<FILE_START>3766</FILE_START>
<IEN_ROOT_END>3794</IEN_ROOT_END>
<IEN_ROOT_START>3794</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3819</FDA_END>
<FDA_START>3807</FDA_START>
<FILE_START>3798</FILE_START>
<IEN_ROOT_END>3824</IEN_ROOT_END>
<IEN_ROOT_START>3824</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3849</FDA_END>
<FDA_START>3837</FDA_START>
<FILE_START>3828</FILE_START>
<IEN_ROOT_END>3854</IEN_ROOT_END>
<IEN_ROOT_START>3854</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3880</FDA_END>
<FDA_START>3867</FDA_START>
<FILE_START>3858</FILE_START>
<IEN_ROOT_END>3886</IEN_ROOT_END>
<IEN_ROOT_START>3885</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3914</FDA_END>
<FDA_START>3899</FDA_START>
<FILE_START>3890</FILE_START>
<IEN_ROOT_END>3920</IEN_ROOT_END>
<IEN_ROOT_START>3919</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3945</FDA_END>
<FDA_START>3933</FDA_START>
<FILE_START>3924</FILE_START>
<IEN_ROOT_END>3950</IEN_ROOT_END>
<IEN_ROOT_START>3950</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3976</FDA_END>
<FDA_START>3963</FDA_START>
<FILE_START>3954</FILE_START>
<IEN_ROOT_END>3982</IEN_ROOT_END>
<IEN_ROOT_START>3981</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4008</FDA_END>
<FDA_START>3995</FDA_START>
<FILE_START>3986</FILE_START>
<IEN_ROOT_END>4014</IEN_ROOT_END>
<IEN_ROOT_START>4013</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4039</FDA_END>
<FDA_START>4027</FDA_START>
<FILE_START>4018</FILE_START>
<IEN_ROOT_END>4044</IEN_ROOT_END>
<IEN_ROOT_START>4044</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4069</FDA_END>
<FDA_START>4057</FDA_START>
<FILE_START>4048</FILE_START>
<IEN_ROOT_END>4074</IEN_ROOT_END>
<IEN_ROOT_START>4074</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4099</FDA_END>
<FDA_START>4087</FDA_START>
<FILE_START>4078</FILE_START>
<IEN_ROOT_END>4104</IEN_ROOT_END>
<IEN_ROOT_START>4104</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4130</FDA_END>
<FDA_START>4117</FDA_START>
<FILE_START>4108</FILE_START>
<IEN_ROOT_END>4136</IEN_ROOT_END>
<IEN_ROOT_START>4135</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4165</FDA_END>
<FDA_START>4149</FDA_START>
<FILE_START>4140</FILE_START>
<IEN_ROOT_END>4171</IEN_ROOT_END>
<IEN_ROOT_START>4170</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4198</FDA_END>
<FDA_START>4184</FDA_START>
<FILE_START>4175</FILE_START>
<IEN_ROOT_END>4204</IEN_ROOT_END>
<IEN_ROOT_START>4203</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4231</FDA_END>
<FDA_START>4217</FDA_START>
<FILE_START>4208</FILE_START>
<IEN_ROOT_END>4238</IEN_ROOT_END>
<IEN_ROOT_START>4236</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4267</FDA_END>
<FDA_START>4251</FDA_START>
<FILE_START>4242</FILE_START>
<IEN_ROOT_END>4276</IEN_ROOT_END>
<IEN_ROOT_START>4272</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4303</FDA_END>
<FDA_START>4289</FDA_START>
<FILE_START>4280</FILE_START>
<IEN_ROOT_END>4310</IEN_ROOT_END>
<IEN_ROOT_START>4308</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4341</FDA_END>
<FDA_START>4323</FDA_START>
<FILE_START>4314</FILE_START>
<IEN_ROOT_END>4350</IEN_ROOT_END>
<IEN_ROOT_START>4346</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4377</FDA_END>
<FDA_START>4363</FDA_START>
<FILE_START>4354</FILE_START>
<IEN_ROOT_END>4384</IEN_ROOT_END>
<IEN_ROOT_START>4382</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4412</FDA_END>
<FDA_START>4397</FDA_START>
<FILE_START>4388</FILE_START>
<IEN_ROOT_END>4420</IEN_ROOT_END>
<IEN_ROOT_START>4417</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4447</FDA_END>
<FDA_START>4433</FDA_START>
<FILE_START>4424</FILE_START>
<IEN_ROOT_END>4454</IEN_ROOT_END>
<IEN_ROOT_START>4452</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4480</FDA_END>
<FDA_START>4467</FDA_START>
<FILE_START>4458</FILE_START>
<IEN_ROOT_END>4486</IEN_ROOT_END>
<IEN_ROOT_START>4485</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4513</FDA_END>
<FDA_START>4499</FDA_START>
<FILE_START>4490</FILE_START>
<IEN_ROOT_END>4520</IEN_ROOT_END>
<IEN_ROOT_START>4518</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4547</FDA_END>
<FDA_START>4533</FDA_START>
<FILE_START>4524</FILE_START>
<IEN_ROOT_END>4554</IEN_ROOT_END>
<IEN_ROOT_START>4552</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4583</FDA_END>
<FDA_START>4567</FDA_START>
<FILE_START>4558</FILE_START>
<IEN_ROOT_END>4591</IEN_ROOT_END>
<IEN_ROOT_START>4588</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4617</FDA_END>
<FDA_START>4604</FDA_START>
<FILE_START>4595</FILE_START>
<IEN_ROOT_END>4623</IEN_ROOT_END>
<IEN_ROOT_START>4622</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4650</FDA_END>
<FDA_START>4636</FDA_START>
<FILE_START>4627</FILE_START>
<IEN_ROOT_END>4657</IEN_ROOT_END>
<IEN_ROOT_START>4655</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4684</FDA_END>
<FDA_START>4670</FDA_START>
<FILE_START>4661</FILE_START>
<IEN_ROOT_END>4691</IEN_ROOT_END>
<IEN_ROOT_START>4689</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4720</FDA_END>
<FDA_START>4704</FDA_START>
<FILE_START>4695</FILE_START>
<IEN_ROOT_END>4728</IEN_ROOT_END>
<IEN_ROOT_START>4725</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4755</FDA_END>
<FDA_START>4741</FDA_START>
<FILE_START>4732</FILE_START>
<IEN_ROOT_END>4762</IEN_ROOT_END>
<IEN_ROOT_START>4760</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4789</FDA_END>
<FDA_START>4775</FDA_START>
<FILE_START>4766</FILE_START>
<IEN_ROOT_END>4796</IEN_ROOT_END>
<IEN_ROOT_START>4794</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4823</FDA_END>
<FDA_START>4809</FDA_START>
<FILE_START>4800</FILE_START>
<IEN_ROOT_END>4830</IEN_ROOT_END>
<IEN_ROOT_START>4828</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4857</FDA_END>
<FDA_START>4843</FDA_START>
<FILE_START>4834</FILE_START>
<IEN_ROOT_END>4864</IEN_ROOT_END>
<IEN_ROOT_START>4862</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4891</FDA_END>
<FDA_START>4877</FDA_START>
<FILE_START>4868</FILE_START>
<IEN_ROOT_END>4898</IEN_ROOT_END>
<IEN_ROOT_START>4896</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4925</FDA_END>
<FDA_START>4911</FDA_START>
<FILE_START>4902</FILE_START>
<IEN_ROOT_END>4932</IEN_ROOT_END>
<IEN_ROOT_START>4930</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4961</FDA_END>
<FDA_START>4945</FDA_START>
<FILE_START>4936</FILE_START>
<IEN_ROOT_END>4970</IEN_ROOT_END>
<IEN_ROOT_START>4966</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4996</FDA_END>
<FDA_START>4983</FDA_START>
<FILE_START>4974</FILE_START>
<IEN_ROOT_END>5002</IEN_ROOT_END>
<IEN_ROOT_START>5001</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5029</FDA_END>
<FDA_START>5015</FDA_START>
<FILE_START>5006</FILE_START>
<IEN_ROOT_END>5036</IEN_ROOT_END>
<IEN_ROOT_START>5034</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5064</FDA_END>
<FDA_START>5049</FDA_START>
<FILE_START>5040</FILE_START>
<IEN_ROOT_END>5072</IEN_ROOT_END>
<IEN_ROOT_START>5069</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5100</FDA_END>
<FDA_START>5085</FDA_START>
<FILE_START>5076</FILE_START>
<IEN_ROOT_END>5106</IEN_ROOT_END>
<IEN_ROOT_START>5105</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5132</FDA_END>
<FDA_START>5119</FDA_START>
<FILE_START>5110</FILE_START>
<IEN_ROOT_END>5137</IEN_ROOT_END>
<IEN_ROOT_START>5137</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5163</FDA_END>
<FDA_START>5150</FDA_START>
<FILE_START>5141</FILE_START>
<IEN_ROOT_END>5168</IEN_ROOT_END>
<IEN_ROOT_START>5168</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5197</FDA_END>
<FDA_START>5181</FDA_START>
<FILE_START>5172</FILE_START>
<IEN_ROOT_END>5202</IEN_ROOT_END>
<IEN_ROOT_START>5202</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5228</FDA_END>
<FDA_START>5215</FDA_START>
<FILE_START>5206</FILE_START>
<IEN_ROOT_END>5233</IEN_ROOT_END>
<IEN_ROOT_START>5233</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5259</FDA_END>
<FDA_START>5246</FDA_START>
<FILE_START>5237</FILE_START>
<IEN_ROOT_END>5264</IEN_ROOT_END>
<IEN_ROOT_START>5264</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5290</FDA_END>
<FDA_START>5277</FDA_START>
<FILE_START>5268</FILE_START>
<IEN_ROOT_END>5295</IEN_ROOT_END>
<IEN_ROOT_START>5295</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5325</FDA_END>
<FDA_START>5308</FDA_START>
<FILE_START>5299</FILE_START>
<IEN_ROOT_END>5330</IEN_ROOT_END>
<IEN_ROOT_START>5330</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5359</FDA_END>
<FDA_START>5343</FDA_START>
<FILE_START>5334</FILE_START>
<IEN_ROOT_END>5364</IEN_ROOT_END>
<IEN_ROOT_START>5364</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5390</FDA_END>
<FDA_START>5377</FDA_START>
<FILE_START>5368</FILE_START>
<IEN_ROOT_END>5395</IEN_ROOT_END>
<IEN_ROOT_START>5395</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5422</FDA_END>
<FDA_START>5408</FDA_START>
<FILE_START>5399</FILE_START>
<IEN_ROOT_END>5427</IEN_ROOT_END>
<IEN_ROOT_START>5427</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5454</FDA_END>
<FDA_START>5440</FDA_START>
<FILE_START>5431</FILE_START>
<IEN_ROOT_END>5459</IEN_ROOT_END>
<IEN_ROOT_START>5459</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5489</FDA_END>
<FDA_START>5472</FDA_START>
<FILE_START>5463</FILE_START>
<IEN_ROOT_END>5494</IEN_ROOT_END>
<IEN_ROOT_START>5494</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5524</FDA_END>
<FDA_START>5507</FDA_START>
<FILE_START>5498</FILE_START>
<IEN_ROOT_END>5529</IEN_ROOT_END>
<IEN_ROOT_START>5529</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5557</FDA_END>
<FDA_START>5542</FDA_START>
<FILE_START>5533</FILE_START>
<IEN_ROOT_END>5562</IEN_ROOT_END>
<IEN_ROOT_START>5562</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5589</FDA_END>
<FDA_START>5575</FDA_START>
<FILE_START>5566</FILE_START>
<IEN_ROOT_END>5594</IEN_ROOT_END>
<IEN_ROOT_START>5594</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5620</FDA_END>
<FDA_START>5607</FDA_START>
<FILE_START>5598</FILE_START>
<IEN_ROOT_END>5625</IEN_ROOT_END>
<IEN_ROOT_START>5625</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5651</FDA_END>
<FDA_START>5638</FDA_START>
<FILE_START>5629</FILE_START>
<IEN_ROOT_END>5656</IEN_ROOT_END>
<IEN_ROOT_START>5656</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5681</FDA_END>
<FDA_START>5669</FDA_START>
<FILE_START>5660</FILE_START>
<IEN_ROOT_END>5686</IEN_ROOT_END>
<IEN_ROOT_START>5686</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5712</FDA_END>
<FDA_START>5699</FDA_START>
<FILE_START>5690</FILE_START>
<IEN_ROOT_END>5717</IEN_ROOT_END>
<IEN_ROOT_START>5717</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5744</FDA_END>
<FDA_START>5730</FDA_START>
<FILE_START>5721</FILE_START>
<IEN_ROOT_END>5749</IEN_ROOT_END>
<IEN_ROOT_START>5749</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5776</FDA_END>
<FDA_START>5762</FDA_START>
<FILE_START>5753</FILE_START>
<IEN_ROOT_END>5781</IEN_ROOT_END>
<IEN_ROOT_START>5781</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5807</FDA_END>
<FDA_START>5794</FDA_START>
<FILE_START>5785</FILE_START>
<IEN_ROOT_END>5812</IEN_ROOT_END>
<IEN_ROOT_START>5812</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5839</FDA_END>
<FDA_START>5825</FDA_START>
<FILE_START>5816</FILE_START>
<IEN_ROOT_END>5844</IEN_ROOT_END>
<IEN_ROOT_START>5844</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5871</FDA_END>
<FDA_START>5857</FDA_START>
<FILE_START>5848</FILE_START>
<IEN_ROOT_END>5877</IEN_ROOT_END>
<IEN_ROOT_START>5876</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5904</FDA_END>
<FDA_START>5890</FDA_START>
<FILE_START>5881</FILE_START>
<IEN_ROOT_END>5910</IEN_ROOT_END>
<IEN_ROOT_START>5909</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5938</FDA_END>
<FDA_START>5923</FDA_START>
<FILE_START>5914</FILE_START>
<IEN_ROOT_END>5944</IEN_ROOT_END>
<IEN_ROOT_START>5943</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5970</FDA_END>
<FDA_START>5957</FDA_START>
<FILE_START>5948</FILE_START>
<IEN_ROOT_END>5976</IEN_ROOT_END>
<IEN_ROOT_START>5975</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6001</FDA_END>
<FDA_START>5989</FDA_START>
<FILE_START>5980</FILE_START>
<IEN_ROOT_END>6006</IEN_ROOT_END>
<IEN_ROOT_START>6006</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6032</FDA_END>
<FDA_START>6019</FDA_START>
<FILE_START>6010</FILE_START>
<IEN_ROOT_END>6038</IEN_ROOT_END>
<IEN_ROOT_START>6037</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6064</FDA_END>
<FDA_START>6051</FDA_START>
<FILE_START>6042</FILE_START>
<IEN_ROOT_END>6070</IEN_ROOT_END>
<IEN_ROOT_START>6069</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6099</FDA_END>
<FDA_START>6083</FDA_START>
<FILE_START>6074</FILE_START>
<IEN_ROOT_END>6106</IEN_ROOT_END>
<IEN_ROOT_START>6104</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6133</FDA_END>
<FDA_START>6119</FDA_START>
<FILE_START>6110</FILE_START>
<IEN_ROOT_END>6140</IEN_ROOT_END>
<IEN_ROOT_START>6138</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6166</FDA_END>
<FDA_START>6153</FDA_START>
<FILE_START>6144</FILE_START>
<IEN_ROOT_END>6172</IEN_ROOT_END>
<IEN_ROOT_START>6171</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6198</FDA_END>
<FDA_START>6185</FDA_START>
<FILE_START>6176</FILE_START>
<IEN_ROOT_END>6204</IEN_ROOT_END>
<IEN_ROOT_START>6203</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6232</FDA_END>
<FDA_START>6217</FDA_START>
<FILE_START>6208</FILE_START>
<IEN_ROOT_END>6238</IEN_ROOT_END>
<IEN_ROOT_START>6237</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6264</FDA_END>
<FDA_START>6251</FDA_START>
<FILE_START>6242</FILE_START>
<IEN_ROOT_END>6270</IEN_ROOT_END>
<IEN_ROOT_START>6269</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6297</FDA_END>
<FDA_START>6283</FDA_START>
<FILE_START>6274</FILE_START>
<IEN_ROOT_END>6303</IEN_ROOT_END>
<IEN_ROOT_START>6302</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6330</FDA_END>
<FDA_START>6316</FDA_START>
<FILE_START>6307</FILE_START>
<IEN_ROOT_END>6336</IEN_ROOT_END>
<IEN_ROOT_START>6335</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6363</FDA_END>
<FDA_START>6349</FDA_START>
<FILE_START>6340</FILE_START>
<IEN_ROOT_END>6369</IEN_ROOT_END>
<IEN_ROOT_START>6368</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6396</FDA_END>
<FDA_START>6382</FDA_START>
<FILE_START>6373</FILE_START>
<IEN_ROOT_END>6402</IEN_ROOT_END>
<IEN_ROOT_START>6401</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6429</FDA_END>
<FDA_START>6415</FDA_START>
<FILE_START>6406</FILE_START>
<IEN_ROOT_END>6435</IEN_ROOT_END>
<IEN_ROOT_START>6434</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6462</FDA_END>
<FDA_START>6448</FDA_START>
<FILE_START>6439</FILE_START>
<IEN_ROOT_END>6468</IEN_ROOT_END>
<IEN_ROOT_START>6467</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6497</FDA_END>
<FDA_START>6481</FDA_START>
<FILE_START>6472</FILE_START>
<IEN_ROOT_END>6505</IEN_ROOT_END>
<IEN_ROOT_START>6502</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6533</FDA_END>
<FDA_START>6518</FDA_START>
<FILE_START>6509</FILE_START>
<IEN_ROOT_END>6540</IEN_ROOT_END>
<IEN_ROOT_START>6538</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6566</FDA_END>
<FDA_START>6553</FDA_START>
<FILE_START>6544</FILE_START>
<IEN_ROOT_END>6572</IEN_ROOT_END>
<IEN_ROOT_START>6571</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6598</FDA_END>
<FDA_START>6585</FDA_START>
<FILE_START>6576</FILE_START>
<IEN_ROOT_END>6604</IEN_ROOT_END>
<IEN_ROOT_START>6603</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6631</FDA_END>
<FDA_START>6617</FDA_START>
<FILE_START>6608</FILE_START>
<IEN_ROOT_END>6637</IEN_ROOT_END>
<IEN_ROOT_START>6636</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6663</FDA_END>
<FDA_START>6650</FDA_START>
<FILE_START>6641</FILE_START>
<IEN_ROOT_END>6669</IEN_ROOT_END>
<IEN_ROOT_START>6668</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6694</FDA_END>
<FDA_START>6682</FDA_START>
<FILE_START>6673</FILE_START>
<IEN_ROOT_END>6699</IEN_ROOT_END>
<IEN_ROOT_START>6699</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6725</FDA_END>
<FDA_START>6712</FDA_START>
<FILE_START>6703</FILE_START>
<IEN_ROOT_END>6730</IEN_ROOT_END>
<IEN_ROOT_START>6730</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6756</FDA_END>
<FDA_START>6743</FDA_START>
<FILE_START>6734</FILE_START>
<IEN_ROOT_END>6761</IEN_ROOT_END>
<IEN_ROOT_START>6761</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6787</FDA_END>
<FDA_START>6774</FDA_START>
<FILE_START>6765</FILE_START>
<IEN_ROOT_END>6792</IEN_ROOT_END>
<IEN_ROOT_START>6792</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6818</FDA_END>
<FDA_START>6805</FDA_START>
<FILE_START>6796</FILE_START>
<IEN_ROOT_END>6823</IEN_ROOT_END>
<IEN_ROOT_START>6823</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6849</FDA_END>
<FDA_START>6836</FDA_START>
<FILE_START>6827</FILE_START>
<IEN_ROOT_END>6854</IEN_ROOT_END>
<IEN_ROOT_START>6854</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6880</FDA_END>
<FDA_START>6867</FDA_START>
<FILE_START>6858</FILE_START>
<IEN_ROOT_END>6885</IEN_ROOT_END>
<IEN_ROOT_START>6885</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6911</FDA_END>
<FDA_START>6898</FDA_START>
<FILE_START>6889</FILE_START>
<IEN_ROOT_END>6916</IEN_ROOT_END>
<IEN_ROOT_START>6916</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6942</FDA_END>
<FDA_START>6929</FDA_START>
<FILE_START>6920</FILE_START>
<IEN_ROOT_END>6947</IEN_ROOT_END>
<IEN_ROOT_START>6947</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6973</FDA_END>
<FDA_START>6960</FDA_START>
<FILE_START>6951</FILE_START>
<IEN_ROOT_END>6978</IEN_ROOT_END>
<IEN_ROOT_START>6978</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7003</FDA_END>
<FDA_START>6991</FDA_START>
<FILE_START>6982</FILE_START>
<IEN_ROOT_END>7009</IEN_ROOT_END>
<IEN_ROOT_START>7008</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7034</FDA_END>
<FDA_START>7022</FDA_START>
<FILE_START>7013</FILE_START>
<IEN_ROOT_END>7040</IEN_ROOT_END>
<IEN_ROOT_START>7039</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7066</FDA_END>
<FDA_START>7053</FDA_START>
<FILE_START>7044</FILE_START>
<IEN_ROOT_END>7072</IEN_ROOT_END>
<IEN_ROOT_START>7071</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7100</FDA_END>
<FDA_START>7085</FDA_START>
<FILE_START>7076</FILE_START>
<IEN_ROOT_END>7107</IEN_ROOT_END>
<IEN_ROOT_START>7105</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7136</FDA_END>
<FDA_START>7120</FDA_START>
<FILE_START>7111</FILE_START>
<IEN_ROOT_END>7143</IEN_ROOT_END>
<IEN_ROOT_START>7141</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7170</FDA_END>
<FDA_START>7156</FDA_START>
<FILE_START>7147</FILE_START>
<IEN_ROOT_END>7175</IEN_ROOT_END>
<IEN_ROOT_START>7175</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7200</FDA_END>
<FDA_START>7188</FDA_START>
<FILE_START>7179</FILE_START>
<IEN_ROOT_END>7206</IEN_ROOT_END>
<IEN_ROOT_START>7205</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7230</FDA_END>
<FDA_START>7219</FDA_START>
<FILE_START>7210</FILE_START>
<IEN_ROOT_END>7235</IEN_ROOT_END>
<IEN_ROOT_START>7235</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7259</FDA_END>
<FDA_START>7248</FDA_START>
<FILE_START>7239</FILE_START>
<IEN_ROOT_END>7264</IEN_ROOT_END>
<IEN_ROOT_START>7264</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7281</FDA_END>
<FDA_START>7277</FDA_START>
<FILE_START>7268</FILE_START>
<IEN_ROOT_END>7286</IEN_ROOT_END>
<IEN_ROOT_START>7286</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7306</FDA_END>
<FDA_START>7299</FDA_START>
<FILE_START>7290</FILE_START>
<IEN_ROOT_END>7312</IEN_ROOT_END>
<IEN_ROOT_START>7311</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7325</FDA_END>
<FDA_START>7325</FDA_START>
<FILE_START>7316</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7352</FDA_END>
<FDA_START>7338</FDA_START>
<FILE_START>7329</FILE_START>
<IEN_ROOT_END>7366</IEN_ROOT_END>
<IEN_ROOT_START>7357</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7396</FDA_END>
<FDA_START>7379</FDA_START>
<FILE_START>7370</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7414</FDA_END>
<FDA_START>7409</FDA_START>
<FILE_START>7400</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7437</FDA_END>
<FDA_START>7427</FDA_START>
<FILE_START>7418</FILE_START>
<IEN_ROOT_END>7442</IEN_ROOT_END>
<IEN_ROOT_START>7442</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7464</FDA_END>
<FDA_START>7455</FDA_START>
<FILE_START>7446</FILE_START>
<IEN_ROOT_END>7469</IEN_ROOT_END>
<IEN_ROOT_START>7469</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7497</FDA_END>
<FDA_START>7482</FDA_START>
<FILE_START>7473</FILE_START>
<IEN_ROOT_END>7504</IEN_ROOT_END>
<IEN_ROOT_START>7502</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7529</FDA_END>
<FDA_START>7517</FDA_START>
<FILE_START>7508</FILE_START>
<IEN_ROOT_END>7535</IEN_ROOT_END>
<IEN_ROOT_START>7534</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7559</FDA_END>
<FDA_START>7548</FDA_START>
<FILE_START>7539</FILE_START>
<IEN_ROOT_END>7564</IEN_ROOT_END>
<IEN_ROOT_START>7564</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7597</FDA_END>
<FDA_START>7577</FDA_START>
<FILE_START>7568</FILE_START>
<IEN_ROOT_END>7602</IEN_ROOT_END>
<IEN_ROOT_START>7602</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7623</FDA_END>
<FDA_START>7615</FDA_START>
<FILE_START>7606</FILE_START>
<IEN_ROOT_END>7628</IEN_ROOT_END>
<IEN_ROOT_START>7628</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7653</FDA_END>
<FDA_START>7641</FDA_START>
<FILE_START>7632</FILE_START>
<IEN_ROOT_END>7659</IEN_ROOT_END>
<IEN_ROOT_START>7658</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7705</FDA_END>
<FDA_START>7672</FDA_START>
<FILE_START>7663</FILE_START>
<IEN_ROOT_END>7710</IEN_ROOT_END>
<IEN_ROOT_START>7710</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7732</FDA_END>
<FDA_START>7723</FDA_START>
<FILE_START>7714</FILE_START>
<IEN_ROOT_END>7737</IEN_ROOT_END>
<IEN_ROOT_START>7737</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7767</FDA_END>
<FDA_START>7750</FDA_START>
<FILE_START>7741</FILE_START>
<IEN_ROOT_END>7774</IEN_ROOT_END>
<IEN_ROOT_START>7772</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7794</FDA_END>
<FDA_START>7787</FDA_START>
<FILE_START>7778</FILE_START>
<IEN_ROOT_END>7799</IEN_ROOT_END>
<IEN_ROOT_START>7799</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7819</FDA_END>
<FDA_START>7812</FDA_START>
<FILE_START>7803</FILE_START>
<IEN_ROOT_END>7824</IEN_ROOT_END>
<IEN_ROOT_START>7824</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7844</FDA_END>
<FDA_START>7837</FDA_START>
<FILE_START>7828</FILE_START>
<IEN_ROOT_END>7849</IEN_ROOT_END>
<IEN_ROOT_START>7849</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7869</FDA_END>
<FDA_START>7862</FDA_START>
<FILE_START>7853</FILE_START>
<IEN_ROOT_END>7874</IEN_ROOT_END>
<IEN_ROOT_START>7874</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7907</FDA_END>
<FDA_START>7887</FDA_START>
<FILE_START>7878</FILE_START>
<IEN_ROOT_END>7916</IEN_ROOT_END>
<IEN_ROOT_START>7912</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7936</FDA_END>
<FDA_START>7929</FDA_START>
<FILE_START>7920</FILE_START>
<IEN_ROOT_END>7941</IEN_ROOT_END>
<IEN_ROOT_START>7941</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7961</FDA_END>
<FDA_START>7954</FDA_START>
<FILE_START>7945</FILE_START>
<IEN_ROOT_END>7966</IEN_ROOT_END>
<IEN_ROOT_START>7966</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7995</FDA_END>
<FDA_START>7979</FDA_START>
<FILE_START>7970</FILE_START>
<IEN_ROOT_END>8002</IEN_ROOT_END>
<IEN_ROOT_START>8000</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8039</FDA_END>
<FDA_START>8015</FDA_START>
<FILE_START>8006</FILE_START>
<IEN_ROOT_END>8051</IEN_ROOT_END>
<IEN_ROOT_START>8044</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8074</FDA_END>
<FDA_START>8064</FDA_START>
<FILE_START>8055</FILE_START>
<IEN_ROOT_END>8079</IEN_ROOT_END>
<IEN_ROOT_START>8079</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8109</FDA_END>
<FDA_START>8092</FDA_START>
<FILE_START>8083</FILE_START>
<IEN_ROOT_END>8116</IEN_ROOT_END>
<IEN_ROOT_START>8114</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8140</FDA_END>
<FDA_START>8129</FDA_START>
<FILE_START>8120</FILE_START>
<IEN_ROOT_END>8145</IEN_ROOT_END>
<IEN_ROOT_START>8145</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8174</FDA_END>
<FDA_START>8158</FDA_START>
<FILE_START>8149</FILE_START>
<IEN_ROOT_END>8182</IEN_ROOT_END>
<IEN_ROOT_START>8179</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8215</FDA_END>
<FDA_START>8195</FDA_START>
<FILE_START>8186</FILE_START>
<IEN_ROOT_END>8223</IEN_ROOT_END>
<IEN_ROOT_START>8220</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8246</FDA_END>
<FDA_START>8236</FDA_START>
<FILE_START>8227</FILE_START>
<IEN_ROOT_END>8251</IEN_ROOT_END>
<IEN_ROOT_START>8251</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8282</FDA_END>
<FDA_START>8264</FDA_START>
<FILE_START>8255</FILE_START>
<IEN_ROOT_END>8289</IEN_ROOT_END>
<IEN_ROOT_START>8287</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8315</FDA_END>
<FDA_START>8302</FDA_START>
<FILE_START>8293</FILE_START>
<IEN_ROOT_END>8321</IEN_ROOT_END>
<IEN_ROOT_START>8320</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8355</FDA_END>
<FDA_START>8334</FDA_START>
<FILE_START>8325</FILE_START>
<IEN_ROOT_END>8360</IEN_ROOT_END>
<IEN_ROOT_START>8360</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8383</FDA_END>
<FDA_START>8373</FDA_START>
<FILE_START>8364</FILE_START>
<IEN_ROOT_END>8388</IEN_ROOT_END>
<IEN_ROOT_START>8388</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8419</FDA_END>
<FDA_START>8401</FDA_START>
<FILE_START>8392</FILE_START>
<IEN_ROOT_END>8426</IEN_ROOT_END>
<IEN_ROOT_START>8424</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8460</FDA_END>
<FDA_START>8439</FDA_START>
<FILE_START>8430</FILE_START>
<IEN_ROOT_END>8465</IEN_ROOT_END>
<IEN_ROOT_START>8465</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8487</FDA_END>
<FDA_START>8478</FDA_START>
<FILE_START>8469</FILE_START>
<IEN_ROOT_END>8492</IEN_ROOT_END>
<IEN_ROOT_START>8492</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8518</FDA_END>
<FDA_START>8505</FDA_START>
<FILE_START>8496</FILE_START>
<IEN_ROOT_END>8524</IEN_ROOT_END>
<IEN_ROOT_START>8523</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8545</FDA_END>
<FDA_START>8537</FDA_START>
<FILE_START>8528</FILE_START>
<IEN_ROOT_END>8550</IEN_ROOT_END>
<IEN_ROOT_START>8550</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8572</FDA_END>
<FDA_START>8563</FDA_START>
<FILE_START>8554</FILE_START>
<IEN_ROOT_END>8577</IEN_ROOT_END>
<IEN_ROOT_START>8577</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8607</FDA_END>
<FDA_START>8590</FDA_START>
<FILE_START>8581</FILE_START>
<IEN_ROOT_END>8614</IEN_ROOT_END>
<IEN_ROOT_START>8612</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8635</FDA_END>
<FDA_START>8627</FDA_START>
<FILE_START>8618</FILE_START>
<IEN_ROOT_END>8640</IEN_ROOT_END>
<IEN_ROOT_START>8640</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8660</FDA_END>
<FDA_START>8653</FDA_START>
<FILE_START>8644</FILE_START>
<IEN_ROOT_END>8665</IEN_ROOT_END>
<IEN_ROOT_START>8665</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8695</FDA_END>
<FDA_START>8678</FDA_START>
<FILE_START>8669</FILE_START>
<IEN_ROOT_END>8702</IEN_ROOT_END>
<IEN_ROOT_START>8700</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8742</FDA_END>
<FDA_START>8715</FDA_START>
<FILE_START>8706</FILE_START>
<IEN_ROOT_END>8755</IEN_ROOT_END>
<IEN_ROOT_START>8747</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8778</FDA_END>
<FDA_START>8768</FDA_START>
<FILE_START>8759</FILE_START>
<IEN_ROOT_END>8783</IEN_ROOT_END>
<IEN_ROOT_START>8783</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8814</FDA_END>
<FDA_START>8796</FDA_START>
<FILE_START>8787</FILE_START>
<IEN_ROOT_END>8821</IEN_ROOT_END>
<IEN_ROOT_START>8819</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8846</FDA_END>
<FDA_START>8834</FDA_START>
<FILE_START>8825</FILE_START>
<IEN_ROOT_END>8851</IEN_ROOT_END>
<IEN_ROOT_START>8851</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8881</FDA_END>
<FDA_START>8864</FDA_START>
<FILE_START>8855</FILE_START>
<IEN_ROOT_END>8889</IEN_ROOT_END>
<IEN_ROOT_START>8886</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8923</FDA_END>
<FDA_START>8902</FDA_START>
<FILE_START>8893</FILE_START>
<IEN_ROOT_END>8931</IEN_ROOT_END>
<IEN_ROOT_START>8928</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8952</FDA_END>
<FDA_START>8944</FDA_START>
<FILE_START>8935</FILE_START>
<IEN_ROOT_END>8957</IEN_ROOT_END>
<IEN_ROOT_START>8957</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9034</FDA_END>
<FDA_START>8970</FDA_START>
<FILE_START>8961</FILE_START>
<IEN_ROOT_END>9040</IEN_ROOT_END>
<IEN_ROOT_START>9039</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9076</FDA_END>
<FDA_START>9053</FDA_START>
<FILE_START>9044</FILE_START>
<IEN_ROOT_END>9089</IEN_ROOT_END>
<IEN_ROOT_START>9081</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9116</FDA_END>
<FDA_START>9102</FDA_START>
<FILE_START>9093</FILE_START>
<IEN_ROOT_END>9122</IEN_ROOT_END>
<IEN_ROOT_START>9121</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9142</FDA_END>
<FDA_START>9135</FDA_START>
<FILE_START>9126</FILE_START>
<IEN_ROOT_END>9147</IEN_ROOT_END>
<IEN_ROOT_START>9147</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9174</FDA_END>
<FDA_START>9160</FDA_START>
<FILE_START>9151</FILE_START>
<IEN_ROOT_END>9180</IEN_ROOT_END>
<IEN_ROOT_START>9179</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9208</FDA_END>
<FDA_START>9193</FDA_START>
<FILE_START>9184</FILE_START>
<IEN_ROOT_END>9215</IEN_ROOT_END>
<IEN_ROOT_START>9213</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9237</FDA_END>
<FDA_START>9228</FDA_START>
<FILE_START>9219</FILE_START>
<IEN_ROOT_END>9242</IEN_ROOT_END>
<IEN_ROOT_START>9242</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9262</FDA_END>
<FDA_START>9255</FDA_START>
<FILE_START>9246</FILE_START>
<IEN_ROOT_END>9267</IEN_ROOT_END>
<IEN_ROOT_START>9267</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9294</FDA_END>
<FDA_START>9280</FDA_START>
<FILE_START>9271</FILE_START>
<IEN_ROOT_END>9300</IEN_ROOT_END>
<IEN_ROOT_START>9299</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9331</FDA_END>
<FDA_START>9313</FDA_START>
<FILE_START>9304</FILE_START>
<IEN_ROOT_END>9339</IEN_ROOT_END>
<IEN_ROOT_START>9336</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9366</FDA_END>
<FDA_START>9352</FDA_START>
<FILE_START>9343</FILE_START>
<IEN_ROOT_END>9372</IEN_ROOT_END>
<IEN_ROOT_START>9371</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9399</FDA_END>
<FDA_START>9385</FDA_START>
<FILE_START>9376</FILE_START>
<IEN_ROOT_END>9405</IEN_ROOT_END>
<IEN_ROOT_START>9404</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9433</FDA_END>
<FDA_START>9418</FDA_START>
<FILE_START>9409</FILE_START>
<IEN_ROOT_END>9440</IEN_ROOT_END>
<IEN_ROOT_START>9438</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9464</FDA_END>
<FDA_START>9453</FDA_START>
<FILE_START>9444</FILE_START>
<IEN_ROOT_END>9469</IEN_ROOT_END>
<IEN_ROOT_START>9469</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9496</FDA_END>
<FDA_START>9482</FDA_START>
<FILE_START>9473</FILE_START>
<IEN_ROOT_END>9502</IEN_ROOT_END>
<IEN_ROOT_START>9501</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9533</FDA_END>
<FDA_START>9515</FDA_START>
<FILE_START>9506</FILE_START>
<IEN_ROOT_END>9541</IEN_ROOT_END>
<IEN_ROOT_START>9538</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9568</FDA_END>
<FDA_START>9554</FDA_START>
<FILE_START>9545</FILE_START>
<IEN_ROOT_END>9574</IEN_ROOT_END>
<IEN_ROOT_START>9573</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9601</FDA_END>
<FDA_START>9587</FDA_START>
<FILE_START>9578</FILE_START>
<IEN_ROOT_END>9607</IEN_ROOT_END>
<IEN_ROOT_START>9606</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9635</FDA_END>
<FDA_START>9620</FDA_START>
<FILE_START>9611</FILE_START>
<IEN_ROOT_END>9642</IEN_ROOT_END>
<IEN_ROOT_START>9640</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9664</FDA_END>
<FDA_START>9655</FDA_START>
<FILE_START>9646</FILE_START>
<IEN_ROOT_END>9669</IEN_ROOT_END>
<IEN_ROOT_START>9669</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9696</FDA_END>
<FDA_START>9682</FDA_START>
<FILE_START>9673</FILE_START>
<IEN_ROOT_END>9702</IEN_ROOT_END>
<IEN_ROOT_START>9701</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9733</FDA_END>
<FDA_START>9715</FDA_START>
<FILE_START>9706</FILE_START>
<IEN_ROOT_END>9741</IEN_ROOT_END>
<IEN_ROOT_START>9738</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9768</FDA_END>
<FDA_START>9754</FDA_START>
<FILE_START>9745</FILE_START>
<IEN_ROOT_END>9774</IEN_ROOT_END>
<IEN_ROOT_START>9773</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9801</FDA_END>
<FDA_START>9787</FDA_START>
<FILE_START>9778</FILE_START>
<IEN_ROOT_END>9807</IEN_ROOT_END>
<IEN_ROOT_START>9806</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9835</FDA_END>
<FDA_START>9820</FDA_START>
<FILE_START>9811</FILE_START>
<IEN_ROOT_END>9842</IEN_ROOT_END>
<IEN_ROOT_START>9840</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9869</FDA_END>
<FDA_START>9855</FDA_START>
<FILE_START>9846</FILE_START>
<IEN_ROOT_END>9874</IEN_ROOT_END>
<IEN_ROOT_START>9874</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9901</FDA_END>
<FDA_START>9887</FDA_START>
<FILE_START>9878</FILE_START>
<IEN_ROOT_END>9907</IEN_ROOT_END>
<IEN_ROOT_START>9906</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9938</FDA_END>
<FDA_START>9920</FDA_START>
<FILE_START>9911</FILE_START>
<IEN_ROOT_END>9946</IEN_ROOT_END>
<IEN_ROOT_START>9943</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9984</FDA_END>
<FDA_START>9959</FDA_START>
<FILE_START>9950</FILE_START>
<IEN_ROOT_END>9994</IEN_ROOT_END>
<IEN_ROOT_START>9989</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10021</FDA_END>
<FDA_START>10007</FDA_START>
<FILE_START>9998</FILE_START>
<IEN_ROOT_END>10027</IEN_ROOT_END>
<IEN_ROOT_START>10026</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10054</FDA_END>
<FDA_START>10040</FDA_START>
<FILE_START>10031</FILE_START>
<IEN_ROOT_END>10060</IEN_ROOT_END>
<IEN_ROOT_START>10059</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10088</FDA_END>
<FDA_START>10073</FDA_START>
<FILE_START>10064</FILE_START>
<IEN_ROOT_END>10095</IEN_ROOT_END>
<IEN_ROOT_START>10093</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10123</FDA_END>
<FDA_START>10108</FDA_START>
<FILE_START>10099</FILE_START>
<IEN_ROOT_END>10128</IEN_ROOT_END>
<IEN_ROOT_START>10128</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10155</FDA_END>
<FDA_START>10141</FDA_START>
<FILE_START>10132</FILE_START>
<IEN_ROOT_END>10161</IEN_ROOT_END>
<IEN_ROOT_START>10160</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10192</FDA_END>
<FDA_START>10174</FDA_START>
<FILE_START>10165</FILE_START>
<IEN_ROOT_END>10200</IEN_ROOT_END>
<IEN_ROOT_START>10197</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10227</FDA_END>
<FDA_START>10213</FDA_START>
<FILE_START>10204</FILE_START>
<IEN_ROOT_END>10233</IEN_ROOT_END>
<IEN_ROOT_START>10232</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10260</FDA_END>
<FDA_START>10246</FDA_START>
<FILE_START>10237</FILE_START>
<IEN_ROOT_END>10266</IEN_ROOT_END>
<IEN_ROOT_START>10265</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10293</FDA_END>
<FDA_START>10279</FDA_START>
<FILE_START>10270</FILE_START>
<IEN_ROOT_END>10300</IEN_ROOT_END>
<IEN_ROOT_START>10298</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10329</FDA_END>
<FDA_START>10313</FDA_START>
<FILE_START>10304</FILE_START>
<IEN_ROOT_END>10334</IEN_ROOT_END>
<IEN_ROOT_START>10334</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10361</FDA_END>
<FDA_START>10347</FDA_START>
<FILE_START>10338</FILE_START>
<IEN_ROOT_END>10367</IEN_ROOT_END>
<IEN_ROOT_START>10366</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10398</FDA_END>
<FDA_START>10380</FDA_START>
<FILE_START>10371</FILE_START>
<IEN_ROOT_END>10406</IEN_ROOT_END>
<IEN_ROOT_START>10403</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10437</FDA_END>
<FDA_START>10419</FDA_START>
<FILE_START>10410</FILE_START>
<IEN_ROOT_END>10444</IEN_ROOT_END>
<IEN_ROOT_START>10442</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10471</FDA_END>
<FDA_START>10457</FDA_START>
<FILE_START>10448</FILE_START>
<IEN_ROOT_END>10477</IEN_ROOT_END>
<IEN_ROOT_START>10476</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10504</FDA_END>
<FDA_START>10490</FDA_START>
<FILE_START>10481</FILE_START>
<IEN_ROOT_END>10510</IEN_ROOT_END>
<IEN_ROOT_START>10509</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10538</FDA_END>
<FDA_START>10523</FDA_START>
<FILE_START>10514</FILE_START>
<IEN_ROOT_END>10545</IEN_ROOT_END>
<IEN_ROOT_START>10543</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10572</FDA_END>
<FDA_START>10558</FDA_START>
<FILE_START>10549</FILE_START>
<IEN_ROOT_END>10577</IEN_ROOT_END>
<IEN_ROOT_START>10577</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10604</FDA_END>
<FDA_START>10590</FDA_START>
<FILE_START>10581</FILE_START>
<IEN_ROOT_END>10610</IEN_ROOT_END>
<IEN_ROOT_START>10609</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10643</FDA_END>
<FDA_START>10623</FDA_START>
<FILE_START>10614</FILE_START>
<IEN_ROOT_END>10651</IEN_ROOT_END>
<IEN_ROOT_START>10648</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10678</FDA_END>
<FDA_START>10664</FDA_START>
<FILE_START>10655</FILE_START>
<IEN_ROOT_END>10684</IEN_ROOT_END>
<IEN_ROOT_START>10683</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10711</FDA_END>
<FDA_START>10697</FDA_START>
<FILE_START>10688</FILE_START>
<IEN_ROOT_END>10717</IEN_ROOT_END>
<IEN_ROOT_START>10716</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10745</FDA_END>
<FDA_START>10730</FDA_START>
<FILE_START>10721</FILE_START>
<IEN_ROOT_END>10752</IEN_ROOT_END>
<IEN_ROOT_START>10750</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10777</FDA_END>
<FDA_START>10765</FDA_START>
<FILE_START>10756</FILE_START>
<IEN_ROOT_END>10782</IEN_ROOT_END>
<IEN_ROOT_START>10782</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10809</FDA_END>
<FDA_START>10795</FDA_START>
<FILE_START>10786</FILE_START>
<IEN_ROOT_END>10815</IEN_ROOT_END>
<IEN_ROOT_START>10814</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10849</FDA_END>
<FDA_START>10828</FDA_START>
<FILE_START>10819</FILE_START>
<IEN_ROOT_END>10857</IEN_ROOT_END>
<IEN_ROOT_START>10854</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10884</FDA_END>
<FDA_START>10870</FDA_START>
<FILE_START>10861</FILE_START>
<IEN_ROOT_END>10890</IEN_ROOT_END>
<IEN_ROOT_START>10889</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10917</FDA_END>
<FDA_START>10903</FDA_START>
<FILE_START>10894</FILE_START>
<IEN_ROOT_END>10923</IEN_ROOT_END>
<IEN_ROOT_START>10922</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10951</FDA_END>
<FDA_START>10936</FDA_START>
<FILE_START>10927</FILE_START>
<IEN_ROOT_END>10958</IEN_ROOT_END>
<IEN_ROOT_START>10956</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10989</FDA_END>
<FDA_START>10971</FDA_START>
<FILE_START>10962</FILE_START>
<IEN_ROOT_END>10994</IEN_ROOT_END>
<IEN_ROOT_START>10994</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11021</FDA_END>
<FDA_START>11007</FDA_START>
<FILE_START>10998</FILE_START>
<IEN_ROOT_END>11027</IEN_ROOT_END>
<IEN_ROOT_START>11026</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11061</FDA_END>
<FDA_START>11040</FDA_START>
<FILE_START>11031</FILE_START>
<IEN_ROOT_END>11069</IEN_ROOT_END>
<IEN_ROOT_START>11066</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11101</FDA_END>
<FDA_START>11082</FDA_START>
<FILE_START>11073</FILE_START>
<IEN_ROOT_END>11108</IEN_ROOT_END>
<IEN_ROOT_START>11106</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11135</FDA_END>
<FDA_START>11121</FDA_START>
<FILE_START>11112</FILE_START>
<IEN_ROOT_END>11141</IEN_ROOT_END>
<IEN_ROOT_START>11140</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11168</FDA_END>
<FDA_START>11154</FDA_START>
<FILE_START>11145</FILE_START>
<IEN_ROOT_END>11174</IEN_ROOT_END>
<IEN_ROOT_START>11173</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11202</FDA_END>
<FDA_START>11187</FDA_START>
<FILE_START>11178</FILE_START>
<IEN_ROOT_END>11209</IEN_ROOT_END>
<IEN_ROOT_START>11207</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11251</FDA_END>
<FDA_START>11222</FDA_START>
<FILE_START>11213</FILE_START>
<IEN_ROOT_END>11256</IEN_ROOT_END>
<IEN_ROOT_START>11256</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11283</FDA_END>
<FDA_START>11269</FDA_START>
<FILE_START>11260</FILE_START>
<IEN_ROOT_END>11289</IEN_ROOT_END>
<IEN_ROOT_START>11288</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11323</FDA_END>
<FDA_START>11302</FDA_START>
<FILE_START>11293</FILE_START>
<IEN_ROOT_END>11331</IEN_ROOT_END>
<IEN_ROOT_START>11328</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11362</FDA_END>
<FDA_START>11344</FDA_START>
<FILE_START>11335</FILE_START>
<IEN_ROOT_END>11369</IEN_ROOT_END>
<IEN_ROOT_START>11367</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11400</FDA_END>
<FDA_START>11382</FDA_START>
<FILE_START>11373</FILE_START>
<IEN_ROOT_END>11407</IEN_ROOT_END>
<IEN_ROOT_START>11405</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11433</FDA_END>
<FDA_START>11420</FDA_START>
<FILE_START>11411</FILE_START>
<IEN_ROOT_END>11440</IEN_ROOT_END>
<IEN_ROOT_START>11438</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11470</FDA_END>
<FDA_START>11453</FDA_START>
<FILE_START>11444</FILE_START>
<IEN_ROOT_END>11477</IEN_ROOT_END>
<IEN_ROOT_START>11475</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11501</FDA_END>
<FDA_START>11490</FDA_START>
<FILE_START>11481</FILE_START>
<IEN_ROOT_END>11509</IEN_ROOT_END>
<IEN_ROOT_START>11506</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11534</FDA_END>
<FDA_START>11522</FDA_START>
<FILE_START>11513</FILE_START>
<IEN_ROOT_END>11539</IEN_ROOT_END>
<IEN_ROOT_START>11539</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11593</FDA_END>
<FDA_START>11552</FDA_START>
<FILE_START>11543</FILE_START>
<IEN_ROOT_END>11599</IEN_ROOT_END>
<IEN_ROOT_START>11598</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11623</FDA_END>
<FDA_START>11612</FDA_START>
<FILE_START>11603</FILE_START>
<IEN_ROOT_END>11628</IEN_ROOT_END>
<IEN_ROOT_START>11628</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11676</FDA_END>
<FDA_START>11641</FDA_START>
<FILE_START>11632</FILE_START>
<IEN_ROOT_END>11682</IEN_ROOT_END>
<IEN_ROOT_START>11681</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11734</FDA_END>
<FDA_START>11695</FDA_START>
<FILE_START>11686</FILE_START>
<IEN_ROOT_END>11740</IEN_ROOT_END>
<IEN_ROOT_START>11739</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11834</FDA_END>
<FDA_START>11753</FDA_START>
<FILE_START>11744</FILE_START>
<IEN_ROOT_END>11840</IEN_ROOT_END>
<IEN_ROOT_START>11839</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11863</FDA_END>
<FDA_START>11853</FDA_START>
<FILE_START>11844</FILE_START>
<IEN_ROOT_END>11868</IEN_ROOT_END>
<IEN_ROOT_START>11868</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11904</FDA_END>
<FDA_START>11881</FDA_START>
<FILE_START>11872</FILE_START>
<IEN_ROOT_END>11916</IEN_ROOT_END>
<IEN_ROOT_START>11909</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11943</FDA_END>
<FDA_START>11929</FDA_START>
<FILE_START>11920</FILE_START>
<IEN_ROOT_END>11949</IEN_ROOT_END>
<IEN_ROOT_START>11948</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11976</FDA_END>
<FDA_START>11962</FDA_START>
<FILE_START>11953</FILE_START>
<IEN_ROOT_END>11982</IEN_ROOT_END>
<IEN_ROOT_START>11981</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12009</FDA_END>
<FDA_START>11995</FDA_START>
<FILE_START>11986</FILE_START>
<IEN_ROOT_END>12015</IEN_ROOT_END>
<IEN_ROOT_START>12014</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12043</FDA_END>
<FDA_START>12028</FDA_START>
<FILE_START>12019</FILE_START>
<IEN_ROOT_END>12050</IEN_ROOT_END>
<IEN_ROOT_START>12048</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12074</FDA_END>
<FDA_START>12063</FDA_START>
<FILE_START>12054</FILE_START>
<IEN_ROOT_END>12079</IEN_ROOT_END>
<IEN_ROOT_START>12079</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12113</FDA_END>
<FDA_START>12092</FDA_START>
<FILE_START>12083</FILE_START>
<IEN_ROOT_END>12121</IEN_ROOT_END>
<IEN_ROOT_START>12118</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12148</FDA_END>
<FDA_START>12134</FDA_START>
<FILE_START>12125</FILE_START>
<IEN_ROOT_END>12154</IEN_ROOT_END>
<IEN_ROOT_START>12153</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12181</FDA_END>
<FDA_START>12167</FDA_START>
<FILE_START>12158</FILE_START>
<IEN_ROOT_END>12187</IEN_ROOT_END>
<IEN_ROOT_START>12186</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12214</FDA_END>
<FDA_START>12200</FDA_START>
<FILE_START>12191</FILE_START>
<IEN_ROOT_END>12220</IEN_ROOT_END>
<IEN_ROOT_START>12219</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12248</FDA_END>
<FDA_START>12233</FDA_START>
<FILE_START>12224</FILE_START>
<IEN_ROOT_END>12255</IEN_ROOT_END>
<IEN_ROOT_START>12253</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12279</FDA_END>
<FDA_START>12268</FDA_START>
<FILE_START>12259</FILE_START>
<IEN_ROOT_END>12284</IEN_ROOT_END>
<IEN_ROOT_START>12284</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12315</FDA_END>
<FDA_START>12297</FDA_START>
<FILE_START>12288</FILE_START>
<IEN_ROOT_END>12323</IEN_ROOT_END>
<IEN_ROOT_START>12320</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12354</FDA_END>
<FDA_START>12336</FDA_START>
<FILE_START>12327</FILE_START>
<IEN_ROOT_END>12361</IEN_ROOT_END>
<IEN_ROOT_START>12359</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12388</FDA_END>
<FDA_START>12374</FDA_START>
<FILE_START>12365</FILE_START>
<IEN_ROOT_END>12394</IEN_ROOT_END>
<IEN_ROOT_START>12393</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12421</FDA_END>
<FDA_START>12407</FDA_START>
<FILE_START>12398</FILE_START>
<IEN_ROOT_END>12427</IEN_ROOT_END>
<IEN_ROOT_START>12426</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12455</FDA_END>
<FDA_START>12440</FDA_START>
<FILE_START>12431</FILE_START>
<IEN_ROOT_END>12462</IEN_ROOT_END>
<IEN_ROOT_START>12460</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12486</FDA_END>
<FDA_START>12475</FDA_START>
<FILE_START>12466</FILE_START>
<IEN_ROOT_END>12491</IEN_ROOT_END>
<IEN_ROOT_START>12491</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12518</FDA_END>
<FDA_START>12504</FDA_START>
<FILE_START>12495</FILE_START>
<IEN_ROOT_END>12524</IEN_ROOT_END>
<IEN_ROOT_START>12523</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12555</FDA_END>
<FDA_START>12537</FDA_START>
<FILE_START>12528</FILE_START>
<IEN_ROOT_END>12563</IEN_ROOT_END>
<IEN_ROOT_START>12560</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12590</FDA_END>
<FDA_START>12576</FDA_START>
<FILE_START>12567</FILE_START>
<IEN_ROOT_END>12596</IEN_ROOT_END>
<IEN_ROOT_START>12595</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12623</FDA_END>
<FDA_START>12609</FDA_START>
<FILE_START>12600</FILE_START>
<IEN_ROOT_END>12629</IEN_ROOT_END>
<IEN_ROOT_START>12628</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12657</FDA_END>
<FDA_START>12642</FDA_START>
<FILE_START>12633</FILE_START>
<IEN_ROOT_END>12664</IEN_ROOT_END>
<IEN_ROOT_START>12662</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12689</FDA_END>
<FDA_START>12677</FDA_START>
<FILE_START>12668</FILE_START>
<IEN_ROOT_END>12694</IEN_ROOT_END>
<IEN_ROOT_START>12694</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12721</FDA_END>
<FDA_START>12707</FDA_START>
<FILE_START>12698</FILE_START>
<IEN_ROOT_END>12727</IEN_ROOT_END>
<IEN_ROOT_START>12726</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12758</FDA_END>
<FDA_START>12740</FDA_START>
<FILE_START>12731</FILE_START>
<IEN_ROOT_END>12766</IEN_ROOT_END>
<IEN_ROOT_START>12763</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12795</FDA_END>
<FDA_START>12779</FDA_START>
<FILE_START>12770</FILE_START>
<IEN_ROOT_END>12802</IEN_ROOT_END>
<IEN_ROOT_START>12800</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12829</FDA_END>
<FDA_START>12815</FDA_START>
<FILE_START>12806</FILE_START>
<IEN_ROOT_END>12835</IEN_ROOT_END>
<IEN_ROOT_START>12834</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12862</FDA_END>
<FDA_START>12848</FDA_START>
<FILE_START>12839</FILE_START>
<IEN_ROOT_END>12868</IEN_ROOT_END>
<IEN_ROOT_START>12867</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12896</FDA_END>
<FDA_START>12881</FDA_START>
<FILE_START>12872</FILE_START>
<IEN_ROOT_END>12903</IEN_ROOT_END>
<IEN_ROOT_START>12901</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12927</FDA_END>
<FDA_START>12916</FDA_START>
<FILE_START>12907</FILE_START>
<IEN_ROOT_END>12932</IEN_ROOT_END>
<IEN_ROOT_START>12932</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12959</FDA_END>
<FDA_START>12945</FDA_START>
<FILE_START>12936</FILE_START>
<IEN_ROOT_END>12965</IEN_ROOT_END>
<IEN_ROOT_START>12964</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12996</FDA_END>
<FDA_START>12978</FDA_START>
<FILE_START>12969</FILE_START>
<IEN_ROOT_END>13004</IEN_ROOT_END>
<IEN_ROOT_START>13001</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13033</FDA_END>
<FDA_START>13017</FDA_START>
<FILE_START>13008</FILE_START>
<IEN_ROOT_END>13040</IEN_ROOT_END>
<IEN_ROOT_START>13038</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13070</FDA_END>
<FDA_START>13053</FDA_START>
<FILE_START>13044</FILE_START>
<IEN_ROOT_END>13077</IEN_ROOT_END>
<IEN_ROOT_START>13075</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13104</FDA_END>
<FDA_START>13090</FDA_START>
<FILE_START>13081</FILE_START>
<IEN_ROOT_END>13110</IEN_ROOT_END>
<IEN_ROOT_START>13109</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13137</FDA_END>
<FDA_START>13123</FDA_START>
<FILE_START>13114</FILE_START>
<IEN_ROOT_END>13143</IEN_ROOT_END>
<IEN_ROOT_START>13142</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13171</FDA_END>
<FDA_START>13156</FDA_START>
<FILE_START>13147</FILE_START>
<IEN_ROOT_END>13178</IEN_ROOT_END>
<IEN_ROOT_START>13176</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13202</FDA_END>
<FDA_START>13191</FDA_START>
<FILE_START>13182</FILE_START>
<IEN_ROOT_END>13207</IEN_ROOT_END>
<IEN_ROOT_START>13207</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13234</FDA_END>
<FDA_START>13220</FDA_START>
<FILE_START>13211</FILE_START>
<IEN_ROOT_END>13240</IEN_ROOT_END>
<IEN_ROOT_START>13239</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13272</FDA_END>
<FDA_START>13253</FDA_START>
<FILE_START>13244</FILE_START>
<IEN_ROOT_END>13280</IEN_ROOT_END>
<IEN_ROOT_START>13277</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13310</FDA_END>
<FDA_START>13293</FDA_START>
<FILE_START>13284</FILE_START>
<IEN_ROOT_END>13316</IEN_ROOT_END>
<IEN_ROOT_START>13315</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13343</FDA_END>
<FDA_START>13329</FDA_START>
<FILE_START>13320</FILE_START>
<IEN_ROOT_END>13349</IEN_ROOT_END>
<IEN_ROOT_START>13348</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13376</FDA_END>
<FDA_START>13362</FDA_START>
<FILE_START>13353</FILE_START>
<IEN_ROOT_END>13382</IEN_ROOT_END>
<IEN_ROOT_START>13381</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13410</FDA_END>
<FDA_START>13395</FDA_START>
<FILE_START>13386</FILE_START>
<IEN_ROOT_END>13417</IEN_ROOT_END>
<IEN_ROOT_START>13415</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13441</FDA_END>
<FDA_START>13430</FDA_START>
<FILE_START>13421</FILE_START>
<IEN_ROOT_END>13446</IEN_ROOT_END>
<IEN_ROOT_START>13446</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13470</FDA_END>
<FDA_START>13459</FDA_START>
<FILE_START>13450</FILE_START>
<IEN_ROOT_END>13475</IEN_ROOT_END>
<IEN_ROOT_START>13475</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13502</FDA_END>
<FDA_START>13488</FDA_START>
<FILE_START>13479</FILE_START>
<IEN_ROOT_END>13508</IEN_ROOT_END>
<IEN_ROOT_START>13507</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13542</FDA_END>
<FDA_START>13521</FDA_START>
<FILE_START>13512</FILE_START>
<IEN_ROOT_END>13551</IEN_ROOT_END>
<IEN_ROOT_START>13547</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13580</FDA_END>
<FDA_START>13564</FDA_START>
<FILE_START>13555</FILE_START>
<IEN_ROOT_END>13586</IEN_ROOT_END>
<IEN_ROOT_START>13585</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13615</FDA_END>
<FDA_START>13599</FDA_START>
<FILE_START>13590</FILE_START>
<IEN_ROOT_END>13622</IEN_ROOT_END>
<IEN_ROOT_START>13620</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13649</FDA_END>
<FDA_START>13635</FDA_START>
<FILE_START>13626</FILE_START>
<IEN_ROOT_END>13655</IEN_ROOT_END>
<IEN_ROOT_START>13654</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13682</FDA_END>
<FDA_START>13668</FDA_START>
<FILE_START>13659</FILE_START>
<IEN_ROOT_END>13688</IEN_ROOT_END>
<IEN_ROOT_START>13687</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13716</FDA_END>
<FDA_START>13701</FDA_START>
<FILE_START>13692</FILE_START>
<IEN_ROOT_END>13723</IEN_ROOT_END>
<IEN_ROOT_START>13721</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13750</FDA_END>
<FDA_START>13736</FDA_START>
<FILE_START>13727</FILE_START>
<IEN_ROOT_END>13755</IEN_ROOT_END>
<IEN_ROOT_START>13755</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13786</FDA_END>
<FDA_START>13768</FDA_START>
<FILE_START>13759</FILE_START>
<IEN_ROOT_END>13791</IEN_ROOT_END>
<IEN_ROOT_START>13791</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13822</FDA_END>
<FDA_START>13804</FDA_START>
<FILE_START>13795</FILE_START>
<IEN_ROOT_END>13827</IEN_ROOT_END>
<IEN_ROOT_START>13827</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13862</FDA_END>
<FDA_START>13840</FDA_START>
<FILE_START>13831</FILE_START>
<IEN_ROOT_END>13867</IEN_ROOT_END>
<IEN_ROOT_START>13867</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13894</FDA_END>
<FDA_START>13880</FDA_START>
<FILE_START>13871</FILE_START>
<IEN_ROOT_END>13900</IEN_ROOT_END>
<IEN_ROOT_START>13899</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13941</FDA_END>
<FDA_START>13913</FDA_START>
<FILE_START>13904</FILE_START>
<IEN_ROOT_END>13952</IEN_ROOT_END>
<IEN_ROOT_START>13946</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13983</FDA_END>
<FDA_START>13965</FDA_START>
<FILE_START>13956</FILE_START>
<IEN_ROOT_END>13990</IEN_ROOT_END>
<IEN_ROOT_START>13988</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14022</FDA_END>
<FDA_START>14003</FDA_START>
<FILE_START>13994</FILE_START>
<IEN_ROOT_END>14030</IEN_ROOT_END>
<IEN_ROOT_START>14027</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14051</FDA_END>
<FDA_START>14043</FDA_START>
<FILE_START>14034</FILE_START>
<IEN_ROOT_END>14056</IEN_ROOT_END>
<IEN_ROOT_START>14056</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14117</FDA_END>
<FDA_START>14069</FDA_START>
<FILE_START>14060</FILE_START>
<IEN_ROOT_END>14123</IEN_ROOT_END>
<IEN_ROOT_START>14122</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14147</FDA_END>
<FDA_START>14136</FDA_START>
<FILE_START>14127</FILE_START>
<IEN_ROOT_END>14152</IEN_ROOT_END>
<IEN_ROOT_START>14152</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14179</FDA_END>
<FDA_START>14165</FDA_START>
<FILE_START>14156</FILE_START>
<IEN_ROOT_END>14185</IEN_ROOT_END>
<IEN_ROOT_START>14184</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14215</FDA_END>
<FDA_START>14198</FDA_START>
<FILE_START>14189</FILE_START>
<IEN_ROOT_END>14221</IEN_ROOT_END>
<IEN_ROOT_START>14220</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14246</FDA_END>
<FDA_START>14234</FDA_START>
<FILE_START>14225</FILE_START>
<IEN_ROOT_END>14251</IEN_ROOT_END>
<IEN_ROOT_START>14251</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14275</FDA_END>
<FDA_START>14264</FDA_START>
<FILE_START>14255</FILE_START>
<IEN_ROOT_END>14280</IEN_ROOT_END>
<IEN_ROOT_START>14280</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14312</FDA_END>
<FDA_START>14293</FDA_START>
<FILE_START>14284</FILE_START>
<IEN_ROOT_END>14321</IEN_ROOT_END>
<IEN_ROOT_START>14317</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14356</FDA_END>
<FDA_START>14334</FDA_START>
<FILE_START>14325</FILE_START>
<IEN_ROOT_END>14364</IEN_ROOT_END>
<IEN_ROOT_START>14361</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14392</FDA_END>
<FDA_START>14377</FDA_START>
<FILE_START>14368</FILE_START>
<IEN_ROOT_END>14398</IEN_ROOT_END>
<IEN_ROOT_START>14397</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14424</FDA_END>
<FDA_START>14411</FDA_START>
<FILE_START>14402</FILE_START>
<IEN_ROOT_END>14431</IEN_ROOT_END>
<IEN_ROOT_START>14429</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14455</FDA_END>
<FDA_START>14444</FDA_START>
<FILE_START>14435</FILE_START>
<IEN_ROOT_END>14462</IEN_ROOT_END>
<IEN_ROOT_START>14460</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14484</FDA_END>
<FDA_START>14475</FDA_START>
<FILE_START>14466</FILE_START>
<IEN_ROOT_END>14490</IEN_ROOT_END>
<IEN_ROOT_START>14489</IEN_ROOT_START>
</COMPONENT>
</INDEX>
</REMINDER_EXCHANGE_FILE_ENTRY>
